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ABSTRACT 
Obese Zucker Rats as a Reverse Translational Model of Human Left Ventricular 
Hypertrophy 
Mackenzie Shelby Newman 
Heart failure is a lifelong disability that is a comorbidity in nearly one out of eight deaths and 
leads to mortality within five years for over half of those affected. Left ventricular hypertrophy 
(LVH) is one of the most reliable independent predictors of heart failure. It has been observed to 
occur in nearly 20% of individuals in a large, representative US population study with sex-
specific disparities. Obesity, cardiovascular diseases, and increased age are common 
comorbidities. Pathological LVH is irreversible in humans and early diagnosis is often missed 
due to lack of symptoms. Obese Zucker rats (OZR) are a rat strain that naturally develop 
phenotypical LVH without surgical intervention or a high fat diet. OZR develop obesity due to 
dysfunctional leptin signaling, which mimics the situation most often seen in obese humans. 
These animals also develop many conditions, such as hypertension and glucose intolerance, that 
mimic the human population at risk for LVH. These animal models are necessary for research as 
live human donor tissue is scarce. The central hypothesis is that genes and proteins that are 
differentially expressed during development of LVH, with regard to sex and obesity status, may 
serve as clinical biomarkers or therapeutic targets for detection and prevention of heart failure. 
No previous studies have addressed these comparisons on an exome-wide basis. In the present 
research, I address these knowledge gaps with transcriptome analysis of rat and human left 
ventricle (LV) tissue in a sex- and obesity-specific manner. Specific genes that were identified 
and which are involved in cardiac development and function were then validated at the protein 
level to form a gene signature (NPPA, NPPB, HBB, MYL7, PDK4) that may be targetable as a 
future diagnostic or represent targets for intervention. Finally, I provide a novel method to reduce 
the expression of NPPA, the gene with the highest upregulation in both male and female obese 
humans and rats using targeted siRNA. In conclusion, this work defines novel genome-wide 
transcriptomes of LVH in male and female humans with or without regard to obesity, and male 
and female obese Zucker rats. Comparison of these datasets coupled to cross-species protein 
expression allows for confirmation of whether an individual gene or geneset is translationally-
relevant for further investigation in LVH. Future work should address transcriptomic and 
proteomic changes throughout the course of LVH development and whether intervention of 
specific gene targets can ameliorate onset of LVH. The work presented here provides a 
framework for the discovery of future LVH-related genes and proteins in order to improve the 
quality of life and burden on the healthcare system from LVH and, ultimately, heart failure. 
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Heart Failure (HF) 
HF occurs when the heart cannot sufficiently supply blood to the body. A lack of blood 
means a lack of oxygen and other nutrient delivery to tissues and organs, resulting in fatigue, 
peripheral edema, organ dysfunction, and fainting, among many other symptoms. It is an 
extremely detrimental disease because by the time it is diagnosed, significant irreversible 
damage is already present, thus explaining the high mortality rates. The most common 
comorbidities of HF, namely obesity, chronic kidney disease, hypertension, diabetes, and 
smoking, are present in 52% of HF patients (13, 38, 52). HF can present acutely or chronically. 
In acute situations, frequently caused by underlying conditions such as arrhythmias or 
myocardial infarction, immediate treatment is pivotal because the heart has not had the same 
adaptive changes that accompany chronic HF. Although adaptive changes in chronic HF may be 
beneficial initially, they may ultimately lead to worse damage over time. 
In HF, the Frank-Starling mechanism fails. In a healthy heart, this mechanism describes 
the positive correlation between simultaneous increases in cardiac output and right atrial pressure 
(reflective of blood returning to the heart from circulation). The hallmark of HF is decreased 
cardiac output, yet right atrial pressure is still increased. Cardiac output is defined as the product 
of stroke volume and heart rate. In HF, decreases in stroke volume are the result of diastolic 
and/or systolic dysfunction. In the former, ventricular filling is reduced (often due to stiffness or 
reduced lumen volume; ejection fraction is preserved), leading to less blood being pumped into 
circulation. In the latter, loss of myocyte contractility reduces the heart’s capacity to pump. 




Multiple systems facilitate adaptive changes for HF. Sympathetic input, endothelin, and 
angiotensin II are elevated in order to increase systemic vascular resistance and therefore both 
arterial and venous pressure. This causes vasoconstriction to compensate for reduced cardiac 
output. Sympathetic input, endothelin, and angiotensin II also increase contractility and heart rate 
to raise cardiac output in light of reduced stroke volume, but these can also promote arrythmias. 
Vasopressin and aldosterone are also elevated, in order to increase blood volume, but these can 
also cause peripheral edema. Atrial and brain natriuretic peptides (ANP and BNP, respectively) 
are released in HF to counterbalance the effects of these extremely elevated neurohumoral 
adaptations. Increases in blood volume (preload) and arterial vasoconstriction (afterload) can 
exacerbate HF by increasing the amount of total work output from the heart, as it is pumping a 
larger volume against a higher pressure gradient.  
Treatment of HF 
There is no treatment that can reverse HF, as cardiac tissue damage is irreparable (65). 
Despite this, numerous treatments have been shown to aid in patient survival, and survival rates 
have been increasing over the last few decades. Many medications have been shown to be 
effective post-HF; these have varying effects on the cardiovascular system that are principally 
related to hypertension and heart rate. Some of these classes of drugs include angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and angiotensin 
receptor neprilsyin inhibitors (ARNIs) (to reduce afterload and therefore reduce work required 
per stroke), If blockers and beta-blockers (to reduce heart rate/risk of arrhythmias in individuals 
with tachycardia), aldosterone antagonists and diuretics (to reduce blood volume), and digoxin 
(to increase contractility) (90). Heart transplant has been shown to be effective, but this is 




approximately 9.5 years after transplant, but the average is only five years. Transplantable hearts 
are in extreme demand, too, with less than 50% of patients desiring them actually receiving them 
from 1987-2012 (10). Heart transplant requires frequent post-operative attention because reduced 
parasympathetic cardiac innervation result in increased resting heart rate, reduced stroke volume, 
and increases in systolic and diastolic blood pressures (3, 104). Implantable devices, such as 
cardioverter-defibrillators, have been shown to be effective in patients with reduced ejection 
fraction. Left ventricular assist devices (LVAD), which are mechanical pumps that aid the LV to 
pump blood to the body, have been shown to be effective as well: from 2006-2014, the survival 
rate at one year was 80% and at two years was 70% in those who received implanted devices 
(58). Similarly, the in-hospital mortality rate dropped from 47% to 13% from 2005-2011 (58). 
Though still costly, these devices are not as expensive as a transplant and are much more widely 
available. However, they are extremely invasive, too: the 30-day readmission rate after 
implantation was 44% in one meta-study (57). The most common complications were infection, 
stroke, and gastrointestinal bleeding, as well arrhythmias and device malfunction. Like 
pacemakers, LVAD require new batteries over time, and therefore another invasive surgery (72).  
HF Impact and Detection 
 HF is a devastating condition that affects over 2% of the global population (48) and is a 
comorbidity in one out of eight deaths (22). Nearly $40 billion USD in annual healthcare costs 
are attributed to HF (124), yet these are expected to rise to $69.8 billion USD by 2030 (48). 
From 2013-2016, HF affected 6.2 million Americans aged 20 or greater, with projections of a 
46% increase leading into 2030 and an overall 0.5% greater occurrence in the global population 
(48). Individuals aged 40 or greater are at a 20% risk of developing HF regardless of sex, but 




that are 6-14% greater than females. In the 60-79 age demographic, males and females develop 
HF at rates of 6.9% and 4.8%, respectively, while above age 80, these rates rise to 12.8% and 
12%, respectively (10). Lifetime risks are 30-42% in white males, 20-29% in black males, 32-
39% in white females, and 24-46% in black females (52). From 2005-2015, there was a 27% 
increase in HF incidence (10, 48). The one-year mortality rate after HF for those aged less than 
55 years was 17% in males and 14% in females, but for those aged 85 or greater, the rates 
sharply increased to 58% in men and 49% in women (10). The five-year mortality rate for all HF 
patients in a 1,282-patient study was 42%, with no significant difference between sexes (68). 
Obesity (BMI > 30kg/m2) doubles the risk of HF over lean individuals (BMI < 25kg/m2) (52) 
with or without hypertension, a 100% increase in males and a 90% increase in females, 
according to the Framingham study (56, 63).  
Common markers of cardiovascular damage, such as elevated circulating BNP, urinary 
albumin to creatine ratio, serum γ-glutamyl transferase, and hematocrit (28, 34, 122), typically 
precede HF, but these may not be assessed in patients with no outward symptoms of 
cardiovascular damage. Left ventricular (LV) dysfunction is a hallmark feature of pending HF. 
Systolic LV dysfunction is present in 5% of patients, while diastolic dysfunction is present in 
36% (60). In data from 2005-2010, lowered ejection fraction, a marker of LV function, was 
present in 50% of individuals (113) with HF.  
Left Ventricle (LV) 
 Proper function of the LV is critical to whole-body homeostasis as this chamber is 
responsible for pumping blood from the heart back into circulation. The LV is nearly 60% of 
overall heart volume (66) and is made up primarily of cardiomyocytes, a specialized type of 




which carries cardiac action potentials that allow for rapid cycles of polarization and 
depolarization resulting in heart contraction. These cells have a low turnover rate with age; fewer 
than 50% are considered to be replaced under normal growth over a lifetime (11, 134). Fetal 
cardiomyocytes, instead of dividing, increase in size as the organism ages (134). There is a 
growing body of evidence for resident cardiac stem/progenitor cells, but their capacity to replace 
lost cells has not been fully elucidated (11, 134). The remaining minor cell populations in the LV 
are primarily fibroblasts, smooth muscle cells, and endothelial cells, which provide support and 
help maintain cardiomyocyte function (111). 
Left Ventricular Hypertrophy (LVH) 
 The hallmark of LVH, as the name implies, is an enlargement and thickening of the LV. 
There are two focal types: inward hypertrophic remodeling, wherein the chamber lumen volume 
is reduced, and outward hypertrophic remodeling, wherein the lumen volume increases. The 
former is associated with pathological cardiac hypertrophy and the latter is necessary in 
physiological hypertrophy. Numerous structural and functional changes underlie LVH, and 
although many have been investigated, none are completely understood. The most common 
feature of LVH is increased cardiomyocyte size (61). Electrical restructuring of the ventricle is 
secondary to cellular reorganization, as thickening of the ventricle wall leads to decreased 
conduction (18), which is usually accompanied by alterations in extracellular matrix composition 
and fibrosis (12). Compensatory mechanisms lead typically to increases in voltage within the 
QRS complex, as recorded by ECG (116), but changes have been witnessed in LVH such as 
increased R wave peak time, ST depression or elevation, and T wave inversion (14, 116). The 
QRS complex represents the period of ventricular depolarization (i.e. isovolumetric contraction) 




these parameters, such as lengthened time period or increased voltage, reflect thickened ventricle 
tissue, resulting in greater resistance to the propagation of electrical signal. However, these 
electrical changes do not occur in all cases (4, 5).  
Physiological LVH 
 Importantly, not all LVH is detrimental. Physiological LVH occurs in normal 
circumstances: growth from childhood to adulthood, pregnancy, and exercise, i.e. situations 
where there is an increased tissue demand for oxygen and other nutrition in circulation (and 
therefore increased bloodflow) (61, 71, 74). The focal biochemical pathways involved are often 
growth factor-based, such as the insulin-like growth factor-1 (IGF1) pathway, which leads to 
activation of phosphoinositol-3 kinase, Akt, and downstream mTOR (75, 85, 99). Although 
increased activity of this pathway is seen in some cancers (128), it is considered to have only 
necessary, transient effects with regard to physiological LVH (74). Cardiac fetal gene expression 
(e.g. calcineurin, nuclear factor of activated T cells (NFAT), atrial natriuretic peptide (ANP), 
BNP, skeletal α-actin, and myosin heavy chain 7) is not significantly upregulated (70, 129). 
Proteins involved in the sarcomere, such sarco/endoplasmic reticulum Ca2+-ATPase, actin, and 
alpha- and beta-myosin heavy chains are increased in physiological LVH to facilitate 
contraction. The activation and increased production of these cellular components are considered 
to be reversible, even in cases of chronic exercise training. Cardiac function remains normal or 
increases over the period of exercise acclimation (74). 
Pathological LVH 
 Pathological LVH develops due to a chronic insult such as increased pressure load (e.g. 
hypertension), volume load (valvular disease), or an underlying cardiomyopathy. Similar to 




fibrosis and cellular necrosis/apoptosis are common. Changes in cardiac function are essentially 
the same as those seen in chronic HF: cardiac output decreases without a decrease in right atrial 
pressure. Hypertension in particular causes increased peripheral resistance and therefore 
increased right atrial pressure. Typically, diastolic dysfunction precedes systolic dysfunction, i.e. 
decreased passive compliance (filling) precedes decreased contractility. 
 Adaptive changes are similar as well. As previously discussed, increases in sympathetic 
input and angiotensin II (which are associated with and promote hypertension), and endothelin 
increase heart rate and contractility in order to compensate for reduced stroke volume and 
therefore raise cardiac output. These hormones all act through G protein-coupled receptor 
pathways that are mediated by Gαq, which have been directly implicated in the development of 
cardiac hypertrophy. Gαq activates phospholipase C (PLC), which causes protein kinase C to 
activate numerous mitogen-activated protein kinases (MAPKs) associated with cellular stress. 
Activation of these pathways is also known to cause pro-fibrotic signaling, therefore further 
decreasing cardiac compliance. These hormones also activate phospholipase C, which causes 
downstream changes in calcium homeostasis and activation/nuclear translocation of NFAT, a 
transcription factor that causes expression of many cardiac-specific genes (31, 49, 74, 77). 
Expression of fetal genes such as NPPA and NPPB, which encode for ANP and BNP, 
respectively, is increased (32, 35, 44, 50, 86), in order to counterbalance elevations in 
aldosterone seen in hypertensive situations. Chronic elevations in these hormones ultimately 








Atrial and Brain Natriuretic Peptides 
The primary function of ANP and BNP is to decrease fluid volume by acting on distal 
portions of the nephron through binding to their cognate receptors, NPRA (gene NPR1) and 
NPRB (gene NPR2), respectively. Receptor activation in the heart and vasculature counteracts 
angiotensin: ANP and BNP are anti-hypertrophic, anti-fibroproliferative, and anti-hypertensive 
at physiological concentrations. ANP preferentially binds NPR1 and BNP preferentially binds 
NPR2, likely due to sequence homology. A third receptor, NPRC (gene NPR3), internalizes 
circulating natriuretic peptides, leading to their degradation. All three receptors are widely 
expressed, but with some tissue-specific enrichment: NPR1 in breast, lung, adipose tissue, and 
kidney, with NPR2 in brain, muscle, and female tissues (endometrium, cervix, uterus), and 
NPR3 in lung, kidney and urinary bladder, muscle, and adipose and soft tissue (121). NPRA and 
NPRB are GTPases upon activation; ligand binding causes receptor dimerization and initiates the 
conversion of intracellular GTP to cGMP. Elevated cGMP then may activate protein kinase G 
(PKG) to cause downstream effects such as ion channel modulation via phosphorylation (98, 
115). 
N-terminal pro B-type natriuretic peptide (pro-NT BNP) is currently used as a clinical 
marker for LVH and HF (88, 91, 92). NPPA/ANP (measured as NT-pro-ANP) has been shown 
to be associated with cardiovascular dysfunction and death (110). However, these findings have 
not resulted in approval for use of ANP as a biomarker of HF. Pro-NT BNP is preferred to ANP 
due to its longer circulating half-life (40). ANP and ANP mimetics have been explored 
pharmaceutically for kidney injury due to expression of NPRA in distal nephron to regulate 
sodium clearance (84) and have been shown to have benefits in HF patients (83, 130), with one 




 Elevated ANP and BNP are generally considered to be beneficial in LVH. Despite this, 
extreme, persistent increases may be detrimental. Elevated levels of ANP have been shown to 
modulate heart rate (HR), effective refractory period (ERP), and action potential duration (APD) 
in cardiac tissue and cell preparations in mice, rats, dogs, rabbits, guinea pigs, and humans with 
mixed effects across species (8, 9, 55, 80, 112). ANP was shown to have no effect or decrease 
HR in dogs (8, 9), decrease HR in rats (80), and have no effect or an increase on HR in humans 
(80). ERP was shown to be increased in dogs and decreased in humans (80). ANP decreased 
APD in human, dog, rabbit, and guinea pig cardiac preparations (80), but had no effect on guinea 
pigs or dogs in another set of studies (55, 112). Natriuretic peptide receptor activation in 
cardiomyocytes is a likely cause of cardiac disturbances due to the dependence of 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels on intracellular cGMP; 
these channels are pivotal in maintaining the “funny” current in pacemaker cells that regulates 
and maintains heart rate. One human NPPA mutation, a single base deletion which causes a 
frameshift resulting in an extra 12 amino acids at the C-terminus, has been identified in humans 
that causes elevated, persistent ANP levels in the blood. Both humans and mice expressing this 
mutant NPPA exhibit atrial fibrillation (41). Overall, these data suggest that chronically elevated 
ANP signaling may contribute to the presentation of abnormal cardiac functions. Conversely, 
there is evidence in mice that NPPA or NPRA ablation results in pronounced cardiac 
hypertrophy and hypertension, leading to early mortality (81, 93). 
Diagnosis of LVH 
 LVH is frequently asymptomatic, particularly early in its progression or in those with no 
obvious comorbidities. Initial diagnosis is derived from echocardiography (the same 




resonance imaging). These data can be analyzed as a pressure-volume loop, in order to determine 
basic cardiac parameters such as stroke volume, cardiac output, and ejection fraction. These 
parameters can then be used to gauge the presence of LVH. A basic representation of the 
changes in a pressure-volume loop due to LVH is shown in Figure 1. In line with this analysis, 
direct measurements of the LV can be taken directly from imaging and interpreted. These are 
often used in the Devereux formula to calculate LV mass: 
 
LV mass = 0.8 (1.04[ ([LVEDd + IVSd + PWd]3 − LVEDd3)]) + 0.6  
 
LVEDd: LV end diastolic diameter 
IVSd: intraventricular septal diameter at end diastole 
PWd: posterior wall thickness at end diastole 
 (all units are centimeters) 
 
The resultant value is then normalized to body weight (39). LVH is initially suspected in males 
with LV mass >115g/m2 and in females with LV mass >95g/m2 in females (47).  
 However, LVH diagnosis is not based on a single test and, beyond echocardiography, 12-
lead electrocardiography is required in order to confirm electrical disturbances in the heart. 
Changes in electrical conduction manifest inconsistently in LVH, so clinical criteria seek to 
address multiple parameters at once. QRS complex alterations are most commonly seen in LVH 
(116) as this mechanism is active at the end of diastole and initiates systole, therefore reflecting 
the beginning of the period when the ventricle is contracting. Using Sokolow-Lyon criteria, the 




than or equal to 35mm and an R wave greater than or equal to 11mm in the aVL lead are 
indicative of LVH (47, 109). Using Cornell and Cornell Product criteria, where the sum of the S 
wave in V3 and the R wave in aVL leads is used, a value greater than 28mm in men or 20mm in 
females indicates LVH (21). Differences in accuracy between the criteria have been shown to be 
dependent on BMI status (101), age (108), underlying condition such as myocardial infarction 
(102) or hypertension (132) and the population studied (94, 114).  
 Cardiac MRI may also be used to diagnose LVH. This technique allows for higher 
accuracy and precision versus echocardiography, as well as the identification of subtypes of 
LVH. This technique is expensive, however, and not necessary for patients who have met LVH 
diagnostic criteria using other methods (89, 107). 
Treatment of LVH 
 There is no cure for LVH, given that it is considered to be irreversible, yet many 
treatments have been implicated. Lifestyle changes, such as diet, exercise, and cessation of 
smoking, may have the largest impact on overall cardiovascular health. Like with HF, 
pharmaceuticals that reduce blood pressure have been shown to be effective at alleviating 
comorbidities of LVH, particularly hypertension or other conditions that increase the mechanical 
load put on the heart. Some of these drug classes include angiotensin converting enzyme 
inhibitors, angiotensin receptors blockers, calcium channel blockers, beta-blockers, and diuretics  
(133).  
Models of LVH 
 LVH is nearly impossible to study in primary human cardiac tissue due to the scarcity of 
live donor tissue. Despite this, there are currently no laboratory models of cardiac hypertrophy 




develops over an extended period of time. Surgical methods of LVH induction are extremely 
rapid and thus may not follow the same transcriptional changes seen in humans. Genetic animal 
models of LVH have phenotypical changes that are seen in human LVH but are not directly 
translatable due to the overexpression or deletion of a gene not being relevant to the vast 
majority of the population. 
 Transverse aortic constriction (TAC), the most common model used in rodents and larger 
mammals, requires invasive surgery to place a tie around the aorta and a follow-up procedure to 
remove it. Due to invasiveness and human variability with tightness of the tie, there is a mortality 
risk and experimental inconsistency with aortic banding (62, 118, 119). Improvements to the 
model have been made, such as applying the band during closed-chest surgery, but many of the 
previous issues with variability remain (36, 51). A recent study used o-rings rather than nylon 
sutures around the aorta in order to allow for more reproducibility between animals and found a 
markedly decreased mortality rate and greater reproducibility in results (76). 
 Transgenic models have also been investigated, but often lack direct translational 
applicability in humans because humans seldom have only a single gene entirely knocked out or 
overexpressed in isolation. In a rat model overexpressing Ren2 (the gene encoding for renin, an 
enzyme that helps regulate angiotensin levels and therefore blood pressure), LV weights were 
increased in tandem with blood pressure and markers of fibrosis (123). These rats do not develop 
obesity. Overexpression of α1 adrenergic receptors leads to LVH by a proposed mechanism 
involving Gαq, as described above (74, 78, 78). Overexpression of Gαq itself, a G-protein linked 
to alpha-1 adrenergic receptors, angiotensin II receptors, and endostatin type A receptors, has 
been shown to have a role in general cardiac hypertrophic development (31, 74, 77). 




and expression of pro-fibrotic genes, purportedly via phospholipase C activation (74, 125). In a 
study comparing mice overexpressing RAS versus wild-type mice exposed to TAC treatment, 
the degree of LVH was equal between the two and this was associated with significant increases 
in collagen deposition (a marker of fibrosis) as well as in ANP and BNP levels (43, 74). 
 The MAPK signaling pathway has been widely accepted to play an important role in 
cardiac hypertrophy and HF in both humans and rodents, but the specific mechanisms involved 
are debated (74, 136). Neonatal rat cardiomyocytes in vitro have been shown to exhibit 
hypertrophy when expressing lentiviral-mediated, constituently-active MAP2K3 (126) or via 
pharmacological activation of the direct downstream effector p38α (27). In contrast, transgenic 
mice overexpressing constituently-active MAP2K3 do not produce cardiac hypertrophy (64), and 
mice possessing dominant-negative p38α in vivo have exhibited significant increases in 
hypertrophy versus controls according to one group of investigators (17) and demonstrated no 
changes in LV thickness compared to wild-type mice from another group (135). These 
inconsistent results from rodents do not clarify the role of MAP2K3 in myocyte hypertrophy. 
MAP2K3 transcript levels have been shown to increase 4.7-fold in human HF (15) and increased 
MAP2K3 activity has been associated with hypertrophy in human embryonic stem cell-derived 
cardiomyocytes (37). In our preliminary dataset of 18 human hearts, we found increased protein 
expression of MAP2K3 and phosphorylation of p38 in LVH that was positively associated with 
BMI in male, but not female, hearts (87). 
The Role of Obesity in LVH 
Obesity is the most powerful independent predictor of LVH and it nearly doubles the risk 
of HF in both males and females. It is one of the simplest diagnostics to measure due to lack of 




susceptibility. Generally speaking, body mass increases in obesity require increased cardiac 
output due to more tissue needing to be perfused compared to lean individuals. This leads to an 
increase in blood volume, thus increasing venous pressure and thus right atrial pressure. Under 
the Frank-Starling mechanism, this causes an increase in overall cardiac output, and therefore 
work done by the heart. Obesity is also frequently accompanied by hypertension (over 50% of 
cases (2)), further perpetuating workload on the heart by increasing afterload (96, 105). 
Chronically, this leads to diastolic dysfunction and systolic dysfunction via the mechanisms 
described for LVH and HF. 
Models of Obesity 
 As previously stated, obesity is one of the most common risk factors associated with both 
LVH and HF. Many rodent models of obesity have been developed, but the majority of them fall 
under two categories: diet-induced obesity (DIO) or transgenically-induced obesity. Whereas 
most models under either category are hyperphagic, sedentary, and develop insulin resistance, 
the transgenic models tend to develop more pronounced hyperglycemia, another risk factor for 
HF, as compared to DIO animals (69). DIO animals do not develop HF (16, 73). The most 
common type of DIO, using a 45% or 60% high-fat diet, does not produce the degree of obesity 
observed in many transgenic models (69). While transgenic animals allow for focused research 
into the mechanisms induced by discrete genetic changes with regard to obesity, these specific 
genetic changes may not be relevant to the wider human population. By contrast, obesity in 
humans is nearly always diet-induced. Although the polygenic nature of outbred animals in these 
studies may better mimic the wider human population, the underlying mechanisms may not be as 




difficult to discern whether the physiological differences are the result of genetic alteration per se 
or versus the obesity itself.  
Leptin Signaling 
 The most well-known transgenic models of rodent obesity share one common feature: 
disruptions in leptin input. Leptin is a hormone principally produced and secreted by adipose 
tissue in levels positively associated with fat mass. It was originally discovered by genome 
sequencing in the ob/ob mouse, a mouse that exhibits extreme obesity due to the fact that it lacks 
leptin. There are multiple isoforms of the leptin receptor (all encoded from a single LEPR gene 
that undergoes exon shuffling), denoted as Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re, and Ob-Rf. 
All six isoforms contain an N-terminal domain that binds leptin and contains fibronectin III 
binding domains. The short (Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf) and long (Ob-Rb) isoforms have 
a single transmembrane spanning domain, then a box 1 motif and a janus kinase (JAK) binding 
domain, but the short isoforms do little to any intracellular signaling. The long isoform, Ob-Rb, 
also has a suppressor of cytokine signaling (SOCS) domain, a box 2 domain, and a box 3 
domain; these are necessary for full JAK-STAT pathway signaling. Ob-Re is a circulating, 
soluble receptor that serves to bind and transport leptin, though its role, if any, in obesity is 
unclear. The short isoforms are thought to perhaps play a role in leptin transport in areas such as 
the blood-brain barrier, but they do not contain all domains necessary for full JAK-STAT 
activation, and thus only Ob-Rb is considered to be a fully active receptor (42). Not surprisingly, 
loss of Ob-Rb, such as occurs in the db/db mouse, also leads to excessive obesity. 
 Leptin receptors on the cell surface (10-20% of the overall receptors per cell) typically 
exist as dimers (127). Upon a dimerized receptor binding one leptin molecule, the dimers form a 




and box 2 domains and phosphorylates the receptor at Tyr985 and Tyr1138. Next, members of 
the STAT protein family (notably STAT3) bind Tyr1138, are phosphorylated, then dimerize and 
translocate to the nucleus to act as transcription factors. PI3K, the major intracellular signaling 
molecule activated by insulin, is also activated by leptin binding Ob-Rb. This leads to 
downstream Akt/mTOR, MAPK/ERK/JNK, and p38MAPK induction (33, 42). One notable gene 
that is upregulated by STAT3 activation is SOCS3, which serves to negatively regulate leptin 
receptor activation by feeding back in a manner that inhibits intracellular signaling induced by 
leptin (33, 42). Downstream of STAT3 activation, protein tyrosine phosphatase 1B (PTP1B) is 
also activated and reduces leptin signaling.  
 Leptin receptors are widely distributed throughout the body and serve to regulate many 
physiological processes, including cell growth and energy expenditure, and possess the ability to 
communicate with other cytokines and hormones. The central effect of leptin on body weight 
comes from its actions in the arcuate nucleus (ARC) of the hypothalamus, where it binds 
functional leptin receptors on two distinct populations of neurons. Pro-opiomelanocortin 
(POMC) neurons are activated by leptin and secrete alpha-melanocyte stimulating hormone 
(αMSH) amongst other POMC-derived peptides whereas leptin inhibits neurons coexpressing 
Agouti-related peptide and neuropeptide Y (AgRP/NPY). These first-order neurons then project 
to other areas of the hypothalamus, such as the paraventricular nucleus and lateral hypothalamus, 
as well as to areas of the brain stem to regulate food intake and energy expenditure. αMSH and 
AgRP neurons, along with melanocortin 3 receptor (MC3R) and melanocortin 4 receptors 
(MC4R), form what is referred to as the melanocortin system. αMSH and AgRP compete for 
binding at these receptors and deletion of MC4R leads to an obese phenotype, suggesting that 




POMC and AgRP/NPY neurons, suggesting a highly coordinated response to changes in leptin 
that occurs with starvation or obesity. Overall, the actions of leptin in the hypothalamus lead to 
increased satiety, anorexia, and energy expenditure. By contrast, these central actions of leptin 
are directly opposed by that of ghrelin, a hormone released from the stomach that stimulates 
hunger (1, 42, 69, 120). Importantly, a lack of leptin is only rarely an explanation for human 
obesity and, typically, obese individuals have very high circulating levels of leptin. These 
individuals are considered to be resistant to the anorexigenic effects of leptin, and the sites of this 
resistance may include decreased transport at the blood-brain barrier as well as deficits in neural 
responses to leptin. 
Transgenic Models of Obesity 
 The more commonly used rodent models of obesity are those with mutations in LEP or 
LEPR. There are notable examples of rodents with mutations or deletions in downstream 
effectors, such as POMC knockout mice (23, 131), POMC and AgRP double knockout mice 
(30), MC3R knockout mice (19), MC4R knockout mice and rats (53, 82), MC3R and MC4R 
double knockout mice (25), and AgRP overexpressing mice (45). In a mouse model with 
designer receptors exclusively activated by designer drugs (DREADDs), activation of AgRP 
neurons led to feeding and eventual increased adiposity, while inhibition of these populations 
reduced feeding (59). Lesser-used models that have direct leptin or leptin receptor mutations or 
deletions include s/s mice (mutated Tyr1138 in Ob-Rb, which is critical for STAT3 binding) (6, 
7) and Koletsky rats (LEPR mutation resulting in undetectable Ob-Rb mRNA levels) (117).  
Nonetheless, the most common rodent models of obesity are the ob/ob mouse, db/db mouse, and 
OZR. ob/ob mice contain an early stop codon in the mRNA for leptin, leading to the ablation of 




on food intake, metabolism, and neuroendocrine dysfunction in this mouse model are entirely 
ameliorated by leptin injection (79). As mentioned above, obese humans are rarely obese due to 
a lack of leptin, so while the ob/ob mouse has been invaluable as a tool to examine how leptin 
influences body weight regulation, they may not be a good translational model. db/db mice and 
OZR have separate missense mutations in the LEPR gene that result in either an absence of 
receptor (db/db mice) or a significantly reduced ability of Ob-Rb to signal (OZR). Both models 
have elevated circulating concentrations of leptin (46, 69, 95). A hallmark of db/db mice is their 
development of diabetes type II-like symptoms, thus they are frequently used as a model of 
diabetes in addition to obesity (46, 69). A parallel model of diabetes and obesity has been 
outbred into OZR, and is known as the Zucker diabetic fatty rat (106). 
Zucker Rats and Human Relevance 
 OZR are used as a model for a variety of human diseases, e.g. hypertension, metabolic 
syndrome, chronic kidney disease, hyperlipidemia, and mild diabetes, depending on the age of 
the animal. They were initially inbred from rats that spontaneously developed obesity when 
given free access to food, developing up to 50% of their body mass as fat (compared to around 
20% in lean controls). They are hyperphagic at a young age (fewer than three weeks) and can 
become over twice the body weight of lean controls as early as six weeks of age (24). In 
research, they have been historically favored, as compared to ob/ob and db/db mice, because 
Zuckers do not develop hyperglycemia to an extreme extent, therefore making this model more 
suitable for studying the effect of obesity alone (54, 74).  
 Despite a persistent increase in body weight starting early in life, no changes in mean 
arterial pressure of OZR were noted at 8 weeks of age in one study (97) and at both 9 and 13 




Cardiomyocyte hypertrophy has been seen in OZR that exhibited increased QT interval as young 
as 16 weeks of age (67). A study of young rats (aged 9-13 weeks) looking at mRNA levels for 
NPPA and NPPB, both of which are elevated in human LVH and HF, only found a significant 
increase in NPPB, and this was unexpectedly in the lean animals (20). Another study in 5-6 
month old Zucker rats found increases in both ANP and BNP, the peptide products of NPPA and 
NPPB (26). The longer amount of time required for LVH development in these animals is more 
comparable to human LVH than other TAC models, and their shared cardiac hormone profile, 
make them a viable model for obesity-related LVH. 
Conclusions 
Pathological LVH is a poorly-understood disease with many negative prognostic 
outcomes, most notably HF. As a comorbidity with obesity and rising obesity rates throughout 
the world, research into the development of LVH is implicit for future diagnoses and treatment. 
Investigating LVH in humans directly is hindered by the lack of availability of live donor tissue, 
therefore the development of new animal models is critical for the future of LVH research. The 
purpose of this research is to validate genes and proteins known to play a role in human HF that 
are also present in LVH as potential biomarkers of heart damage, then develop a novel model of 
LVH to further study the roles of these genes and proteins. The central hypothesis is that genes 
and proteins that are differentially expressed in HF and LVH, with regard to sex and obesity 
status, may serve as clinical biomarkers or therapeutic targets for detection and prevention of HF. 
This will be explored via two specifics aims: 
1. To identify differentially expressed genes that are common between human HF and LVH 
compared to non-failed hearts 





Figure 1. Representative pressure-volume loop of LVH and normal heart 
 
Figure 1. A basic representation of changes in a pressure-volume loop for a normal heart (blue) 
and an LVH heart (red). The narrowing of the LVH heart loop shows decreased total filling 
volume, reflecting reduced left ventricular lumen. The increased height of the loop represents 
increased pressure necessary for ejection, as seen in hypertension. 
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How obesity or sex may affect the gene expression profiles of human cardiac hypertrophy is 
unknown. We hypothesized that body-mass index (BMI) and sex can affect gene expression 
profiles of cardiac hypertrophy. Human heart tissues were grouped according to sex (male, 
female), BMI (lean<25 kg/m2, obese>30 kg/m2), or LVH and non-LVH nonfailed controls (NF). 
We identified 24 differentially expressed (DE) genes comparing female with male samples. In 
obese subgroup, there were 236 DE genes comparing LVH with NF; in lean subgroup, there 
were seven DE genes comparing LVH with NF. In female subgroup, we identified 1,320 
significant genes comparing LVH with NF; in male subgroup, there were 1,383 significant genes 
comparing LVH with NF. There were seven significant genes comparing obese LVH with lean 
NF; comparing male obese LVH with male lean NF samples we found 106 significant genes; 
comparing female obese LVH with male lean NF, we found no significant genes. Using absolute 
value of log2 fold-change > 2 or extremely small P value (10−20) as a criterion, we identified nine 
significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, 
PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in 
HF. We identified a potential gene expression signature that distinguishes between patients with 
high BMI or between men and women with cardiac hypertrophy. Expression of established 
biomarkers natriuretic peptide A (NPPA) and B (NPPB) were already significantly increased in 
hypertrophy compared with controls. 
Introduction 
In a recent global body mass index (BMI) mortality collaboration study from data 
collected from 3.9 million adults, the risk of dying before 70 yr of age was 19% for men and 




for men and 15% for women; thus, obesity caused an absolute increased risk of 11% for men and 
4% for women (12). While this large-scale study confirmed the obesity-mortality causal link, it 
did not address the question, “why does obesity cause nearly three times more premature death in 
men than in women?” 
While HF is frequently the final state of cardiovascular disease, cardiac hypertrophy is a 
major independent predictor of progressive heart disease and increased mortality (11). Cardiac 
hypertrophy is also one of the most common independent features in obesity, even in the absence 
of hypertension or diabetes mellitus (1, 3, 20, 34, 45, 48). Cardiomyocyte hypertrophy has been 
found to be the most common cause of sudden cardiac death in morbid obese patients (14). 
Advances in studies of signaling pathways in both physiological and pathological hypertrophies 
have led to a recent proposal that aims to treat cardiac hypertrophy as a new therapeutic target (6, 
17). 
Numerous studies from animal models, mostly rodents, have yielded at least 26 “key 
signaling molecules or processes” critical in hypertrophy and HF and thus are potential targets 
for new treatment of HF (38). However, clinical trials for new drugs have seldom been 
successful (22, 38). While finding new therapeutic targets in HF remains important, 
understanding genetic and molecular mechanisms of cardiac hypertrophy has recently gained 
increasing interest due to early-stage presentation during the time course of HF development (6, 
17). 
Studies in molecular signaling pathways have revealed different responses of several key 
signaling proteins to physiological and pathological hypertrophic stimuli (4). Notably, the 




receiving aortic banding compared with sham in an experimental mouse cardiac hypertrophy 
model (4). 
Adding to the complexity of understanding the underlying mechanisms of cardiac 
hypertrophy is the potential contribution of obesity and sex. Obesity caused higher rates of 
cardiac hypertrophy, reduced quality of life, and shorter life expectancies compared with age-
matched lean individuals (29, 35). A recent study in 2.3 million adolescents from 1967 to 2010 
found that overweight and obese individuals (measured by BMI) were strongly associated with 
increased cardiovascular mortality in adults (43). A high rate of sudden cardiac death in 
individuals with morbid obesity has been recognized for centuries (9). A high prevalence of 
sudden cardiac death has also been found in young obese people (5). For every 1 kg/m2 increase 
in BMI, HF risk increases by 5% in men and 7% in women (23). In ventricular biopsy samples 
from obese patients, the number of adipocytes increases as the ejection fraction decreases (30). 
Comparatively, sex differences in cardiovascular physiology are well known, but sex-specific 
manifestations in human cardiovascular disease have only been recently recognized (19, 21, 32). 
In the meantime, most mechanistic studies of cardiac hypertrophy have only been conducted in 
male animal models. 
Methodologically, previous studies used Northern blotting, real-time PCR, and 
microarray cDNA for cardiac gene expression profiling under various hypertrophic conditions 
(26). Recent advances in next-generation sequencing (NGS) such as RNA-Seq (or transcriptome 
analysis) offer a unique opportunity to provide an overall snapshot of mRNA expression of all 
cardiac genes with high accuracy. Advantages of RNA-Seq over other sequencing methods such 




low background noise, and a wide dynamic range for quantification of gene expression levels 
(46). 
In this work, we used RNA-Seq to investigate the potential effects of BMI and sex on 
gene expression profiles of human heart with LVH. 
Methods 
Human Heart Samples 
Acquisition of human heart samples was approved by the Institutional Review Board 
(IRB) for the protection of human subjects at both West Virginia University and Duke 
University. Deidentified frozen human heart samples with pathological characterization were 
provided by the Department of Surgery at Duke University School of Medicine. Whole heart 
tissue was snap-frozen in liquid nitrogen immediately after collection from surgical procedures. 
LV were dissected and stored in −80°C freezer until use. Patient characterizations of the samples 
are provided in Table 1. Average age of patients is 47.21 ± 2.65 yr (ranging from 19 to 67 yr). 
The control group, in which hearts had no hypertrophy or failure, is designated the nonfailed 
(NF) group, with a mean age of 46.00 ± 3.69 yr (n = 12). In the hypertrophy group, the mean age 
is 48.42 ± 2.65 yr (n = 12). LVH (n = 12, 6 women, 6 men) samples were verified by 
echocardiograph (echo) measurement and interpreted by a cardiologist. NF hearts (n = 12, 6 
female, 6 male) with echo data showing the absence of LVH were used as controls. Information 
of patients’ age, sex, and BMI was obtained from pathological reports. BMI <25 was considered 
“lean” and BMI >30 was considered “obese.” 
Ethics Approval and Consent to Participate 
Use of human heart samples in this research was approved by the West Virginia 




Total RNA Isolation, NGS (RNA-Seq), and Bioinformatics Analysis 
Total RNA was isolated using an RNA Fibrous Tissue Miniprep Kit (Qiagen). Quality of 
RNA was verified with an Agilent 2100 Bioanalyzer and RNA 6000 Pico Kit. Only samples that 
had RNA integrity number >7.0 were submitted for sequencing. The samples were then 
subjected to polyA enrichment followed by fragmentation, first- and second-strand synthesis, 
adenylation of 3′-ends, adapter ligation, DNA fragment enrichment, and real-time PCR 
quantification. 
Sequencing was performed using NextSeq 500 (Illumina). Bcl sequencing data were 
converted to FastQ using onboard instrument software. Reads were mapped to human reference 
genome (hg38) using Spliced Transcripts Alignment to a Reference (STAR) (13). 
Differential expression analysis was performed with NOISeq (v.2.14.1) (41) using 
RStudio version 0.99.879 (37). NOISeq is a newly developed tool for differential expression 
analysis. Compared with the commonly used DeSeq (2), NOISeq offered a set of tools for better 
quality control to avoid false positive discoveries (41). Gene annotation information was 
obtained from the Ensembl Biomart database, release 85 (50). Gene expression levels are 
indicated by FPKM (fragments per kilobase of transcript per million mapped reads) (42). FPKM 
was then normalized for batch effect using the ARSyNseq module included with the NOISeq 
package. Data were analyzed by the noiseqbio method under default conditions. The CPM 
filtering method was used for differential analyses where at least one group contained five or 
fewer replicates; otherwise, the Wilcoxon test was used for filtering. 
The HF data set was extracted from a recent publication by Liu et al. (28). We used this 




differentially expressed (DE) genes as “a gene expression signature” for prediction during the 
course of HF. 
Gene Ontology Enrichment and Pathway Analysis 
Gene Ontology (GO) enrichment analysis was carried out by using a comprehensive gene 
set enrichment tool, Enrichr (10, 25). This web-based tool contains 180,184 annotated gene sets 
from 102 gene set libraries (25). It calculates four parameters: P value, q value or adjusted P 
value, z score, and a combinational score; higher indicates larger significance. Interaction 
Network Analysis of Differentially Expressed Genes (GeneMANIA) (47) was used for 
coexpression and association of significant DE genes. 
Immunoblotting 
Tissues sections were submerged in minimal lysis buffer [fresh protease and phosphatase 
inhibitors (Sigma), 20 mM Tris, 150 mM NaCl, 10 mM EGTA, and 10 mM EDTA at pH 7.4] on 
ice and homogenized briefly at high speed. Samples were then centrifuged for 15 min increments 
at 10,000 g to pellet debris. Supernatants were placed into new tubes, and protein concentration 
was recorded with Bradford’s method on an Eppendorf Biophotometer. 
For Western blotting procedures, protein concentrations were normalized between 
samples to 10–30 μg and mixed with Non-Reducing Lane Marker (Thermo Scientific) with 5% 
β-mercaptoethanol. After being heated in a water bath to 95°C for 5 min, samples were cooled to 
4°C and then loaded into a 4–12% bis-Tris gel (Invitrogen). Electrophoresis was carried out at 80 
V for 30 min and then 140 V for the remainder. 
Proteins were transferred to 0.45 micron nitrocellulose membranes (Thermo Fisher) at 30 
V for 1 h. Blots were blocked with 3% BSA-V in Tris-buffered saline plus Tween 20 (TBS-T) 




overnight. Primary antibody solution was replaced with fresh 3% BSA-V in TBS-T containing 
secondary antibodies at 1:10,000 dilution for 1 h at room temperature on a shaker. After five 
washes with TBS-T, blots were developed with a standard ECL kit (Life Technologies) or ECL 
Prime (Amersham) on X-ray film or using a G:BOX digital imaging system (Syngene). 
Statistics 
For Western blots, data are shown as means ± SE; Student’s t-test was used for statistical 
analysis with P < 0.05 being considered as statistically significant, marked with the symbol *. 
For gene expression, gene size adjusted P value (false discovery rate) < 0.05 was used (p_adj < 
0.05) to identify significant genes. 
We used DE gene data (FPKM) and statistics in ischemic cardiomyopathy (ISCH) and 
dilated cardiomyopathy from a recent publication (28). It is possible to obtain the test statistic 
based on a single pair of objects (one disease, one nondisease control) due to the availability of 
multiple reads per subject in RNA-Seq methodology. 
Results 
Human Heart Sample Characteristics 
Table 1 summarizes the characteristics of human hearts used in the study. The average 
age of the patients is 47.21 ± 2.65 yr (ranging from 19 to 67 yr, n = 24), 48.42 ± 3.93 yr for the 
LVH group (n = 12), and 46.00 ± 3.69 yr for the NF group (n = 12). LVH (n = 12, 6 women, 6 
men) samples were diagnosed by echo measurement and interpreted by a cardiologist. Nonfailed 
without LVH (NF) hearts (n = 12, 6 female, 6 male) confirmed with echo were used as controls 







Sex-Specific LVH Gene Expression Profiles 
Comparing LVH with NF samples (n = 9 for each group), we found only one significant 
gene, NPPA (Fig. 1A). NPPA was increased by 11.6-fold in LVH (p_adj = 0.004). This result 
contradicts previous gene expression reports on human cardiac hypertrophy, which have 
identified at least 76 significant genes by using conventional techniques such as PCR, Southern 
blotting, and Northern blotting (26). We wondered whether sex might play a role in this 
unexpected result. 
When we compared gene expression profiles of women vs. men, independent of LVH 
and BMI, we found 24 significantly DE genes (Fig. 1B, Supplemental Table S1 in Appendix A). 
A heat map generated from these 24 DE genes shows different patterns of cardiac gene 
expression between women and men (Fig. 1C). Furthermore, female and male samples can be 
clearly separated using the 24 DE genes, illustrated by principal component analysis (Fig. 1D). 
Informed by the sex influence on gene expression, we next examined the effect of LVH 
on gene expression profiles in female and male groups separately. When comparing female LVH 
(n = 4) with female NF (n = 3) samples, we found 1,320 DE genes (Fig. 1E, Supplemental Table 
S2 in Appendix A). In the male LVH over NF comparison, we identified 1,383 DE genes (Fig. 
1F, Supplemental Table S3 in Appendix A). 
BMI- and Sex-Specific LVH Gene Expression Profiles 
To investigate potential effects of obesity on cardiac gene expression, we compared 
obese (BMI30) with lean (BMI25) groups (n = 9 for each group) and found no significant DE 
genes. However, in the obese group, we found 236 significant genes in LVH compared with NF 




group, we found seven significant genes in LVH compared with NF samples (n = 3 for each 
group) (Fig. 2B, Supplemental Table S5 in Appendix A). 
Next, when we compared obese LVH with lean NF samples (n = 4 for each group), we 
found seven significant genes (Fig. 2C, also see Supplemental Table S6 in Appendix A). 
Considering the factor of sex, we compared male obese LVH with male lean NF samples (n = 3 
for each group) and found 106 significant genes (Fig. 2D, Supplemental Table S7 in Appendix 
A). However, comparing female obese LVH with female lean NF samples (n = 3 for each group) 
yielded no significant DE genes. One possibility is that LVH and obesity can independently alter 
the expression levels of DE genes but in opposite directions. 
Distribution of Sex- and BMI-Specific Significant Cardiac Gene Expression 
Figure 3 summarizes the distribution of DE genes under different conditions. We identified a 
total of 23,521 genes in human hearts. No significant DE genes were found in obesity over lean 
samples and in female lean NF compared with female obese LVH. One gene was found to be 
upregulated in LVH compared with NF. Seven DE genes were identified in lean LVH (six 
upregulated and one downregulated). Seven DE genes were found in lean NF vs. obese LVH 
(five upregulated and two downregulated). Among the 24 DE genes found in women vs. men, 
five were upregulated, and 19 downregulated. Among 106 DE genes found in male lean NF 
compared with male obese LVH, 61 were upregulated, and 45 were downregulated. Among the 
236 DE genes found in the obese group, 38 were upregulated, and 198 were downregulated. 
Among 1,320 DE genes found in female LVH, 330 were upregulated and 990 downregulated. 






Sex- and BMI-Specific Significant Gene Expression Signature 
To identify sex-specific LVH DE genes, we compared male LVH and female LVH DE 
genes. Figure 4A shows a scatterplot of DE genes shared by LVH-M and LVH-F. Quadrant I 
displays 80 genes that are upregulated in female LVH but downregulated in male LVH; quadrant 
II displays six genes that are upregulated in both female and male LVH; quadrant III displays 
141 genes that are downregulated in both female and male LVH; quadrant IV displays 15 genes 
that are downregulated in female LVH but upregulated in male LVH. Figure 4B shows a heat 
map generated from the 80 DE genes from quadrant I of Fig. 4A, demonstrating the sex-specific 
modulation of gene expression in LVH. 
Using abs(log2FC) > 1 as a criterion, we identified 213 sex- and BMI-specific significant 
genes (Supplemental Table S8 in Appendix A). Using abs(log2FC) > 2 as a criterion, we 
identified 27 sex- and BMI-specific significant genes (Supplemental Table S9 in Appendix A). 
Significance of LVH DE Genes: Implication in Ischemic and/or Dilated Cardiomyopathy in 
HF Patients 
To explore the potential significance of these findings, we compared LVH DE genes with 
those recently identified in ischemic cardiomyopathy (ISCH) and dilated cardiomyopathy 
(DCM) (28). Supplemental Figure S1A shows a scatterplot of DE genes found in obese LVH and 
in the previously published ISCH data set (28). There are 37 LVH DE genes found in ISCH 
(Supplemental Table S10 in Appendix A). Quadrant I displays 16 genes that are upregulated in 
obese LVH but downregulated in ISCH; quadrant II displays four gene that is upregulated in 
both obese LVH and ISCH; quadrant III displays 14 genes that are downregulated in both obese 
LVH and ISCH; quadrant IV displays three genes that are downregulated in obese LVH and 




LVH and in the published DCM data set (28). There are 58 LVH DE genes found in DCM (see 
Supplemental Table S11 in Appendix A). Quadrant I displays 27 genes that are upregulated in 
obese LVH but downregulated in DCM; quadrant II displays three genes that are upregulated in 
both obese LVH and DCM; quadrant III displays 17 genes that are downregulated in both obese 
LVH and DCM; quadrant IV displays 11 genes that are downregulated in obese LVH and 
upregulated in DCM. Supplemental Figure S1C shows a scatterplot of DE genes found in obese 
LVH and in the published ISCH/DCM data set (28). There are 31 LVH DE genes found in 
ISCH/DCM data set (see Supplemental Table S12 in Appendix A). Quadrant I displays 16 genes 
that are upregulated in obese LVH but downregulated in ISCH/DCM; quadrant II displays three 
genes that are upregulated in both obese LVH and ISCH/DCM; quadrant III displays eight genes 
that are downregulated in both obese LVH and ISCH/DCM; quadrant IV displays four genes that 
are downregulated in obese LVH and upregulated in ISCH/DCM. 
Supplemental Fig. S2A shows a scatterplot of DE genes found in female LVH and in the 
published ISCH data set (28). There are 111 female LVH DE genes found in ISCH 
(Supplemental Table S13 in Appendix A). Quadrant I displays 41 genes that are upregulated in 
obese LVH but downregulated in ISCH; quadrant II displays 14 genes that are upregulated in 
both obese LVH and ISCH; quadrant III displays 46 genes that are downregulated in both obese 
LVH and ISCH; quadrant IV displays 10 genes that are downregulated in obese LVH and 
upregulated in ISCH. Supplemental Fig. S2B shows a scatterplot of DE genes found in female 
LVH and in the published DCM data set (28). There are 181 female LVH DE genes found in 
DCM (Supplemental Table S14 in Appendix A). Quadrant I displays 63 genes that are 
upregulated in obese LVH but downregulated in DCM; quadrant II displays 20 genes that are 




in both obese LVH and DCM; quadrant IV displays 22 genes that are downregulated in obese 
LVH and upregulated in DCM.  
Supplemental Figure S2C shows a scatterplot of DE genes found in female LVH and in 
the published ISCH/DCM data set (28). There are 98 LVH DE genes found in ISCH/DCM 
(Supplemental Table S15 in Appendix A). Quadrant I displays 56 genes that are upregulated in 
obese LVH but downregulated in ISCH/DCM; quadrant II displays six genes that are 
upregulated in both obese LVH and ISCH/DCM; quadrant III displays 26 genes that are 
downregulated in both obese LVH and ISCH/DCM; quadrant IV displays 10 genes that are 
downregulated in obese LVH and upregulated in ISCH/DCM. Supplemental Figure S2D shows a 
scatterplot of DE genes found in male LVH and in published ISCH data set (28). There are 121 
LVH DE genes found in ISCH (Supplemental Table S16 in Appendix A). Quadrant I displays 46 
genes that are upregulated in obese LVH but downregulated in ISCH; quadrant II displays 16 
genes that are upregulated in both obese LVH and ISCH; quadrant III displays 44 genes that are 
downregulated in both obese LVH and ISCH; quadrant IV displays 15 genes that are 
downregulated in obese LVH and upregulated in ISCH. Supplemental Figure S2E shows a 
scatterplot of DE genes found in male LVH and in the published DCM data set (28). There are 
196 LVH DE genes found in DCM (Supplemental Table S17 in Appendix A). Quadrant I 
displays 98 genes that are upregulated in obese LVH but downregulated in DCM; quadrant II 
displays 17 genes that are upregulated in both obese LVH and DCM; quadrant III displays 46 
genes that are downregulated in both obese LVH and DCM; quadrant IV displays 35 genes that 
are downregulated in obese LVH and upregulated in DCM. Supplemental Figure S2F shows a 
scatterplot of DE genes found in male LVH and in the published ISCH/DCM data set (28). There 




Quadrant I displays 33 genes that are upregulated in obese LVH but downregulated in 
ISCH/DCM; quadrant II displays 15 genes that are upregulated in both obese LVH and 
ISCH/DCM; quadrant III displays 21 genes that are downregulated in both obese LVH and 
ISCH/DCM; quadrant IV displays 11 genes that are downregulated in obese LVH and 
upregulated in ISCH/DCM. 
Gene Expression Signatures 
To explore potential implications of LVH DE genes for future development of HF, we 
selected 10 DE genes according to three criteria: abs(log2FC)>2, extremely small p_adj value 
(10−20), and whether they have been found in the published ISCH and DCM HF data set (28) 
(Table 2). Figure 5A shows the heat map of male LVH (LVH-M) and female LVH (LVH-F) 
compared with their respective NF controls. In male LVH, among expression levels of 10 DE 
genes, four (HBB, PLA2G2A, HBA1, PLXDC2) are changed by less than one standard 
deviation, five (NPPA, NPPB, PDK4, HIST1H2AC, GSTT1) are increased, and one (MYL7) is 
decreased. In female LVH, among expression levels of 10 DE genes, eight (HBB, NPPA, NPPB, 
PDK4, PLA2G2A, HBA1, HIST1H2AC, PLXDC2) are increased, and two (MYL7, GSTT1) are 
decreased. Figure 5B shows the heat map of ISCH and DCM compared with NF using the 
published data (28). Among the expression levels of these 10 genes, seven (HBB, NPPA, NPPB, 
MYL7, PDK4, HIST1H2AC, PLXDC2) are increased in ISCH, seven (HBA1, HBB, NPPA, 
NPPB, MYL7, PDK4, HIST1H2AC) are increased in DCM, and two (PLA2G2A, GSTT1) are 








Validation of 10 DE Genes 
Expression of NPPA (ANP) and NPPB (BNP) in LVH, ISCH, and DCM. 
ANP and brain-type natriuretic peptide (BNP) are biomarkers for HF with left ventricular 
dysfunction (8, 16). We found that the transcripts of NPPA (gene that encodes ANP) were 
increased in LVH by 24-fold in men (LVH_M, 697 FPKM; NF_M, 29 FPKM; p_adj = 0.01825), 
7.4-fold in women (LVH_F, 148 FPKM; NF_F, 20 FPKM; p_adj = 0.0324), 13.3-fold in BMI25 
(LVH_BMI25, 601 FPKM; NF_BMI25, 45 FPKM; p_adj = 7×10−15), and 16.4-fold in the 
BMI30 (LVH_BMI30, 327 FPKM, NF_BMI30, 23 FPKM; p_adj = 1.4×10−14) subgroup, 
respectively (Fig. 6A, top). Its expression was also increased by 19-fold in ISCH (ISCH 234, 876 
FPKM; NF-ISCH, 46 FPKM; p_adj = 0) and 5.4-fold in DCM (DCM 333, 251 FPKM; NF-
DCM, 46 FPKM; p_adj = 4.4×10−7) (Fig. 6A, top) (28). Immunoblotting experiments confirmed 
that ANP protein expression was increased by 90% in LVH compared with NF after being 
normalized to α-actin (LVH: 1.10 ± 0.15, n = 8; NF: 0.58 ± 0.05, n = 5) (Fig. 6A, middle and 
bottom). 
Similarly, we found that the transcripts of NPPB (gene that encodes BNP) were increased 
in LVH by 7.5-fold in male (LVH_M, 121 FPKM; NF_M, 16 FPKM; p_adj = 0.0136), fivefold 
in female (LVH_F, 130 FPKM; NF_F, 28 FPKM; p_adj = 0.0146), and 3.4-fold in BMI30 
(LVH_BMI30, 121 FPKM; NF_BMI30, 36 FPKM; p_adj = 0.04) subgroups, respectively (Fig. 
6B, top). Its expression was also increased by 11-fold in ISCH (ISCH 234, 1,772 FPKM; NF-
ISCH, 159 FPKM; p_adj = 1.79×10−13) and fourfold in DCM (DCM 333, 617 FPKM; NF-
DCM, 159 FPKM; p_adj = 8.96×10−7) (28) (Fig. 6B, top). BNP protein expression was 
increased by 151% in LVH compared with NF control (NF) after being normalized to α-actin 




Expression of HBA1 and HBB in LVH, ISCH, and DCM. 
Figure 7 shows the protein expression of HBA1 (Fig. 7A) and HBB (Fig. 7D). Both were 
increased in female LVH over NF (HBA1: LVH_F = 0.46 ± 0.029, NF_F = 0.26 ± 0.04, n = 3, P 
< 0.05; HBB: LVH_F = 0.36 ± 0.42, NF_F = 0.23 ± 0.02, n = 3, P < 0.05) but were not changed 
in male LVH compared with NF (HBA1: LVH_M = 0.17 ± 0.07, NF_M = 0.17 ± 0.06, n = 6, P 
> 0.05; HBB: LVH_M = 0.98 ± 0.14, NF_M = 0.94 ± 0.13, n = 6, P > 0.05) (Fig. 7, B and E). 
These female LVH-specific increases in protein expression of HBA1 and HBB are consistent 
with the corresponding increase in transcripts in female LVH (~11-fold increase of HBA1, Fig. 
7C; ~44-fold increase of HBB, Fig. 7F). HBA1 transcripts were reported to increase by 3.8-fold 
in ischemic and 6.9-fold in dilated cardiomyopathy, respectively (Fig. 7C) (28); similarly, HBB 
transcripts were reported to increase by sixfold in ISCH and 11.6-fold in DCM, respectively 
(Fig. 7F) (28). 
Expression of GSTT1 and PLA2G2A in LVH, ISCH, and DCM. 
Figure 8 shows the protein expression of GSTT1 and PLA2G2A (Fig. 8A, men; Fig. 8B, 
women). GSTT1 levels were increased by 10-fold in male LVH (LVH_M = 0.70 ± 0.22, NF_M 
= 0.07 ± 0.06, n = 3, P < 0.05) but no significant changes were detected in female LVH (LVH_F 
= 0.94 ± 0.57, NF_F = 0.97 ± 0.61, n = 3, P > 0.05) (Fig. 8C). PLA2G2A levels were increased 
in female LVH by fivefold (LVH_F = 0.25 ± 0.20, NF_F = 0.05 ± 0.01, n = 3, P < 0.05) and in 
male LVH by sevenfold (LVH_M = 0.07 ± 0.02, NF_M = 0.01 ± 0.005, n = 3, P < 0.05) (Fig. 
8D). PLA2G2A levels are noticeably lower in male (Fig. 10A, middle lane) than in female (Fig. 
8B, middle lane) LV. 
Changes in protein expression levels of GSTT1 are consistent with those in transcripts, a 13.7-




increase in transcripts in female LVH (6.4-fold) than in male LVH (1.8-fold) (Fig. 8F). In ISCH 
and DCM, GSTT1 transcripts were reported to increase by 40 and 260%, respectively (28), 
whereas PLA2G2A transcripts were increased by 4.2-fold and 5.6-fold, respectively (28). 
Expression of PDK4 and MYL7 in LVH, ISCH, and DCM. 
Figure 9 shows the protein expression of PDK4 and MYL7 (Fig. 9A, women; Fig. 9B, 
men). PDK4 levels were increased by 2.2-fold in male LVH over NF (LVH_M = 1.335 ± 0.307, 
NF_M = 0.514 ± 0.107, n = 3, P < 0.05) but not significantly altered in female LVH compared 
with NF (LVH_M = 1.282 ± 0.3594, NF_M = 0.5801 ± 0.08030, n = 3, P > 0.05) (Fig. 9C). On 
the other hand, MYL7 levels were decreased by 27% in female LVH over NF (LVH_F = 0.8958 
± 0.1007, NF_F = 1.225 ± 0.04868, n = 3, P < 0.05) but not significantly changed in male LVH 
compared with NF (LVH_M = 1.687 ± 0.2885, NF_M = 1.646 ± 0.2225, n = 3, P > 0.05) (Fig. 
9D). 
PDK4 transcript levels were increased in male LVH by 2.3-fold and in female LVH by 
1.4-fold (Fig. 9E). PDK4 transcripts levels were reported to increase (by 2.2-fold) only in 
ischemic HF (28) (Fig. 9E). 
MYL7 transcript levels were increased in male LVH by 74% and in female LVH by 60% 
(Fig. 9F). MYL7 transcripts levels were reported to increase by 3.2-fold in both ISCH and DCM 
(28) (Fig. 9F). 
Expression of HIST1H2AC in LVH, ISCH, and DCM. 
Figure 10 shows the protein expression of HISTH2AC (Fig. 10A). The expression levels 
were increased by 154% in female LVH over NF (LVH_F = 1.55 ± 0.29, NF_F = 0.61 ± 0.09, n 
= 3, P < 0.05) and by 254% in male LVH over NF (LVH_M = 2.49 ± 0.41, NF_M = 0.98 ± 0.37, 




LVH (~5-fold) and male-LVH (~2-fold) (Fig. 10C). HIST1H2AC transcripts were reported to 
increase by 2.9-fold in ISCH and 5.4-fold in DCM, respectively (Fig. 10C) (28). 
Finally, protein expression and re-examination of gene expression for PLXDC2 showed 
insignificant changes in LVH over NF. Thus, it was removed from DE genes for further data 
analysis. 
GO Enrichment and Pathway Analysis 
We performed GO enrichment analysis for nine DE genes (NPPA, NPPB, HBB, HBA1, 
PDK4, MYL7, HIST1H2AC, GSTT1, PLA2G2A). In “biological process,” the top two most 
significant processes are receptor guanylyl cyclase signaling pathway (q value = 0.0004) 
(involving NPPA, NPPB) and oxygen transport (q value = 0.0005) (involving HBB, HBA1) 
(Supplemental Table 19). In “cellular component,” the top two most significant components are 
endocytic vesicle lumen and hemoglobin complex (q value = 0.0004), both involving HBB and 
HBA1 (Supplemental Table 20). In “molecular function,” HBB and HBA1 are involved in the 
top five most significant functions, including oxygen transporter activity (q value = 0.0003), 
oxygen binding (q value = 0.0008), peroxidase activity (q value = 0.0008), oxidoreductase 
activity (q value = 0.0008), and antioxidant activity (q value = 0.002) (Supplemental Table 21). 
DE Gene Interaction Network Analysis 
To further explore potential interactions among nine DE genes, we performed gene 
interaction network analysis using GeneMANIA (47). Network interaction in terms of predicted 
physical interaction and coexpression was analyzed. Among our nine DE genes, we found three 
clusters: NPPA, NPPB, HBB, HBA1, HIST1H2AC, and MYL7 form the largest cluster; PDK4 
and PLA2G2A are coexpressed together; and GSTT1 is not associated with other eight DE genes 




HBB is coexpressed and associated with HBA1 and HIST1H2AC. NPPB also is associated with 
HBB and HIST1H2AC. 
Discussion 
In the present work, we used transcriptome sequencing to explore the potential effects of 
BMI and sex on gene expression profiles of human hearts with and without LVH. We found both 
BMI and sex can unmask a large set of genes whose expression levels are significantly affected 
by LVH. 
We explored the implications of BMI- and sex-specific LVH DE genes in HF. 
Previously, sex-specific differences in gene expression profiles of HF were investigated using 
cDNA microarray. In new-onset HF, 35 upregulated and 16 downregulated transcripts were 
identified in men vs. women (21). At end-stage DCM, there were 55 and 31 differentially 
regulated genes in female and male, respectively (19). Nineteen DE genes were shared by both 
males and females (19). Most recently, RNA-Seq was used on six patients to identify 983 DE 
genes in ISCH vs. NF [union of three pairs, see Table 1 in (28)], 1,109 DE genes in DCM vs. NF 
[union of six pairs, Table 1 in (28)], and 825 DE genes [union of two pairs, Table 1 in (28)] in 
which 476 genes were overexpressed in ISCH and 349 genes were overexpressed in DCM. Sex 
and obesity status were not specified in the article. We performed correlation studies of our LVH 
data and the published data in both types of HF, ISCH and DCM (28). Our scatterplots display 
numerous downregulated (quadrant II) and upregulated (quadrant III) DE genes in obese LVH, 
women, and male LVH, which are also found in ISCH and DCM. 
We selected nine DE genes that were significantly changed in multiple LVH vs. NF 
analyses within our data set and were shared by LVH, ISCH, and DCM, to provide a gene 




HIST1H2AC); one downregulated gene, GSTT1; and three regulated in opposite directions 
(MYL7 decreased in LVH, increased in cardiomyopathy; PLA2G2A increased in female LVH, 
but decreased in cardiomyopathy; HBA1 increased in female LVH and DCM, but decreased in 
ISCH). For male LVH, the expression levels of three genes (HBB, PLA2G2A, HBA1) were not 
changed by more than one standard deviation. 
Roles of Nine DE Genes in Human Cardiac Hypertrophy and Failure 
Using GeneChip and TaqMan PCR, the first gene expression fingerprint of HF revealed 
103 genes in 10 functional groups between NF and HF samples (40). ANP and BNP were two 
upregulated genes in HF. Using quantitative PCR, we found NPPA transcripts to be increased in 
dilated HF patients of both sexes (7). “Expression profiling-based biomarkers” was proposed in a 
transcriptome analysis of endomyocardial biopsies from 48 HF patients, which used 96 DE genes 
to predict cardiomyopathy etiology accurately (ischemic vs. nonischemic) (24). A clinical study 
in 2008 on 3,580 patients found that women had new-onset acute HF more frequently and less 
DCM compared with men (33). 
In both male and female samples from end-stage DCM, microarrays identified 
upregulated NPPA and downregulated PLA2G2A expression, respectively (19). NPPA and 
NPPB overexpression was also detected, by microarrays, in new-onset HF patients (both male 
and female) with DCM (21). Most recently, RNA-Seq was used to show overexpressed NPPA 
and NPPB as well as decreased expression of PLA2G2A in both DCM and ischemic 
cardiomyopathy (Fig. 7) using a much smaller sample size (one disease vs. one control) (28). 
ANP is mainly produced in the atria, whereas BNP is primarily produced in the 
ventricles, in response to myocardial stress. Both peptides have been reported as valuable 




(MR-proANP) are inactive precursors of BNP and ANP, respectively, with long half-lives. These 
peptides are both current standards of care for patients with acute or chronic HF (31, 49). 
Increased NT-proBNP has also been found to be closely associated with HF patients with 
cachexia (BMI <20) (18). NT-proBNP has recently been confirmed as a reliable risk biomarker 
for fatal cardiovascular events in Type 2 diabetes patients (44). 
Increased transcripts and protein expression of ANP and BNP were readily detected in 
LVH compared with NF in our study (Fig. 6). However, we found much higher NPPA 
expression than NPPB in male LVH (NPPA, 697 FPKM; NPPB, 121 FPKM) but not in female 
LVH (NPPA, 148 FPKM; NPPB, 130 FPKM). NPPA expression was increased more in male 
(24-fold) than in female (7.4-fold) LVH. In addition, the strongest association of LVH with 
increased NPPA expression was found between lean and obese groups, and such an association 
was not found for NPPA. In previously published HF gene expression data (28) we found both 
NPPA and NPPB expression levels are higher in ISCH (NPPA, 876 FPKM; NPPB, 1,772) than 
in DCM (NPPA, 251 FPKM; NPPB, 617). 
In a 2014 report that examined mRNA expression of LV with sudden cardiac death, the 
expression of HBA1 and HBB mRNA was found to be increased, while PDK4 levels were 
downregulated (39). PDK4 is one of the key regulators of metabolism (36). Its expression levels 
in human hearts are decreased during development and tend to be reduced in HF (36). We found 
the gene expression levels for HBA1 and HBB were upregulated only in female LVH, while 
PDK4 levels were increased only in male LVH. 
MYL7, one of the myosin light chains that plays a key role in cardiogenesis (15), is 
increased in human hypertrophic cardiomyopathy (26). We found its gene expression levels were 




The roles of GSTT1, PLA2G2A, and HIST1H2AC in human cardiac hypertrophy or 
failure are unknown. We found that GSTT1 gene expression levels were upregulated in male, but 
not in female, LVH. Gene expression levels for PLA2G2A and HIST1H2AC were upregulated 
in LVH of both sexes with a greater increase in female LVH. 
Limitations of the Study 
Small sample size 
We used a total of 18 samples. For subgroups such as obese female LVH, there were 
three samples for each group. Although it fulfills the minimal requirement for statistical analysis, 
it may lead to underestimates of the amount of significant genes in each subgroup, as well as 
large variations in expression levels. However, small samples sizes have demonstrated impact of 
the identified significant genes, particularly with very small p_adj values, such as PDK4 (p_adj < 
10−6). In a recent study, the gene signatures identified by RNA-Seq from only six HF patients 
were used to accurately classify a large set of 313 patients with microarray data (28). It 
illustrated the use of RNA-Seq as an effective approach to discover novel gene expression 
signature based on an extremely small sample size. 
Sample variations. 
Intrinsic individual differences exist at genetic levels. Clinical diagnoses of LVH were 
based on echo. As shown in patient sample characteristics (Table 1), there are some samples with 
borderline LVH that were deemed as NF in pathological reports. 
Despite these limitations our data provide an argument for using BMI- and sex-specific 
gene expression signatures containing multiple significant genes, rather than a single gene, to 





We identified nine differentially expressed genes in LVH that are BMI- and sex-
sensitive. Validation of these nine genes (forming a “gene expression signature”) in a large 
cardiac hypertrophy population may have the potential to help in the early diagnosis of HF, 
which occurs at a significantly high rate in the obese population. 
Figures 
Figure 1: Sex-specific left ventricle hypertrophy (LVH) differential expression profiles 
(volcano) 
 
Figure 1. A: NF vs. LVH (n = 9 in each group). B: female (F) vs. male (M) samples (n = 9 in 
each group). C: heat map generated from 24 differentially expressed genes comparing females 
with males (B) using unsupervised k-means clustering. D: principal component analysis plot of 
female and male samples from these 24 differentially expressed genes (B). E: differential 
expression profile of female NF (n = 4) vs. female LVH (n = 3). F: differential expression profile 
of male NF vs. male LVH (n = 3 in each group). Red dashed lines mark p_adj = 0.05. Dark dots 




(p_adj > 0.05). Red dots: significant genes (p_adj < 0.05) with abs(log2FC < 1); green dots with 





Figure 2: Body mass index (BMI)- and sex-specific LVH differential expression profiles 
(volcano) 
 
Figure 2. A: lean vs. obese samples (n = 9 in each group). B: obese NF vs. obese LVH (n = 4 in 
each group). C: lean NF vs. lean LVH (n = 3 in each group). D: lean NF vs. obese LVH (n = 3 in 
each group). Red dashed lines mark p_adj = 0.05. Dark dots indicate genes without significant 
changes in expression levels comparing 2 individual groups (p_adj > 0.05). Red dots: significant 
genes (p_adj < 0.05) with abs(log2FC < 1); green dots with labels: significant genes with p_adj < 






Figure 3: Distribution of LVH differentially expressed genes under different conditions 
 
Figure 3. The number of significantly upregulated, downregulated, or non-significant genes 
when analyzed by different groupings (all_BMI = all samples, analyzed as lean versus obese; 
all_sex = all samples, analyzed as male versus female; all_LVH = all samples, analyzed as LVH 
versus non-failed control; LVH-M = male samples, analyzed as LVH versus non-failed control; 
LVH-F = female samples, analyzed as LVH versus non-failed control; BMI25 = samples with 
BMI<25, analyzed as LVH versus non-failed control; BMI30 = samples with BMI>30, analyzed 
as LVH versus non-failed control; BMI25NF vs BMI30LVH = non-failed control samples with 
BMI<25 versus LVH samples with BMI>30; BMI25NF vs BMI30LVH M = non-failed control 




BMI30LVH F = non-failed control samples with BMI<25 versus LVH samples with BMI>30, 
females only). Green indicates upregulation, red indicates downregulation, and blue indicates no 




Figure 4: Shared LVH differentially expressed (DE) genes in both sexes 
 
Figure 4. A: scatterplot of male vs. female LVH DE genes. Quadrant I contains DE genes 
upregulated in male LVH but downregulated in female LVH. Quadrant II contains DE genes 
downregulated in both male and female LVH. Quadrant III contains DE genes upregulated in 
both male and female LVH. Quadrant IV contains DE genes upregulated in female LVH but 
downregulated in male LVH. B: heat map from the 80 DE genes from quadrant I of male vs. 




Figure 5: Gene expression signature in LVH and HF 
 
Figure 5. A: heat map of 10 DE genes in male and female LVH; B: heat map of 10 DE genes in 




Figure 6: Gene and protein expression of NPPA/ANP 
 
Figure 6. (A) and NPPB/BNP (B). Top: transcript expression of NPPA (A) or NPPB (B) in 
female and male LVH, ISCH, and DCM. Middle: ANP (A) or BNP (B) immunoblots in LVH 
and NF, α-actin was used as a loading control. Bottom: ANP (A) or BNP (B) protein expression 
normalized to α-actin in LVH and NF. ANP, NPPA, atrial natriuretic peptide A; BNP, NPPB, 




Figure 7: Gene and protein expression of HBA1 and HBB 
 
Figure 7. A: HBA1 immunoblots in female (top) and male (bottom) samples. α-Actin was used 
as a loading control. B: HBA1 protein expression normalized to α-actin in LVH and NF. C: 
HBA1 transcript changes in LVH over NF. D: HBB immunoblots in female (top) and male 
(bottom) samples. α-Actin was used as a loading control. E: HBB protein expression normalized 
to α-actin in LVH and NF. F: HBB transcript changes in LVH over NF. *Statistically significant 
difference between the 2 groups (P < 0.05). FC, fold change; FPKM, fragments per kilobase of 




Figure 8: Gene and protein expression of GSTT1 and PLA2G2A 
 
Figure 8. GSTT1 and PLA2G2A immunoblots in male (A) and female (B) samples. α-Actin was 
used as a loading control. C: GSTT1 protein expression normalized to α-actin in LVH and NF. 
D: PLA2G2A protein expression normalized to α-actin in LVH and NF. E: GSTT1 transcript 
changes in LVH over NF. F: PLA2G2A transcript changes in LVH over NF. *Statistically 




Figure 9: Gene and protein expression of PDK4 and MYL7 
 
Figure 9. PDK4 and MYL7 immunoblots in female (A) and male (B) samples. α-Actin was used 
as a loading control. C: PDK4 protein expression normalized to α-actin in LVH and NF. D: 
MYL7 protein expression normalized to α-actin in LVH and NF. E: PDK4 transcript changes in 
LVH over NF. F: MYL7 transcript changes in LVH over NF. *Statistically significant difference 




Figure 10: Gene and protein expression of HIST1H2AC 
 
Figure 10. A: immunoblots in male (top) and female (bottom) samples. α-Actin was used as a 
loading control. B: HIST1H2AC protein expression normalized to α-actin in LVH and NF. C: 
HIST1H2AC transcript changes in LVH over NF. *Statistically significant difference between 






Table 1. Patient characterization 
Human 
Sample Sex BMI Age, yr 
LV Mass, 
g Path Report (LVH) 
NF1 M 29.3 57 126 no 
NF2 M 17.2 54 175 borderline 
NF3 M 30.1 41 194 none to mild 
NF4 M 22.5 67 97 no 
NF5 M 34.9 38   none-mild 
NF6 M 21.6 36 97 no 
NF7 F 21.1 66   no 
NF8 F 23 33   no 
NF9 F 29.7 54 104 no 
NF10 F 22.6 43 103 no 
NF11 F 34.3 64   no 
NF12 F 38.1 28 162 no 
LVH1 M 23 53 378 moderate-severe 
LVH2 M 51.1 54 300 moderate 
LVH3 M 33.2 51 248 mild 
LVH4 M 19 53 347 severe 
LVH5 M 39.1 59 276 mild 
LVH6 M 21.1 19 348 severe 
LVH7 F 42.9 25   mild-moderate 
LVH8 F 16.8 38 176 mild 
LVH9 F 22.5 42 176 mild 
LVH10 F 31.5 59 141 moderate 
LVH11 F 33.5 49   severe 
LVH12 F 19.5 50   moderate 
 
BMI, body mass index; M, male; F, female; LVH, left ventricular hypertrophy; NF: non-LVH 





Table 2. Significant differentially expressed genes in LVH [abs(log2FC) > 2, extreme small 
p_adj, also found in HF data set] 
Gene N/25 Y/30 log2FC p_adj Protein 
HBB 5.385036 236.2845 −5.45543 0.000788 hemoglobin subunit beta 
NPPA 28.79361 697.1588 −4.59767 0.018249 natriuretic peptides A 
HBA1 2.670161 28.20004 −3.4007 0.001351 hemoglobin subunit alpha 
NPPB 16.17904 120.645 −2.89857 0.013588 natriuretic peptides B 
PDK4 66.72739 465.2543 −2.80167 4.00E-15 pyruvate dehydrogenase kinase 
isozyme 4 
PLA2G2A 22.78948 142.7502 −2.64705 0.045658 phospholipase A2 
HIST1H2AC 4.108 20.4747 −2.31733 0.003876 histone H2A type 1-C 
GSTT1 2.927 13.489 −2.204 0.011703 glutathione S-transferase theta-1 
PLXDC2 4.073109 16.66727 −2.03282 0.011265 plexin domain- containing protein 
2 
MYL7 493.851 205.222 1.267 <10E-20 myosin light chain 7 
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Supplemental Figure 1: Obese LVH DE genes found in HF patients 
 
Supplementary Figure 1. A) Scatterplot of obese LVH and ischemia cardiomyopathy 
differentially expressed genes. Quadrant (I) contains DE genes upregulated in LVH but 
downregulated in ISCH. Quadrant (II) contains DE genes downregulated in both LVH and 
ISCH. Quadrant (III) contains DE genes upregulated in both LVH and ISCH. Quadrant (IV) 
contains DE genes upregulated in ISCH but downregulated in LVH. B) Scatterplot of obese 
LVH and dilated cardiomyopathy differentially expressed genes. Quadrant (I) contains DE genes 




downregulated in both LVH and DCM. Quadrant (III) contains DE genes upregulated in both 
LVH and DCM. Quadrant (IV) contains DE genes upregulated in DCM but downregulated in 
LVH. C) Scatterplot of obese LVH and ISCH/DCM differentially expressed genes. Quadrant (I) 
contains DE genes upregulated in LVH but downregulated in ISCH/DCM. Quadrant (II) contains 
DE genes downregulated in both LVH and ISCH/DCM. Quadrant (III) contains DE genes 
upregulated in both LVH and ISCH/DCM. Quadrant (IV) contains DE genes upregulated in 





Supplemental Figure 2: Sex-specific LVH DE genes found in HF patients 
 
Supplementary Figure 2. A) Scatterplot of female LVH and ischemia cardiomyopathy 




downregulated in ISCH. Quadrant (II) contains DE genes downregulated in both LVH and 
ISCH. Quadrant (III) contains DE genes upregulated in both LVH and ISCH. Quadrant (IV) 
contains DE genes upregulated in ISCH but downregulated in LVH. B) Scatterplot of female 
LVH and dilated cardiomyopathy differentially expressed genes. Quadrant (I) contains DE genes 
upregulated in LVH but downregulated in DCM. Quadrant (II) contains DE genes 
downregulated in both LVH and DCM. Quadrant (III) contains DE genes upregulated in both 
LVH and DCM. Quadrant (IV) contains DE genes upregulated in DCM but downregulated in 
LVH. C) Scatterplot of female LVH and ISCH/DCM differentially expressed genes. Quadrant (I) 
contains DE genes upregulated in LVH but downregulated in ISCH/DCM. Quadrant (II) contains 
DE genes downregulated in both LVH and ISCH/DCM. Quadrant (III) contains DE genes 
upregulated in both LVH and ISCH/DCM. Quadrant (IV) contains DE genes upregulated in 
ISCH/DCM but downregulated in LVH. D) Scatterplot of male LVH and ischemia 
cardiomyopathy differentially expressed genes. Quadrant (I) contains DE genes upregulated in 
LVH but downregulated in ISCH. Quadrant (II) contains DE genes downregulated in both LVH 
and ISCH. Quadrant (III) contains DE genes upregulated in both LVH and ISCH. Quadrant (IV) 
contains DE genes upregulated in ISCH but downregulated in LVH. E) Scatterplot of male LVH 
and dilated cardiomyopathy differentially expressed genes. Quadrant (I) contains DE genes 
upregulated in LVH but downregulated in DCM. Quadrant (II) contains DE genes 
downregulated in both LVH and DCM. Quadrant (III) contains DE genes upregulated in both 
LVH and DCM. Quadrant (IV) contains DE genes upregulated in DCM but downregulated in 
LVH. F) Scatterplot of male LVH and ISCH/DCM differentially expressed genes. Quadrant (I) 
contains DE genes upregulated in LVH but downregulated in ISCH/DCM. Quadrant (II) contains 




upregulated in both LVH and ISCH/DCM. Quadrant (IV) contains DE genes upregulated in 





Supplemental Figure 3: nine DE genes interaction network analysis by GeneMANIA 
 
 
Supplementary Figure 3. Associations between the nine-gene panel with other genes estimated to 
have interactions were derived via GeneMANIA. Yellow indicates shared protein domains, red 







Supplemental Table 1. DEG from comparing men to women (p_adj < 0.05) 
GeneName p_adj log2FC 
XIST 0 1.331247 
DDX3Y 0 -2.28647 
EIF1AY 0 -4.84517 
RPS4Y1 0 -4.89043 
FAM155B 0 -1.25799 
KDM5D 5.00E-15 -1.59888 
USP9Y 5.00E-15 -1.93858 
TTTY14 1.52E-13 -1.70475 
CCL2 0.000175 1.84234 
ZFY 0.001617 -0.83281 
EIF4EBP1 0.004783 -0.57846 
COQ10A 0.008654 -0.61595 
HPR 0.015133 -2.55647 
HSPB6 0.020229 -0.83095 
HS6ST3 0.02362 -0.98824 
MBNL3 0.029631 -1.27373 
ASIP 0.031702 -1.01184 
EIF1B 0.03191 -0.60913 
SFRP1 0.03445 -1.29097 
SORBS1 0.036844 -0.45915 
S100A9 0.040507 1.311026 
FN1 0.041244 1.560714 
LGALS1 0.042249 0.379527 






Supplemental Table 2. DEG in females 
when comparing NF to LVH (p_adj < 
0.05) 
GeneName p_adj log2FC 
ATP5F1 0 1.372359 
COX5A 0 0.655162 
NDUFAB1 2.00E-15 0.971683 
UQCRC1 4.00E-15 0.78536 
DCAF6 6.99E-15 0.894946 
NDUFS2 7.99E-15 0.903111 
TPM1 1.80E-14 0.852596 
UQCRHL 3.00E-14 0.854599 
ACADVL 1.30E-13 0.891492 
CALM2 4.98E-09 0.48869 
PGK1 1.52E-08 0.640531 
RNF14 1.90E-07 1.344973 
ANXA6 1.92E-07 0.346138 
NFIX 1.93E-07 1.237286 
AES 1.98E-07 0.773747 
MYBPC3 3.07E-07 0.794732 
TNS1 3.08E-07 0.423984 
DBNDD2 3.19E-07 1.116301 
TNNI3 3.21E-07 0.752848 
TFG 2.12E-06 0.797028 
SMIM4 4.14E-06 0.795172 
RAB4A 5.53E-06 1.515827 
MLYCD 6.48E-06 0.893457 
PTPRM 7.06E-06 0.629126 
NDUFV1 7.71E-06 0.442041 
OAZ1 8.39E-06 0.687205 
CAPZB 1.37E-05 0.593617 
CKMT2 1.95E-05 0.826101 
ANKRD9 2.22E-05 0.733555 
CPT1A 2.31E-05 1.291808 
MRPL16 3.43E-05 0.571236 
COQ9 4.03E-05 0.591581 
MRPL33 5.81E-05 0.685197 
PDK2 0.000122 0.837148 
TXLNB 0.000129 0.492954 
EEF1G 0.000136 2.018869 
DYNLL2 0.000138 0.593348 
PTDSS1 0.00014 0.73936 
CYR61 0.000146 -1.8073 
PPP1R12B 0.000174 0.592238 
MZT2A 0.000177 1.152776 
FTH1 0.000189 0.948478 
GATA6 0.000195 0.756302 
TIMM21 0.00028 0.528606 
PDHB 0.000373 0.973631 
ATP6V1D 0.000455 0.531776 
PSMB1 0.000497 -0.80433 
TRAPPC5 0.000584 1.354619 
DENND5A 0.000663 0.90012 
HBB 0.000788 -5.45543 
ABCF3 0.000789 1.080317 
S100A1 0.000813 1.472048 
COX6C 0.000854 0.434718 
ASB8 0.000864 0.483151 
SEPW1 0.000884 0.425352 
C19orf43 0.001003 -0.58583 
CSDE1 0.001139 0.58907 
GNL3 0.001164 -0.81165 
RPLP1 0.001217 0.862792 
HBA1 0.001351 -3.4007 
SDHC 0.001403 0.739299 
SCARB2 0.00142 -0.49507 
MCL1 0.001421 -0.55364 
ADIPOR1 0.001502 1.190279 
HNRNPA2B1 0.001525 1.093875 
NDUFB1 0.001829 0.339606 
ANKRD36B 0.001861 -3.04052 
NNT 0.002013 1.040709 
TTC21A 0.002043 -2.47755 
SLC8A1 0.002115 0.685781 
ATP5A1 0.002269 0.754705 
GPR4 0.002359 -1.58775 
ARL6IP4 0.002399 1.532074 
NEAT1 0.002411 -1.10139 
ETFB 0.002431 1.068367 




TFE3 0.002656 -0.80107 
CCDC39 0.002766 -3.18253 
SMARCA1 0.002783 0.990988 
ETFA 0.003112 0.602531 
GOT2 0.003261 0.596243 
NCOA4 0.003347 -1.25799 
TSFM 0.003479 1.156395 
CAST 0.003565 1.515 
TACC2 0.003703 0.563731 
HIST1H2AC 0.003876 -2.31733 
NDUFS6 0.004104 0.487713 
PTGDS 0.004501 0.646333 
MRPL41 0.004511 0.420448 
ILK 0.004515 1.653967 
FH 0.004539 0.588753 
GIMAP6 0.004831 -0.94894 
PFDN1 0.00486 -1.49717 
LTBP1 0.004871 -1.15454 
C1QTNF1 0.004932 -0.867 
BOD1 0.005182 -0.51195 
ATP5C1 0.005275 0.33629 
NONO 0.005596 1.256768 
AK1 0.005699 0.897919 
TADA3 0.005769 -0.71523 
MPC1 0.00577 0.985969 
TRAP1 0.005888 0.768733 
C15orf59 0.006123 0.693259 
PARVB 0.006333 1.004308 
COX7B 0.006368 1.091807 
UCKL1 0.006433 -0.91676 
MAGEF1 0.006657 -1.50688 
ANXA2 0.006722 -0.7149 
GABARAP 0.006902 2.005869 
UBE2Q1 0.007324 -0.77789 
TIMMDC1 0.007489 0.460374 
MOB4 0.007926 -2.45158 
GPRASP2 0.007945 -1.95928 
ACAA1 0.008231 0.976931 
MDH2 0.008315 1.042324 
FXYD1 0.009307 1.676 
MYL3 0.00939 0.551532 
HNRNPH2 0.009874 -2.03727 
VSTM5 0.010137 -1.45653 
MRPL37 0.010439 0.571961 
GABARAPL1 0.011234 -0.46525 
PLXDC2 0.011265 -2.03282 
SRSF1 0.01148 -0.72824 
TIMM8B 0.012035 -1.1086 
GNB1 0.012427 -0.47342 
TCEAL8 0.012464 -0.48375 
LMNA 0.012465 -0.36963 
LINC00657 0.012465 -0.4487 
ERCC1 0.012481 -0.63265 
S100A8 0.012523 -0.84811 
FAM46A 0.012548 -0.6472 
NEMF 0.012557 -0.70149 
ATP5E 0.01258 -0.94383 
MRPL9 0.012593 -0.62379 
RRAGA 0.012651 -0.42521 
NTMT1 0.012669 -1.15378 
POLR2J 0.012691 -1.02605 
NPTN-IT1 0.012711 -1.49524 
SDF4 0.012714 -0.47181 
MIR4458HG 0.012752 -0.92531 
RDH14 0.012763 -1.08698 
AAMDC 0.012768 0.720372 
MAT2A 0.012773 -3.98597 
CD93 0.012803 -0.59718 
FBLN5 0.012826 -0.55134 
PDIA3P1 0.01289 -0.57568 
SPARCL1 0.012917 -0.59801 
C12orf57 0.013003 -0.54987 
TMEM178B 0.013058 0.987441 
TMEM14B 0.013071 -0.8565 
TRIM35 0.013302 -1.52477 
MB 0.013673 -0.36649 
FAM162A 0.013689 0.502189 
TNPO1 0.013703 -0.65171 
ZNRF2P1 0.013769 -0.88818 
ANAPC11 0.013918 1.566538 
SHC1 0.014001 -0.77541 




TUSC1 0.014086 -0.59556 
MAGED2 0.014172 -0.74103 
COX17 0.014284 -1.71685 
GLRX5 0.014313 0.701564 
SEPN1 0.014316 -0.44066 
DEXI 0.01443 1.425424 
SERTAD3 0.014546 -0.90384 
NPPB 0.014572 -2.21326 
TINAGL1 0.01468 0.714199 
ATP5J 0.014702 0.284947 
AKAP17A 0.014985 -1.03412 
TGFBR3 0.014996 -0.6507 
GMEB1 0.015111 -1.08091 
FOXO3 0.015136 -0.76924 
EHD2 0.015141 -0.48756 
ANAPC2 0.015146 -1.12143 
RNF185 0.01517 -0.83125 
FAM217B 0.015182 -0.79726 
NCBP2-AS2 0.015262 -0.9356 
IPO8 0.015302 -0.77556 
CCNG1 0.015352 -1.33632 
GBGT1 0.015357 -1.08937 
RFPL4AL1 0.015363 -1.82569 
KLHDC3 0.015367 -0.74213 
RAB12 0.015422 -0.67548 
FANCI 0.015449 -1.70713 
AP1S2 0.015457 -0.78901 
PTGES3 0.015534 -0.50628 
CD2BP2 0.015536 -0.58723 
PSMB2 0.01563 -0.88634 
RFTN1 0.015701 -0.77574 
HMGN4 0.015742 -0.54851 
A2M 0.015751 -0.41594 
NES 0.015887 -0.88792 
GNAT1 0.015907 -1.57915 
SPRY1 0.01593 -0.99367 
SOCS5 0.015948 -1.25689 
ERLEC1 0.016148 -0.75281 
PTBP3 0.016169 -0.95234 
SLIRP 0.016174 0.781915 
ZNF22 0.016207 -0.71381 
ACSM1 0.016208 -2.13365 
SMPX 0.016208 -0.5787 
LARP1B 0.016209 -1.10904 
ZSWIM1 0.01621 -1.14273 
PBDC1 0.016215 -0.60672 
SPRY4 0.016248 -1.08951 
NDUFB8 0.016282 -0.7828 
IFT52 0.016284 -0.80741 
NEDD8 0.016298 -0.83441 
IMMP1L 0.016304 -1.26851 
RPS24 0.016319 -0.68556 
SYNPO 0.016324 -0.61107 
UQCC1 0.016391 -1.03014 
PDIA4 0.016406 -0.53875 
STAT1 0.016494 -0.6334 
ARHGAP29 0.016538 -0.89775 
MOGS 0.016616 -0.63599 
MT1A 0.016679 -1.31961 
PPIG 0.016724 -0.638 
TRAM1 0.016725 -0.37237 
LMF2 0.016726 -0.67529 
OLFM1 0.016731 -0.87629 
DHRS4L2 0.01678 -1.16709 
A4GALT 0.016789 -0.51533 
MEF2D 0.016819 -0.5289 
FKBP8 0.016863 -0.58714 
MYLIP 0.016882 -0.77689 
SLC6A6 0.016902 -1.15071 
HTR2B 0.016906 -1.63789 
C14orf166 0.016924 0.698352 
GAS7 0.016998 -0.83087 
HNRNPDL 0.01702 -0.43099 
MCCC2 0.017026 -0.90751 
TXN 0.017065 -0.49235 
PIN4P1 0.017103 -0.79958 
POMP 0.017144 -0.38022 
NCLN 0.017161 -0.6726 
IGF2 0.017209 -1.4621 
TPM3 0.017233 -0.81961 
ANP32B 0.017281 -0.50937 




FAM219A 0.017339 -0.54698 
RNMTL1 0.017371 -0.74583 
TMEM14C 0.017412 -0.60308 
PUM2 0.017423 -0.45941 
ZFP36 0.017465 -0.99179 
SF1 0.017507 -1.01606 
FAM160A2 0.017523 -0.96128 
SERPINB1 0.017524 -0.63034 
DENND2A 0.017611 -1.00146 
PEF1 0.017654 -0.93352 
EIF3I 0.017689 -0.81232 
PLVAP 0.017747 -1.26576 
LAMP2 0.017906 -0.9885 
ZNF146 0.017951 -0.67501 
SYPL1 0.017992 -0.31657 
STK38 0.018017 -0.66665 
EIF2B5 0.018254 -0.5767 
CDC42EP1 0.018263 -0.60669 
RBMS1 0.018418 -0.81146 
MEA1 0.018451 -0.71157 
MAPKAPK5-
AS1 0.018459 -0.94441 
SERINC1 0.018497 -0.664 
PTX3 0.018539 -1.36678 
BCAS2 0.018574 -0.83626 
COL6A2 0.018589 -0.40003 
OSBP 0.018598 -1.05728 
ARHGDIA 0.018617 -0.83641 
USP48 0.018636 -0.94575 
RASSF3 0.018653 -0.75999 
HTRA1 0.018696 -0.60734 
PPIL4 0.018708 -0.9021 
H6PD 0.01873 -0.69978 
FUCA2 0.018749 -1.24515 
AAR2 0.018794 -0.91337 
PIP5K1C 0.018903 -0.63887 
SAMHD1 0.018941 -0.5876 
CNTRL 0.018993 -1.53438 
DDX6 0.019062 -0.66268 
PIP4K2A 0.019064 -0.86742 
SLC45A3 0.019074 -1.48551 
SAP18 0.019095 -0.46939 
RFNG 0.019152 -0.98073 
DCAF7 0.019219 -0.87273 
PARK7 0.019226 -0.60096 
CRKL 0.019327 -1.12111 
CMYA5 0.019486 0.409973 
EDN1 0.01956 -0.97511 
APMAP 0.019589 -0.5634 
PSIP1 0.019633 -0.76878 
ATP1A1 0.01965 -1.06399 
ARL6IP5 0.019765 -0.47494 
GTPBP6 0.019788 -1.53881 
ST13 0.019796 -0.40785 
RN7SL2 0.019873 1.481054 
FAM114A1 0.019887 -0.71223 
CACFD1 0.01989 -0.89916 
METTL7B 0.019927 -1.4323 
NEK7 0.020017 1.095569 
RARA 0.020098 -0.75894 
FAM127B 0.020183 -0.71564 
KLHDC8B 0.020214 -0.67781 
EIF5 0.020246 -0.58398 
TEAD4 0.02039 -0.83812 
RD3L 0.020528 -0.84725 
SLC25A5 0.020744 -0.24487 
DENND6A 0.020744 -0.74386 
CTNND1 0.020838 -0.49509 
LMBRD1 0.020879 -0.75413 
CRTAP 0.021056 -0.60928 
MTURN 0.021131 -1.28667 
CD59 0.021177 -0.57223 
MTPN 0.021198 -2.09273 
APOL1 0.021276 -0.78233 
WDR61 0.021294 -1.02132 
TMEM204 0.021325 -0.6529 
UFM1 0.021325 -0.57161 
ELOVL1 0.021326 -1.17358 
H3F3B 0.02141 -0.61227 
MKNK2 0.021436 -0.56249 
PYURF 0.021461 1.332057 




NDUFB9 0.021655 0.376823 
ABL1 0.021665 -0.5416 
RPS5 0.021779 0.882141 
CSRP3 0.021814 -1.03479 
PPP1R3F 0.021921 -0.75372 
JAG1 0.021947 -0.64807 
CBY1 0.021961 -0.81745 
ALS2 0.0221 -0.83072 
BTG2 0.022147 -0.54751 
FSTL3 0.022169 1.277475 
MGST2 0.022194 0.697938 
SNRPN 0.022304 -1.23539 
SRSF7 0.02232 -1.06689 
SLC35D2 0.022325 -0.74864 
NOP56 0.02236 -0.59664 
CHST7 0.022374 -0.85819 
TIMP3 0.02239 -0.39229 
OSER1 0.022407 -0.54049 
SLC19A2 0.022419 -0.7377 
TLE1 0.022419 -0.82577 
F11R 0.022427 -0.96876 
DRAM2 0.022444 -0.72639 
ASMTL 0.022448 -1.53306 
ABCB7 0.022454 -0.73559 
RBBP4 0.022462 -0.89412 
MAGI1 0.022467 -1.14043 
SLC7A2 0.02247 -0.88932 
UGDH 0.022474 -0.74032 
C10orf71 0.022517 0.497432 
POPDC2 0.022602 0.851896 
TRIM54 0.022801 0.39224 
PHB 0.022854 0.58039 
LDHB 0.023095 0.331912 
TAX1BP3 0.023178 -1.44566 
HAGH 0.023181 0.522402 
BCKDHA 0.023183 1.361748 
DGCR6L 0.023394 -0.86207 
RBM18 0.023495 -0.88136 
GNL2 0.023609 -0.56566 
SAT1 0.023627 -0.40087 
ZNF648 0.023648 -0.99854 
ELK3 0.023721 -0.97643 
HLA-DRB1 0.023762 -2.0529 
RNF11 0.023794 -0.66954 
ILF2 0.023796 -0.58265 
AMOTL1 0.023841 -0.70949 
POM121L10P 0.023984 -3.57981 
HSPA14 0.024087 -0.88951 
CES2 0.024136 0.651625 
WDR89 0.024138 -1.19626 
FAM134B 0.024207 -0.88409 
CPXCR1 0.024216 -1.39867 
ARHGEF15 0.024341 -0.67695 
MFAP3 0.024431 -0.78174 
PELI1 0.024498 -1.17581 
PITPNA 0.024619 -0.55463 
CNIH4 0.02465 -0.61098 
SDHD 0.024683 -0.56053 
CHTF8 0.024691 -0.48262 
FABP3 0.024869 0.596267 
TJP2 0.024913 -0.66178 
C19orf53 0.02494 -0.83764 
HSD17B11 0.02501 -0.69315 
CLIC2 0.025025 -0.88174 
OIP5-AS1 0.025046 -0.37826 
TBCK 0.025073 -0.90682 
TAF10 0.025111 0.9115 
MYO1B 0.025112 -0.60631 
TRPC4AP 0.025144 -0.4905 
MAPRE1 0.025203 1.119034 
CREM 0.025267 -2.14778 
ALDH2 0.025329 0.862575 
CYBRD1 0.025364 -0.90081 
BRK1 0.025368 -0.6395 
RPL9 0.025397 -1.02426 
TOPORS 0.025448 -0.93365 
SCNM1 0.025512 -0.93321 
SH3BP4 0.025523 -0.70647 
EDNRB 0.025631 -0.52333 
ZBED1 0.025655 -1.19893 
HNRNPF 0.025691 -0.95398 




RMDN1 0.025816 0.62209 
CERK 0.025916 -0.34257 
BOP1 0.025938 -0.50992 
UBR4 0.02598 -0.87303 
ANGPTL4 0.026011 -0.9783 
RPN2 0.026012 -0.32802 
CNPY3 0.02602 -1.06098 
TMEM165 0.026022 1.050255 
IL33 0.026093 -0.79908 
NUMB 0.02612 -0.70918 
NUDT15 0.026191 -0.84827 
GTF3A 0.02623 0.395008 
NUP153 0.026253 -0.59072 
TMEM258 0.026373 0.779827 
C1QBP 0.026389 0.445172 
ARID4A 0.026396 -0.623 
BLOC1S1 0.026446 -0.8507 
TNFAIP1 0.026486 -1.42484 
FNBP1 0.026615 -0.5942 
RPS27A 0.026615 -0.50182 
MAF1 0.026624 -0.37243 
PCBP1 0.026636 1.265688 
MYOZ2 0.026657 -0.55598 
AKAP12 0.026665 -0.73199 
YJEFN3 0.026669 -0.97526 
TWF1 0.026748 -0.78106 
AFG3L2 0.02694 0.504829 
SNRPD3 0.026984 -0.90152 
MGC16275 0.027125 -1.16985 
LAMTOR3 0.027132 -0.73631 
ATE1 0.02715 -0.82397 
NFKBIB 0.027203 -0.63057 
TP53RK 0.027302 -0.98484 
LAMTOR2 0.027347 1.016552 
C17orf58 0.027375 -0.97783 
CC2D1A 0.02742 -0.61838 
DCUN1D5 0.027445 -0.74856 
KDR 0.027446 -1.01649 
TCHH 0.027454 -1.91902 
ANKRD10 0.027476 -0.70009 
TRAPPC2 0.027511 -0.90358 
SNTA1 0.027513 -0.50956 
KCNH2 0.027536 0.701117 
CHCHD3 0.027589 -1.8757 
WAC 0.027652 -0.54735 
RAI2 0.027658 -0.5362 
ILF3 0.027679 -0.62026 
UXT 0.02774 -0.443 
VEZF1 0.027757 -0.62697 
MAOA 0.027791 -0.67088 
PRKACA 0.027812 0.296659 
PRPF4B 0.027885 -0.56489 
PALM 0.027912 -0.62806 
ATG9A 0.028019 1.094103 
CNN3 0.028099 -0.67041 
NAT6 0.028176 -1.26624 
SRF 0.028178 0.885317 
SGCA 0.028242 0.496243 
EDF1 0.028375 -0.81059 
PDLIM7 0.028378 -0.57968 
VBP1 0.028457 0.418934 
CCDC3 0.028467 -1.26406 
BCAM 0.028571 -0.62411 
LAMTOR5 0.028573 0.967197 
SEMA3G 0.028594 -0.65991 
IQGAP1 0.028623 -0.86433 
ACTG1 0.028634 -0.80754 
PSPH 0.028652 -0.83482 
GIMAP7 0.028666 -0.55439 
RBM17 0.028738 -0.4027 
ITM2B 0.028784 0.887048 
RBP7 0.028813 -0.8759 
KCTD11 0.028872 -1.32702 
RETN 0.02888 -0.97095 
TIMP1 0.028892 -1.00851 
VAMP7 0.028929 -1.15256 
DIRAS3 0.028944 -1.01864 
MT2A 0.029011 2.208718 
KCTD9 0.029115 -0.65237 
GAS5 0.029155 -0.84549 
CCNI 0.029275 -0.64834 




LRRFIP2 0.029348 0.529637 
TMEM123 0.029487 -0.88018 
SUPT4H1 0.02952 -0.44879 
HNRNPA3 0.029563 -0.54081 
COX6A2 0.029613 0.439694 
ARL4A 0.029713 -0.87392 
GCSHP3 0.029797 1.258673 
COL6A1 0.029819 -0.56227 
NPY6R 0.030041 -0.38687 
EEF1B2 0.03009 -0.36574 
MON1B 0.0301 -0.59648 
IPO7 0.030296 -0.4767 
CTGF 0.030305 -1.18947 
TUBA8 0.030328 1.599595 
CSRNP1 0.030347 -1.44187 
MIR3147 0.030514 -1.29703 
HBQ1 0.03057 -1.68139 
ALG2 0.030579 -1.47132 
SUMO1P3 0.030593 -0.87541 
EFHD2 0.030605 -1.574 
RAB28 0.030613 -0.47433 
UTP11L 0.030623 -0.75675 
C17orf62 0.030703 -0.72837 
DCAF11 0.030771 0.664734 
NDRG2 0.030812 0.411303 
GSTK1 0.030825 0.410994 
BOLA3 0.030894 0.76345 
FUNDC2 0.030896 0.748066 
COPG1 0.030907 -0.35733 
ATP13A1 0.030911 -0.67598 
MRPL4 0.030916 0.673332 
PRELID1 0.030932 -0.60757 
SDCBP 0.031003 -0.79818 
DDX54 0.031005 -0.98504 
MAPK14 0.031107 -0.55155 
NBL1 0.03112 -0.79322 
RBL1 0.031134 -0.87852 
PHAX 0.031149 -0.50805 
RBMS2 0.031211 -0.61912 
EFNB2 0.031279 -0.5343 
MEIS3P1 0.031286 -0.62686 
ANXA9 0.031306 -0.63019 
C12orf45 0.031349 -0.74622 
HSPB2 0.031367 1.211078 
UFL1 0.031372 -0.64279 
UBB 0.03149 -0.31754 
PPP2CA 0.03149 -0.71545 
OSMR 0.031521 -0.68846 
TSR1 0.031523 -0.67585 
SDF2L1 0.031523 -0.49901 
ST3GAL4 0.031551 -0.43762 
5-Sep 0.031609 -1.92603 
ZFP62 0.031615 -0.59505 
ZNF436 0.031663 -0.85345 
AGPAT2 0.031696 -0.86246 
NDUFC1 0.031717 0.831897 
SLC50A1 0.031719 -0.62206 
GPR157 0.031724 -0.82673 
PPP1R15A 0.031771 -0.60994 
NCBP2 0.031874 -0.49276 
CLIC5 0.031906 0.419942 
SRSF4 0.032 -0.63244 
ECSIT 0.032002 0.285857 
PIR 0.032021 -0.62167 
AP3S2 0.032022 -0.97934 
SESTD1 0.032037 -1.46671 
POT1 0.032046 -0.87773 
MYL9 0.032117 0.544829 
ZFAND5 0.032133 -0.76114 
FAM129B 0.032265 -0.71755 
HOMER2 0.032295 0.967059 
PSAP 0.032314 0.423236 
NPPA 0.032393 -2.89607 
UTP14C 0.032418 -0.94049 
ATF4 0.032427 -0.7596 
PGM3 0.032448 -0.79205 
SCN2B 0.032449 -0.81912 
SLC39A1 0.03246 -0.37595 
MIR3164 0.032498 -0.87443 
HIAT1 0.032549 -0.40538 
FAM73B 0.032558 -0.49709 




SOCS4 0.032568 -0.632 
NDUFB5 0.032568 0.694388 
NRAS 0.032582 -0.45616 
PUS7 0.032602 -0.5256 
BMI1 0.032605 -0.66256 
EIF5AL1 0.032612 -0.47659 
PTPDC1 0.032649 -0.62867 
SEC14L1 0.03269 -0.42509 
KLF8 0.032702 -2.63556 
RBKS 0.032737 -0.81206 
6-Sep 0.032737 -0.63976 
CSNK1E 0.032738 -0.40218 
ESPNP 0.032743 -2.91051 
PDLIM3 0.032775 -0.56979 
RBCK1 0.032778 -0.43379 
GADD45B 0.032794 -0.53031 
THOC2 0.032848 -0.54631 
CCDC71L 0.032897 -0.64345 
MPHOSPH8 0.032906 -0.49484 
THAP10 0.032907 -0.73962 
METTL9 0.032916 -0.4444 
ARL5B 0.03292 -0.53217 
CMC4 0.032923 1.087351 
ALPK3 0.032942 -0.44771 
RPL5 0.032976 -0.27665 
GCA 0.033035 -0.53446 
PRRC2B 0.033054 -0.64584 
GDI2 0.033085 -0.41097 
GBAS 0.033094 0.476362 
YWHAH 0.033102 -0.32555 
KIF5B 0.033119 -0.23947 
KLHL11 0.033127 -0.78492 
USP9X 0.033127 0.696856 
MIR6766 0.033181 -1.11136 
MTHFR 0.033204 -0.68037 
GPR173 0.033213 -1.28738 
REXO4 0.033222 -0.51427 
SMIM13 0.033326 -0.85932 
PTTG1IP 0.033331 -0.3002 
UHMK1 0.033356 -0.51687 
VPS29 0.033375 -0.31233 
GCHFR 0.033375 -0.75276 
ENG 0.033416 -0.57515 
AZIN1 0.033503 -0.45722 
HTATIP2 0.033517 -0.54413 
DDI2 0.03353 -0.90494 
CLINT1 0.033752 -0.69543 
BZW2 0.033752 0.659553 
SNORD116-
24 0.033788 -0.91374 
COQ10A 0.033817 0.483454 
PKD1 0.033835 0.806112 
P2RY8 0.033891 -0.76635 
CDC73 0.033939 -0.47904 
LDB1 0.033968 -0.37502 
HIF1A-AS2 0.033996 -1.13095 
RTN3 0.034032 -0.49811 
MSANTD3 0.034098 -0.78896 
EZR 0.034111 -0.37383 
TMEM184B 0.034171 -0.44936 
GABARAPL2 0.034229 -0.26784 
MRPS10 0.034247 -0.5015 
B2M 0.034341 -0.4811 
CTNNAL1 0.034383 -0.66536 
CCL21 0.034425 -1.99891 
RPS3 0.034478 -0.40227 
ARGLU1 0.034482 -0.49591 
CX3CL1 0.034502 -0.86239 
TRIM44 0.034555 -0.36939 
PIAS1 0.034565 0.893026 
FBXO21 0.034565 0.614546 
MRPS15 0.034569 0.417615 
KRBA2 0.034582 0.801596 
IWS1 0.034587 -0.36654 
PREX1 0.034587 -0.99797 
HAX1 0.034595 0.354228 
MRPL28 0.034597 0.448777 
TBCE 0.034601 -0.45664 
WWP1 0.034621 0.461459 
KRTCAP2 0.034655 0.910631 
CD302 0.034665 -0.72754 




SCP2 0.034692 -0.63056 
TBCA 0.034697 -0.48424 
PSMB7 0.034751 -0.55098 
LUC7L 0.03476 -0.66488 
NDUFA5 0.034772 0.423046 
POLDIP2 0.034779 -0.49773 
MIR6723 0.034877 1.031906 
MFGE8 0.034907 0.580005 
MSANTD4 0.034921 -0.88134 
PTPN18 0.034949 -0.67142 
C10orf32 0.034966 -0.73241 
HDLBP 0.034983 0.316667 
MACROD1 0.035013 0.505591 
GNAQ 0.035014 -0.81753 
ALDH9A1 0.035017 -0.30472 
EEF2 0.035026 -0.20504 
SPEN 0.035042 -0.50484 
ZNF516 0.035045 -0.59417 
SLC7A8 0.035062 -0.97264 
IFNGR1 0.035065 -0.64936 
HIST1H4H 0.035099 -1.18434 
TES 0.035128 -0.61007 
VAMP8 0.035165 -0.56384 
BTF3 0.035173 -0.36123 
CKB 0.035218 0.524482 
KLC1 0.035226 1.002591 
ATG4D 0.035229 -0.43271 
SEL1L 0.035252 -0.44253 
HS2ST1 0.035255 -0.88546 
PMP22 0.035297 0.650094 
STOML2 0.035338 0.283353 
RAD21 0.035372 0.391218 
MCTS1 0.035379 -1.18667 
IQCB1 0.035386 -0.57608 
FIGF 0.035388 -1.15941 
PPP1R2P3 0.035424 -0.80427 
PGRMC2 0.035455 -0.42042 
ARPP19 0.035456 -0.37512 
EIF2S2 0.035465 -0.51712 
QSOX1 0.035483 0.570679 
NOP14 0.035532 -0.42275 
HINT2 0.035535 0.617047 
ZNF652 0.035536 -0.6381 
NOLC1 0.03558 -0.51815 
SSBP4 0.035593 -0.55126 
RAP1A 0.035604 -0.42128 
MFN2 0.035641 -0.7874 
TREX1 0.035693 -0.7033 
LY75 0.035726 -1.27058 
STK39 0.035728 -0.61687 
CEBPB 0.035736 -0.4419 
AFAP1 0.035746 -0.60729 
COPG2 0.035784 -1.62398 
VPS4A 0.035788 0.72838 
HSPA5 0.035795 1.758879 
TGFB1 0.035802 -0.4841 
CUTC 0.035822 -0.55877 
SLC25A29 0.035854 -0.61363 
ABCC2 0.035875 -0.87705 
FAM84B 0.035885 -0.91927 
GAS2L1 0.035893 -0.66278 
NFYB 0.035894 -0.4614 
TAF13 0.035928 -0.51109 
CMAHP 0.035959 -0.86088 
UBA52 0.035992 -0.33506 
PTMS 0.035995 -0.42609 
MCAM 0.036015 0.68023 
ARF1 0.036022 -0.33003 
PCBD1 0.03609 -0.40595 
FOSL2 0.036099 -0.74138 
HNRNPD 0.036109 -0.44658 
CDV3 0.036113 -0.49624 
PRELP 0.036116 -0.5701 
SRPX 0.036118 -0.38798 
THBS3 0.036129 -0.82807 
STAT3 0.036138 -0.97262 
PA2G4P4 0.036143 -0.6932 
AGPAT9 0.036148 -0.65693 
DBN1 0.036149 -0.64856 
ADPRM 0.036149 -0.72515 
SENP5 0.036158 -1.4376 




NDUFA7 0.036176 1.782766 
PHKA2 0.036178 0.764127 
RARG 0.0362 -0.61422 
IL6ST 0.036204 -0.34621 
CANX 0.036208 -0.61134 
MRPS36 0.036218 -0.4783 
SNORD59A 0.036337 -0.74182 
PFKP 0.036359 0.496966 
TRIB1 0.036371 0.87391 
TMEM120A 0.036375 -0.19527 
GPATCH1 0.036451 -0.81312 
SMC2 0.03646 -0.61163 
COMMD1 0.036537 0.628965 
LIMS2 0.036658 0.460768 
USF1 0.036674 -0.78181 
TAX1BP1 0.036848 0.279872 
C17orf89 0.036896 -0.36637 
TMA7 0.036909 0.615817 
CCT3 0.036911 -0.20703 
TRIM55 0.036942 -0.56786 
C19orf18 0.037 -0.74323 
LRPAP1 0.037026 -0.34356 
FAM219B 0.037046 0.717804 
CD151 0.037071 0.472685 
SPTLC2 0.037092 -0.48621 
APOD 0.037102 -0.89267 
ADAM19 0.037114 -0.63014 
FAM21A 0.037179 -0.91629 
PIGU 0.037222 -0.48946 
IL3RA 0.037239 -1.12638 
GNG5 0.037263 -0.2129 
TRUB2 0.037263 0.703895 
CFL1 0.037271 0.512821 
DDX19A 0.037332 -0.66125 
FAM133DP 0.037353 -0.73167 
MTX2 0.03736 -0.42275 
GLIPR2 0.037362 -0.67926 
SCAND1 0.037369 -0.34499 
IDH3A 0.037432 0.65059 
SBK2 0.037448 -0.71113 
PEX6 0.037461 -0.49797 
RNU6-7 0.037551 -1.09696 
RSBN1L 0.03758 -0.60546 
IL1R1 0.037637 -0.51121 
OTUD1 0.037677 -1.47141 
NAA10 0.03768 1.111668 
PDLIM5 0.037684 -0.75044 
C8orf4 0.03769 -0.88364 
XRCC6 0.037731 -0.38855 
MAP7D1 0.037767 0.542422 
CEACAM3 0.037795 -0.83183 
RGL1 0.037807 -1.12518 
GLB1 0.037873 -0.55021 
RWDD1 0.037879 0.742311 
OAT 0.037903 -0.55549 
IGSF8 0.037906 -0.43315 
UBE2G2 0.037969 0.673819 
C7orf55-
LUC7L2 0.037975 -0.94018 
NGRN 0.038009 0.494214 
RNF145 0.038072 -0.50542 
NDUFA12 0.038093 0.614495 
NME4 0.038097 -0.48284 
SUN1 0.038098 -0.45082 
MMGT1 0.038143 -0.55294 
MAP4 0.038209 -0.67629 
RHOU 0.03821 -0.64759 
HAND2 0.038228 0.564561 
CUL4A 0.038228 0.372001 
KLHL41 0.038234 -0.70921 
PCF11 0.038267 -0.5163 
ECI2 0.038296 0.474806 
ZMAT3 0.038366 -0.65019 
AIMP1 0.038396 -0.40934 
SRPK2 0.038399 -0.56518 
UBXN4 0.038413 -0.4632 
TRA2A 0.038457 -0.55665 
ENAH 0.038479 -0.95222 
GAPDH 0.03848 0.825841 
SORT1 0.038485 -0.68327 
SPTSSA 0.038521 -0.72997 




UQCRB 0.038548 0.451971 
RPL38 0.038549 -0.33469 
VGLL2 0.038578 -1.19911 
CHURC1 0.038615 -0.7249 
C22orf46 0.038672 -0.80934 
TACC1 0.038676 -0.37055 
P2RY2 0.038731 -0.64591 
EGFL7 0.038757 -0.82415 
PEBP1 0.038836 -0.40075 
HMGN3 0.038909 -0.59267 
NFIA 0.038917 -0.44679 
GRIN2D 0.038948 -0.83435 
UBIAD1 0.038962 -0.89191 
SPCS1 0.038992 0.574248 
SELE 0.039042 -0.7997 
PLCB4 0.039118 -0.76018 
TNFSF12 0.039249 -0.67128 
GOLGA3 0.039346 -0.58309 
RTN4 0.039426 -1.07648 
ARFGAP3 0.039465 -0.59693 
GSTP1 0.039562 -0.27793 
TAF7 0.039646 -0.23116 
HIF1A 0.039666 -0.79076 
ZMIZ1 0.039673 -0.69877 
GFM1 0.039675 0.593327 
LINC00961 0.039683 -0.63191 
TMEM100 0.039693 -0.62459 
EMILIN1 0.039703 -0.57114 
CDC42 0.039715 -0.44212 
CNRIP1 0.039717 -0.8034 
CXCL1 0.039718 -1.11979 
RFC1 0.039781 -0.48255 
MFAP4 0.039794 -0.52445 
FAM168A 0.039818 -0.41783 
ARL2BP 0.039899 1.290096 
NAALADL2-
AS3 0.039902 -0.92872 
BEST4 0.039922 -1.08126 
TBCC 0.039962 -0.44151 
ETS2 0.039999 -0.55495 
LRBA 0.040005 0.83503 
GPRASP1 0.040016 -0.74586 
STK25 0.040145 -0.47793 
VSTM2L 0.04021 -0.86326 
EIF3K 0.040228 0.330053 
LLPH 0.040231 -0.65674 
KIDINS220 0.040251 -0.33558 
SPOP 0.040271 -0.39701 
MED18 0.040278 -0.57297 
ART4 0.04032 -0.71393 
GNA13 0.040322 -0.90702 
POU3F4 0.040361 -0.92947 
PSMB4 0.040406 -0.2754 
YIPF5 0.040414 -0.54419 
C19orf47 0.040417 0.457919 
WIPI1 0.040437 0.488378 
AP1M1 0.040449 0.584028 
SPRYD3 0.040467 -0.29592 
SCO1 0.040469 0.476124 
HIBCH 0.040508 0.61161 
LAMC2 0.040528 -0.75161 
ADNP 0.040531 -0.51295 
C11orf68 0.040532 -0.37281 
BTN2A3P 0.040561 -0.8744 
RAVER2 0.040586 0.4035 
PPP1R16A 0.040596 0.710287 
DYNC1LI1 0.040613 0.455161 
PSMC1 0.040634 0.78906 
TP53BP2 0.040641 -0.57646 
UBTD2 0.040645 -0.42758 
FAM214B 0.04066 -0.55939 
KLHL31 0.040682 -0.96742 
ATP5J2 0.040698 1.053234 
RNF144B 0.040792 -0.53885 
LPL 0.040803 -0.43864 
PRMT2 0.040809 -0.45257 
CHCHD4 0.04081 0.979294 
RPL18A 0.040965 0.921168 
CLNS1A 0.040977 0.537933 
HHATL 0.041005 0.690944 
MLLT1 0.041049 -0.49458 




TMEM205 0.041111 0.656153 
H2AFY 0.041137 0.600628 
SKI 0.041146 0.527366 
GRTP1 0.041158 -0.73563 
PRPF6 0.041213 -0.3822 
LYSMD1 0.041222 -0.51025 
GNAS 0.041232 0.18082 
ABCC4 0.041241 -0.73659 
NHP2L1 0.041246 0.325181 
USF2 0.041262 0.461716 
SMARCA5 0.041267 -0.54153 
AKAP8 0.041305 0.719672 
ITGA6 0.041332 -0.38656 
CHMP2B 0.041367 -0.4139 
PSMB6 0.041415 0.38315 
RNF146 0.041492 -0.37161 
SZRD1 0.041493 -0.30777 
TMEM59 0.041521 0.442592 
LZTS1 0.041571 -0.84388 
CLCC1 0.041678 -0.7063 
HADHB 0.04173 0.454091 
C1GALT1C1 0.041735 -0.50868 
FAM3C 0.041765 0.732974 
ANO5 0.04182 0.49683 
CCL2 0.041833 0.861443 
TRAM2 0.041837 -0.55606 
FXYD6 0.041837 -0.61561 
HSPA9 0.041839 0.33245 
ATXN10 0.041858 -0.31479 
CTNNA1 0.041888 0.216737 
SPRYD4 0.04193 0.677688 
PKM 0.041946 0.538092 
LTV1 0.041958 -0.48423 
SDHA 0.041978 0.649552 
DCTN3 0.041992 0.483169 
CMTM8 0.042006 -0.53464 
KDM5C 0.042023 -0.45856 
PLS3 0.042088 -0.59148 
TCAP 0.042106 -0.13006 
FXYD5 0.04211 -0.74162 
PTPN11 0.042125 -0.40738 
STX12 0.042183 -1.23808 
ZNF777 0.042188 -0.65165 
TEK 0.042213 -0.66509 
HSPB6 0.04228 0.654175 
KPNA6 0.042351 0.521901 
ESF1 0.042366 -0.4259 
EID1 0.042432 -0.4688 
DENND5B-
AS1 0.042446 -0.84422 
CYB5R1 0.042453 0.622642 
WASF2 0.042467 -0.61661 
RAMP3 0.04247 -0.60506 
ACTA1 0.042476 -1.1199 
DDX42 0.042477 -0.42944 
MYO18B 0.042532 -0.40501 
ZCCHC24 0.04263 -0.4355 
HSPA6 0.042634 -1.46953 
GPR137B 0.042676 -0.41419 
LPCAT3 0.042718 0.759429 
PXYLP1 0.042773 -0.70605 
MBTPS1 0.042804 0.439015 
ABHD14B 0.042806 -0.79084 
LAMB1 0.042876 -0.23987 
PROS1 0.042894 -0.925 
RNF10 0.042923 0.322112 
PPIA 0.042948 -0.39158 
ULK1 0.042966 0.844633 
WDR5 0.043029 -0.35205 
SGTA 0.043111 0.405405 
NR1D2 0.043119 -0.36619 
PSMB5 0.043129 0.264588 
DNAJC11 0.043135 0.437261 
SERPINH1 0.043145 -0.564 
RPA1 0.043152 -0.34369 
SPTAN1 0.043153 -0.35344 
ZBTB21 0.043154 -0.573 
S100P 0.043155 -0.62072 
ANKRD11 0.043157 -0.4622 
MIR621 0.043158 -0.65688 
RPL28 0.04316 -0.35673 




CCNL2 0.043166 -0.60767 
BACE2 0.043168 -0.47492 
ST3GAL6 0.043173 -0.37651 
NDUFAF1 0.043183 -0.445 
LRRC2 0.043188 -0.51305 
ATP5SL 0.04319 0.429372 
TXNRD1 0.043213 -0.39736 
PAFAH2 0.04322 -0.49065 
HSPA8 0.043225 -0.35936 
ISCA1 0.043227 -0.37738 
CRIP2 0.043242 0.308317 
SPOPL 0.043249 -0.48301 
RHPN2 0.043263 -0.6109 
IRS1 0.043275 -0.49894 
CERS6 0.043281 0.829045 
SLC35B3 0.0433 -0.43175 
PRICKLE3 0.043329 -0.45225 
TRIM65 0.043333 -0.51273 
WAC-AS1 0.04334 -0.4838 
B4GALT1 0.043353 -0.63432 
FKBP5 0.043381 -0.51771 
SLC35A2 0.043402 -0.41879 
RIMS1 0.043419 -0.72291 
ARV1 0.043446 -0.4904 
SNORD63 0.043456 -0.60599 
PANX1 0.043457 -0.64611 
MYH7 0.043476 0.725402 
ADPRH 0.043478 -0.73527 
HCFC1 0.043483 -0.44703 
GTPBP1 0.043497 -0.39791 
UBE2A 0.043511 0.435335 
UQCR11 0.043526 0.768241 
TMEM70 0.043542 -0.43259 
CYC1 0.04356 -0.51256 
RHBDD1 0.043564 -0.53431 
POLE3 0.043578 -0.30923 
XPC 0.043598 -0.47842 
LINC00998 0.043603 0.544187 
ELK1 0.043625 -0.39441 
FOS 0.043634 -1.05858 
NCKIPSD 0.043648 -0.40907 
ZNHIT2 0.043652 -0.96854 
CASP3 0.043676 -0.66391 
DENND4C 0.043721 -0.4932 
RBMXL1 0.043723 -0.45167 
RPS14 0.043761 0.724838 
CALHM2 0.04377 -0.4685 
FAM210B 0.043793 -0.36254 
ATP8B2 0.043809 -0.42195 
CTNNBL1 0.043831 -0.42786 
TGFB3 0.043859 -0.45892 
ROCK2 0.04386 -0.38353 
SMIM3 0.043864 -0.3364 
FAM8A1 0.043881 -0.428 
SCO2 0.043892 -0.83004 
DAAM2 0.043894 -0.50534 
FAM78B 0.043911 -0.62746 
DNMBP 0.043928 -0.53882 
MYO10 0.04393 -0.53448 
HDAC1 0.043974 -0.57812 
UPP1 0.043985 -0.56422 
LSM3 0.043996 0.678043 
EPHA4 0.044019 -0.5129 
BCAR3 0.044029 -0.79978 
TRIP11 0.044051 -0.38457 
KLF7 0.044053 -0.39001 
MED6 0.044066 -0.68885 
CLUH 0.044091 0.533426 
DUSP27 0.044104 -0.54408 
TSC1 0.044115 -0.53249 
CDKN1A 0.044115 -0.42907 
DGKE 0.044135 -0.55624 
DYNLT3 0.044156 -0.34186 
NFIB 0.044163 -0.29183 
STX5 0.044175 -0.40774 
PSMD11 0.044179 0.974021 
CS 0.044195 0.634064 
CYP20A1 0.044198 -0.60404 
PPP1R17 0.044203 -1.20029 
FAM98B 0.044205 -0.46231 
C1orf43 0.044205 -0.23152 




INTS10 0.044233 -0.43167 
CRIPT 0.04425 -0.52125 
SYT9 0.044262 -0.71172 
SPSB1 0.044285 -0.41671 
ODC1 0.044311 -0.25745 
SAYSD1 0.044315 -0.49224 
TECR 0.044317 0.682883 
CNBP 0.044329 -0.36659 
CD68 0.044368 0.939055 
GAR1 0.044412 -0.42803 
PPP1CC 0.044417 0.660556 
DANCR 0.044424 0.485809 
HSD3B7 0.044425 -0.59878 
DDR2 0.044432 -0.52046 
MYLK3 0.044447 -0.4339 
CREB1 0.04448 -0.4684 
PPP6R2 0.044507 -0.32101 
NSMF 0.044562 -0.43373 
TRMT61A 0.044654 -0.44573 
GATAD2A 0.044678 -0.36954 
TMEM167A 0.044683 -0.51829 
FBXL7 0.044687 -0.37815 
ARRDC1 0.044708 -0.44123 
RHAG 0.044719 -0.83399 
S100A9 0.044725 -0.93497 
SFTPB 0.044732 -0.92639 
THBS2 0.044745 -0.66519 
BLOC1S2 0.044748 -0.37961 
IKZF5 0.044775 -0.51802 
NUPL1 0.044795 -0.41339 
ZBTB44 0.044803 -0.42604 
MTIF3 0.044814 -0.29802 
CALM3 0.044816 -0.26617 
CFDP1 0.04486 -0.3963 
VPS28 0.044971 0.682919 
NOP10 0.044991 -0.32865 
DMWD 0.044996 -0.36496 
HYPK 0.045092 0.872538 
NR2F2 0.045107 -0.51244 
MSMP 0.045127 0.807117 
GPD2 0.045132 -0.62732 
KLHL38 0.045138 0.335281 
ZNF324B 0.045164 -0.84753 
NDUFS3 0.045181 0.280477 
RAI14 0.045196 -0.5097 
GPKOW 0.045223 -0.35042 
TRIM38 0.045223 -0.5031 
SBDS 0.045268 -0.21392 
EMCN 0.045297 -0.39739 
FTL 0.045301 -0.67871 
AKT1S1 0.045308 -0.3399 
EFEMP1 0.04534 -0.72991 
TM9SF3 0.045344 -0.294 
RPS12 0.04535 -0.36671 
MINPP1 0.045369 -0.5057 
SGK223 0.04538 -0.59039 
BTBD10 0.045469 -1.28796 
THAP9-AS1 0.045504 -0.54543 
LPAR1 0.045525 -0.46803 
MAPK8IP3 0.045532 -0.58917 
XPO7 0.045555 -0.35552 
ARHGAP30 0.045572 -0.69869 
GPATCH11 0.045615 -0.4265 
LSM1 0.045632 0.470032 
CXorf36 0.04564 -0.52947 
PLA2G2A 0.045658 -2.64705 
DYRK2 0.045658 -0.48669 
CMAS 0.04569 -0.32507 
ATXN3 0.04571 -2.43236 
AAK1 0.045716 -1.78202 
TUBA1B 0.045721 0.712811 
FAF1 0.045739 0.416979 
TCEAL7 0.045743 -0.55323 
ENO2 0.045746 -0.61311 
NUDT16P1 0.045758 -0.5736 
CTTNBP2NL 0.045785 -0.53209 
ZFYVE27 0.045792 -0.45599 
PRKCDBP 0.045832 -0.26048 
DGAT1 0.045874 -0.40077 
LRRN4CL 0.045889 -0.74009 
AC007392.3 0.045933 -0.82613 




ATN1 0.046005 -0.36858 
DNAJB1 0.046029 -0.62176 
CD81 0.046032 0.616659 
PRDX2 0.046318 0.610194 
RPL14 0.046364 0.820702 
MIR568 0.046373 -0.46123 
SIK3 0.046385 -0.53583 
PBX4 0.046398 -0.8201 
CHMP7 0.04643 -0.32032 
PRKAA2 0.046432 -0.42629 
NEDD9 0.046449 -0.52443 
COPE 0.046456 0.427074 
DLGAP4 0.046479 -0.46245 
SLC11A2 0.046479 -0.71511 
PSMD8 0.046502 -0.32555 
DAPK2 0.046529 0.741447 
SEC24A 0.046569 -0.50265 
MYCT1 0.046578 -0.54874 
ZNF793 0.046632 -0.78982 
DNAJA2 0.046654 -0.309 
E2F6 0.0467 -0.50392 
RAB2A 0.046706 -0.35634 
APP 0.046741 -0.19958 
SLC25A37 0.046742 -0.54723 
INPP5J 0.046762 -0.45787 
MRPL51 0.046781 0.399561 
MAML1 0.046807 -0.46279 
LRRC14B 0.046813 0.601274 
FBXO7 0.04684 -0.33304 
RAB39B 0.046864 -0.6923 
SNAPC2 0.046896 -0.41126 
ATP5H 0.046897 1.01046 
7-Mar 0.046901 -0.49283 
MAP2K7 0.046903 -0.36906 
PLAA 0.046927 -0.52849 
CALCOCO1 0.047034 0.655995 
ATP2B4 0.047037 -0.47315 
YAE1D1 0.047064 -0.52899 
SRL 0.047072 -0.49114 
SLC29A3 0.047088 -0.56336 
PPP1R15B 0.047125 -0.66899 
RPL41 0.047202 -0.46263 
CMC2 0.04727 0.928306 
KANK2 0.047282 0.397004 
KIAA0368 0.047288 -0.21364 
NDUFA13 0.047299 0.553808 
DHRS3 0.047324 -0.49842 
COMMD10 0.047459 -0.75317 
ATP6AP2 0.047549 -0.2996 
MRPS6 0.047567 0.605533 
TP53 0.04764 -0.47344 
INPP5A 0.047664 0.353673 
HIVEP1 0.047682 -0.57953 
GRHPR 0.047712 0.471827 
YDJC 0.047741 -0.4309 
LRRC47 0.047796 -0.28552 
SPANXC 0.047797 -0.76043 
DOCK1 0.047808 -0.46818 
NEXN 0.04781 -0.31415 
MLIP 0.047821 0.32587 
PCYT1A 0.047841 0.625988 
KTN1-AS1 0.047945 -0.62535 
C1orf52 0.04795 -0.45743 
PCNXL2 0.047952 -0.98865 
CIAPIN1 0.047955 -0.35584 
SFXN1 0.047968 -0.43105 
THBS1 0.048008 -0.37739 
LTBP4 0.048019 -0.40618 
FAM195A 0.048103 0.683693 
CTNNB1 0.048125 -0.36302 
FLAD1 0.048152 -0.44251 
ATP6V0C 0.048154 0.795255 
UQCRC2 0.048197 0.327542 
MAFG 0.048208 -0.65158 
TPI1 0.048222 0.369575 
ZNF768 0.048268 -0.4432 
FAM222B 0.048367 -0.55818 
CRIM1 0.048377 -0.4341 
WDR26 0.048381 0.434243 
TIMM50 0.048402 0.469425 
NMRK2 0.048413 0.585886 




CWF19L2 0.048419 -0.60657 
GOLGA1 0.048422 0.732444 
MORF4L2 0.048428 -0.51525 
JAK1 0.048446 0.507475 
RPRD1B 0.048459 -0.50933 
MAGOH 0.048468 -0.30745 
SNORA33 0.048468 -1.16312 
NAAA 0.048474 -0.45585 
CD1D 0.04848 -0.663 
SOAT1 0.048506 -0.50051 
SPG7 0.048523 0.461449 
THBS4 0.048544 1.196572 
MTHFD1 0.048549 0.512123 
JAZF1 0.048565 -0.63113 
NUCKS1 0.048583 -0.33916 
ZSCAN26 0.04859 -0.48147 
CLPTM1 0.048591 0.37098 
MIR3936 0.048604 -0.71114 
DFFA 0.048607 -0.45858 
TRIM24 0.048612 0.630467 
PECAM1 0.048628 -0.53376 
HSBP1 0.048629 0.504809 
SSH1 0.048667 -0.62376 
CLEC10A 0.048724 -0.78745 
GOLGA5 0.048731 -0.45546 
TXNDC15 0.048733 -0.45751 
GRAMD4 0.048737 -0.54644 
CHTOP 0.048751 -0.42894 
ASB1 0.048754 -0.4207 
C4orf27 0.048773 -0.39327 
CDH2 0.048778 -0.28261 
PARS2 0.048787 -0.68577 
TMEM181 0.048791 -0.58895 
SUSD1 0.048805 -0.66238 
RPE 0.048814 -0.62216 
CAMK2D 0.048827 -0.51715 
ZNF136 0.048863 -0.7799 
MRTO4 0.048896 -0.51359 
APLP2 0.048905 -0.31988 
XIRP1 0.048919 -0.78224 
MBD3 0.048919 0.640065 
UBE2D3 0.048927 0.403792 
HDHD2 0.048934 0.560806 
ERRFI1 0.048981 -0.49895 
POLR2M 0.049007 -0.52703 
TLR4 0.049015 -0.51025 
MTUS2 0.049071 0.370084 
LARS 0.049073 -0.50774 
TMSB4X 0.049079 -0.51899 
CBLB 0.049091 -0.50192 
POLI 0.049111 -0.65863 
METRN 0.049113 0.568665 
JUND 0.049129 -0.30596 
TNFRSF10B 0.049134 -0.50488 
PORCN 0.049136 -0.64084 
PWAR1 0.049174 -1.02416 
EGR1 0.049178 -0.77867 
TTL 0.049195 0.703811 
ASUN 0.049196 -0.39201 
EIF4A3 0.04925 -0.43556 
PITPNM1 0.049337 -0.57986 
AVIL 0.049382 -0.61709 
MPP1 0.049409 0.568199 
NUDT4 0.049429 -0.57452 
ATL3 0.04943 -0.54625 
PNMAL1 0.049439 -0.63464 
ZDHHC3 0.049442 -0.46304 
FGD4 0.049444 -0.70371 
FBXO40 0.049521 0.559935 
NCS1 0.049573 -0.61313 
DYNLL1 0.04959 -0.74122 
RPS15A 0.049643 1.025891 
RPL37A 0.049679 0.515517 
GJA1 0.049747 -0.35022 
GAS2 0.04977 -0.53259 
SYNM 0.04979 0.325806 
FASTKD1 0.049842 0.519079 
ENPEP 0.049861 -0.57397 
ZFAT 0.049905 -0.53663 
CETN2 0.049919 -0.28869 
PDE4D 0.04992 -0.51969 





PGRMC1 0.049922 -0.3399 
RECK 0.049922 -0.42461 
ANKIB1 0.049923 -0.38159 
RAB6A 0.049923 -0.1895 
ANGPTL1 0.049924 -0.41541 
MGLL 0.049925 -0.37542 
SLC25A16 0.049926 -0.49931 
ZNF438 0.049926 -0.41161 
ANKRD13C 0.049934 -0.42953 
SLC31A1 0.049937 -0.47657 
ENOSF1 0.049938 -0.51981 
RBM12 0.049945 -0.38949 
ZNF302 0.049949 -0.33246 
DNAJC3 0.049951 -0.37766 
LIMA1 0.049959 -0.57653 
C14orf2 0.049972 0.367813 
SLC25A38 0.049973 -0.42679 
ZNF841 0.049978 -0.4047 






Supplemental Table 3. DEG in males 
when comparing NF to LVH (p_adj < 
0.05) 
GeneName p_adj log2FC 
AZGP1 0 -1.30798 
IGFBP2 0 -0.86226 
ACKR3 0 0.671192 
HSPG2 0 0.733618 
PPP1R12C 0 -0.42178 
DYNLRB1 0 -0.37811 
IDH3A 0 0.511248 
FKBP8 0 -0.42929 
RAB11B 0 -0.48372 
PSMA7 0 -0.33594 
SLC5A1 0 0.724038 
SOD1 0 -0.33697 
GPNMB 0 0.834657 
TTN 0 0.614038 
NEXN 0 -0.52548 
SRM 0 -0.35759 
RHOC 0 -0.27958 
C19orf53 0 -0.31797 
PNRC1 0 -0.56502 
HSD17B10 0 -0.27013 
RAMP1 0 -0.59369 
IDH2 0 0.289888 
SPG21 2.00E-15 -0.50108 
ARL2 2.00E-15 -0.47455 
FAM50A 2.00E-15 -0.42732 
UBL7 2.00E-15 -0.28434 
UBXN6 2.00E-15 -0.45076 
PCBD1 2.00E-15 -0.44015 
LDHD 2.00E-15 -0.26791 
PPAPDC3 2.00E-15 -0.22663 
JUP 2.00E-15 -0.35173 
IGSF8 3.00E-15 -0.49134 
PLVAP 3.00E-15 -1.29896 
CDIPT 3.00E-15 -0.29615 
C10orf10 3.00E-15 -0.77617 
UBL5 3.00E-15 -0.28347 
PPP2R1A 3.00E-15 -0.27626 
PACSIN3 3.00E-15 -0.34172 
GPX4 3.00E-15 -0.22506 
DUSP27 3.00E-15 -0.41684 
TRIM63 3.00E-15 -0.64008 
YPEL3 4.00E-15 -0.7847 
HRSP12 4.00E-15 -0.4346 
COPRS 4.00E-15 -0.35458 
MPHOSPH8 4.00E-15 -0.40987 
DAPK3 4.00E-15 -0.57591 
LRPAP1 4.00E-15 -0.39917 
CD151 4.00E-15 -0.51077 
PEBP1 4.00E-15 -0.34523 
LMOD2 4.00E-15 -0.63874 
CLPP 5.00E-15 -0.34131 
RBM42 5.00E-15 -0.35417 
NUDC 5.00E-15 -0.52612 
SF3B5 5.00E-15 -0.40871 
ATP6V0E1 5.00E-15 -0.36647 
RRAS 5.00E-15 -0.40779 
PLEKHO1 6.00E-15 -0.59572 
DYNLT1 6.00E-15 -0.44132 
TRNP1 6.00E-15 -0.49843 
EDF1 6.00E-15 -0.31412 
RBPMS2 6.00E-15 -0.28934 
DRG1 6.99E-15 -0.32335 
ALDOC 6.99E-15 -0.45447 
GIPC1 7.99E-15 -0.3734 
FDFT1 7.99E-15 -0.52811 
DIAPH1 7.99E-15 -0.39074 
PPP1R7 7.99E-15 -0.33032 
SGCA 7.99E-15 -0.45226 
RBM3 7.99E-15 0.274338 
GABARAPL1 7.99E-15 -0.31891 
TCAP 7.99E-15 -0.29492 
OS9 8.99E-15 -0.33479 
PLA2G16 8.99E-15 -0.42933 
ACTR1A 8.99E-15 -0.28631 
TBC1D8 9.99E-15 -0.5583 




DNASE2 1.10E-14 -0.45549 
TMEM140 1.20E-14 -0.89372 
TSPO 1.20E-14 -0.44565 
NDUFAF3 1.30E-14 -0.24658 
SDF4 1.30E-14 -0.3565 
TRIM54 1.30E-14 -0.40356 
PSMD4 1.40E-14 -0.36071 
SORT1 1.40E-14 -0.41997 
FBXW5 1.60E-14 -0.39062 
SYNGR2 1.80E-14 -0.48952 
PNPLA2 1.80E-14 -0.4725 
HSPB8 2.00E-14 -0.30308 
NUCB1 2.10E-14 -0.31163 
EIF5A 2.40E-14 -0.38269 
CTSD 2.60E-14 -0.47497 
TRIP10 2.80E-14 -0.59969 
EPN1 2.90E-14 -0.36742 
BRK1 2.90E-14 -0.28194 
PDHX 3.10E-14 0.25964 
AC018464.3 3.20E-14 -0.27882 
CCDC85B 3.60E-14 -0.62642 
SNTA1 3.70E-14 -0.25705 
KCNN2 3.90E-14 0.669077 
CCDC124 4.10E-14 -0.48253 
CDK2AP2 7.21E-14 -0.69732 
BSG 1.07E-13 -0.40526 
HIST2H2BE 1.11E-13 -0.52488 
HSPB7 4.91E-13 -0.3482 
WDR62 2.15E-12 1.07249 
TALDO1 4.47E-12 -0.32684 
RAB40B 1.33E-11 -0.49743 
RPL35 1.57E-11 -0.26922 
EMD 3.27E-11 -0.3251 
BLVRA 2.66E-09 -0.31132 
MT2A 7.38E-09 -1.04872 
PEBP4 8.73E-09 -0.44419 
S1PR3 1.29E-08 0.779523 
PTPRB 1.29E-08 0.897076 
TANGO2 1.46E-08 -0.40924 
NCOA4 2.30E-08 0.20876 
SCARA5 1.67E-07 0.976601 
MYL4 1.01E-06 1.123475 
ZBTB47 3.25E-06 -0.41997 
CCL2 9.02E-06 0.671466 
CD81 9.22E-06 -0.36777 
PLP2 9.72E-06 -0.41521 
LAMTOR5 1.83E-05 -0.17459 
RRAD 1.96E-05 -0.58697 
AURKAIP1 2.33E-05 -0.19937 
SERF2 2.39E-05 -0.31704 
MGAT4B 2.62E-05 -0.29272 
MYH14 3.04E-05 -0.29136 
DLAT 3.39E-05 0.330348 
KCTD17 3.80E-05 -0.56372 
ITM2A 4.45E-05 0.703263 
PRPF6 5.66E-05 -0.32279 
MXI1 5.68E-05 -0.44513 
LRRC14B 6.69E-05 -0.58266 
GTF3A 9.33E-05 -0.37791 
FAM89B 9.57E-05 -0.44927 
MASP1 9.84E-05 -0.6278 
UXT 0.000104 -0.37965 
MRPS23 0.000108 -0.33421 
HDAC5 0.000133 -0.29006 
ALDH2 0.000141 -0.30653 
LRRC23 0.000151 -0.65684 
ETFA 0.00019 -0.1549 
SSB 0.000191 -0.3278 
OSER1 0.00021 -0.45161 
RSL24D1 0.000229 -0.32297 
SLC6A8 0.000258 -0.35093 
DUSP26 0.000341 -0.54462 
SLC25A3 0.000341 0.25135 
EMCN 0.000356 0.55574 
CDC34 0.000616 -0.3254 
B4GALT2 0.000621 -0.35529 
HSP90B1 0.000756 -0.26208 
RPL13A 0.000944 -0.18863 
ZNF358 0.001 -0.31875 
KEAP1 0.001042 -0.30105 
INMT 0.001049 0.824406 




WBP2 0.001109 -0.377 
LAMTOR2 0.001135 -0.32041 
C11orf68 0.001147 -0.31843 
SQSTM1 0.001194 -0.39029 
PIGT 0.001263 -0.25638 
NRTN 0.001353 -0.74845 
GYPC 0.001467 -0.25195 
CKB 0.001634 -0.40248 
ELN 0.001639 0.558139 
ST3GAL4 0.001644 -0.68865 
ANXA11 0.001677 -0.20158 
PARK7 0.001698 -0.2137 
ASIP 0.001734 -0.44131 
SAT2 0.001785 -0.27437 
FXR2 0.001807 -0.32765 
ERP29 0.001823 -0.36148 
C11orf31 0.001837 -0.51545 
DAD1 0.001894 -0.25769 
HTRA1 0.001916 -0.55285 
MSRB1 0.001945 -0.47805 
BRE 0.002095 -0.31542 
VPS4A 0.002283 -0.26511 
TERF2IP 0.002383 -0.38456 
JOSD2 0.002388 -0.38476 
TPRG1L 0.0024 -0.30609 
CAMK2B 0.002571 -0.37192 
SWI5 0.002661 -0.40895 
EIF4B 0.002731 -0.25102 
TMEM256 0.002757 -0.47367 
LPL 0.003074 -0.52964 
GSTP1 0.00341 -0.26256 
COBL 0.003417 -0.36775 
HIST1H1C 0.003543 -0.41015 
ZNF204P 0.003762 -0.5165 
GPS1 0.003858 -0.30609 
SORBS1 0.00392 -0.11485 
PIGQ 0.003927 -0.54206 
NECAB3 0.003934 -0.24182 
LSM10 0.003997 -0.27941 
HRC 0.004002 -0.29343 
UROD 0.004004 -0.33644 
JUND 0.004008 -0.34378 
TMEM14C 0.00412 -0.20294 
TNIP2 0.004136 -0.43109 
IK 0.004208 -0.28593 
NKX2-5 0.004208 -0.2459 
SGSM3 0.004221 -0.31954 
DES 0.004376 -0.27321 
NUPR1 0.004378 -0.71661 
UQCR10 0.004388 -0.24074 
ILVBL 0.004582 -0.26735 
MIR4482 0.00467 -0.81714 
ATP6AP1 0.004765 -0.30002 
KARS 0.004848 -0.25315 
GAPDH 0.004859 -0.14026 
CYCS 0.004879 0.279535 
PFDN5 0.004886 -0.22338 
CHCHD2 0.00496 -0.21494 
EIF3I 0.005083 -0.28683 
NPTN 0.005114 0.209032 
MYEOV2 0.005117 -0.34901 
PABPC1 0.005194 -0.38188 
CHPF 0.005284 -0.33398 
SOD3 0.00539 -0.40206 
SLC25A39 0.005428 -0.3899 
LRP10 0.00543 -0.36537 
PRKAG1 0.005935 -0.35304 
MRPL28 0.005952 -0.24936 
CERK 0.006085 -0.48008 
PPP1R16A 0.006205 -0.37085 
CSTB 0.00636 -0.39138 
EXOSC1 0.006372 -0.39537 
TMUB1 0.006399 -0.47745 
TADA3 0.00641 -0.3553 
MTA1 0.00647 -0.28772 
VIPAS39 0.006582 -0.4012 
CHMP2A 0.006599 -0.27158 
LARP7 0.006649 -0.34372 
SPARC 0.006824 0.610476 
DDRGK1 0.006945 -0.42941 
POLDIP2 0.006972 -0.14408 




HSPB1 0.00706 -0.58607 
INPP5K 0.007167 -0.44067 
SNRPD2 0.007275 -0.31241 
ERI3 0.007414 -0.29734 
GTF3C6 0.007485 -0.17151 
TSPYL2 0.0075 -0.8597 
ENO2 0.007665 -0.4759 
SDC4 0.007675 -0.3726 
POMP 0.007815 -0.23334 
CIR1 0.007818 -0.37751 
ANP32B 0.008025 -0.2556 
SPR 0.008157 -0.57869 
TRIM28 0.008165 -0.31917 
WDR83OS 0.00831 -0.36759 
DYNLL1 0.008446 -0.37751 
PTGES3 0.008463 -0.34736 
SAP18 0.008474 -0.1488 
ALDH6A1 0.008789 -0.45957 
RRAS2 0.008991 -0.4177 
MXRA7 0.009181 -0.53303 
PABPC4 0.009273 -0.26604 
ATP6V0B 0.00929 -0.3209 
GRHPR 0.0093 -0.20137 
STX2 0.009303 -0.38346 
PLEKHM2 0.009372 -0.27695 
TMEM147 0.009384 -0.27193 
FAM134B 0.009389 -0.44629 
MRPL15 0.009423 -0.12168 
IFT43 0.009442 -0.50101 
MTRNR2L8 0.009458 -3.57542 
RPS24 0.00946 -0.32826 
VAMP2 0.00948 -0.16891 
CCT3 0.00952 -0.41748 
OTUD1 0.009595 -0.36497 
LCMT1 0.009618 -0.23454 
UFC1 0.009768 -0.23932 
PSENEN 0.009805 -0.48937 
C9orf78 0.009811 -0.32238 
KIAA2013 0.009924 -0.26446 
SPCS1 0.009987 -0.2743 
PACS1 0.01 -0.26715 
PSMB1 0.010017 -0.23548 
LSM4 0.010025 -0.24831 
NAP1L3 0.010078 -0.49295 
TSG101 0.010191 -0.22809 
CCT7 0.010264 -0.31043 
TBC1D17 0.01028 -0.37313 
SMARCC2 0.010316 -0.30411 
GSTM4 0.010332 -0.26552 
CCT4 0.01034 -0.25732 
TMEM164 0.010365 -0.30622 
ESF1 0.010457 -0.41539 
COPA 0.010497 -0.26554 
SNRPC 0.010573 -0.33658 
AP2S1 0.010589 -0.31414 
RNF181 0.01059 -0.26769 
STAMBP 0.010618 -0.36705 
CLU 0.010655 -1.00447 
GCDH 0.010661 -0.34981 
PCOLCE2 0.010665 -0.55002 
POLRMT 0.010672 -0.42072 
HHATL 0.010686 -0.32177 
ZCRB1 0.010689 -0.27024 
DPM3 0.01069 -0.37206 
RNF20 0.010705 -0.28119 
VPS28 0.010734 -0.21248 
MLLT1 0.010817 -0.41122 
TMEM127 0.010858 -0.19741 
SLC25A5 0.010859 -0.5597 
PLOD3 0.010886 -0.43705 
GLUL 0.010959 -0.56715 
GPC1 0.010965 -0.33923 
POLD4 0.01097 -0.50326 
GUK1 0.010998 -0.19952 
TPT1 0.011014 -0.26429 
FSTL3 0.011028 -0.41328 
POLR2E 0.011031 -0.22606 
ZNF688 0.011044 -0.42493 
MYOF 0.011076 -0.39664 
EI24 0.011102 -0.21384 
IER5 0.011172 -0.51078 




C11orf24 0.011191 -0.33337 
LAMTOR4 0.011205 -0.34185 
PKIG 0.011212 -0.19222 
PRDX1 0.01138 -0.42611 
SDHAF1 0.011418 -0.31634 
EIF3B 0.011534 -0.26048 
RTFDC1 0.011569 -0.22657 
C19orf43 0.011595 -0.22252 
COPS6 0.01161 -0.16468 
WBSCR16 0.01163 -0.24281 
TCEAL4 0.011643 -0.23189 
PCBP2 0.011658 -0.19845 
YBX3 0.011689 -0.3657 
PDAP1 0.01169 -0.25235 
GDI1 0.011732 -0.28311 
DKK3 0.011774 -0.74641 
EIF3G 0.011847 -0.24517 
NELFB 0.011884 -0.40404 
TSR3 0.011897 -0.33253 
C6orf1 0.011928 -0.50915 
DBI 0.011937 -0.28167 
RAB1B 0.011951 -0.173 
IFT22 0.011969 -0.30612 
PLEKHA6 0.011977 -0.42819 
TTC38 0.01202 -0.61326 
SLC27A6 0.012021 -0.72589 
C1orf122 0.012048 -0.29349 
SCYL1 0.012188 -0.2842 
TTLL12 0.012313 -0.52602 
TGM2 0.012428 -0.49285 
TCEA3 0.012457 -0.33137 
ARF5 0.012464 -0.25538 
UCHL1 0.012504 -0.87673 
CSNK2A2 0.012581 -0.34957 
ACOT11 0.012581 -0.3613 
PAIP2 0.012586 -0.25219 
CTSF 0.012649 -0.60939 
COMTD1 0.01268 -0.32352 
MRPS21 0.012689 -0.26227 
RTN2 0.012714 -0.31004 
EFNA5 0.012737 -0.32865 
EXOSC4 0.012762 -0.36018 
ABTB1 0.012788 -0.46099 
POP5 0.012837 -0.52448 
RTCB 0.012912 -0.19915 
ALDH4A1 0.012927 -0.53248 
MRFAP1 0.01297 -0.12913 
USP5 0.013017 -0.34138 
CNBP 0.013039 -0.08732 
ZER1 0.013115 -0.29479 
EIF2S2 0.013166 -0.30553 
PHLDA1 0.013169 -0.9679 
GNAS 0.013184 -0.13999 
COX14 0.013328 -0.25528 
ATP6V1F 0.013414 -0.3454 
ROGDI 0.01346 -0.27556 
EIF2S3 0.013473 -0.27167 
SCN1B 0.013482 -0.52847 
RPS11 0.013484 -0.14012 
MFAP4 0.013485 -0.36431 
ULK1 0.013491 -0.38666 
CHP1 0.013576 -0.30846 
RALY 0.013578 -0.4703 
NPPB 0.013588 -2.89857 
RNF103 0.013768 -0.31533 
SCAND1 0.013792 -0.35362 
TST 0.013797 -0.72148 
SYMPK 0.013798 -0.36044 
PPCS 0.013805 -0.26008 
ALDH1L1 0.013817 -0.42288 
PAF1 0.013831 -0.23495 
RABAC1 0.013844 -0.34446 
ECHS1 0.013861 -0.25719 
FAM58A 0.013924 -0.42815 
SGTA 0.013971 -0.22424 
RPS19BP1 0.013983 -0.40534 
AGPAT2 0.014057 -0.30517 
MRPL57 0.014129 -0.29881 
SAMD1 0.014196 -0.44126 
LSM7 0.014202 -0.56597 
DYNLL2 0.014215 -0.20829 




MAP3K3 0.014245 -0.35698 
FXYD1 0.014267 -0.48232 
EIF4A2 0.014294 -0.39294 
LSM3 0.014327 -0.2158 
EPDR1 0.014425 0.426137 
HSF1 0.014428 -0.24261 
POLR2G 0.014437 -0.31933 
LYNX1 0.014458 -0.32746 
C10orf76 0.014545 -0.37873 
DNTTIP2 0.014579 -0.25529 
NFE2L1 0.014752 -0.27819 
MTURN 0.014763 -0.47446 
KIAA1191 0.014774 -0.20948 
PPP1R15A 0.014806 -0.32126 
MB 0.014812 -0.22725 
RPL36 0.014829 -0.21354 
MTMR14 0.014979 -0.31443 
NINJ1 0.014992 -0.43303 
BOLA1 0.015013 -0.42337 
CETN2 0.015106 -0.33188 
CYB5R1 0.015145 -0.46927 
ARF1 0.015199 -0.12529 
RNPS1 0.015199 -0.29905 
ST6GALNAC6 0.015234 -0.41203 
ZBED5-AS1 0.015267 -0.6205 
ST6GALNAC4 0.015328 -0.441 
ATP6V1E1 0.015334 -0.24877 
MRPL55 0.015397 -0.34849 
CDK5 0.015408 -0.36628 
EDNRB 0.015444 0.572002 
MLIP 0.015451 -0.22347 
TMEM120A 0.015642 -0.3858 
CRCP 0.015655 -0.25161 
CYSTM1 0.015682 -0.42572 
FADS1 0.015691 -0.32319 
CRELD1 0.015765 -0.57105 
METRN 0.015824 -0.30801 
UBXN1 0.015828 -0.37412 
KCTD2 0.015842 -0.40662 
LDHA 0.016036 -0.51813 
CDKN2D 0.016106 -0.39297 
MAF1 0.016223 -0.28331 
FGF12 0.016281 0.915237 
MIRLET7D 0.016287 -0.56492 
SLC14A1 0.016378 0.566344 
DRAP1 0.016476 -0.2622 
GNG8 0.016495 1.058843 
CAPN1 0.016533 -0.22307 
UBC 0.016678 -0.49693 
POLR1D 0.016683 -0.34645 
EMC2 0.016794 -0.33008 
ATRAID 0.016827 -0.33128 
ELK1 0.016899 -0.34555 
DGCR6L 0.016903 -0.3252 
C12orf10 0.016919 -0.30345 
HEPH 0.016989 -0.38567 
TSSC4 0.017028 -0.41571 
KLF15 0.017053 -0.70023 
UBE2B 0.017103 -0.30749 
DPP7 0.017114 -0.26966 
MAFK 0.017121 -0.41121 
PRDX6 0.017153 -0.41316 
HINT2 0.017255 -0.35427 
MBD3 0.017335 -0.31668 
LIN52 0.017343 -0.40293 
CFL1 0.017353 -0.2372 
FBXW4 0.017386 -0.27573 
HSPE1 0.017401 -0.62629 
MAOA 0.017421 -0.29269 
UBE2L3 0.017429 -0.31198 
ADRM1 0.017531 -0.26227 
SPTB 0.017546 -0.30281 
HDGFRP2 0.017564 -0.29361 
MRPS33 0.017572 -0.23304 
CTNNBL1 0.017573 -0.32895 
ITPA 0.017598 -0.54934 
DDAH1 0.017604 -0.5688 
RASL10B 0.017747 -0.60467 
LYAR 0.017756 -0.50277 
NEMF 0.017773 -0.28863 
PPP1R1C 0.017784 0.517569 




EIF1B 0.017796 -0.39273 
RALBP1 0.017856 -0.26441 
TCEAL3 0.017945 -0.35498 
LRRC10 0.017955 -0.47799 
DCAF11 0.017956 -0.23243 
HMG20B 0.018001 -0.41925 
ARL8A 0.018211 -0.16732 
S100A13 0.018239 -0.37145 
CCDC59 0.018244 -0.46895 
NPPA 0.018249 -4.59767 
ATG101 0.018275 -0.35859 
PTMS 0.018308 -0.20457 
TUSC2 0.018326 -0.24854 
PCYT2 0.018328 -0.44157 
ZC3H15 0.018443 -0.26553 
ASNA1 0.018446 -0.22283 
HSP90AA1 0.018487 -1.38355 
DNAJB2 0.01849 -0.41515 
BTF3 0.018499 -0.19986 
RPLP2 0.018504 -0.20578 
SRI 0.018627 -0.2971 
KDELR1 0.018636 -0.36962 
SLC25A38 0.018641 -0.43073 
EIF5B 0.018641 -0.22733 
DPM2 0.018683 -0.35311 
TCEA2 0.018721 -0.38428 
CTDSP1 0.018866 -0.26382 
QSOX1 0.018983 -0.3826 
CDC37 0.018999 -0.15495 
RPS27A 0.019056 -0.32018 
FNDC5 0.019081 0.420695 
CALCRL 0.019111 0.604543 
FHL2 0.01912 0.565827 
BAD 0.019143 -0.29838 
SBDS 0.019144 -0.10968 
ASCC2 0.019171 -0.32559 
ZSCAN18 0.019217 -0.29695 
AHSA1 0.019274 -0.46542 
RPL15 0.019279 -0.25243 
BAMBI 0.019297 -0.4425 
STMN1 0.01937 -0.58359 
CES4A 0.019489 -0.70206 
PPP1CA 0.019498 -0.34569 
PSMB4 0.019554 -0.27062 
EMC10 0.019562 -0.32654 
DPH6-AS1 0.019774 -0.6062 
GSTM3 0.019815 -0.53335 
VWF 0.019926 0.704071 
FKBP4 0.020063 -0.52346 
ORMDL3 0.020082 -0.28424 
C5orf15 0.020115 0.35937 
SMG5 0.020116 -0.37037 
DMWD 0.020142 -0.34524 
C15orf65 0.020157 -0.40466 
SND1 0.020159 -0.37093 
NAP1L1 0.020236 -0.3132 
PSMC5 0.020254 -0.27883 
NT5M 0.020328 -0.38042 
NPM1 0.020339 -0.26878 
CD300LG 0.020405 0.770143 
FBXO32 0.020543 -0.51296 
ZNHIT1 0.020717 -0.31106 
PLEKHA4 0.020773 -0.49707 
APLP1 0.020786 -0.49427 
DCBLD2 0.020852 -0.2775 
NDUFS1 0.020927 0.309691 
CD59 0.020933 -0.26825 
OAZ1 0.021006 -0.13158 
RNPEPL1 0.021057 -0.22856 
ANAPC11 0.021095 -0.22134 
POR 0.02111 -0.51248 
SMYD1 0.021132 0.293732 
FAM195A 0.021138 -0.35168 
HFE2 0.021178 -0.41659 
DBNL 0.021185 -0.43991 
LINC01137 0.021186 -0.48382 
COL4A3BP 0.021196 -0.30889 
RRAGA 0.021263 -0.18647 
UBE2Z 0.021294 -0.22151 
RBM10 0.021521 -0.33803 
SAE1 0.021552 -0.31922 




B4GALNT3 0.021696 -0.43816 
SNRPA 0.021733 -0.32029 
UNC45B 0.021746 -0.90511 
PACRG 0.021758 -0.45468 
SLU7 0.021769 -0.29272 
JAGN1 0.021776 -0.32502 
HIST1H2BD 0.022086 -0.44462 
SET 0.022102 -0.25376 
HAX1 0.022118 -0.1331 
MAPRE2 0.022163 -0.31408 
SMTN 0.022189 0.264174 
PRDX3 0.022218 0.14066 
ITPKB 0.022309 0.683888 
CTNNAL1 0.022452 -0.59542 
PROS1 0.022481 -0.63447 
FAM3A 0.022545 -0.42221 
PLK2 0.022569 -0.74157 
LSM1 0.022598 -0.27895 
SERPINB6 0.022689 -0.2639 
SOX12 0.022776 -0.4053 
PTDSS1 0.022819 0.495418 
RPL18 0.022836 -0.28869 
RPL19 0.022951 -0.16645 
CWC15 0.02303 -0.26389 
IGFBP7 0.023042 -0.36395 
COL23A1 0.023043 -0.75928 
SURF1 0.023068 -0.25652 
SKP1 0.023151 -0.16183 
CYHR1 0.023158 -0.37718 
CNPPD1 0.023171 -0.30237 
SEC61G 0.02318 -0.29678 
GTF2F1 0.02322 -0.22978 
TRAPPC1 0.023272 -0.26542 
UCK1 0.023313 -0.38595 
HMCES 0.023375 -0.21037 
TP53I13 0.023406 -0.36419 
HSPBP1 0.02344 -0.32118 
PDK4 0.023484 -1.19085 
C11orf74 0.023496 -0.33449 
AMZ2 0.023585 -0.35328 
PYGM 0.023586 0.297264 
TUBB6 0.023596 0.430748 
RPS4X 0.023605 -0.17722 
HSP90AB1 0.02364 -0.5772 
CTSH 0.02375 0.322121 
COX6A1 0.023755 -0.30993 
HGS 0.023923 -0.45271 
NENF 0.023928 -0.31267 
PKN1 0.023964 -0.29225 
TAF7 0.023997 -0.24279 
COL15A1 0.024047 0.861246 
MRPL14 0.024102 -0.28668 
ITFG3 0.024142 -0.27646 
PSMC3 0.024173 -0.23743 
EEF1B2 0.024322 -0.25242 
PLA2G15 0.024427 -0.42828 
RPL36AL 0.024495 -0.21821 
ERH 0.024512 -0.27679 
SHB 0.024556 -0.38377 
AAMP 0.024565 -0.32935 
TBX20 0.0246 0.935813 
MFGE8 0.02466 -0.42171 
RP9 0.024743 -0.31803 
NOL7 0.024744 -0.24137 
DMPK 0.024775 -0.41788 
C16orf13 0.024814 -0.29099 
GSTO1 0.024931 -0.25031 
FIS1 0.024969 -0.28059 
ZFAND5 0.024971 -0.25691 
C3 0.025013 0.990502 
LRRC20 0.025057 -0.2855 
SF3B6 0.025115 -0.34123 
HINT1 0.025154 -0.21309 
SLC27A1 0.025159 -0.45903 
ZNF622 0.025306 -0.34891 
DSP 0.025423 0.169735 
FAM127B 0.025447 -0.29674 
OST4 0.025479 -0.14268 
DTNBP1 0.025485 -0.3453 
C5orf46 0.025592 -0.63812 
GRN 0.025626 -0.33901 




SSR4 0.02579 -0.3286 
LTBP3 0.025806 -0.31484 
SEC14L5 0.025826 1.203995 
BCAT2 0.025828 -0.39913 
GAS6 0.025831 -0.27298 
SPRYD3 0.025875 -0.23889 
IQSEC1 0.025878 0.472077 
MLYCD 0.025974 -0.39841 
NSFL1C 0.026126 -0.27258 
RRP12 0.026194 -0.50065 
EMC3 0.026352 -0.39285 
RPS12 0.026385 0.178465 
NME3 0.026409 -0.42944 
XIRP2 0.026453 0.508832 
RAB13 0.026459 -0.35692 
TNIP1 0.026482 -0.34038 
PA2G4 0.026486 -0.26629 
ERGIC3 0.026502 -0.27067 
MPST 0.026537 -0.49941 
GPR137B 0.026581 -0.33007 
CHST9 0.026745 0.537514 
HIPK3 0.026941 0.347339 
CTSA 0.02735 -0.22709 
SLITRK4 0.027366 -0.72626 
WIPI2 0.027404 -0.24828 
SARS 0.027439 -0.21692 
ST3GAL3 0.027532 -0.29576 
SYNJ2BP 0.027682 0.275491 
APLN 0.027729 0.4261 
INSR 0.027943 -0.25008 
PMP22 0.027949 -0.25453 
RPL24 0.028027 -0.20131 
EIF2B4 0.028117 -0.29439 
GMPR 0.028127 -0.12988 
HCFC1R1 0.028189 -0.26988 
POPDC2 0.028197 -0.24067 
GPR137 0.028202 -0.33936 
ISCU 0.028242 -0.13404 
DNAJA1 0.028375 -0.3996 
BUD31 0.028401 -0.3016 
ZNF444 0.028468 -0.32209 
MAP1LC3A 0.028534 -0.23328 
UQCR11 0.028558 -0.20712 
THBS1 0.028597 -0.52502 
NUTF2 0.028654 -0.22124 
KIF1B 0.028657 0.307622 
OSER1-AS1 0.028788 -0.39574 
RPS27 0.028815 -0.3501 
COMMD6 0.028834 -0.28021 
METTL5 0.028893 -0.34246 
CBX7 0.028918 -0.1791 
SUMO1 0.029073 -0.2358 
CBR1 0.029114 -0.35687 
MGLL 0.029221 0.557831 
TSPAN15 0.029257 0.632717 
TJP2 0.029268 -0.2175 
NAA10 0.029307 -0.28236 
FAM180A 0.029324 -0.92246 
COMMD7 0.029367 -0.32804 
RNF126 0.029394 -0.40166 
FBL 0.029427 -0.22109 
TIMM17B 0.029525 -0.22288 
YPEL2 0.029564 -0.29997 
MOB2 0.029577 -0.35481 
AGTRAP 0.029608 -0.43219 
SURF2 0.029614 -0.3161 
SSNA1 0.029669 -0.15168 
BCL7C 0.029712 -0.26555 
FABP3 0.029774 -0.24525 
AGPAT9 0.029837 -0.47228 
HSPB2 0.029863 -0.26549 
TEAD1 0.029968 0.289096 
FIBP 0.030052 -0.27112 
COA3 0.030084 -0.24036 
JTB 0.030102 -0.29281 
TOM1 0.030337 -0.40531 
FAM228B 0.030479 -0.44692 
SLC38A10 0.030654 -0.31889 
GSS 0.030691 -0.32203 
CCDC167 0.030783 -0.27559 
WDR45 0.030806 -0.38495 




APEX1 0.030872 -0.26722 
UBA52 0.030973 -0.18546 
ALDH1L1-
AS2 0.031011 -0.56135 
RUVBL1 0.031159 -0.31242 
PXDNL 0.031173 -0.58521 
HIF3A 0.031215 -0.36726 
LPAR5 0.031229 0.49944 
MKRN1 0.03124 -0.2462 
SUGT1 0.031268 -0.3227 
CEBPB 0.031278 -0.46473 
PSMD13 0.03144 -0.16577 
STX8 0.031652 -0.26619 
CLSTN1 0.031657 -0.17756 
SRP14 0.031665 -0.16348 
GATA6-AS1 0.031717 -0.23575 
MTCH1 0.031753 -0.44486 
ADO 0.0318 -0.25563 
ACOT9 0.031855 -0.18189 
CYB5D2 0.031951 -0.5814 
RPL26 0.031971 -0.14777 
RUVBL2 0.032053 -0.37922 
NEAT1 0.032055 -0.35596 
SPATA24 0.032056 -0.31896 
CHN1 0.032057 -0.34155 
POLR2L 0.032057 -0.26405 
KANK2 0.032067 -0.32401 
TUFM 0.032069 -0.14371 
TMEM258 0.032069 -0.24075 
SSBP1 0.032073 -0.28029 
PSMA5 0.032107 -0.22166 
PERM1 0.03213 -0.24044 
WISP2 0.032136 -0.61489 
TYRP1 0.032138 -0.2615 
ABCF2 0.03214 -0.29159 
AP2A1 0.032148 -0.27227 
OARD1 0.032151 -0.30922 
CD55 0.032166 -0.25869 
COPE 0.03217 -0.26005 
ABHD11 0.032183 -0.29422 
SLC25A29 0.032238 -0.36921 
TIMMDC1 0.032249 -0.15166 
RPL13 0.03225 -0.25975 
VPS45 0.032287 -0.23252 
ARHGAP24 0.032372 -0.44656 
PPP2R4 0.032413 -0.24363 
ITGA6 0.032435 0.499611 
P4HB 0.032444 -0.27061 
RPL34 0.032458 -0.19978 
TOMM40 0.032473 -0.27085 
CCNB1IP1 0.032583 -0.20411 
TOMM7 0.032642 -0.18831 
PHLDA3 0.032697 -0.31311 
SEMA5A 0.0327 -0.35377 
IFI6 0.032703 -0.34789 
ISG15 0.032719 -0.4353 
DDX54 0.032735 -0.27439 
CDKN2AIPNL 0.032748 -0.25254 
CIZ1 0.032753 -0.25381 
SYF2 0.032798 -0.3305 
TAF10 0.032805 -0.27692 
CNN2 0.032806 -0.23453 
PES1 0.032812 -0.34474 
APLP2 0.032846 -0.21945 
WDTC1 0.032879 -0.24767 
GPIHBP1 0.032929 0.716162 
SLC2A4RG 0.032933 -0.31134 
ADIPOR1 0.032961 -0.19009 
NSMCE2 0.033041 -0.2607 
ANTXR2 0.033088 -0.23948 
TXN 0.033112 -0.32177 
HAGH 0.033144 -0.26948 
CERS4 0.03322 -0.42398 
CCDC107 0.033226 -0.28906 
THYN1 0.033229 -0.26346 
RPL28 0.033283 -0.21538 
ZNF394 0.033332 -0.30539 
ARHGAP10 0.033369 -0.2098 
TUBA8 0.033375 0.687207 
GSTT1 0.033376 -1.14097 
UBA1 0.033394 -0.17864 




TMEM106C 0.033492 -0.33189 
NSA2 0.033509 -0.61507 
PHB 0.033533 -0.1705 
GABARAP 0.033543 -0.27524 
RAI2 0.033563 -0.27666 
ZC3H13 0.03359 -0.24509 
IPO13 0.033605 -0.19624 
RHOBTB1 0.033645 -0.34881 
MORN4 0.033678 -0.41256 
ZRSR2 0.03368 -0.30277 
FKBP2 0.03378 -0.28402 
IMP4 0.033791 -0.2654 
CD320 0.033797 -0.39382 
CEP85 0.033799 -0.35432 
NDUFA2 0.033836 -0.21085 
EIF3D 0.033886 -0.21668 
NUDT16P1 0.033931 -0.35165 
PNMA1 0.033934 -0.2806 
TAF1D 0.033934 -0.33269 
NFIC 0.033942 -0.21991 
BCAP31 0.03395 -0.25814 
ADCY5 0.033955 -0.22636 
ARMCX2 0.033972 -0.35739 
SF3A2 0.033972 -0.25171 
MT1E 0.03398 -0.37435 
TIMM9 0.033989 -0.24866 
FLNC 0.033991 -0.29921 
COG4 0.034012 -0.28871 
ZMAT2 0.034018 -0.25549 
TMEM219 0.034024 -0.2405 
MRPL40 0.034028 -0.18299 
FTSJ3 0.034082 -0.32143 
TNPO3 0.034111 -0.24098 
ARHGAP1 0.034159 -0.2206 
C1orf35 0.034189 -0.29119 
BRMS1 0.034189 -0.35444 
FAM177A1 0.03419 -0.3486 
TMEM109 0.034242 -0.1514 
TTF1 0.034247 -0.28503 
ARFRP1 0.034255 -0.22561 
CBY1 0.034258 -0.33169 
AAGAB 0.034268 -0.27342 
EFTUD2 0.03428 -0.28831 
ENKD1 0.03433 -0.45241 
STK40 0.034331 -0.38054 
SVOP 0.034337 -1.06419 
CREG1 0.034368 -0.14789 
TMEM44-AS1 0.034374 -0.45809 
DEDD2 0.034377 -0.26013 
IL11RA 0.034381 -0.34646 
BOP1 0.034388 -0.33889 
NABP2 0.034394 -0.30164 
PSMB6 0.034398 -0.10589 
RPP25L 0.034401 -0.25943 
PTRF 0.03446 -0.13256 
MAP2K7 0.034484 -0.2147 
MYH7 0.034499 -0.14756 
PIK3IP1 0.034509 -0.51557 
MAGED2 0.034542 -0.24398 
GPAA1 0.034604 -0.189 
OXLD1 0.034606 -0.33125 
MARK4 0.034611 -0.33795 
CUEDC2 0.034613 -0.16919 
ATG14 0.034698 -0.24888 
SF3B2 0.034737 -0.2289 
COPG1 0.034749 -0.16548 
TBCA 0.034805 -0.26488 
COMMD1 0.034815 -0.15443 
GADD45B 0.034827 -0.49784 
SHISA4 0.034849 -0.19029 
CRNDE 0.034849 -0.52827 
AHCY 0.03485 -0.3178 
RBX1 0.034867 -0.22541 
RPL10A 0.034873 -0.17068 
ODF2 0.034886 -0.31579 
NFKBIB 0.034893 -0.38029 
HACL1 0.034896 -0.35284 
IFT46 0.034921 -0.31926 
ARID5B 0.03493 -0.36754 
ANKH 0.034957 -0.25857 
JMJD8 0.034976 -0.31651 




RHEB 0.034982 -0.29912 
BRSK1 0.034994 -0.3673 
THOC5 0.03501 -0.39403 
RBMS3-AS3 0.035034 -0.51495 
ZNF524 0.035041 -0.33402 
KPNB1 0.035045 -0.20564 
WDR18 0.035078 -0.42631 
ANKZF1 0.035082 -0.27192 
UBAC2 0.035092 -0.2381 
SUPV3L1 0.035109 -0.2505 
CALCOCO1 0.035111 -0.21693 
CTDNEP1 0.035115 -0.17151 
EMC9 0.035121 -0.27157 
RNF26 0.035136 -0.31242 
ATXN10 0.035143 -0.19459 
NDRG2 0.035152 -0.14695 
NCL 0.035189 -0.18666 
SCCPDH 0.03519 -0.20731 
GLTP 0.035217 -0.27896 
NUBP2 0.035226 -0.28845 
ORAI3 0.035237 -0.41031 
NAB2 0.03527 -0.35302 
AIP 0.035335 -0.39889 
TBL3 0.035351 -0.32247 
BABAM1 0.03536 -0.21146 
UBALD1 0.035361 -0.30137 
UBE2Q2 0.035361 -0.21968 
TWF2 0.035362 -0.32439 
GNB2 0.035362 -0.28174 
FLOT2 0.035363 -0.24019 
ANKRD1 0.035363 -0.60096 
CTIF 0.035364 -0.34031 
CEBPZ 0.03537 -0.25298 
CWC27 0.035398 -0.25741 
CD99L2 0.03543 -0.21221 
MPG 0.035503 -0.28327 
RRP9 0.035529 -0.36141 
RORC 0.035537 -0.43576 
UBE2T 0.035552 -0.44856 
LRP3 0.03561 -0.24281 
RIOK3 0.035647 -0.24306 
ABAT 0.035648 -0.43632 
RPL37 0.035649 -0.15853 
SDF2L1 0.035695 -0.39462 
USP11 0.035701 -0.32699 
LAMTOR1 0.035708 -0.17128 
C14orf1 0.035729 -0.27531 
CEBPD 0.035732 -0.49284 
FAU 0.035748 -0.15049 
RPL39 0.035752 -0.28673 
DYNC1LI1 0.035781 -0.15102 
RPL23A 0.03584 -0.22563 
BTBD2 0.03585 -0.38041 
C11orf73 0.035856 -0.24875 
GTF2F2 0.035857 -0.24101 
COMMD9 0.035885 -0.29688 
RAD23A 0.035914 -0.15544 
PRPF19 0.035933 -0.16993 
PLBD1 0.03597 -0.24267 
RPUSD3 0.035973 -0.24711 
DVL1 0.036015 -0.20339 
POLR3GL 0.036017 -0.2946 
COPS3 0.036025 -0.17417 
NONO 0.036063 -0.20707 
AP2M1 0.036118 -0.21351 
SNRPB2 0.036128 -0.2526 
TMEM203 0.036133 -0.17728 
H1FX 0.036183 -0.38973 
TXNRD1 0.036189 -0.49065 
ZDHHC2 0.036191 -0.26944 
SCAF1 0.036192 -0.17292 
NOP16 0.036193 -0.36398 
C1orf226 0.036197 -0.34229 
GOLGA2 0.036199 -0.19635 
EDEM2 0.0362 -0.33971 
GLE1 0.036204 -0.26479 
HARS 0.036207 -0.25595 
CTSB 0.03621 -0.22159 
FBXL15 0.036216 -0.30803 
PKD1 0.036223 -0.22321 
ABHD8 0.036223 -0.27618 




SNCA 0.036233 -0.48798 
PDK2 0.036234 -0.23697 
XIRP1 0.036235 -0.31783 
CDKN1B 0.036237 -0.28838 
MMGT1 0.036237 -0.2194 
MAX 0.036242 -0.33015 
FAM96B 0.036243 -0.2586 
ELOF1 0.036243 -0.2683 
BANF1 0.036243 -0.31316 
TNK2 0.036253 -0.31504 
CALR 0.036253 -0.20634 
TMUB2 0.036254 -0.2077 
ARHGAP5-
AS1 0.036256 -0.36162 
PRAF2 0.036294 -0.33803 
CDK4 0.036296 -0.23838 
TCP1 0.036297 -0.2326 
COMMD3 0.036309 -0.26026 
RNF167 0.036315 -0.18438 
DNAJC6 0.036332 0.473468 
LAPTM4A 0.036384 -0.09958 
CAMK2G 0.036408 -0.30398 
MEAF6 0.036434 -0.25225 
ARPC4 0.036517 -0.35209 
PPID 0.036546 -0.3233 
RFXANK 0.036547 -0.26278 
COX7A2L 0.036559 -0.23144 
AKR7A2 0.036639 -0.26411 
PDCD5 0.036652 -0.18871 
MKNK2 0.036684 -0.56656 
MIF4GD 0.036688 -0.34444 
PREB 0.036703 -0.20891 
SNAP47 0.036703 -0.44979 
SHMT2 0.036704 -0.29907 
PFDN2 0.036764 -0.18553 
HIGD2A 0.036793 -0.1969 
A4GALT 0.036802 -0.21474 
SYNPO 0.036819 -0.12529 
PKDCC 0.036829 -0.50866 
TP53TG1 0.036838 -0.28175 
EIF1 0.03684 -0.22448 
UGT2B4 0.036872 0.96781 
AES 0.036878 -0.12894 
TRAM1 0.036889 0.303004 
NOL3 0.036899 -0.28388 
OGFR 0.036914 -0.28894 
NCAM1 0.036984 -0.17442 
LYSMD1 0.036994 -0.34905 
TOX4 0.037001 -0.21988 
PPP2R5B 0.037015 -0.27286 
NOC2L 0.037018 -0.2637 
ABHD4 0.037021 -0.32842 
WBSCR22 0.037038 -0.22916 
CCND2 0.037071 -0.33213 
C19orf24 0.037155 -0.44343 
MARK2 0.037193 -0.19623 
NUDT16L1 0.037198 -0.1828 
LMAN2 0.037204 -0.24025 
HTATSF1 0.037221 -0.17907 
CDK5RAP3 0.037227 -0.30484 
CRIP2 0.037283 -0.31158 
ABHD12 0.037286 -0.27832 
PLIN4 0.037297 -0.34226 
MRFAP1L1 0.037329 -0.19483 
VPS51 0.037355 -0.19631 
FGFRL1 0.037363 -0.32622 
BCL7B 0.037446 -0.21312 
TPD52L2 0.037452 -0.23359 
YPEL1 0.037534 -0.31246 
MYLK3 0.037545 -0.29417 
RBCK1 0.037584 -0.32562 
MLF2 0.037649 -0.16014 
ELP3 0.037705 -0.21595 
UBB 0.037717 -0.19496 
NDUFB2 0.037727 0.167528 
XAB2 0.037745 -0.24261 
NDUFA1 0.037752 -0.23606 
RAB20 0.037768 -0.38825 
ILKAP 0.037808 -0.28373 
LRRC47 0.037826 -0.14233 
LDB3 0.037827 -0.19309 




VPS16 0.037848 -0.33445 
KLHL21 0.03786 -0.30959 
FMOD 0.03788 -0.66788 
HSPD1 0.037896 -0.40253 
ITPRIP 0.037923 -0.39424 
ATOX1 0.037927 -0.25732 
CD2BP2 0.037935 -0.21861 
CTSL 0.037947 -0.16436 
EPN2 0.037971 -0.25437 
CCDC53 0.037993 -0.44427 
TMEM160 0.037993 -0.30858 
GPX3 0.037995 -0.28328 
RSL1D1 0.038042 -0.19426 
GRINA 0.03811 -0.182 
PRKCSH 0.038133 -0.19147 
RPL11 0.038158 -0.12005 
GPR22 0.038161 0.72637 
NKIRAS2 0.03819 -0.21491 
FAM98C 0.038198 -0.29988 
LAD1 0.038212 -0.70958 
SLC25A34 0.038229 -0.6356 
RP11-451G4.2 0.038241 -0.6335 
VPS72 0.038241 -0.28147 
TSC22D4 0.038241 -0.19438 
ITGB1BP1 0.038246 -0.3411 
POLR2K 0.038276 -0.25759 
ADAM9 0.038311 0.324659 
SLCO2A1 0.038314 -0.40719 
PHC2 0.038315 -0.25133 
YIPF3 0.038328 -0.23518 
TCEB2 0.038371 -0.26271 
C1orf115 0.038375 0.560171 
NUDT16 0.038384 -0.31382 
MIR126 0.038384 0.588636 
PTOV1 0.038386 -0.40275 
CDC16 0.038389 -0.20721 
MAPKAPK5-
AS1 0.038403 -0.26467 
LMBRD2 0.03841 0.45269 
RPS19 0.038423 -0.36706 
FTH1 0.038454 -0.27768 
PDZD2 0.038455 0.357551 
SART1 0.038459 -0.25815 
TMEM129 0.038468 -0.20959 
DCTN2 0.038477 -0.18366 
DGUOK 0.038496 -0.31123 
CYB5R3 0.038505 -0.22288 
ARVCF 0.038517 -0.3541 
UBALD2 0.038531 -0.32891 
GSK3A 0.03855 -0.23396 
CDKN1A 0.03855 -0.3932 
CCS 0.038581 -0.2738 
TNS1 0.038613 -0.19777 
MAP2K3 0.038615 -0.31403 
ACOX2 0.038629 -0.31187 
RPL8 0.038643 -0.1336 
PMM1 0.038654 -0.44972 
EHD3 0.038657 -0.41696 
TIMM10 0.038672 -0.32651 
MIR5690 0.038673 -1.01813 
MRPL51 0.038675 -0.1205 
H2AFX 0.038681 -0.23258 
CCDC9 0.038686 -0.31105 
AP3D1 0.038688 -0.23903 
EGLN3 0.038702 -0.36243 
SMPD1 0.038714 -0.20845 
GKAP1 0.038723 -0.33471 
IDH1-AS1 0.038727 -0.43623 
SERGEF 0.03873 -0.32063 
SETD3 0.038731 -0.20027 
C1QTNF1 0.038739 -0.5785 
TMA7 0.038743 -0.29814 
MAD2L2 0.038743 -0.41339 
PLD3 0.038744 -0.22871 
DDOST 0.038749 -0.14211 
RPF1 0.038758 -0.20963 
POLE4 0.038764 -0.30762 
C19orf70 0.038769 -0.26739 
CCM2 0.038772 -0.27933 
CTF1 0.038807 -0.37463 
NAT14 0.038835 -0.45773 




DCAKD 0.038868 -0.26436 
DNAJC21 0.038868 -0.26833 
EIF3H 0.038869 -0.12197 
RNF208 0.038875 -0.21658 
RPS27L 0.038886 -0.45338 
RABGGTB 0.038889 -0.29911 
CDK18 0.038997 -0.20614 
EEF1A1 0.039115 -0.29709 
ATP5J2 0.039351 0.152296 
MTSS1 0.039649 0.405886 
PFKFB2 0.03972 -0.50091 
CD248 0.039828 0.682005 
COMP 0.039889 -0.84929 
UTRN 0.039902 0.391413 
SYNE1 0.039974 0.420362 
NDUFA11 0.040079 -0.27112 
XPR1 0.040079 -0.40453 
PKIA 0.040133 0.190573 
DUSP23 0.040206 -0.3803 
ARPC2 0.04023 -0.18688 
IVNS1ABP 0.040303 -0.50274 
ZMYND19 0.040303 -0.32232 
AKT1S1 0.040327 -0.30619 
APOPT1 0.040328 -0.31231 
MANBAL 0.040437 -0.31077 
HIST3H2A 0.040552 -0.39049 
SNAP29 0.040615 -0.26867 
NCEH1 0.040649 0.47032 
TIMP3 0.040691 0.458962 
TUBB4B 0.040782 0.721508 
HMGN4 0.04093 -0.21951 
AQP7 0.040948 -0.33909 
TXN2 0.040982 -0.2091 
NR1H2 0.041104 -0.33779 
JAM3 0.0412 -0.45255 
TSR2 0.04123 -0.23005 
MAP7D3 0.041242 -0.3786 
P4HTM 0.04128 -0.23929 
SH3BGR 0.041381 -1.03842 
ETNPPL 0.041395 0.520276 
HMGA1 0.041419 -0.19421 
CHMP1A 0.04147 -0.3999 
MIIP 0.041477 -0.58435 
MT1X 0.041477 -0.82048 
EML1 0.041581 0.398453 
OPA1 0.041586 0.179787 
TAOK1 0.041596 0.273087 
TMEM261 0.04169 -0.23682 
KLHL31 0.041734 0.331983 
EXOSC5 0.04175 -0.33487 
TFRC 0.041854 1.359095 
MAN2C1 0.042233 -0.27072 
ZNF41 0.042259 0.340503 
ABCA8 0.042578 0.648874 
FRA10AC1 0.042611 -0.32812 
RBPMS 0.042622 -0.19739 
SPC24 0.042623 -0.42661 
CLNS1A 0.042626 -0.14629 
PTGR2 0.042626 -0.24052 
GALNT18 0.042629 -0.27594 
KRI1 0.04263 -0.3348 
NAPA 0.042632 -0.1559 
C18orf8 0.042648 -0.32397 
ARHGEF17 0.042658 -0.2543 
NUCB2 0.04266 -0.22229 
SNX17 0.042689 -0.24286 
VPS35 0.042693 -0.16446 
LINC00847 0.042694 -0.30445 
RTF1 0.042714 -0.15155 
GRK6 0.042721 -0.27522 
ASUN 0.042725 -0.21673 
TMEM141 0.042731 -0.18739 
UBE2MP1 0.042739 -0.20882 
PFN1 0.042746 -0.18697 
BSDC1 0.042749 -0.16824 
SNHG8 0.042777 -0.34416 
R3HDM4 0.042781 -0.20931 
TSPAN17 0.042792 -0.26126 
PAFAH1B1 0.042805 0.142887 
OSGIN1 0.042848 -0.45382 
KLHDC8B 0.042867 -0.18668 




KCND3 0.04292 0.403417 
ITGB1 0.042933 0.292811 
4-Sep 0.042957 -0.21332 
MIEN1 0.04298 -0.21318 
C7orf26 0.042984 -0.21517 
TM4SF1 0.04299 0.367067 
EMILIN3 0.042993 0.743265 
FAM127A 0.043012 -0.13189 
GPR153 0.043028 -0.68191 
PTS 0.043102 -0.26375 
LOH12CR1 0.043119 -0.26707 
CAST 0.043171 -0.1509 
POSTN 0.043196 -0.71602 
MAP3K10 0.043217 -0.28638 
NSRP1 0.043228 -0.22539 
ADAMTS15 0.043257 0.546947 
TAF3 0.043265 -0.23352 
TCOF1 0.043275 -0.24971 
PPM1G 0.043291 -0.18035 
STRA13 0.043304 -0.34545 
GARS 0.043332 -0.16787 
DHX29 0.043332 -0.19836 
RBM24 0.043341 -0.24186 
EML2 0.043345 -0.2887 
IRX3 0.043472 -0.40778 
ZNF579 0.043485 -0.24029 
IRS2 0.043535 -0.44685 
PRDX5 0.043545 -0.12374 
ORC3 0.043559 -0.17899 
F3 0.043564 -0.26721 
LSAMP 0.04362 0.662075 
ANKRD12 0.043635 -0.22516 
MIR6748 0.043642 0.576951 
BCCIP 0.043651 -0.23845 
RXRG 0.043663 -0.43099 
EXOSC7 0.04368 -0.31322 
OTUB1 0.043746 -0.18332 
YIF1B 0.043766 -0.26359 
ADCK3 0.043788 -0.32058 
MRPS26 0.043817 -0.16512 
MRPS15 0.043821 -0.13981 
ZNF274 0.043824 -0.22026 
PPIG 0.043832 -0.1633 
GLG1 0.043851 -0.1679 
FOXN3-AS1 0.043859 -0.3671 
TMOD1 0.043875 -0.12936 
PSME1 0.044005 -0.18707 
ATP5G1 0.044025 0.252811 
CCT8 0.044075 -0.23011 
SSRP1 0.044078 -0.22359 
DNAJB1 0.044088 -0.19553 
POLR1E 0.04409 -0.2488 
OGDH 0.044109 0.164603 
KIAA1462 0.044113 0.656201 
C19orf54 0.044118 -0.37015 
VPS13D 0.044122 0.260475 
FIGF 0.044151 0.53526 
SHARPIN 0.044177 -0.1874 
RPS13 0.044187 -0.11095 
PPP2R3C 0.044233 -0.25372 
LPAR3 0.044328 0.474278 
DDB1 0.044389 -0.12906 
IFITM1 0.044422 -0.27235 
SOBP 0.044503 -0.25994 
AZIN1 0.044509 -0.23306 
MYPOP 0.044571 -0.19777 
PPP1R3G 0.044642 -0.36934 
IGBP1 0.04468 -0.181 
GOLGB1 0.044739 -0.23189 
LONP1 0.044766 -0.2357 
SLC12A4 0.044854 -0.21426 
PPP4C 0.044869 -0.26589 
PDE6D 0.044909 -0.30053 
ENO1 0.045018 0.368078 
CBX3 0.045028 -0.23295 
CYGB 0.045147 0.484722 
PTTG1IP 0.045153 -0.14804 
EEF1G 0.045169 -0.23034 
C11orf96 0.045204 -0.28625 
DHPS 0.045206 -0.17092 
PGLS 0.045295 -0.31026 




TMEM245 0.045476 0.238885 
CDPF1 0.045552 -0.27819 
TRAPPC6A 0.04559 -0.32744 
TBC1D22A 0.045678 -0.22663 
URM1 0.045749 -0.23648 
PPP1R35 0.04587 -0.43023 
DNAJA4 0.045952 -0.73967 
MFSD6 0.045963 0.455339 
KAT2B 0.045965 0.276942 
YWHAB 0.046168 -0.09964 
RAPGEF2 0.046195 0.348173 
FGFBP2 0.046198 0.626356 
ST3GAL6 0.046284 -0.24462 
TAF11 0.046295 -0.24922 
TRPC4AP 0.046408 -0.20512 
TRDN 0.046461 -0.15193 
TMEM71 0.046493 -0.33857 
TMED9 0.046493 -0.23333 
ALDH7A1 0.046532 -0.28075 
CSNK1E 0.046613 -0.19763 
RPPH1 0.046663 -0.44324 
ARL3 0.046702 -0.227 
ATP6V1H 0.046822 -0.20221 
RSG1 0.046887 -0.35664 
MAP3K7CL 0.046917 -0.50744 
NT5C1A 0.046935 0.656828 
NAA20 0.046991 -0.14086 
STARD10 0.047049 -0.29455 
CRYAB 0.047064 -0.4513 
C22orf39 0.047064 -0.22494 
ATP13A3 0.047239 -0.30394 
SCARNA7 0.047274 -0.32296 
INTS10 0.047293 -0.23943 
SAFB 0.047321 -0.19663 
EEFSEC 0.047366 -0.33974 
FBXW11 0.047424 -0.19659 
KLC2 0.047432 -0.27713 
CREB3L2 0.047452 0.320287 
GNPAT 0.047476 -0.14615 
SGCG 0.047528 -0.22029 
BNIP3 0.047535 -0.15576 
ETV1 0.047575 -0.34829 
PAX8-AS1 0.047598 0.515569 
CTNNA3 0.047603 0.420902 
TLR4 0.047667 0.507093 
C1orf43 0.047679 -0.14213 
EHBP1L1 0.047699 -0.22378 
UBE3A 0.047775 -0.14015 
CDH5 0.047911 0.7136 
SLC16A1 0.047959 0.342604 
ZNF667-AS1 0.047976 -0.3176 
PRKAR2B 0.048108 -0.28691 
ELK3 0.048157 0.621871 
AIF1L 0.04817 0.760357 
MYCT1 0.048203 0.49137 
APRT 0.048238 -0.26923 
NEDD8 0.048326 -0.23093 
ZNF404 0.048442 -0.30295 
RPA1 0.048614 -0.28105 
APOOL 0.048967 0.380361 
NT5C 0.049081 -0.24269 
LINC00957 0.049119 -0.32978 
HDDC2 0.04915 -0.26761 
HLA-B 0.049228 0.583581 
SHISA3 0.049266 0.929802 
TNNI1 0.049448 0.738987 
MTHFD1 0.049485 -0.20469 
NDUFS5 0.049485 -0.15074 
GLTSCR2 0.049597 -0.1596 
NMT1 0.049633 -0.13706 
VPS4B 0.049698 0.267645 
QTRT1 0.049764 -0.27948 
ELOVL2 0.049783 0.395433 
CAMK2A 0.049788 -0.25057 
APP 0.04983 0.252107 
NEIL2 0.049882 -0.37047 
PPAP2B 0.049882 0.270841 
GSR 0.049948 -0.21135 
IL6ST 0.049957 0.330776 






Supplemental Table 4. DEG in obese 
samples when comparing NF to LVH, 
(p_adj < 0.05) 
GeneName p_adj log2FC 
HMGCS2 0 -1.52337 
NUPR1 0 -0.84992 
MLYCD 0 -0.63952 
SEC14L5 0 1.368913 
PCDH7 0 1.017951 
PLIN2 0 -1.26669 
TINAGL1 0 -0.45178 
PDHB 0 0.283917 
SUCLA2 0 0.381001 
NDUFS1 0 0.45615 
ACADM 0 0.311292 
DLD 0 0.313703 
CLIC5 0 0.403322 
NDUFS2 0 0.220307 
RGS5 0 0.517071 
GPNMB 0 0.917826 
MYL4 0 1.223488 
FAM129A 0 0.530084 
UBC 0 -0.78413 
ACADVL 0 -0.20461 
NEXN 0 -0.36827 
IDH2 0 0.329235 
RYR2 0 0.722121 
MYL7 0 1.550622 
AGT 2.00E-15 0.45158 
PDK4 4.00E-15 -2.80167 
TAF7 4.00E-15 -0.35599 
CDKN1A 6.99E-15 -0.78787 
SLC25A34 1.40E-14 -1.2642 
NPPA 1.40E-14 -4.02274 
GADD45G 1.60E-14 -0.97254 
TRIM63 2.20E-14 -0.55388 
CTSD 4.60E-14 -0.4451 
AZGP1 1.46E-13 -1.21571 
CEBPB 5.28E-09 -0.61231 
POSTN 5.92E-09 -1.06062 
PLVAP 7.69E-08 -1.02931 
FABP3 1.33E-05 -0.4155 
TRIP10 1.47E-05 -0.51549 
HSP90AB1 0.000225 -0.55578 
RPS24 0.000506 -0.44797 
DNAJA4 0.000586 -1.25998 
MRFAP1 0.000686 -0.20271 
SNHG5 0.000939 -0.65023 
PABPC1 0.002124 -0.43332 
ANXA11 0.002186 -0.31079 
ATP11A 0.002511 0.533909 
TBX20 0.002823 0.827152 
PPIF 0.003478 0.342752 
ZNF622 0.007096 -0.51671 
FKBP5 0.007155 -0.86411 
RASD1 0.007468 -1.23112 
TSPO 0.010087 -0.32877 
PDE3A 0.012594 0.494364 
ANGPTL4 0.012837 -1.54119 
DNAJB1 0.014125 -0.59205 
SS18L2 0.014448 -0.53527 
CCL21 0.014933 -0.81735 
RPS19BP1 0.015094 -0.37503 
SPSB1 0.015303 -0.62767 
ETFA 0.016655 -0.253 
EIF4A2 0.017004 -0.36697 
TST 0.017433 -0.6759 
PGAM2 0.017968 0.356582 
SLC16A1 0.01809 0.359136 
RPL10A 0.018447 -0.22134 
PLA2G16 0.018502 -0.4033 
COX6A1 0.018897 -0.27185 
TSR3 0.019015 -0.31082 
SDHA 0.019244 0.2945 
THSD4 0.01937 0.612104 
JTB 0.019502 -0.35856 
TXNIP 0.019841 -0.67479 
ATP5B 0.020097 0.160013 
SF3B5 0.020807 -0.3282 




C10orf10 0.02189 -0.50913 
GPR22 0.021962 0.6118 
AMOTL2 0.022329 -0.4103 
EIF3D 0.022381 -0.25298 
PNRC1 0.022442 -0.32237 
BTF3 0.022593 -0.1762 
SPR 0.023243 -0.54463 
NSA2 0.023588 -0.65499 
CLPP 0.023947 -0.32218 
HDDC2 0.024731 -0.3461 
PIM3 0.025119 -0.48626 
CHP1 0.025409 -0.35118 
CES2 0.025626 -0.59991 
ILF3-AS1 0.026093 -0.60451 
DDIT4 0.026101 -0.5924 
DNAJB2 0.026361 -0.48136 
KLF15 0.02653 -0.70413 
GLUL 0.026805 -0.57424 
APOPT1 0.026905 -0.40913 
LAD1 0.026985 -0.72085 
HIST1H2BD 0.026992 -0.37751 
HIGD2A 0.027319 -0.20007 
MAP3K7CL 0.027687 -0.5808 
P4HA2 0.027888 -0.51364 
ETFB 0.028124 -0.22952 
FAM212B 0.028241 -0.58876 
SCARB2 0.028244 -0.19712 
BCS1L 0.028414 -0.31361 
AGTRAP 0.028565 -0.42563 
FTL 0.028623 -0.35963 
CERK 0.028674 -0.47531 
SRSF3 0.028815 -0.37009 
TAF11 0.029432 -0.32988 
B3GALT2 0.029454 0.496169 
LMAN2 0.029648 -0.22971 
ENO2 0.029835 -0.40776 
NDUFA1 0.030201 -0.14984 
SLC25A20 0.030399 -0.63407 
BRK1 0.030816 -0.16216 
DUSP1 0.031356 -0.47569 
FLOT2 0.031435 -0.17131 
SQSTM1 0.031502 -0.29943 
PTGES3 0.031626 -0.26122 
RP11-
451G4.2 0.031715 -1.02284 
RPS4X 0.031805 -0.17197 
SNRNP70 0.032196 -0.30914 
GNL3 0.032279 -0.386 
MT1M 0.032563 -0.60151 
PSME1 0.032774 -0.20252 
TXNRD1 0.032906 -0.68006 
CLU 0.033301 -0.8501 
GSS 0.033486 -0.42971 
CCDC85B 0.033578 -0.35189 
HIF3A 0.0337 -0.48731 
HSPA4 0.033707 -0.24471 
TMEM109 0.033713 -0.20255 
C11orf24 0.033819 -0.37851 
HLA-A 0.033857 -1.07959 
CYSTM1 0.034106 -0.47757 
HS6ST1 0.034253 -0.34455 
CCT3 0.03428 -0.41886 
KEAP1 0.034344 -0.22295 
ATP6V1G1 0.034351 -0.15847 
PSMB4 0.03439 -0.16743 
MANBAL 0.034404 -0.32331 
TSSC4 0.034527 -0.33444 
EEF1B2 0.034575 -0.22103 
HSPE1 0.034606 -0.66784 
CRYAB 0.034918 -0.64407 
LRRC4 0.035271 -0.49529 
PLEKHO1 0.035305 -0.59406 
ADAM11 0.035425 0.963323 
PEBP1 0.035486 -0.18038 
TNNC1 0.035576 0.099498 
FDFT1 0.035763 -0.35421 
YBX3 0.035845 -0.31249 
MT1X 0.036025 -0.93198 
IMPDH2 0.036094 -0.39243 
TRIM54 0.036123 -0.31441 
NGFR 0.036183 0.731879 




SPRYD3 0.036704 -0.26283 
TUBA3E 0.036916 -0.48888 
GGPS1 0.037146 -0.23481 
GGTA1P 0.037154 0.872429 
SND1 0.0372 -0.3163 
C10orf54 0.037269 -0.31484 
POLR3GL 0.037398 -0.38815 
LSM7 0.037624 -0.58806 
GOT2 0.037858 0.255418 
MRFAP1L1 0.037936 -0.26112 
DUSP23 0.038242 -0.48478 
ITGB5 0.038249 -0.3956 
MYO1C 0.038317 -0.21544 
APOOL 0.038404 0.351662 
SCN1B 0.038415 -0.50331 
KLHL36 0.038418 -0.48906 
RSL1D1 0.038745 -0.21678 
HADHA 0.038791 -0.34315 
CHCHD2 0.038807 -0.15763 
TTLL12 0.039027 -0.62207 
ADCK3 0.039031 -0.5208 
SLC25A39 0.039036 -0.32232 
CCT7 0.039088 -0.28018 
ADO 0.039112 -0.29512 
MIR5690 0.039171 -0.61361 
TERF2IP 0.039215 -0.26911 
PRDX1 0.039357 -0.41997 
NPPB 0.039417 -1.72874 
STIP1 0.039604 -0.39623 
H1FX 0.039639 -0.79503 
FAM96B 0.039689 -0.25402 
VSTM2L 0.039785 -0.97141 
C11orf68 0.039816 -0.24351 
FIS1 0.040053 -0.18151 
DYNLRB1 0.040103 -0.23809 
OSER1 0.040119 -0.40278 
SAMD1 0.040196 -0.42475 
MAF1 0.040273 -0.2453 
MPST 0.04035 -0.39317 
SRM 0.040441 -0.28869 
PLOD1 0.04053 -0.46537 
KANK2 0.040589 -0.29737 
CHURC1 0.040622 -0.34072 
KLF10 0.040722 -0.49371 
CENPB 0.040746 -0.27682 
IMP4 0.040824 -0.30508 
PHF5A 0.040864 -0.35502 
HSPB2 0.041105 -0.34623 
SIAE 0.041108 -0.30127 
SNHG8 0.041204 -0.37071 
UBXN6 0.041528 -0.26849 
CA3 0.041911 1.622109 
POPDC2 0.042035 -0.2717 
LAMTOR4 0.042074 -0.21479 
ABCF2 0.042127 -0.27423 
HSPA2 0.042397 -0.67426 
PSMA7 0.042442 -0.23883 
RABAC1 0.043129 -0.31624 
DRAP1 0.043515 -0.29077 
PLEKHA4 0.043644 -0.47818 
GDI2 0.043684 -0.21875 
NABP2 0.043803 -0.31278 
MORN4 0.04407 -0.48357 
NGFRAP1 0.044122 0.294436 
CMYA5 0.044239 0.34836 
HMGA1 0.044499 -0.27266 
DBI 0.045126 -0.2712 
FLJ42969 0.045495 -1.10766 
PLIN5 0.045642 -0.36538 
FAM3A 0.04754 -0.35208 
SDPR 0.047867 -0.3549 
CSNK2A2 0.04787 -0.28847 
ORAI3 0.047875 -0.42071 
ACSL1 0.047905 -0.3018 
NOP10 0.047961 -0.24819 
LARP7 0.048245 -0.31615 
TP53I13 0.048609 -0.30731 
TADA3 0.04919 -0.31025 





Supplemental Table 5. DEG in all lean samples when comparing NF to LVH (p_adj < 0.05) 
GeneName p_adj log2FC 
NPPA 6.99E-15 -3.73254 
DCN 2.90E-14 1.003963 
MIR6723 2.71E-11 3.901165 
CNN1 0.015874 1.230719 
C1QA 0.027665 0.985104 
SPARCL1 0.038244 0.600471 






Supplemental Table 6. DEG in when comparing lean NF to obese LVH samples (p_adj < 
0.05) 
GeneName p_adj log2FC 
MYL7 0 1.231699 
MYL9 1.30E-14 0.501845 
TPM1 1.60E-14 0.26546 
TPM2 2.49E-10 0.422366 
ACTC1 0.00024 0.611517 
ECHDC3 0.035165 -0.73491 






Supplemental Table 7. DEG in when 
comparing lean NF to obese LVH 
samples, males only (p_adj < 0.05) 
GeneName p_adj log2FC 
SLC16A7 0 0.739186 
DANCR 0 -0.371 
IRX3 0 -0.72525 
MYL7 0 1.26689 
PRKAR1A 0 0.331577 
SLC38A1 2.00E-15 0.602805 
FAM155B 3.00E-15 -0.59298 
HSPB3 6.99E-15 -0.32055 
PPAPDC3 7.99E-15 -0.33143 
FAM107A 1.30E-14 -0.35431 
NINJ1 1.60E-14 -0.48848 
SAT2 1.70E-14 -0.35145 
BSG 1.90E-14 -0.20203 
NRAP 1.90E-14 0.489586 
LDHD 2.10E-14 -0.33736 
LGR4 2.60E-14 0.811303 
DHRS7C 3.10E-14 1.799902 
NEBL 5.90E-14 0.406793 
ACTN2 6.49E-14 0.514332 
ABCA8 8.50E-14 0.783352 
NDUFS5 9.10E-14 0.130064 
FAM129A 7.66E-12 0.445771 
UBXN6 1.75E-10 -0.45321 
NR1D2 2.66E-10 0.916154 
ECH1 7.66E-09 -0.3775 
HYAL1 2.32E-08 -0.3605 
MFN2 4.96E-08 0.19523 
MYL12A 6.60E-08 0.433722 
RYR2 9.76E-08 0.502612 
EGLN1 2.47E-07 0.555696 
OIP5-AS1 3.69E-07 0.45973 
PDLIM5 8.57E-07 0.395338 
C17orf89 5.14E-06 -0.47029 
C10orf54 1.24E-05 -0.41807 
PEBP1 2.12E-05 -0.22826 
VSTM2L 5.47E-05 -0.7891 
ID3 0.0004 -0.49882 
CPT1A 0.001089 0.684059 
AGPAT9 0.001219 1.075068 
CIRBP 0.001488 -0.66858 
GBAS 0.002905 0.285877 
SLC2A4 0.003014 -0.26979 
HNRNPH1 0.004275 0.48207 
MTRNR2L8 0.004412 -3.25627 
PDE3A 0.006769 0.664528 
ASS1 0.008458 -0.69383 
NFIL3 0.010733 -0.63558 
GSTT1 0.011703 -2.20421 
HOPX 0.011744 1.145151 
RB1CC1 0.012092 0.556311 
DECR1 0.012308 0.357415 
SPR 0.012736 -0.80244 
UQCR11 0.013373 0.134543 
CFL2 0.015294 0.336491 
PPAP2B 0.015298 0.495698 
ACE2 0.015324 0.775487 
AREG 0.015347 0.979501 
LMOD3 0.015389 0.254639 
ZNF844 0.015429 0.511165 
MYOM2 0.015505 0.360828 
MTUS1 0.017233 0.294426 
TRAK2 0.017693 0.412516 
C3 0.017999 0.745286 
GOLGA4 0.018802 0.297001 
RPS12 0.022689 0.22347 
DPY19L2 0.022967 0.713779 
ASB11 0.024143 0.518274 
GATM 0.024475 0.600525 
NR1D1 0.024778 0.726608 
PPARGC1A 0.028884 0.53886 
TNNT1 0.03236 0.454654 
ADRB1 0.032499 0.578817 
DHCR7 0.035029 -0.42659 
HINT2 0.035032 -0.38789 
NPY6R 0.035286 0.161042 




FAM124A 0.036349 0.772011 
HDDC2 0.03684 -0.40888 
PALMD 0.036931 0.36049 
PLOD1 0.037799 -0.53847 
FABP3 0.037937 -0.19022 
UBE2D1 0.038221 0.407133 
TOMM22 0.038638 -0.36846 
PIK3IP1 0.039085 0.851293 
SUCLG2 0.039289 0.429302 
PDXK 0.040214 0.395105 
NACA 0.040426 0.261319 
HIST2H2BE 0.04072 -0.47358 
MRPS26 0.041411 -0.24566 
SRM 0.041446 -0.33945 
GJA1 0.042569 0.458062 
KLHL24 0.043239 0.648831 
F2RL3 0.04369 -1.20011 
C8orf4 0.04381 -0.41677 
GAPDH 0.043989 -0.21032 
IFITM1 0.044485 -0.32031 
SFRP1 0.044853 0.897901 
YBEY 0.045711 0.543591 
SNTA1 0.045962 -0.21448 
RXRG 0.047003 -0.75542 
PFKFB3 0.047302 0.721138 
PDE7B 0.047321 0.646953 
POPDC2 0.047669 -0.43408 
PIK3R3 0.048177 -0.68814 
HK2 0.049065 -0.71184 






Supplemental Table 8. Sex- and BMI-specific DEG with (p_adj < 0.05) and absolute value 
of log2 fold change > 1 
GeneName p_adj log2FC Origin 
AAK1 0.045716 -1.78202 LVH-F 
ABCF3 0.000789 1.080317 LVH-F 
ACSM1 0.016208 -2.13365 LVH-F 
ACTA1 0.042476 -1.1199 LVH-F 
ADIPOR1 0.001502 1.190279 LVH-F 
AGPAT9 0.001219 1.075068 
BMI25NF vs 
BMI30LVH M 
AKAP17A 0.014985 -1.03412 LVH-F 
ALG2 0.030579 -1.47132 LVH-F 
ANAPC11 0.013918 1.566538 LVH-F 
ANAPC2 0.015146 -1.12143 LVH-F 
ANGPTL4 0.012837 -1.54119 BMI30 
ANKRD36B 0.001861 -3.04052 LVH-F 
ARL2BP 0.039899 1.290096 LVH-F 
ARL6IP4 0.002399 1.532074 LVH-F 
ASMTL 0.022448 -1.53306 LVH-F 
ATG9A 0.028019 1.094103 LVH-F 
ATP1A1 0.01965 -1.06399 LVH-F 
ATP5F1 0 1.372359 LVH-F 
ATP5H 0.046897 1.01046 LVH-F 
ATP5J2 0.040698 1.053234 LVH-F 
ATXN3 0.04571 -2.43236 LVH-F 
AZGP1 1.46E-13 -1.21571 BMI30 
AZGP1 0 -1.30798 LVH-M 
BCKDHA 0.023183 1.361748 LVH-F 
BEST4 0.039922 -1.08126 LVH-F 
BTBD10 0.045469 -1.28796 LVH-F 
C1QC 0.043925 1.175501 BMI25 
CA3 0.041911 1.622109 BMI30 
CAST 0.003565 1.515 LVH-F 
CCDC3 0.028467 -1.26406 LVH-F 
CCDC39 0.002766 -3.18253 LVH-F 
CCL21 0.034425 -1.99891 LVH-F 
CCNG1 0.015352 -1.33632 LVH-F 
CHCHD3 0.027589 -1.8757 LVH-F 
CKAP5 0.021646 1.106586 LVH-F 




CMC4 0.032923 1.087351 LVH-F 
CNN1 0.015874 1.230719 BMI25 
CNPY3 0.02602 -1.06098 LVH-F 
CNTRL 0.018993 -1.53438 LVH-F 
COPG2 0.035784 -1.62398 LVH-F 
COX17 0.014284 -1.71685 LVH-F 
COX7B 0.006368 1.091807 LVH-F 
CPT1A 2.31E-05 1.291808 LVH-F 
CPXCR1 0.024216 -1.39867 LVH-F 
CREM 0.025267 -2.14778 LVH-F 
CRKL 0.019327 -1.12111 LVH-F 
CSRNP1 0.030347 -1.44187 LVH-F 
CSRP3 0.021814 -1.03479 LVH-F 
CTGF 0.030305 -1.18947 LVH-F 
CXCL1 0.039718 -1.11979 LVH-F 
CYR61 0.000146 -1.8073 LVH-F 
DBNDD2 3.19E-07 1.116301 LVH-F 
DCN 2.90E-14 1.003963 BMI25 
DENND2A 0.017611 -1.00146 LVH-F 
DEXI 0.01443 1.425424 LVH-F 
DHRS4L2 0.01678 -1.16709 LVH-F 
DHRS7C 3.10E-14 1.799902 
BMI25NF vs 
BMI30LVH M 
DIRAS3 0.028944 -1.01864 LVH-F 
DNAJA4 0.000586 -1.25998 BMI30 
EEF1G 0.000136 2.018869 LVH-F 
EFHD2 0.030605 -1.574 LVH-F 
ELOVL1 0.021326 -1.17358 LVH-F 
ESPNP 0.032743 -2.91051 LVH-F 
ETFB 0.002431 1.068367 LVH-F 
F2RL3 0.04369 -1.20011 
BMI25NF vs 
BMI30LVH M 
FANCI 0.015449 -1.70713 LVH-F 
FIGF 0.035388 -1.15941 LVH-F 
FLJ42969 0.045495 -1.10766 BMI30 
FOS 0.043634 -1.05858 LVH-F 
FSTL3 0.022169 1.277475 LVH-F 
FUCA2 0.018749 -1.24515 LVH-F 
FXYD1 0.009307 1.676 LVH-F 
GABARAP 0.006902 2.005869 LVH-F 
GBGT1 0.015357 -1.08937 LVH-F 




GMEB1 0.015111 -1.08091 LVH-F 
GNAT1 0.015907 -1.57915 LVH-F 
GNG8 0.016495 1.058843 LVH-M 
GPR173 0.033213 -1.28738 LVH-F 
GPR4 0.002359 -1.58775 LVH-F 
GPRASP2 0.007945 -1.95928 LVH-F 
GSTT1 0.011703 -2.20421 
BMI25NF vs 
BMI30LVH M 
GSTT1 0.033376 -1.14097 LVH-M 
GTPBP6 0.019788 -1.53881 LVH-F 
HBA1 0.001351 -3.4007 LVH-F 
HBB 0.000788 -5.45543 LVH-F 
HBQ1 0.03057 -1.68139 LVH-F 
HIF1A-AS2 0.033996 -1.13095 LVH-F 
HIST1H2AC 0.003876 -2.31733 LVH-F 
HIST1H4H 0.035099 -1.18434 LVH-F 
HLA-A 0.033857 -1.07959 BMI30 
HLA-DRB1 0.023762 -2.0529 LVH-F 
HMGCS2 0 -1.52337 BMI30 
HNRNPA2B1 0.001525 1.093875 LVH-F 
HNRNPH2 0.009874 -2.03727 LVH-F 
HOPX 0.011744 1.145151 
BMI25NF vs 
BMI30LVH M 
HSP90AA1 0.035951 -1.39985 
BMI25NF vs 
BMI30LVH M 
HSP90AA1 0.018487 -1.38355 LVH-M 
HSPA5 0.035795 1.758879 LVH-F 
HSPA6 0.042634 -1.46953 LVH-F 
HSPB2 0.031367 1.211078 LVH-F 
HTR2B 0.016906 -1.63789 LVH-F 
IGF2 0.017209 -1.4621 LVH-F 
IL3RA 0.037239 -1.12638 LVH-F 
ILK 0.004515 1.653967 LVH-F 
IMMP1L 0.016304 -1.26851 LVH-F 
KCTD11 0.028872 -1.32702 LVH-F 
KDR 0.027446 -1.01649 LVH-F 
KLC1 0.035226 1.002591 LVH-F 
KLF8 0.032702 -2.63556 LVH-F 
LAMTOR2 0.027347 1.016552 LVH-F 
LARP1B 0.016209 -1.10904 LVH-F 
LTBP1 0.004871 -1.15454 LVH-F 




MAGEF1 0.006657 -1.50688 LVH-F 
MAGI1 0.022467 -1.14043 LVH-F 
MAPRE1 0.025203 1.119034 LVH-F 
MAT2A 0.012773 -3.98597 LVH-F 
MATR3 0.029278 1.100102 LVH-F 
MCTS1 0.035379 -1.18667 LVH-F 
MDH2 0.008315 1.042324 LVH-F 
METTL7B 0.019927 -1.4323 LVH-F 
MGC16275 0.027125 -1.16985 LVH-F 
MOB4 0.007926 -2.45158 LVH-F 
MT1A 0.016679 -1.31961 LVH-F 
MT2A 0.029011 2.208718 LVH-F 
MT2A 7.38E-09 -1.04872 LVH-M 
MTPN 0.021198 -2.09273 LVH-F 
MTRNR2L8 0.004412 -3.25627 
BMI25NF vs 
BMI30LVH M 
MTRNR2L8 0.009458 -3.57542 LVH-M 
MTURN 0.021131 -1.28667 LVH-F 
MYL4 0 1.223488 BMI30 
MYL4 1.01E-06 1.123475 LVH-M 
MYL7 0 1.231699 
BMI25NF vs 
BMI30LVH 
MYL7 0 1.26689 
BMI25NF vs 
BMI30LVH M 
MYL7 0 1.550622 BMI30 
MZT2A 0.000177 1.152776 LVH-F 
NAA10 0.03768 1.111668 LVH-F 
NAT6 0.028176 -1.26624 LVH-F 
NCOA4 0.003347 -1.25799 LVH-F 
NDUFA7 0.036176 1.782766 LVH-F 
NEAT1 0.002411 -1.10139 LVH-F 
NEK7 0.020017 1.095569 LVH-F 
NFIX 1.93E-07 1.237286 LVH-F 
NNT 0.002013 1.040709 LVH-F 
NONO 0.005596 1.256768 LVH-F 
NPPA 0.004457 -3.54329 All_LVH 
NPPA 6.99E-15 -3.73254 BMI25 
NPPA 1.40E-14 -4.02274 BMI30 
NPPA 0.032393 -2.89607 LVH-F 
NPPA 0.018249 -4.59767 LVH-M 
NPPB 0.039417 -1.72874 BMI30 




NPPB 0.013588 -2.89857 LVH-M 
NPTN-IT1 0.012711 -1.49524 LVH-F 
NTMT1 0.012669 -1.15378 LVH-F 
OSBP 0.018598 -1.05728 LVH-F 
OTUD1 0.037677 -1.47141 LVH-F 
PARVB 0.006333 1.004308 LVH-F 
PCBP1 0.026636 1.265688 LVH-F 
PCDH7 0 1.017951 BMI30 
PDK4 4.00E-15 -2.80167 BMI30 
PDK4 0.023484 -1.19085 LVH-M 
PELI1 0.024498 -1.17581 LVH-F 
PFDN1 0.00486 -1.49717 LVH-F 
PLA2G2A 0.045658 -2.64705 LVH-F 
PLIN2 0 -1.26669 BMI30 
PLVAP 7.69E-08 -1.02931 BMI30 
PLVAP 0.017747 -1.26576 LVH-F 
PLVAP 3.00E-15 -1.29896 LVH-M 
PLXDC2 0.011265 -2.03282 LVH-F 
POLR2J 0.012691 -1.02605 LVH-F 
POM121L10P 0.023984 -3.57981 LVH-F 
POSTN 5.92E-09 -1.06062 BMI30 
PPP1R17 0.044203 -1.20029 LVH-F 
PTX3 0.018539 -1.36678 LVH-F 
PWAR1 0.049174 -1.02416 LVH-F 
PYURF 0.021461 1.332057 LVH-F 
RAB4A 5.53E-06 1.515827 LVH-F 
RASD1 0.007468 -1.23112 BMI30 
RDH14 0.012763 -1.08698 LVH-F 
RFPL4AL1 0.015363 -1.82569 LVH-F 
RGL1 0.037807 -1.12518 LVH-F 
RN7SL2 0.019873 1.481054 LVH-F 
RNF14 1.90E-07 1.344973 LVH-F 
RNU6-7 0.037551 -1.09696 LVH-F 
RP11-
451G4.2 0.031715 -1.02284 BMI30 
RPL9 0.025397 -1.02426 LVH-F 
RPS15A 0.049643 1.025891 LVH-F 
RTN4 0.039426 -1.07648 LVH-F 
S100A1 0.000813 1.472048 LVH-F 
SEC14L5 0 1.368913 BMI30 




SENP5 0.036158 -1.4376 LVH-F 
5-Sep 0.031609 -1.92603 LVH-F 
SESTD1 0.032037 -1.46671 LVH-F 
SF1 0.017507 -1.01606 LVH-F 
SH3BGR 0.041381 -1.03842 LVH-M 
SLC25A34 1.40E-14 -1.2642 BMI30 
SLC45A3 0.019074 -1.48551 LVH-F 
SLC6A6 0.016902 -1.15071 LVH-F 
SNORA33 0.048468 -1.16312 LVH-F 
SNRPN 0.022304 -1.23539 LVH-F 
SOCS5 0.015948 -1.25689 LVH-F 
SPRY4 0.016248 -1.08951 LVH-F 
SRSF7 0.02232 -1.06689 LVH-F 
STX12 0.042183 -1.23808 LVH-F 
SVOP 0.034337 -1.06419 LVH-M 
TAX1BP3 0.023178 -1.44566 LVH-F 
TCHH 0.027454 -1.91902 LVH-F 
TFRC 0.041854 1.359095 LVH-M 
THBS4 0.048544 1.196572 LVH-F 
TIMM8B 0.012035 -1.1086 LVH-F 
TIMP1 0.028892 -1.00851 LVH-F 
TMEM165 0.026022 1.050255 LVH-F 
TNFAIP1 0.026486 -1.42484 LVH-F 
TRAPPC5 0.000584 1.354619 LVH-F 
TRIM35 0.013302 -1.52477 LVH-F 
TSFM 0.003479 1.156395 LVH-F 
TTC21A 0.002043 -2.47755 LVH-F 
TUBA8 0.030328 1.599595 LVH-F 
UQCC1 0.016391 -1.03014 LVH-F 
VAMP7 0.028929 -1.15256 LVH-F 
VGLL2 0.038578 -1.19911 LVH-F 
VSTM5 0.010137 -1.45653 LVH-F 
WDR61 0.021294 -1.02132 LVH-F 
WDR62 2.15E-12 1.07249 LVH-M 
WDR89 0.024138 -1.19626 LVH-F 
ZBED1 0.025655 -1.19893 LVH-F 






Supplemental Table 9. Sex- and BMI-specific DEG with (p_adj < 0.05) and absolute value 
of log2 fold change > 2 
GeneName p_adj log2FC Origin 
HBB 0.000788 -5.45543 LVH-F 
NPPA 0.018249 -4.59767 LVH-M 
NPPA 1.40E-14 -4.02274 BMI30 
MAT2A 0.012773 -3.98597 LVH-F 
NPPA 6.99E-15 -3.73254 BMI25 
POM121L10P 0.023984 -3.57981 LVH-F 
MTRNR2L8 0.009458 -3.57542 LVH-M 
NPPA 0.004457 -3.54329 All_LVH 
HBA1 0.001351 -3.4007 LVH-F 
MTRNR2L8 0.004412 -3.25627 
BMI25NF vs 
BMI30LVH M 
CCDC39 0.002766 -3.18253 LVH-F 
ANKRD36B 0.001861 -3.04052 LVH-F 
ESPNP 0.032743 -2.91051 LVH-F 
NPPB 0.013588 -2.89857 LVH-M 
NPPA 0.032393 -2.89607 LVH-F 
PDK4 4.00E-15 -2.80167 BMI30 
PLA2G2A 0.045658 -2.64705 LVH-F 
KLF8 0.032702 -2.63556 LVH-F 
TTC21A 0.002043 -2.47755 LVH-F 
MOB4 0.007926 -2.45158 LVH-F 
ATXN3 0.04571 -2.43236 LVH-F 
HIST1H2AC 0.003876 -2.31733 LVH-F 
NPPB 0.014572 -2.21326 LVH-F 
MT2A 0.029011 2.208718 LVH-F 
GSTT1 0.011703 -2.20421 
BMI25NF vs 
BMI30LVH M 
CREM 0.025267 -2.14778 LVH-F 
ACSM1 0.016208 -2.13365 LVH-F 
MTPN 0.021198 -2.09273 LVH-F 
HLA-DRB1 0.023762 -2.0529 LVH-F 
HNRNPH2 0.009874 -2.03727 LVH-F 
PLXDC2 0.011265 -2.03282 LVH-F 
EEF1G 0.000136 2.018869 LVH-F 





Supplemental Table 10. DEG shared between obesity-related LVH and ischemic heart 
datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs LVH, 
BMI30 p_adj 
log2FC NF vs 
ISCH p_adj 
ADAM11 0.963323248 0.035425 1.859819771 1.99E-05 
AMOTL2 -0.410297052 0.022329 2.454941712 1.72E-09 
ANGPTL4 -1.541190467 0.012837 -1.62521166 0.046472 
ATP11A 0.533909197 0.002511 0.933140384 0.011395 
AZGP1 -1.215705163 0 -1.138888768 0.040662 
C10orf10 -0.509127057 0.02189 2.175525819 1.54E-07 
CA3 1.622109468 0.041911 -4.806058253 1.20E-09 
CCL21 -0.817354828 0.014933 -4.445963698 4.26E-13 
CDKN1A -0.787871528 0 1.066409299 0.042891 
CES2 -0.599913795 0.025626 -1.29788074 0.000568 
DNAJA4 -1.259979001 0.000586 -1.318690893 0.005975 
DUSP1 -0.475690762 0.031356 1.50041234 0.002321 
ENO2 -0.407758301 0.029835 1.329284641 0.01159 
GADD45G -0.972541723 0 -2.141900654 8.62E-06 
GLUL -0.574244275 0.026805 1.511265015 4.26E-05 
HIF3A -0.487311467 0.0337 1.90209774 2.88E-11 
HIST1H2BD -0.377505615 0.026992 -1.819527247 0.008223 
KLF10 -0.493714422 0.040722 1.981681166 2.83E-06 
KLHL36 -0.489064934 0.038418 1.118522643 0.044766 
MT1X -0.931977954 0.036025 -3.148047139 3.10E-06 
MYL4 1.223488273 0 5.061522714 0 
NGFR 0.731879187 0.036183 -1.468816887 0.006195 
NPPA -4.022740194 0 -4.275261149 0 
NPPB -1.728742349 0.039417 -3.478505958 1.79E-13 
P4HA2 -0.513644739 0.027888 -1.327847131 0.000437 
PCDH7 1.017950806 0 -1.342352722 0.001533 
PDK4 -2.801668723 0 -1.621761989 0.003644 
PIM3 -0.486255599 0.025119 1.148851509 0.031203 
PLIN5 -0.365375409 0.045642 1.522271323 0.000835 
POSTN -1.060620451 6.00E-09 -5.398096936 0 
RASD1 -1.231118925 0.007468 -4.302868698 0 
SDPR -0.354902106 0.047867 1.540942135 0.001267 
SEC14L5 1.368913328 0 2.532045159 4.07E-09 
SNHG8 -0.370713939 0.041204 1.326354211 0.025361 
TUBA3E -0.488877251 0.036916 2.13283323 3.49E-07 









Supplemental Table 11. DEG shared between obesity-related LVH and dilated 
cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs LVH, 
BMI30 p_adj 
log2FC NF vs 
DCM p_adj 
ACADM 0.311292269 0 -1.635131511 0.024369 
ACSL1 -0.301796691 0.047905 -1.237893201 0.028694 
ADAM11 0.963323248 0.035425 -1.705143444 0.000396 
ANGPTL4 -1.541190467 0.012837 2.676261492 7.52E-07 
AZGP1 -1.215705163 0 2.180581657 2.13E-06 
C10orf54 -0.314841388 0.037269 1.198134446 0.039901 
C11orf24 -0.37851224 0.033819 1.146685791 0.045062 
C6orf1 -0.444222465 0.021257 1.462087575 0.00141 
CCDC85B -0.351885521 0.033578 1.451714992 0.003356 
CCL21 -0.817354828 0.014933 -2.08871703 0.010486 
CDKN1A -0.787871528 0 1.293184109 0.041044 
CEBPB -0.612313557 5.00E-09 1.446932885 0.038798 
CES2 -0.599913795 0.025626 1.624109893 3.83E-05 
CLIC5 0.403321879 0 -1.829084965 0.024395 
DUSP1 -0.475690762 0.031356 -1.092128327 0.041697 
ENO2 -0.407758301 0.029835 2.196136473 0.0023 
FAM129A 0.530083934 0 -1.595061831 0.010247 
FAM96B -0.254020969 0.039689 1.007933098 0.042718 
FKBP5 -0.864105785 0.007155 2.79848211 1.39E-10 
GADD45G -0.972541723 0 -2.628999414 2.73E-09 
GGTA1P 0.872428613 0.037154 -1.706254443 0.012987 
GLUL -0.574244275 0.026805 1.664537577 5.94E-08 
GPNMB 0.91782649 0 -1.545983281 0.000353 
HIF3A -0.487311467 0.0337 2.0184829 6.70E-10 
HIST1H2BD -0.377505615 0.026992 -1.796075408 0.0122 
HLA-A -1.079594248 0.033857 1.632995353 0.003143 
HMGCS2 -1.523371969 0 2.238661292 2.33E-06 
HSPA2 -0.6742577 0.042397 -1.921073556 0.005923 
HSPB2 -0.346226709 0.041105 1.552376496 0.031126 
HSPE1 -0.66784361 0.034606 -1.424482306 0.044167 
KLF10 -0.493714422 0.040722 -2.844803667 7.04E-09 
KLF15 -0.70413339 0.02653 2.244450656 6.56E-06 
KLHL36 -0.489064934 0.038418 -1.997317857 0.006246 
MLYCD -0.639518345 0 1.255474711 0.025587 
MYL4 1.223488273 0 7.928132761 0 




NGFR 0.731879187 0.036183 2.775612164 1.05E-07 
NGFRAP1 0.29443617 0.044122 1.03562481 0.043437 
P4HA2 -0.513644739 0.027888 -1.327516966 0.022345 
PCDH7 1.017950806 0 -3.01148407 5.79E-13 
PDE3A 0.494363508 0.012594 -2.310334066 2.07E-05 
PDK4 -2.801668723 0 -2.495837398 3.53E-08 
PIM3 -0.486255599 0.025119 -1.433797174 0.004027 
PLA2G16 -0.403295041 0.018502 1.062296467 0.006247 
PLEKHA4 -0.478182032 0.043644 1.715005619 0.002446 
PLEKHO1 -0.594058511 0.035305 1.581454714 0.030276 
PLIN2 -1.26669077 0 -1.979051483 5.95E-05 
PSME1 -0.20251521 0.032774 -1.220196145 0.026897 
RABAC1 -0.316244037 0.043129 1.466716007 0.048405 
RYR2 0.722120711 0 -2.846601211 0.001689 
SDPR -0.354902106 0.047867 -1.109838725 0.036961 
SIAE -0.301274805 0.041108 -1.596753323 0.029123 
SLC16A1 0.359135811 0.01809 -1.5319772 0.015032 
SNHG8 -0.370713939 0.041204 1.921250812 0.000585 
SPR -0.544625322 0.023243 1.53937965 0.003249 
TUBA3E -0.488877251 0.036916 4.00419486 1.18E-11 
TXNRD1 -0.6800562 0.032906 -0.917006565 0.005121 





Supplemental Table 12. DEG shared between obesity-related LVH and both dilated 
ischemia and cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs LVH, 
BMI30 p_adj 
log2FC ISCH vs 
DCM p_adj 
ACSL1 -0.301796691 0.047905 -1.36779967 0.040646 
AMOTL2 -0.410297052 0.022329 -1.54606353 0.000364 
ATP11A 0.533909197 0.002511 -1.31543383 0.000361 
AZGP1 -1.215705163 0 1.813024958 0.000192 
CA3 1.622109468 0.041911 1.717173576 0.00744 
CCL21 -0.817354828 0.014933 3.211259363 1.73E-08 
ETFB -0.229518502 0.028124 -1.136020685 0.039885 
FKBP5 -0.864105785 0.007155 1.999049339 1.19E-05 
GADD45G -0.972541723 0 2.127923456 0.000128 
HMGCS2 -1.523371969 0 -6.83427681 0 
KLF10 -0.493714422 0.040722 -1.429708621 0.00882 
KLF15 -0.70413339 0.02653 1.466101481 0.017679 
MLYCD -0.639518345 0 -1.107128992 0.038156 
MT1M -0.601514184 0.032563 5 0.027723 
MT1X -0.931977954 0.036025 1.515877998 0.048194 
MYL4 1.223488273 0 2.866610047 1.24E-05 
NGFR 0.731879187 0.036183 2.460128189 3.52E-06 
NPPA -4.022740194 0 1.804016681 0.002728 
NPPB -1.728742349 0.039417 3.95062945 1.28E-12 
PDE3A 0.494363508 0.012594 -1.958909858 0.000798 
PLEKHA4 -0.478182032 0.043644 1.693949792 0.000295 
PLIN2 -1.26669077 0 1.361068302 0.012164 
PLVAP -1.029311185 7.70E-08 1.949632993 0.001075 
POSTN -1.060620451 6.00E-09 4.131445065 0 
RASD1 -1.231118925 0.007468 4.447645806 0 
SDPR -0.354902106 0.047867 -1.293987604 0.023136 
SEC14L5 1.368913328 0 -2.791126985 9.97E-09 
TBX20 0.827151711 0.002823 -2.297082344 1.42E-06 
TUBA3E -0.488877251 0.036916 1.87136163 0.00554 
TXNIP -0.67478941 0.019841 -1.869992367 0.002275 





Supplemental Table 13. DEG shared between female obesity-related LVH and ischemia 
datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_F p_adj 
log2FC NF vs 
ISCH p_adj 
ADAM19 -0.630142749 0.037114 -3.048888723 1.74E-10 
AKAP12 -0.731993228 0.026665 -1.298370962 0.01369 
AKAP8 0.719672413 0.041305 1.190883805 0.022442 
AMOTL1 -0.709487539 0.023841 -1.806957882 0.00021 
ANGPTL4 -0.978298815 0.026011 -1.62521166 0.046472 
ANO5 0.496829866 0.04182 -1.194968001 0.010258 
APOD -0.892669878 0.037102 2.188726773 4.39E-07 
ATE1 -0.823974167 0.02715 -5 2.25E-07 
ATP2B4 -0.473150152 0.047037 -1.590706441 0.000121 
AZIN1 -0.457215273 0.033503 -1.355458125 0.00242 
B2M -0.481096356 0.034341 1.263669684 0.019571 
BCAR3 -0.799783333 0.044029 1.256167644 0.020878 
BTG2 -0.547514523 0.022147 -1.680509038 0.000236 
CBLB -0.501922722 0.049091 1.736718946 0.000114 
CCL21 -1.998910656 0.034425 -4.445963698 4.26E-13 
CD151 0.472684984 0.037071 -1.076847186 0.003615 
CD68 0.939054502 0.044368 -1.102746724 0.045551 
CDKN1A -0.429068187 0.044115 1.066409299 0.042891 
CES2 0.651625466 0.024136 -1.29788074 0.000568 
COPG2 -1.623978704 0.035784 -5 1.32E-05 
COQ10A 0.483453731 0.033817 1.023565636 0.025646 
COX6A2 0.439693907 0.029613 1.183127397 0.036892 
CSRNP1 -1.441867051 0.030347 1.25190798 0.017483 
CYR61 -1.807300387 0.000146 1.922649835 1.06E-05 
DAAM2 -0.505335353 0.043894 1.699349677 0.000119 
DAPK2 0.74144734 0.046529 1.472556324 0.003215 
DRAM2 -0.726386837 0.022444 -5 2.46E-05 
DUSP1 -0.830211926 0.045995 1.50041234 0.002321 
DYNLL1 -0.741219481 0.04959 -1.775643022 3.34E-05 
EDNRB -0.523326087 0.025631 2.168141571 1.62E-11 
EFEMP1 -0.729911964 0.04534 -0.95010613 0.030239 
ELK1 -0.394407987 0.043625 1.055086757 0.0086 
EMILIN1 -0.571141425 0.039703 -1.138198488 0.04197 
ENG -0.575150638 0.033416 1.319210813 0.010059 
ENO2 -0.613111978 0.045746 1.329284641 0.01159 




ETS2 -0.554950903 0.039999 1.228682928 0.014796 
FBLN5 -0.551338968 0.012826 1.290762964 0.006991 
FSTL3 1.277475497 0.022169 -1.278100975 0.030781 
FXYD5 -0.741622441 0.04211 -1.168609909 0.049289 
GIMAP6 -0.948944237 0.004831 1.309671928 0.000231 
GIMAP7 -0.554386987 0.028666 1.30526632 0.021863 
GPR157 -0.826733847 0.031724 1.844800392 0.002285 
HIST1H2AC -2.317333894 0.003876 -1.555247681 0.043713 
IL33 -0.799078418 0.026093 -1.589206695 0.028392 
IL6ST -0.346209222 0.036204 -5 1.55E-14 
ITGA6 -0.386557844 0.041332 -1.132163475 0.020601 
KDR -1.01649251 0.027446 1.609651748 0.000579 
KIDINS220 -0.335580105 0.040251 -1.272954014 0.017108 
KLHL31 -0.967419601 0.040682 -1.242447658 0.022627 
KLHL38 0.335280765 0.045138 2.014012569 2.44E-06 
LIMS2 0.460768094 0.036658 1.077500891 0.013085 
LRRC14B 0.601273929 0.046813 2.497809238 2.29E-09 
MAGOH -0.307452819 0.048468 -5 2.79E-06 
MAOA -0.670884366 0.027791 1.156827805 0.033939 
MFAP4 -0.524445582 0.039794 -1.750721346 0.002055 
MON1B -0.59647824 0.0301 1.135406402 0.042159 
MRPL33 0.685197212 5.81E-05 -3.374524114 0 
MYO1B -0.606313032 0.025112 -1.152455909 0.026489 
NCKIPSD -0.409067028 0.043648 1.647170331 5.65E-07 
NDRG2 0.411302702 0.030812 0.914021945 2.83E-06 
NEAT1 -1.101387739 0.002411 1.359837777 0.042058 
NEDD9 -0.524428571 0.046449 1.403249907 0.001187 
NPPA -2.896073668 0.032393 -4.275261149 0 
NPPB -2.213258402 0.014572 -3.478505958 1.79E-13 
NR1D2 -0.366189625 0.043119 -5 8.32E-11 
OTUD1 -1.471407718 0.037677 1.307614166 0.008755 
PLA2G2A -2.647052214 0.045658 2.063800018 9.32E-07 
PLXDC2 -2.032815142 0.011265 -1.64696227 0.027561 
PMEPA1 -0.747667125 0.017309 -1.156183207 0.005308 
PPP1R12B 0.592237795 0.000174 -1.241293709 0.000151 
PRELP -0.570100677 0.036116 1.943073151 5.58E-07 
PREX1 -0.997966408 0.034587 1.63079897 0.000293 
PRKAA2 -0.426292519 0.046432 -1.187609705 0.026793 
PROS1 -0.92499567 0.042894 -1.777064031 0.000208 
PTGDS 0.646333156 0.004501 1.774781138 0.001074 




PTX3 -1.366782142 0.018539 -3.020915462 0.000259 
RNF146 -0.371611904 0.041492 -0.664744793 0.048359 
RPL28 -0.356732224 0.04316 0.86291538 0.047925 
RPL37A 0.515517464 0.049679 1.124108637 0.031403 
RPLP1 0.862792317 0.001217 1.078124335 0.002645 
RPS15A 1.025890917 0.049643 0.955141541 0.018754 
RTN3 -0.498114556 0.034032 -0.871600672 0.016901 
S100A1 1.472047839 0.000813 1.194716866 0.038654 
S100A8 -0.848107813 0.012523 1.735255886 0.006747 
SAMHD1 -0.58759924 0.018941 1.250344989 0.014341 
SCN2B -0.819119857 0.032449 -2.022686998 3.54E-05 
SEC14L1 -0.425089014 0.03269 1.207579863 0.003966 
SEMA3G -0.659911145 0.028594 1.140983505 0.031186 
SERPINH1 -0.564001102 0.043145 -1.417623133 0.004327 
SLC8A1 0.685780929 0.002115 -0.988155998 0.006057 
SPEN -0.504840729 0.035042 1.112858292 0.042159 
STK38 -0.666653177 0.018017 -1.23246269 0.04036 
STK39 -0.616865536 0.035728 -2.1051715 0.000835 
SUN1 -0.450823867 0.038098 0.750215245 0.022747 
TACC1 -0.370545039 0.038676 0.91919359 0.006701 
TAX1BP3 -1.445656879 0.023178 -5 5.68E-07 
THBS2 -0.665188472 0.044745 -2.475548465 7.80E-08 
THBS4 1.196572038 0.048544 -2.581450709 1.48E-09 
TIMP1 -1.008514924 0.028892 -1.301912191 0.012381 
TIMP3 -0.392285917 0.02239 1.659800666 0.004458 
TMEM100 -0.624594284 0.039693 -2.083667615 0.01159 
TNPO1 -0.651711854 0.013703 -0.97428252 0.044435 
TXNRD1 -0.397359953 0.043213 0.786257974 0.033516 
UCKL1 -0.916759905 0.006433 1.164593946 0.006452 
ULK1 0.844633034 0.042966 1.158112048 0.027754 
USP9X 0.696855665 0.033127 -1.085170923 0.041503 
VAMP8 -0.563839444 0.035165 -1.974598288 0.008887 
ZMIZ1 -0.698773614 0.039673 1.461323404 0.004155 





Supplemental Table 14. DEG shared between female obesity-related LVH and dilated 
cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_F p_adj 
log2FC NF vs 
DCM p_adj 
ACAA1 0.976931371 0.008231 1.073799181 0.04415 
ACTA1 -1.119896192 0.042476 1.585652186 0.035032 
AGPAT2 -0.862461622 0.031696 1.173437054 0.014742 
AGPAT9 -0.656929279 0.036148 -1.692568564 0.017186 
AKAP12 -0.731993228 0.026665 -2.360153532 1.43E-05 
AKAP8 0.719672413 0.041305 -1.108378062 0.027646 
AMOTL1 -0.709487539 0.023841 -2.394648442 0.000287 
ANAPC11 1.56653796 0.013918 0.824630217 0.002557 
ANGPTL4 -0.978298815 0.026011 2.676261492 7.52E-07 
ANXA2 -0.714896823 0.006722 -1.291176926 0.006209 
APOD -0.892669878 0.037102 -1.945149012 5.02E-05 
ARHGEF15 -0.676954813 0.024341 0.955448515 0.014902 
ARL6IP4 1.532074342 0.002399 0.839194224 0.013855 
ATE1 -0.823974167 0.02715 -5 2.59E-05 
ATP2B4 -0.473150152 0.047037 -2.249432133 1.86E-06 
AZIN1 -0.457215273 0.033503 -1.234736437 0.014779 
B2M -0.481096356 0.034341 -1.838140453 0.002514 
BCAR3 -0.799783333 0.044029 -1.55715444 0.04658 
BTG2 -0.547514523 0.022147 1.569479725 0.002223 
C17orf89 -0.36636919 0.036896 1.628093417 0.023999 
C1QTNF1 -0.866995909 0.004932 1.86440586 0.000983 
CALHM2 -0.468504076 0.04377 -1.19644797 0.049581 
CALM2 0.488690339 4.98E-09 -1.133345004 0.049818 
CAMK2D -0.517152358 0.048827 -1.21846042 0.005703 
CAST 1.51500001 0.003565 -1.367834595 0.000208 
CBLB -0.501922722 0.049091 -1.541442813 0.002264 
CCL2 0.861442892 0.041833 6.143199949 0.000908 
CCL21 -1.998910656 0.034425 -2.08871703 0.010486 
CD151 0.472684984 0.037071 -1.317019331 2.63E-06 
CD68 0.939054502 0.044368 1.772692722 0.000442 
CDKN1A -0.429068187 0.044115 1.293184109 0.041044 
CEBPB -0.441897123 0.035736 1.446932885 0.038798 
CES2 0.651625466 0.024136 1.624109893 3.83E-05 
CLIC5 0.419941576 0.031906 -1.829084965 0.024395 
CLINT1 -0.69542973 0.033752 -0.858279003 0.046264 




CPT1A 1.291808397 2.31E-05 -1.279781009 0.007423 
CRIM1 -0.434102162 0.048377 1.256178203 0.006172 
CTGF -1.189465404 0.030305 2.120582413 0.001288 
CXorf36 -0.529466638 0.04564 1.723076035 7.56E-05 
CYBRD1 -0.900806819 0.025364 1.184422202 0.02653 
CYR61 -1.807300387 0.000146 -1.254650049 0.019218 
DAAM2 -0.505335353 0.043894 1.768775305 2.20E-05 
DAPK2 0.74144734 0.046529 1.303940902 0.016556 
DCAF11 0.664734382 0.030771 -0.8027819 0.034408 
DCAF6 0.894946081 6.99E-15 -1.170334921 0.002897 
DIRAS3 -1.018644618 0.028944 -4.507392284 9.26E-13 
DNAJC3 -0.377663049 0.049951 -1.638522404 0.02877 
DRAM2 -0.726386837 0.022444 -5 0.000183 
DUSP1 -0.830211926 0.045995 -1.092128327 0.041697 
DYRK2 -0.486689622 0.045658 -1.634574589 0.00945 
EDF1 -0.810589432 0.028375 0.831908111 0.040718 
EDNRB -0.523326087 0.025631 2.827625448 7.91E-13 
EFEMP1 -0.729911964 0.04534 1.409250958 0.000575 
EFNB2 -0.534300677 0.031279 -1.403835955 0.019655 
EHD2 -0.487559748 0.015141 1.398161943 0.004582 
ELK1 -0.394407987 0.043625 1.195326989 0.002194 
EMILIN1 -0.571141425 0.039703 1.95821404 5.42E-05 
ENG -0.575150638 0.033416 -1.014972805 0.026503 
ENO2 -0.613111978 0.045746 2.196136473 0.0023 
ETS2 -0.554950903 0.039999 -1.676128716 0.000133 
FAM134B -0.884094691 0.024207 -1.884835279 0.00021 
FAM46A -0.647202094 0.012548 -1.451241958 0.04004 
FBLN5 -0.551338968 0.012826 -1.514662511 0.003136 
FBXL7 -0.378152289 0.044687 -1.181297147 0.039006 
FKBP5 -0.517708568 0.043381 2.593668358 2.22E-11 
FOS -1.058578228 0.043634 -2.021564297 0.000552 
FXYD1 1.676000427 0.009307 1.416270491 0.002163 
FXYD6 -0.615605462 0.041837 1.19541486 0.000825 
GADD45B -0.530310364 0.032794 1.914790207 0.00068 
GAS2L1 -0.662780815 0.035893 1.569622643 0.009101 
GAS5 -0.845491655 0.029155 -1.886659007 0.02464 
GAS7 -0.830867293 0.016998 0.970841425 0.003611 
GFM1 0.593327245 0.039675 -1.50539242 0.044621 
GIMAP6 -0.948944237 0.004831 5 9.08E-12 
GIMAP7 -0.554386987 0.028666 -1.410024917 0.009221 




GPR157 -0.826733847 0.031724 -1.730715343 0.036692 
HAGH 0.522401715 0.023181 1.028491735 0.03694 
HBB -5.455425115 0.000788 -7.950773935 7.01E-06 
HIST1H2AC -2.317333894 0.003876 -2.444267659 0.002105 
HSPB2 1.21107834 0.031367 1.552376496 0.031126 
HSPB6 0.654174777 0.04228 -1.92991699 0.001118 
IL6ST -0.346209222 0.036204 -5 1.49E-05 
IQGAP1 -0.864329128 0.028623 -1.914008486 0.002439 
JAG1 -0.648073868 0.021947 -1.500158672 0.004055 
JAK1 0.507474682 0.048446 -1.291085313 0.010722 
KCTD9 -0.652371069 0.029115 -1.588741638 0.045577 
KDR -1.01649251 0.027446 -1.618120478 0.001516 
KIDINS220 -0.335580105 0.040251 -1.826845671 0.002914 
KIF5B -0.239468754 0.033119 -1.602393975 0.02837 
KLHL31 -0.967419601 0.040682 -1.879304514 0.001189 
KLHL38 0.335280765 0.045138 -2.19231975 0.001188 
MAFG -0.651584295 0.048208 -1.010092131 0.009541 
MAGOH -0.307452819 0.048468 -5 3.86E-05 
METRN 0.568665031 0.049113 1.393969653 0.016556 
MFAP4 -0.524445582 0.039794 1.412504009 0.002207 
MGLL -0.375416043 0.049925 1.082085931 0.021445 
MKNK2 -0.562491586 0.021436 -0.940147819 0.03771 
MLYCD 0.893456574 6.48E-06 1.255474711 0.025587 
MON1B -0.59647824 0.0301 -1.329558764 0.016891 
MRPL33 0.685197212 5.81E-05 2.628185807 0.001411 
MTUS2 0.370084163 0.049071 1.366734076 0.005888 
MYLK3 -0.433901967 0.044447 -1.349636972 0.037659 
NBL1 -0.793221485 0.03112 -1.407958502 0.039406 
NCKIPSD -0.409067028 0.043648 1.807487423 0.000159 
NCOA4 -1.257988904 0.003347 -1.608733137 0.004488 
NDRG2 0.411302702 0.030812 0.796941477 0.019726 
NDUFAF1 -0.444998855 0.043183 1.320804879 0.031125 
NNT 1.040709158 0.002013 -1.685801348 0.004346 
NUDT4 -0.57452292 0.049429 -1.175784242 0.014874 
OTUD1 -1.471407718 0.037677 1.656789936 0.002426 
P2RY2 -0.645910688 0.038731 -0.949886077 0.044382 
PALM -0.628062223 0.027912 -1.462084762 0.004055 
PARVB 1.004307731 0.006333 -1.086567828 0.006525 
PDLIM3 -0.569792209 0.032775 -1.308620279 0.034935 
PDLIM7 -0.579683763 0.028378 2.236962747 1.13E-06 




PEX6 -0.497972807 0.037461 1.100292214 0.041317 
PLA2G2A -2.647052214 0.045658 5.409285129 0 
PNMAL1 -0.634642632 0.049439 -1.964423567 0.004 
PPP1R12B 0.592237795 0.000174 -2.028461332 0.000287 
PRELP -0.570100677 0.036116 1.33153185 0.000945 
PRKCDBP -0.26048416 0.045832 1.595793765 0.02828 
PTGDS 0.646333156 0.004501 1.322718047 0.028126 
PTMS -0.426086888 0.035995 2.640986855 3.74E-05 
PUM2 -0.45940875 0.017423 -1.520513073 0.025117 
QSOX1 0.570678641 0.035483 1.402760158 0.000116 
RAMP3 -0.605059906 0.04247 -1.03432831 0.046878 
RFTN1 -0.775743929 0.015701 1.628866348 0.000266 
RNF146 -0.371611904 0.041492 -0.889268847 0.026133 
RNF185 -0.83124553 0.01517 -5 1.80E-07 
RPL28 -0.356732224 0.04316 1.619734681 0.00747 
RPLP1 0.862792317 0.001217 1.300726888 0.046657 
RPS27A -0.501818519 0.026615 1.226988387 0.024042 
RTN4 -1.076477799 0.039426 -1.258282951 0.00121 
S100A1 1.472047839 0.000813 -2.005092261 0.000204 
S100A8 -0.848107813 0.012523 3.192432432 1.63E-05 
S100A9 -0.934970606 0.044725 3.700776981 2.27E-06 
SAMHD1 -0.58759924 0.018941 3.066923442 5.41E-10 
SCN2B -0.819119857 0.032449 -2.524350286 1.94E-05 
SDCBP -0.798182227 0.031003 -1.469515535 0.006884 
SEC14L1 -0.425089014 0.03269 1.182266352 0.042053 
SEL1L -0.44253006 0.035252 -1.241379115 0.017791 
SEMA3G -0.659911145 0.028594 -1.095365967 0.02975 
SERPINH1 -0.564001102 0.043145 -1.80990502 0.00023 
SERTAD3 -0.903840592 0.014546 -1.43676246 0.013748 
SGCA 0.496242738 0.028242 0.975357587 0.00212 
SLC25A29 -0.613634157 0.035854 1.485004892 0.035932 
SLC6A6 -1.150709242 0.016902 -1.743431244 0.00046 
SLC7A8 -0.972640406 0.035062 2.456764225 1.18E-07 
SLC8A1 0.685780929 0.002115 -1.420048399 0.000244 
SPARCL1 -0.598007079 0.012917 1.47024442 0.003893 
SPOP -0.397007271 0.040271 5 9.57E-10 
SRGN -0.363394399 0.036167 1.540982699 0.011232 
SRPX -0.387977389 0.036118 1.429851664 0.023931 
STAT1 -0.633400793 0.016494 -1.272018841 0.003775 
STAT3 -0.972618741 0.036138 1.755397946 4.58E-07 




SYNM 0.325806265 0.04979 -1.464381185 0.005351 
TACC1 -0.370545039 0.038676 1.464658566 1.73E-05 
TACC2 0.563731348 0.003703 0.951365548 0.043192 
TAX1BP1 0.279872161 0.036848 -1.262935914 0.024751 
TAX1BP3 -1.445656879 0.023178 5 7.34E-06 
TEAD4 -0.838120353 0.02039 1.917580892 0.000583 
TEK -0.665089599 0.042213 -1.904942937 0.000222 
TGFB1 -0.48409647 0.035802 -1.545663311 0.005583 
THBS4 1.196572038 0.048544 -2.120653978 0.002596 
TIMM8B -1.108598614 0.012035 5 5.43E-10 
TIMP1 -1.008514924 0.028892 1.840233596 0.006884 
TIMP3 -0.392285917 0.02239 2.182312486 4.85E-06 
TMEM204 -0.652903815 0.021325 1.673222066 0.016904 
TMSB4X -0.518989998 0.049079 -1.498036021 0.0037 
TSC1 -0.532485732 0.044115 -0.986793547 0.020307 
TXNRD1 -0.397359953 0.043213 -0.917006565 0.005121 
USP9X 0.696855665 0.033127 -1.591714262 0.022522 
VSTM2L -0.863262469 0.04021 3.223903018 5.23E-06 
WDR26 0.434242526 0.048381 -1.326486608 0.015158 
XIRP1 -0.78224014 0.048919 1.476941227 0.000878 
ZFP36 -0.991785116 0.017465 1.859309472 0.002371 





Supplemental Table 15. DEG shared between female obesity-related LVH and both dilated 
ischemia and cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_F p_adj 
log2FC ISCH vs 
DCM p_adj 
ADAM19 -0.630142749 0.037114 1.489280792 0.002551 
AKAP12 -0.731993228 0.026665 -1.06178257 0.015975 
AP1S2 -0.789011417 0.015457 1.309426583 0.020855 
APOD -0.892669878 0.037102 -1.524595823 0.000468 
APOL1 -0.782334647 0.021276 1.393911307 0.011075 
ATE1 -0.823974167 0.02715 -1.582781094 0.001702 
BCAR3 -0.799783333 0.044029 -1.610550008 0.004017 
BTG2 -0.547514523 0.022147 1.982556367 0.000194 
C1QTNF1 -0.866995909 0.004932 1.983690511 0.000181 
C8orf4 -0.883640814 0.03769 -2.378198117 1.06E-06 
CASP3 -0.66390716 0.043676 1.569891424 0.004874 
CAST 1.51500001 0.003565 -0.923186229 0.005729 
CCL2 0.861442892 0.041833 5.109077051 0.012536 
CCL21 -1.998910656 0.034425 3.211259363 1.73E-08 
CD151 0.472684984 0.037071 1.258355253 0.00377 
CD68 0.939054502 0.044368 1.783816809 0.00035 
CD93 -0.59718142 0.012803 1.638558045 0.000696 
COL6A2 -0.400028873 0.018589 1.196810429 0.046365 
CRIM1 -0.434102162 0.048377 1.280530737 0.0142 
CTGF -1.189465404 0.030305 1.712090851 0.00187 
CXorf36 -0.529466638 0.04564 1.404338257 0.005522 
DAPK2 0.74144734 0.046529 -1.29432394 0.012646 
DIRAS3 -1.018644618 0.028944 -2.755293509 1.15E-09 
DRAM2 -0.726386837 0.022444 5 1.19E-05 
DYRK2 -0.486689622 0.045658 -1.060596127 0.047844 
EFEMP1 -0.729911964 0.04534 1.867728848 3.00E-06 
EFNB2 -0.534300677 0.031279 -1.914497416 0.000313 
EGR1 -0.778673334 0.049178 -1.332175587 0.016758 
EMILIN1 -0.571141425 0.039703 2.041043672 8.13E-06 
ETFB 1.068367319 0.002431 -1.136020685 0.039885 
FAM114A1 -0.712234668 0.019887 1.298243506 0.023462 
FAM134B -0.884094691 0.024207 -1.226478006 0.004017 
FBXO40 0.559934599 0.049521 -1.302725083 0.048941 
FKBP5 -0.517708568 0.043381 1.999049339 1.19E-05 
FOS -1.058578228 0.043634 1.617142342 0.021996 




GJA1 -0.35022164 0.049747 -1.835417002 0.000968 
GLIPR2 -0.67926169 0.037362 1.940228249 0.005741 
GPR157 -0.826733847 0.031724 -1.956324683 0.003773 
HBA1 -3.400698784 0.001351 -2.7929336 4.60E-12 
HBB -5.455425115 0.000788 -2.22489195 1.09E-07 
IL1R1 -0.511212184 0.037637 1.483566641 0.024324 
IL33 -0.799078418 0.026093 1.634526823 0.021856 
IL6ST -0.346209222 0.036204 1.207790986 0.000608 
IQGAP1 -0.864329128 0.028623 1.474355992 0.009234 
ITGA6 -0.386557844 0.041332 1.585582568 0.000365 
JAG1 -0.648073868 0.021947 -1.288054053 0.02486 
KDR -1.01649251 0.027446 -1.766277418 0.000681 
KLHL38 0.335280765 0.045138 -1.661614181 0.001099 
LAMP2 -0.988496109 0.017906 0.967998379 0.031384 
LRRC14B 0.601273929 0.046813 -2.25222654 2.04E-06 
MAPK8IP3 -0.589170794 0.045532 -1.122339641 0.000425 
MLYCD 0.893456574 6.48E-06 -1.107128992 0.038156 
MRPL33 0.685197212 5.81E-05 3.24989797 5.31E-05 
MYO1B -0.606313032 0.025112 1.770265741 0.000998 
NCKIPSD -0.409067028 0.043648 -0.881265111 0.048721 
NEDD9 -0.524428571 0.046449 -2.282312678 1.31E-07 
NNT 1.040709158 0.002013 -1.370583183 0.001314 
NPPA -2.896073668 0.032393 1.804016681 0.002728 
NPPB -2.213258402 0.014572 3.95062945 1.28E-12 
NR1D2 -0.366189625 0.043119 1.769391525 0.000757 
PDLIM3 -0.569792209 0.032775 -1.051610175 0.033209 
PDLIM7 -0.579683763 0.028378 1.237640222 0.003134 
PLA2G2A -2.647052214 0.045658 3.345485111 2.17E-08 
PLVAP -1.265760002 0.017747 1.949632993 0.001075 
PLXDC2 -2.032815142 0.011265 1.934162391 0.005957 
PNMAL1 -0.634642632 0.049439 -1.904599535 0.000101 
PROS1 -0.92499567 0.042894 1.897009877 9.67E-05 
PTGDS 0.646333156 0.004501 -1.841490956 0.001027 
PTX3 -1.366782142 0.018539 5 2.34E-05 
QSOX1 0.570678641 0.035483 1.356787899 0.000798 
RFTN1 -0.775743929 0.015701 1.201772963 0.036786 
RNF145 -0.505423328 0.038072 5 1.05E-10 
RNF185 -0.83124553 0.01517 5 7.02E-08 
S100A1 1.472047839 0.000813 -1.356663715 0.0142 
S100A9 -0.934970606 0.044725 2.81213663 0.000516 




SDCBP -0.798182227 0.031003 -1.519540572 3.79E-05 
SERPINH1 -0.564001102 0.043145 1.273626761 0.012686 
SLC6A6 -1.150709242 0.016902 1.147020506 0.034305 
SLC7A8 -0.972640406 0.035062 1.870262997 0.000332 
SPOP -0.397007271 0.040271 5 2.65E-11 
STAT3 -0.972618741 0.036138 1.106890148 0.003681 
SUN1 -0.450823867 0.038098 -1.068370923 0.000884 
TCEAL7 -0.553228932 0.045743 2.828337491 0.009234 
TEAD4 -0.838120353 0.02039 1.594275865 0.009234 
TEK -0.665089599 0.042213 -1.674114374 0.001404 
TGFB1 -0.48409647 0.035802 1.319426652 0.027066 
THBS1 -0.377386586 0.048008 -1.958430312 6.76E-05 
THBS2 -0.665188472 0.044745 2.628736021 1.33E-08 
THBS4 1.196572038 0.048544 1.363856989 0.026136 
TIMM8B -1.108598614 0.012035 5 3.34E-11 
TIMP1 -1.008514924 0.028892 1.891597357 0.000442 
VAMP8 -0.563839444 0.035165 1.823924832 0.024876 
VSTM2L -0.863262469 0.04021 2.777014645 6.09E-05 
ZMIZ1 -0.698773614 0.039673 -1.238874926 0.040865 
ZNF436 -0.853453662 0.031663 1.7512317 0.03428 





Supplemental Table 16. DEG shared between male obesity-related LVH and ischemia 
datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_M p_adj 
log2FC NF vs 
ISCH p_adj 
ABTB1 -0.460991597 0.012788 0.899951705 0.012014 
ADAM9 0.324658867 0.038311 -1.296514971 0.0169 
ADAMTS15 0.546947449 0.043257 1.328317163 0.004927 
AIF1L 0.760356543 0.04817 1.666590241 0.000101 
ALDH6A1 -0.459566879 0.008789 1.123273643 0.036902 
ANTXR2 -0.239481735 0.033088 1.006537036 0.018857 
APLN 0.42609975 0.027729 -2.034721693 0.001492 
APLP1 -0.494267388 0.020786 -5 1.01E-09 
AQP7 -0.339087891 0.040948 1.111539965 0.040004 
ATP13A3 -0.303941208 0.047239 -2.110450865 6.16E-06 
AZGP1 -1.307980325 0 -1.138888768 0.040662 
AZIN1 -0.233055614 0.044509 -1.355458125 0.00242 
B4GALNT3 -0.438156567 0.021696 1.300729904 0.006208 
C10orf10 -0.776170461 3.00E-15 2.175525819 1.54E-07 
C11orf96 -0.286254062 0.045204 2.224645005 5.09E-06 
C3 0.99050202 0.025013 2.045972787 1.21E-05 
CD151 -0.510771364 4.00E-15 -1.076847186 0.003615 
CD300LG 0.770142832 0.020405 2.773023736 0 
CDKN1A -0.393196018 0.03855 1.066409299 0.042891 
CEP85 -0.354319987 0.033799 1.377027078 0.004362 
COL15A1 0.861245935 0.024047 -1.666558498 0.000493 
COL4A3BP -0.308889968 0.021196 -5 6.23E-08 
COMMD6 -0.280205666 0.028834 -3.151519642 3.22E-07 
COMP -0.849294671 0.039889 -4.065207514 2.18E-07 
CRNDE -0.528269658 0.034849 -2.186615542 0.004521 
CTIF -0.340308488 0.035364 1.15914319 0.000568 
DDAH1 -0.568797795 0.017604 -1.393084172 0.021863 
DNAJA4 -0.739665528 0.045952 -1.318690893 0.005975 
DYNLL1 -0.377506314 0.008446 -1.775643022 3.34E-05 
EDNRB 0.572001611 0.015444 2.168141571 1.62E-11 
ELK1 -0.345545015 0.016899 1.055086757 0.0086 
ENO2 -0.475902084 0.007665 1.329284641 0.01159 
ETV1 -0.348286938 0.047575 -1.585575868 0.000271 
FLNC -0.299205249 0.033991 1.534788946 0.000252 
FMOD -0.667877526 0.03788 -1.556832307 0.004055 




FSTL3 -0.413282056 0.011028 -1.278100975 0.030781 
GLUL -0.567151422 0.010959 1.511265015 4.26E-05 
GPIHBP1 0.716162309 0.032929 2.175472642 1.92E-07 
GPR153 -0.681905951 0.043028 -1.810031993 0.001268 
GSTT1 -1.140967802 0.033376 1.379716623 0.004122 
HCFC1R1 -0.269876232 0.028189 1.813783392 4.68E-09 
HDAC5 -0.290056255 0.000133 1.016822647 0.003741 
HEPH -0.385669396 0.016989 -2.635587422 7.15E-08 
HFE2 -0.416585779 0.021178 -5 2.01E-15 
HIF3A -0.36726417 0.031215 1.90209774 2.88E-11 
HIPK3 0.347338792 0.026941 -5 1.85E-10 
HIST1H2BD -0.444623519 0.022086 -1.819527247 0.008223 
HLA-B 0.583581342 0.049228 1.447469619 0.002137 
IER5 -0.5107848 0.011172 1.11415786 0.032784 
IGFBP2 -0.862259937 0 -2.089911786 5.79E-06 
IL6ST 0.33077625 0.049957 -0.96627322 0.007438 
IRX3 -0.407781337 0.043472 1.642289454 0.000158 
ITGA6 0.49961087 0.032435 -1.130173886 0.004787 
ITGB1 0.292811102 0.042933 -1.012564118 0.006673 
ITPKB 0.68388826 0.022309 1.136878349 0.031003 
JUP -0.351730759 2.00E-15 1.340514078 0.000647 
KCTD17 -0.563715606 3.80E-05 -1.477646367 0.021895 
KLHL21 -0.309586543 0.03786 1.946075397 3.75E-05 
KLHL31 0.331983204 0.041734 -1.242447658 0.022627 
LDB3 -0.193086896 0.037827 0.780896708 0.021489 
LDHA -0.518131046 0.016036 -1.229179915 0.019527 
LRRC14B -0.582658557 6.69E-05 2.497809238 2.29E-09 
MAOA -0.292685908 0.017421 1.156827805 0.033939 
MASP1 -0.627801182 9.84E-05 -1.201667492 0.015218 
MFAP4 -0.36430884 0.013485 -1.750721346 0.002055 
MT1X -0.820480928 0.041477 -3.148047139 3.10E-06 
MTMR14 -0.314430647 0.014979 1.060913826 0.00318 
MTSS1 0.405885732 0.039649 1.302231648 0.008775 
MYL4 1.123474745 1.01E-06 5.061522714 0 
NAP1L1 -0.313200929 0.020236 -0.910734866 0.027081 
NCEH1 0.470319732 0.040649 -5 1.70E-07 
NDRG2 -0.146954763 0.035152 0.914021945 2.83E-06 
NEAT1 -0.355959133 0.032055 1.359837777 0.042058 
NPPA -4.597666596 0.018249 -4.275261149 0 
NPPB -2.898570787 0.013588 -3.478505958 1.79E-13 




OPA1 0.179786546 0.041586 -1.003990391 0.003612 
OTUD1 -0.364965273 0.009595 1.307614166 0.008755 
PDK4 -1.190849404 0.023484 -1.621761989 0.003644 
PHLDA1 -0.967904287 0.013169 -1.533891972 0.00837 
PIK3IP1 -0.515566884 0.034509 1.573888462 0.000162 
PLEKHA6 -0.428192332 0.011977 1.556511571 0.00051 
PLK2 -0.741565424 0.022569 1.372546472 0.009604 
POR -0.512484111 0.02111 1.351443234 0.004687 
POSTN -0.716023612 0.043196 -5.398096936 0 
PPAP2B 0.270841062 0.049882 1.203371662 0.018584 
PROS1 -0.634473414 0.022481 -1.777064031 0.000208 
PTMS -0.204572767 0.018308 1.586696097 0.000379 
RASL10B -0.604665337 0.017747 1.614289113 0.000481 
RBM3 0.274338467 7.99E-15 1.527018038 0.000788 
RPL28 -0.215383175 0.033283 0.86291538 0.047925 
RPS27L -0.453376267 0.038886 -1.237217046 0.026793 
RRAS2 -0.417699346 0.008991 -5 9.89E-07 
RXRG -0.430989662 0.043663 -2.486881571 0.001101 
SEC14L5 1.203995176 0.025826 2.532045159 4.07E-09 
SH3BGR -1.038419793 0.041381 -1.126205863 0.042774 
SHISA3 0.929801987 0.049266 3.030175389 1.33E-08 
SLC27A6 -0.725885867 0.012021 -1.314110357 0.029792 
SLCO2A1 -0.40718502 0.038314 1.689613686 0.000169 
SNHG8 -0.344159108 0.042777 1.326354211 0.025361 
SOD3 -0.402059082 0.00539 -1.490774626 0.002217 
SVOP -1.064191722 0.034337 -2.07588899 0.003099 
TFRC 1.359094592 0.041854 -1.626296372 0.000835 
TGM2 -0.492854217 0.012428 1.284423864 0.028545 
TIMM9 -0.248657524 0.033989 -5 1.94E-05 
TIMP3 0.458961699 0.040691 1.659800666 0.004458 
TMEM140 -0.89371551 1.20E-14 1.502983443 0.001443 
TOM1 -0.405308093 0.030337 0.901618286 0.045771 
TSPYL2 -0.85969565 0.0075 1.54357506 0.000704 
TUBB6 0.430747751 0.023596 1.122036783 0.036911 
TXNRD1 -0.490654157 0.036189 0.786257974 0.033516 
UBAC2 -0.238098048 0.035092 -1.270103527 0.015028 
UBE3A -0.140145749 0.047775 -5 2.61E-09 
UCHL1 -0.876726333 0.012504 -2.745991144 0.002544 
UGT2B4 0.967809667 0.036872 -3.395510497 1.03E-05 
ULK1 -0.386662051 0.013491 1.158112048 0.027754 




XIRP2 0.508831734 0.026453 -1.338335243 0.00205 
XPR1 -0.404531859 0.040079 -0.992860816 0.035245 





Supplemental Table 17. DEG shared between male obesity-related LVH and dilated 
cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_M p_adj 
log2FC NF vs 
DCM p_adj 
ABAT -0.436324244 0.035648 -1.855169072 0.000245 
ABCA8 0.648874255 0.042578 -1.940300807 0.002435 
ABHD11 -0.294215215 0.032183 0.953401699 0.034878 
ACOT11 -0.361296457 0.012581 -1.52973733 0.000207 
ADAMTS15 0.546947449 0.043257 2.160891353 6.59E-06 
AGPAT2 -0.305168768 0.014057 1.173437054 0.014742 
AGPAT9 -0.472276352 0.029837 -1.692568564 0.017186 
AIF1L 0.760356543 0.04817 -1.690830076 5.89E-05 
ALDH1L1 -0.422880657 0.013817 1.464875776 0.00475 
ALDH6A1 -0.459566879 0.008789 -1.487913517 0.003356 
ANAPC11 -0.221336121 0.021095 0.824630217 0.002557 
ANTXR2 -0.239481735 0.033088 -0.934274411 0.046 
APLN 0.42609975 0.027729 -3.647631894 1.65E-07 
APLP1 -0.494267388 0.020786 -5 3.22E-07 
APRT -0.2692331 0.048238 1.479862863 0.036549 
AQP7 -0.339087891 0.040948 1.320446161 0.012755 
AZGP1 -1.307980325 0 2.180581657 2.13E-06 
AZIN1 -0.233055614 0.044509 -1.234736437 0.014779 
B4GALNT3 -0.438156567 0.021696 -1.571730374 0.002181 
BAMBI -0.442504318 0.019297 1.432540867 0.011909 
C10orf76 -0.378725282 0.014545 -1.837503291 0.007708 
C11orf24 -0.333366417 0.011191 1.146685791 0.045062 
C11orf96 -0.286254062 0.045204 1.838403629 0.010094 
C1orf115 0.560171498 0.038375 1.522052774 0.004354 
C1orf122 -0.293493497 0.012048 1.113214233 0.036556 
C1QTNF1 -0.578503513 0.038739 2.113417594 0.001372 
C3 0.99050202 0.025013 1.430493191 0.005785 
C6orf1 -0.509148869 0.011928 1.462087575 0.00141 
CAMK2B -0.371924966 0.002571 0.782785864 0.024498 
CAST -0.150895471 0.043171 -1.367834595 0.000208 
CCDC85B -0.626416075 3.60E-14 1.451714992 0.003356 
CCL2 0.671466177 9.02E-06 6.143199949 0.000908 
CD151 -0.510771364 4.00E-15 -1.317019331 2.63E-06 
CD300LG 0.770142832 0.020405 2.221769286 1.13E-11 
CDH5 0.713600224 0.047911 -1.238663795 0.005578 




CDKN1A -0.393196018 0.03855 1.293184109 0.041044 
CEBPB -0.464728923 0.031278 1.446932885 0.038798 
CEBPD -0.492843424 0.035732 1.639611818 0.015646 
CNN2 -0.234532303 0.032806 1.205382083 0.042821 
COL23A1 -0.759281134 0.023043 1.965826273 0.00649 
COL4A3BP -0.308889968 0.021196 -5 1.04E-06 
COMMD6 -0.280205666 0.028834 1.986287051 0.003216 
CRELD1 -0.571053939 0.015765 1.119429701 0.003928 
CTF1 -0.374627485 0.038807 1.46343487 0.003932 
CTIF -0.340308488 0.035364 -0.901524118 0.031209 
CTNNA3 0.420902413 0.047603 -2.358489586 0.000779 
CTSF -0.609388393 0.012649 1.636528981 0.001335 
CYGB 0.484721501 0.045147 1.603747399 0.000827 
DCAF11 -0.23242679 0.017956 -0.8027819 0.034408 
DKK3 -0.746405642 0.011774 -1.591477235 5.19E-05 
DPM3 -0.372064209 0.01069 -1.330865471 0.04489 
DSP 0.169735277 0.025423 -1.738090398 0.024171 
EDF1 -0.314122494 6.00E-15 0.831908111 0.040718 
EDNRB 0.572001611 0.015444 2.827625448 7.91E-13 
EGLN3 -0.362429875 0.038702 1.213162938 0.017311 
ELK1 -0.345545015 0.016899 1.195326989 0.002194 
ELN 0.558139214 0.001639 3.353674038 7.56E-10 
ENO1 0.36807835 0.045018 -1.04443571 0.039006 
ENO2 -0.475902084 0.007665 2.196136473 0.0023 
EPN1 -0.367415216 2.90E-14 1.140407858 0.034801 
FAM134B -0.446289424 0.009389 -1.884835279 0.00021 
FAM58A -0.428148244 0.013924 1.589540039 0.008686 
FAM96B -0.258604662 0.036243 1.007933098 0.042718 
FAM98C -0.299884112 0.038198 -5 0.00225 
FGF12 0.915237306 0.016281 -1.357459243 0.041842 
FMOD -0.667877526 0.03788 -1.629519375 0.032014 
FXYD1 -0.482324859 0.014267 1.416270491 0.002163 
GADD45B -0.497838091 0.034827 1.914790207 0.00068 
GLUL -0.567151422 0.010959 1.664537577 5.94E-08 
GPIHBP1 0.716162309 0.032929 1.997394735 0.000878 
GPNMB 0.834656999 0 -1.545983281 0.000353 
GPR153 -0.681905951 0.043028 3.330351255 1.19E-10 
HAGH -0.269484135 0.033144 1.028491735 0.03694 
HCFC1R1 -0.269876232 0.028189 2.009929055 7.11E-08 
HDAC5 -0.290056255 0.000133 0.998631607 0.036506 




HIF3A -0.36726417 0.031215 2.0184829 6.70E-10 
HIST1H2BD -0.444623519 0.022086 -1.796075408 0.0122 
HIST3H2A -0.390486066 0.040552 -1.888931371 0.048405 
HLA-B 0.583581342 0.049228 -1.295070572 0.016126 
HSPB2 -0.265488233 0.029863 1.552376496 0.031126 
HSPBP1 -0.321175159 0.02344 1.023892449 0.014184 
HSPE1 -0.626289358 0.017401 -1.424482306 0.044167 
IER5 -0.5107848 0.011172 1.61853436 0.023403 
IFI6 -0.347885446 0.032703 1.410291788 0.002942 
IFT43 -0.501012542 0.009442 1.37413865 0.020028 
IL6ST 0.33077625 0.049957 -5 1.49E-05 
INMT 0.824405867 0.001049 -1.18429467 0.014254 
IRX3 -0.407781337 0.043472 1.929352226 2.35E-05 
ISCU -0.134040132 0.028242 1.33769501 0.01322 
ITGB1 0.292811102 0.042933 -0.980421554 0.045357 
ITM2A 0.703262638 4.45E-05 -1.478001876 0.031951 
ITPKB 0.68388826 0.022309 -1.228955592 0.023999 
JOSD2 -0.384763927 0.002388 2.475679235 0.001562 
JUP -0.351730759 2.00E-15 -0.947178548 0.021847 
KAT2B 0.27694211 0.045965 -1.988769812 0.003654 
KCND3 0.403416768 0.04292 -5 1.18E-05 
KIAA1462 0.656200891 0.044113 -1.673784644 0.019311 
KIF1B 0.307621803 0.028657 -1.420263708 0.020581 
KLC2 -0.277130347 0.047432 1.010816551 0.028992 
KLF15 -0.700234622 0.017053 2.244450656 6.56E-06 
KLHL21 -0.309586543 0.03786 -1.209988358 0.023398 
KLHL31 0.331983204 0.041734 -1.879304514 0.001189 
LDB3 -0.193086896 0.037827 0.661937621 0.036828 
LDHA -0.518131046 0.016036 -1.193485774 0.036046 
LRRC10 -0.477986329 0.017955 -2.556754092 9.14E-05 
MAFK -0.41121213 0.017121 -1.600385839 0.000849 
MASP1 -0.627801182 9.84E-05 -1.236931196 0.011745 
METRN -0.308008848 0.015824 1.393969653 0.016556 
MFAP4 -0.36430884 0.013485 1.412504009 0.002207 
MGLL 0.557831017 0.029221 1.082085931 0.021445 
MKNK2 -0.56656081 0.036684 -0.940147819 0.03771 
MLYCD -0.398413389 0.025974 1.255474711 0.025587 
MRPL55 -0.348486272 0.015397 1.25082383 0.000798 
MTMR14 -0.314430647 0.014979 0.984248097 0.015083 
MXI1 -0.44513223 5.68E-05 -1.014610918 0.034023 




MYL4 1.123474745 1.01E-06 7.928132761 0 
MYLK3 -0.294168859 0.037545 -1.349636972 0.037659 
NCEH1 0.470319732 0.040649 -1.070742336 0.035032 
NCOA4 0.20875989 2.30E-08 -1.608733137 0.004488 
NDRG2 -0.146954763 0.035152 0.796941477 0.019726 
NENF -0.312674229 0.023928 1.113785717 0.041455 
NOL3 -0.283878573 0.036899 1.412768463 0.000199 
NRTN -0.748451624 0.001353 2.237726854 0.013565 
NT5C1A 0.656828147 0.046935 -2.854945342 0.0023 
OPA1 0.179786546 0.041586 -5 4.03E-09 
ORMDL3 -0.28424199 0.020082 1.083147377 0.040718 
OTUD1 -0.364965273 0.009595 1.656789936 0.002426 
PACS1 -0.267153098 0.01 1.081585456 0.020732 
PDK4 -1.190849404 0.023484 -2.495837398 3.53E-08 
PEBP4 -0.444188822 8.73E-09 1.357320348 0.002526 
PHLDA1 -0.967904287 0.013169 -2.900790044 9.89E-09 
PIK3IP1 -0.515566884 0.034509 1.628750929 0.000141 
PLA2G16 -0.429325781 8.99E-15 1.062296467 0.006247 
PLEKHA4 -0.4970689 0.020773 1.715005619 0.002446 
PLEKHO1 -0.595716203 6.00E-15 1.581454714 0.030276 
PLIN4 -0.342258388 0.037297 1.770077196 0.005091 
PLP2 -0.41520749 9.72E-06 2.438307418 0.000171 
PPAP2B 0.270841062 0.049882 -1.148180528 0.012479 
PSME1 -0.187065181 0.044005 -1.220196145 0.026897 
PTGR2 -0.240516468 0.042626 -1.384657793 0.018137 
PTMS -0.204572767 0.018308 2.640986855 3.74E-05 
PTPRB 0.897075719 1.29E-08 -1.293901464 0.028365 
QSOX1 -0.382599933 0.018983 1.402760158 0.000116 
RAB40B -0.497432018 1.33E-11 1.260992128 0.03673 
RABAC1 -0.344457803 0.013844 1.466716007 0.048405 
RAPGEF2 0.348172878 0.046195 -1.486548606 0.029188 
RASL10B -0.604665337 0.017747 1.34844708 0.010022 
RBM3 0.274338467 7.99E-15 -1.142839467 0.013191 
RHOC -0.279578803 0 1.024149951 0.003138 
RPL13 -0.259754186 0.03225 0.96882753 0.038432 
RPL28 -0.215383175 0.033283 1.619734681 0.00747 
RPL34 -0.19977586 0.032458 -1.135965587 0.045212 
RPPH1 -0.443235403 0.046663 -1.490980417 0.007622 
RPS27A -0.320176756 0.019056 1.226988387 0.024042 
RRP12 -0.500648788 0.026194 -1.312136309 0.00381 




SGCA -0.452258165 7.99E-15 0.975357587 0.00212 
SGCG -0.220288165 0.047528 1.390817319 0.00745 
SH3BGR -1.038419793 0.041381 -1.456364189 0.004471 
SHISA3 0.929801987 0.049266 2.945548655 2.73E-05 
SHISA4 -0.190293722 0.034849 1.167445824 0.012045 
SLC16A1 0.342603538 0.047959 -1.5319772 0.015032 
SLC25A29 -0.369212061 0.032238 1.485004892 0.035932 
SLC27A6 -0.725885867 0.012021 -2.371207698 5.90E-05 
SLCO2A1 -0.40718502 0.038314 3.644338952 4.74E-08 
SNAP47 -0.449792851 0.036703 -1.291372522 0.025832 
SNHG8 -0.344159108 0.042777 1.921250812 0.000585 
SPARC 0.610476051 0.006824 2.314285316 0.00014 
SPR -0.578686275 0.008157 1.53937965 0.003249 
ST6GALNAC4 -0.440998042 0.015328 1.038108792 0.027679 
TCEAL3 -0.354979559 0.017945 1.259083776 0.040293 
TCEB2 -0.262708567 0.038371 1.00029373 0.029824 
TEAD1 0.289096382 0.029968 -1.8094642 0.003053 
TGM2 -0.492854217 0.012428 2.399523907 0.001434 
TIMM9 -0.248657524 0.033989 -5 0.006 
TIMP3 0.458961699 0.040691 2.182312486 4.85E-06 
TM4SF1 0.367067279 0.04299 -1.212879539 0.037013 
TMEM140 -0.89371551 1.20E-14 1.440124571 0.005012 
TNK2 -0.315040377 0.036253 1.394373146 0.042979 
TNNI1 0.738987233 0.049448 9.276823467 0 
TRNP1 -0.498430701 6.00E-15 1.369548495 0.014466 
TSPYL2 -0.85969565 0.0075 2.390733186 2.13E-05 
TUBB6 0.430747751 0.023596 1.642746812 0.030168 
TXNRD1 -0.490654157 0.036189 -0.917006565 0.005121 
UTRN 0.391412756 0.039902 -1.589898147 0.013508 
VWF 0.704070796 0.019926 -1.135546205 0.027555 
WDR62 1.072490247 2.15E-12 -1.109653992 0.011913 
WISP2 -0.614891518 0.032136 2.328288849 0.002022 
XIRP1 -0.317827132 0.036235 0.949858802 0.011572 
XIRP2 0.508831734 0.026453 -1.017910018 0.001751 
XPR1 -0.404531859 0.040079 -1.53208742 0.000285 
YIF1B -0.263588099 0.043766 1.10697907 0.029123 





Supplemental Table 18. DEG shared between male obesity-related LVH and both dilated 
ischemia and cardiomyopathy datasets with (p_adj < 0.05) 
Gene 
log2FC NF vs 
LVH_M p_adj 
log2FC ISCH vs 
DCM p_adj 
ABAT -0.436324244 0.035648 1.402124026 0.014941 
ABCA8 0.648874255 0.042578 -1.84507599 0.000274 
ACOT11 -0.361296457 0.012581 1.184750634 0.014629 
ADAM9 0.324658867 0.038311 1.186817111 0.031098 
APLN 0.42609975 0.027729 -1.612910202 0.002372 
AQP7 -0.339087891 0.040948 -1.44003696 0.001261 
ATP13A3 -0.303941208 0.047239 1.838355362 0.000121 
AZGP1 -1.307980325 0 1.813024958 0.000192 
C1QTNF1 -0.578503513 0.038739 1.983690511 0.000181 
C5orf46 -0.638118011 0.025592 2.279946307 0.048626 
CAMK2B -0.371924966 0.002571 -0.758761378 0.020855 
CAST -0.150895471 0.043171 -0.923186229 0.005729 
CCL2 0.671466177 9.02E-06 5.109077051 0.012536 
CD151 -0.510771364 4.00E-15 1.258355253 0.00377 
CD300LG 0.770142832 0.020405 -1.275290819 0.007124 
CHPF -0.333975406 0.005284 1.502751997 0.018214 
COL15A1 0.861245935 0.024047 1.680275526 0.000418 
COL23A1 -0.759281134 0.023043 2.384872695 2.68E-05 
COMMD6 -0.280205666 0.028834 2.877074001 3.04E-06 
COMP -0.849294671 0.039889 3.672769871 1.37E-06 
CTNNA3 0.420902413 0.047603 -1.665848899 0.004357 
DKK3 -0.746405642 0.011774 -1.17219224 0.001464 
ELN 0.558139214 0.001639 2.405718414 2.62E-07 
FAM134B -0.446289424 0.009389 -1.226478006 0.004017 
GADD45B -0.497838091 0.034827 1.423620172 0.03675 
GPR153 -0.681905951 0.043028 2.838701409 5.12E-07 
GSTT1 -1.140967802 0.033376 -1.408853917 0.010118 
HEPH -0.385669396 0.016989 2.343603804 5.93E-07 
HIPK3 0.347338792 0.026941 -1.575941651 6.26E-05 
HIST3H2A -0.390486066 0.040552 -1.597503693 0.044378 
IGFBP2 -0.862259937 0 2.645422346 4.96E-07 
IL6ST 0.33077625 0.049957 1.207790986 0.000608 
ILVBL -0.267348022 0.004582 -1.210007211 0.012376 
IRX3 -0.407781337 0.043472 -1.18400673 0.014833 
ITGA6 0.49961087 0.032435 1.585582568 0.000365 




JOSD2 -0.384763927 0.002388 1.795954224 0.018766 
KCND3 0.403416768 0.04292 -1.876821251 0.001093 
KCTD17 -0.563715606 3.80E-05 2.047177058 0.002859 
KLF15 -0.700234622 0.017053 1.466101481 0.017679 
LDHA -0.518131046 0.016036 1.163646348 0.034742 
LRRC14B -0.582658557 6.69E-05 -2.25222654 2.04E-06 
MAFK -0.41121213 0.017121 -1.418199767 0.005203 
MLYCD -0.398413389 0.025974 -1.107128992 0.038156 
MRPL55 -0.348486272 0.015397 -1.182167424 0.001452 
MT1X -0.820480928 0.041477 1.515877998 0.048194 
MTSS1 0.405885732 0.039649 -1.550740075 0.00301 
MYL4 1.123474745 1.01E-06 2.866610047 1.24E-05 
NOL3 -0.283878573 0.036899 -0.792023062 0.048467 
NPPA -4.597666596 0.018249 1.804016681 0.002728 
NPPB -2.898570787 0.013588 3.95062945 1.28E-12 
PFKFB2 -0.500907657 0.03972 -1.879265511 2.54E-08 
PHLDA1 -0.967904287 0.013169 -1.366898072 0.013516 
PKIA 0.190572744 0.040133 0.958191615 0.03428 
PLEKHA4 -0.4970689 0.020773 1.693949792 0.000295 
PLK2 -0.741565424 0.022569 -2.454955955 5.88E-07 
PLP2 -0.41520749 9.72E-06 1.488051412 0.015975 
PLVAP -1.298964363 3.00E-15 1.949632993 0.001075 
PNPLA2 -0.47250156 1.80E-14 -1.203871191 0.03428 
POSTN -0.716023612 0.043196 4.131445065 0 
PROS1 -0.634473414 0.022481 1.897009877 9.67E-05 
QSOX1 -0.382599933 0.018983 1.356787899 0.000798 
RAPGEF2 0.348172878 0.046195 -1.258547528 0.029287 
RBM24 -0.241858165 0.043341 -1.241857132 0.035328 
RRAS2 -0.417699346 0.008991 5 2.41E-05 
S1PR3 0.77952287 1.29E-08 2.144826087 0.000239 
SEC14L5 1.203995176 0.025826 -2.791126985 9.97E-09 
SLCO2A1 -0.40718502 0.038314 1.954725266 0.004097 
SPARC 0.610476051 0.006824 2.112232792 0.000418 
SVOP -1.064191722 0.034337 3.167780548 4.70E-05 
SYNE1 0.420361736 0.039974 -1.017437725 0.025506 
TBX20 0.935812719 0.0246 -2.297082344 1.42E-06 
TFRC 1.359094592 0.041854 1.549593619 0.001462 
THBS1 -0.525021016 0.028597 -1.958430312 6.76E-05 
TIMM9 -0.248657524 0.033989 5 1.32E-05 
TNNI1 0.738987233 0.049448 5.839519429 0 




WDR18 -0.426309848 0.035078 -1.180729841 0.024547 
WISP2 -0.614891518 0.032136 1.907856911 0.005317 






Supplemental Table 19. Gene ontology results for “biological processes” from Ingenuity 
Pathway Analysis 
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oxygen species 





cellular response to 
oxidative stress 


























negative regulation of cell 





cellular response to 
external stimulus 













(GO:1901293) 2/209 0.00373 0.02112531 -2.3023159 8.880684986 
NPPB; 
NPPA 
positive regulation of 
renal sodium excretion 
(GO:0035815) 1/14 0.00628 0.02563726 
-
2.36912468 8.679782303 NPPB 
cellular modified amino 
acid metabolic process 








regulation of fatty acid 
oxidation (GO:0046320) 1/24 0.01075 0.029401443 
-
2.39620447 8.450721933 PDK4 
response to insulin 





negative regulation of 
growth (GO:0045926) 2/221 0.00416 0.022924024 -2.2225645 8.391447455 
NPPB; 
NPPA 
positive regulation of 
urine volume 
(GO:0035810) 1/13 0.00584 0.025330625 
-
2.26932608 8.341455256 NPPB 
regulation of homeostatic 





regulation of renal 
sodium excretion 
(GO:0035813) 1/22 0.00986 0.029401443 
-
2.34779171 8.279984113 NPPB 
regulation of sulfur 
metabolic process 
(GO:0042762) 1/17 0.00763 0.026820941 
-
2.28302805 8.261302138 PDK4 
renal absorption 
(GO:0070293) 1/13 0.00584 0.025330625 
-
2.24317347 8.245325008 HBB 
regulation of urine 
volume (GO:0035809) 1/18 0.00807 0.027446534 
-
2.29288751 8.244112312 NPPB 
regulation of coenzyme 
metabolic process 
(GO:0051196) 1/14 0.00628 0.02563726 
-
2.24966527 8.242117842 PDK4 
regulation of vascular 
permeability 
(GO:0043114) 1/27 0.01209 0.029401443 
-
2.32303767 8.192683755 NPPB 
response to oxidative 





regulation of cofactor 
metabolic process 
(GO:0051193) 1/14 0.00628 0.02563726 
-
2.22720499 8.159829903 PDK4 
phosphatidylglycerol 
acyl-chain remodeling 
(GO:0036148) 1/17 0.00763 0.026820941 
-
2.24878469 8.137390053 PLA2G2A 
response to inorganic 





regulation of excretion 
(GO:0044062) 1/25 0.0112 0.029401443 
-
2.28068583 8.043321033 NPPB 
negative regulation of 
anoikis (GO:2000811) 1/16 0.00718 0.026820941 
-
2.21378836 8.010753305 PDK4 
regulation of acyl-CoA 
biosynthetic process 
(GO:0050812) 1/13 0.00584 0.025330625 
-
2.17524596 7.995641076 PDK4 
response to peptide 





negative regulation of 
systemic arterial blood 
pressure (GO:0003085) 1/13 0.00584 0.025330625 
-
2.15854699 7.934259986 NPPA 
response to peptide 





regulation of anoikis 
(GO:2000209) 1/20 0.00897 0.028139038 
-
2.20456099 7.871599745 PDK4 
regulation of acetyl-CoA 





regulation of cell growth 





positive regulation of 
macrophage derived foam 
cell differentiation 
(GO:0010744) 1/15 0.00673 0.026820941 
-
2.16462201 7.832841304 PLA2G2A 
phosphatidylcholine acyl-
chain remodeling 
(GO:0036151) 1/26 0.01164 0.029401443 
-
2.21865045 7.824540131 PLA2G2A 
organic anion transport 







(GO:0036149) 1/16 0.00718 0.026820941 
-
2.15382746 7.793780434 PLA2G2A 
phosphatidylserine acyl-
chain remodeling 
(GO:0036150) 1/17 0.00763 0.026820941 
-
2.14615106 7.766002824 PLA2G2A 
phosphatidylethanolamine 
acyl-chain remodeling 
(GO:0036152) 1/23 0.0103 0.029401443 -2.1875258 7.714772466 PLA2G2A 
carbohydrate derivative 
biosynthetic process 





cellular response to fatty 
acid (GO:0071398) 1/27 0.01209 0.029401443 
-
2.15589578 7.603222498 PDK4 
protein oligomerization 





(GO:0034368) 1/23 0.0103 0.029401443 
-
2.14232935 7.55537763 PLA2G2A 
regulation of macrophage 
derived foam cell 
differentiation 
(GO:0010743) 1/28 0.01253 0.029727456 
-
2.14517339 7.541752258 PLA2G2A 
phosphatidylserine 
metabolic process 
(GO:0006658) 1/27 0.01209 0.029401443 
-
2.13577782 7.532272253 PLA2G2A 
low-density lipoprotein 
particle remodeling 
(GO:0034374) 1/11 0.00494 0.025330625 
-
2.04798395 7.527858869 PLA2G2A 
macromolecular complex 
remodeling 
(GO:0034367) 1/23 0.0103 0.029401443 
-
2.13154487 7.517343872 PLA2G2A 
cardiac muscle adaptation 
(GO:0014887) 1/13 0.00584 0.025330625 -2.0425056 7.507721883 NPPA 
plasma lipoprotein 
particle remodeling 
(GO:0034369) 1/23 0.0103 0.029401443 
-
2.12240361 7.485105269 PLA2G2A 
positive regulation of 
nitric oxide biosynthetic 
process (GO:0045429) 1/32 0.01431 0.03199631 
-
2.16432542 7.449899633 HBB 
cellular amino acid 
metabolic process 








muscle hypertrophy in 
response to stress 
(GO:0003299) 1/13 0.00584 0.025330625 
-
2.01519176 7.407323274 NPPA 
cardiac muscle 
hypertrophy 
(GO:0003300) 1/17 0.00763 0.026820941 
-
2.03932258 7.379436253 NPPA 
regulation of fatty acid 
biosynthetic process 
(GO:0042304) 1/29 0.01298 0.03042917 
-
2.09889379 7.330079239 PDK4 
cardiac muscle 
hypertrophy in response 
to stress (GO:0014898) 1/13 0.00584 0.025330625 
-
1.96695067 7.230001514 NPPA 
regulation of bone 
resorption (GO:0045124) 1/33 0.01476 0.032022137 
-
2.09602489 7.213108818 PDK4 
striated muscle 
hypertrophy 
(GO:0014897) 1/18 0.00807 0.027446534 
-
2.00283531 7.201225173 NPPA 
glutathione derivative 
biosynthetic process 
(GO:1901687) 1/27 0.01209 0.029401443 -2.0370459 7.184073249 GSTT1 
glutathione derivative 
metabolic process 
(GO:1901685) 1/27 0.01209 0.029401443 
-
2.03284516 7.16925846 GSTT1 
striated muscle adaptation 
(GO:0014888) 1/23 0.0103 0.029401443 
-
2.03178992 7.165536941 NPPA 
regulation of vasodilation 
(GO:0042312) 1/39 0.01742 0.035889962 
-
2.14413362 7.13417069 NPPB 
muscle hypertrophy 
(GO:0014896) 1/20 0.00897 0.028139038 -1.9959265 7.126649966 NPPA 
phosphatidic acid 
metabolic process 
(GO:0046473) 1/31 0.01387 0.031430911 
-
2.05771477 7.119617883 PLA2G2A 
phosphatidic acid 
biosynthetic process 
(GO:0006654) 1/31 0.01387 0.031430911 
-
2.05288489 7.102906657 PLA2G2A 
anion transport 





(GO:0052646) 1/35 0.01564 0.033242025 
-
2.06963168 7.044902841 PLA2G2A 
muscle adaptation 
(GO:0043500) 1/28 0.01253 0.029727456 
-
1.98762912 6.987876347 NPPA 
phosphatidylglycerol 
metabolic process 
(GO:0046471) 1/34 0.0152 0.032638693 -2.0191409 6.910018702 PLA2G2A 
plasma lipoprotein 
particle organization 
(GO:0071827) 1/31 0.01387 0.031430911 
-
1.99698297 6.909488048 PLA2G2A 
protein-lipid complex 
subunit organization 
(GO:0071825) 1/33 0.01476 0.032022137 
-
1.97523612 6.797435056 PLA2G2A 
negative regulation of 
blood pressure 
(GO:0045776) 1/39 0.01742 0.035889962 
-
2.03903955 6.784491452 NPPA 







regulation of nitric oxide 
biosynthetic process 
(GO:0045428) 1/44 0.01963 0.038879911 
-
1.97249456 6.405237357 HBB 
platelet aggregation 
(GO:0070527) 1/40 0.01786 0.036074095 
-
1.89768215 6.304442187 HBB 
somatic stem cell 
maintenance 
(GO:0035019) 1/44 0.01963 0.038879911 
-
1.88279094 6.113944817 PLA2G2A 
glutathione metabolic 
process (GO:0006749) 1/49 0.02184 0.042838953 
-
1.87070624 5.893299843 GSTT1 
response to fatty acid 
(GO:0070542) 1/50 0.02228 0.043288255 
-
1.85563355 5.826455398 PDK4 
regulation of tissue 
remodeling 
(GO:0034103) 1/58 0.0258 0.048294438 
-
1.87961093 5.696046012 PDK4 
regulation of pH 
(GO:0006885) 1/52 0.02316 0.044160653 
-
1.80164344 5.620985349 PDK4 
regulation of fatty acid 
metabolic process 
(GO:0019217) 1/72 0.03194 0.055696595 -1.9297141 5.572698345 PDK4 
defense response to 
Gram-positive bacterium 
(GO:0050830) 1/52 0.02316 0.044160653 
-
1.76201285 5.497341041 PLA2G2A 
body fluid secretion 
(GO:0007589) 1/71 0.03151 0.055407562 
-
1.89751252 5.489578097 NPPB 
negative regulation of 
angiogenesis 
(GO:0016525) 1/64 0.02844 0.052267585 
-
1.83661158 5.420536652 NPPB 
negative regulation of 
blood vessel 
morphogenesis 
(GO:2000181) 1/66 0.02932 0.053398367 -1.8467018 5.410790326 NPPB 
cellular response to 
mechanical stimulus 
(GO:0071260) 1/67 0.02976 0.053716999 
-
1.84921783 5.407160611 NPPA 
homotypic cell-cell 
adhesion (GO:0034109) 1/57 0.02536 0.047910801 
-
1.75912968 5.344964784 HBB 
negative regulation of 
vasculature development 
(GO:1901343) 1/70 0.03107 0.055407562 
-
1.84564916 5.339535356 NPPB 
cellular response to 
starvation (GO:0009267) 1/74 0.03282 0.056735959 
-
1.85678295 5.32775474 PDK4 
positive regulation of 
inflammatory response 
(GO:0050729) 1/88 0.03892 0.065075659 
-
1.93289789 5.281072705 PLA2G2A 
phosphatidylcholine 
metabolic process 
(GO:0046470) 1/62 0.02756 0.051114936 
-
1.74559521 5.190838994 PLA2G2A 
monovalent inorganic 
cation homeostasis 
(GO:0055067) 1/82 0.03631 0.061723153 
-
1.84987596 5.15208244 PDK4 
pyruvate metabolic 
process (GO:0006090) 1/71 0.03151 0.055407562 
-





(GO:0007565) 1/85 0.03761 0.063414586 
-
1.85992222 5.129779653 NPPA 
cellular response to 
nutrient levels 
(GO:0031669) 1/99 0.04369 0.071871484 
-
1.93686747 5.09953128 PDK4 
regulation of glucose 
metabolic process 
(GO:0010906) 1/94 0.04152 0.068865042 
-
1.90292583 5.091480909 PDK4 
ethanolamine-containing 
compound metabolic 
process (GO:0042439) 1/81 0.03587 0.061495055 
-
1.79894728 5.016901485 PLA2G2A 
regulation of lipid 
biosynthetic process 
(GO:0046890) 1/113 0.04973 0.078635729 
-
1.95971673 4.98342072 PDK4 
negative regulation of 
epithelial cell 
proliferation 
(GO:0050680) 1/110 0.04843 0.077800036 
-
1.93886197 4.951103869 PLA2G2A 
response to starvation 
(GO:0042594) 1/106 0.04671 0.07623123 
-
1.91045262 4.917474601 PDK4 
cellular response to 
extracellular stimulus 
(GO:0031668) 1/119 0.0523 0.082075886 
-
1.93929572 4.848454594 PDK4 
positive regulation of 
homeostatic process 
(GO:0032846) 1/130 0.05701 0.08551943 
-
1.94446727 4.781467733 NPPB 
cellular response to acid 
chemical (GO:0071229) 1/147 0.06425 0.091587408 
-
1.98818964 4.752690749 PDK4 
phosphatidylinositol 
metabolic process 
(GO:0046488) 1/125 0.05487 0.083540694 
-
1.91436713 4.752265974 PLA2G2A 
positive regulation of 
response to wounding 
(GO:1903036) 1/130 0.05701 0.08551943 
-
1.92665788 4.737674233 PLA2G2A 
peptide metabolic process 
(GO:0006518) 1/113 0.04973 0.078635729 
-
1.85387676 4.714277173 GSTT1 
stem cell maintenance 
(GO:0019827) 1/109 0.048 0.077720098 
-
1.84172747 4.704953231 PLA2G2A 
cellular biogenic amine 
metabolic process 
(GO:0006576) 1/125 0.05487 0.083540694 
-
1.88164422 4.671033906 PLA2G2A 
cellular amine metabolic 
process (GO:0044106) 1/125 0.05487 0.083540694 
-
1.87913714 4.664810279 PLA2G2A 
insulin receptor signaling 
pathway (GO:0008286) 1/148 0.06467 0.091587408 
-
1.94291262 4.644457778 PDK4 
multi-multicellular 
organism process 
(GO:0044706) 1/121 0.05316 0.082785256 -1.8619101 4.638958887 NPPA 
regulation of cellular 
carbohydrate metabolic 
process (GO:0010675) 1/137 0.06 0.088694451 
-
1.90665765 4.618988666 PDK4 
amine metabolic process 
(GO:0009308) 1/134 0.05872 0.087437681 
-
1.88203617 4.586200233 PLA2G2A 
regulation of 
carbohydrate metabolic 1/145 0.0634 0.091084176 
-






(GO:0033500) 1/143 0.06255 0.090500943 
-
1.90358622 4.573166033 PDK4 
glucose homeostasis 
(GO:0042593) 1/143 0.06255 0.090500943 
-
1.90108069 4.567146763 PDK4 
regulation of ion 
homeostasis 
(GO:2000021) 1/160 0.06975 0.096798699 
-
1.95252547 4.559384651 NPPB 
glucose metabolic process 
(GO:0006006) 1/149 0.0651 0.091587408 
-
1.89429783 4.528246002 PDK4 
regulation of cellular 
ketone metabolic process 
(GO:0010565) 1/178 0.07732 0.103654301 
-
1.99449004 4.520898482 PDK4 
multi-organism 
reproductive process 
(GO:0044703) 1/140 0.06128 0.08993087 
-
1.87348024 4.512678108 NPPA 
xenobiotic metabolic 
process (GO:0006805) 1/156 0.06806 0.095100819 
-
1.86636234 4.391210346 GSTT1 
regulation of blood 
circulation (GO:1903522) 1/204 0.08816 0.111704914 
-
1.99570569 4.374376481 NPPB 
positive regulation of 
response to external 
stimulus (GO:0032103) 1/201 0.08691 0.111345309 
-
1.98683895 4.361347956 PLA2G2A 
response to mechanical 
stimulus (GO:0009612) 1/176 0.07648 0.103654301 
-
1.91921018 4.350262098 NPPA 
cellular response to 
insulin stimulus 
(GO:0032869) 1/195 0.08442 0.110396313 
-
1.97115366 4.343789029 PDK4 
regulation of angiogenesis 
(GO:0045765) 1/179 0.07774 0.103654301 
-
1.91256909 4.335208772 NPPB 
cellular amide metabolic 
process (GO:0043603) 1/177 0.0769 0.103654301 
-
1.90686125 4.322270856 GSTT1 
hexose metabolic process 
(GO:0019318) 1/187 0.08109 0.106719788 
-
1.92848107 4.315070283 PDK4 
defense response to 
bacterium (GO:0042742) 1/179 0.07774 0.103654301 
-
1.89719298 4.300355833 PLA2G2A 
response to hypoxia 
(GO:0001666) 1/241 0.10339 0.1240641 
-
2.03780663 4.252814632 NPPA 
response to decreased 
oxygen levels 
(GO:0036293) 1/245 0.10502 0.124557829 
-
2.03765987 4.244415298 NPPA 
regulation of vasculature 
development 
(GO:1901342) 1/197 0.08525 0.110774178 
-
1.91926706 4.222889581 NPPB 
response to oxygen levels 
(GO:0070482) 1/259 0.11071 0.128326022 -2.0533001 4.215797179 NPPA 
glycerophospholipid 
biosynthetic process 
(GO:0046474) 1/178 0.07732 0.103654301 
-
1.85850686 4.212666243 PLA2G2A 
response to bacterium 
(GO:0009617) 1/201 0.08691 0.111345309 -1.9173704 4.208856224 PLA2G2A 
transcription initiation 
from RNA polymerase II 
promoter (GO:0006367) 1/187 0.08109 0.106719788 
-




cellular response to 
abiotic stimulus 
(GO:0071214) 1/232 0.0997 0.121793771 
-
1.97971767 4.168149185 NPPA 
regulation of lipid 
metabolic process 
(GO:0019216) 1/245 0.10502 0.124557829 
-
1.98657852 4.138013601 PDK4 
regulation of epithelial 
cell proliferation 
(GO:0050678) 1/258 0.11031 0.128326022 
-
2.01373413 4.134561082 PLA2G2A 
regulation of 
inflammatory response 
(GO:0050727) 1/247 0.10583 0.124799244 
-
1.98605804 4.133083846 PLA2G2A 
response to acid chemical 
(GO:0001101) 1/275 0.11718 0.132070091 
-
2.02976969 4.109111444 PDK4 
cellular response to 
peptide hormone stimulus 
(GO:0071375) 1/261 0.11152 0.128535376 
-
1.99780837 4.098605974 PDK4 
monosaccharide 
metabolic process 
(GO:0005996) 1/221 0.09518 0.118399598 
-
1.92031113 4.09734855 PDK4 
glycerolipid biosynthetic 
process (GO:0045017) 1/202 0.08733 0.111345309 
-
1.86097981 4.085072172 PLA2G2A 
cellular response to 
peptide (GO:1901653) 1/273 0.11637 0.131890227 
-
1.99892269 4.049388232 PDK4 
DNA-templated 
transcription, initiation 
(GO:0006352) 1/220 0.09477 0.118399598 
-
1.89256968 4.038156913 NPPA 
phospholipid biosynthetic 
process (GO:0008654) 1/206 0.08899 0.112059235 
-
1.84130636 4.030118151 PLA2G2A 
positive regulation of 
defense response 
(GO:0031349) 1/272 0.11597 0.131890227 
-
1.98124152 4.013569974 PLA2G2A 
single organismal cell-cell 
adhesion (GO:0016337) 1/235 0.10093 0.122561368 
-
1.90358593 3.995899863 HBB 
muscle system process 
(GO:0003012) 1/237 0.10175 0.122824304 
-
1.89958782 3.98343636 NPPA 
positive regulation of 
secretion (GO:0051047) 1/273 0.11637 0.131890227 
-
1.96230497 3.975208583 NPPB 
glycerophospholipid 
metabolic process 
(GO:0006650) 1/229 0.09847 0.121748516 
-
1.88193914 3.962983126 PLA2G2A 
lipid catabolic process 
(GO:0016042) 1/232 0.0997 0.121793771 
-
1.87427142 3.946139893 PLA2G2A 
cellular response to lipid 
(GO:0071396) 1/315 0.13317 0.145271214 
-
2.04511867 3.945346484 PDK4 
response to nutrient levels 
(GO:0031667) 1/291 0.12361 0.137789387 
-
1.98911959 3.942492597 PDK4 
single organism cell 
adhesion (GO:0098602) 1/259 0.11071 0.128326022 
-
1.89852701 3.898019985 HBB 
response to extracellular 
stimulus (GO:0009991) 1/313 0.13237 0.145271214 -1.9809919 3.821636155 PDK4 
phospholipid metabolic 
process (GO:0006644) 1/288 0.1224 0.137199649 
-
1.89627255 3.766600533 PLA2G2A 
regulation of response to 
wounding (GO:1903034) 1/347 0.14577 0.156508623 
-





process (GO:0046486) 1/296 0.1256 0.139257235 
-
1.87625128 3.69890266 PLA2G2A 
sulfur compound 
metabolic process 
(GO:0006790) 1/314 0.13277 0.145271214 
-
1.87362498 3.614508959 GSTT1 
defense response to other 
organism (GO:0098542) 1/328 0.1383 0.150075488 
-
1.89956945 3.602755435 PLA2G2A 
regulation of system 
process (GO:0044057) 1/371 0.15511 0.165669999 
-
1.99392402 3.584591709 NPPB 
cellular response to 
organonitrogen 
compound (GO:0071417) 1/411 0.17049 0.181140749 
-
2.06158381 3.522176632 PDK4 
alcohol metabolic process 
(GO:0006066) 1/340 0.14303 0.154376223 
-
1.87990284 3.512340243 PLA2G2A 
cellular response to 
nitrogen compound 
(GO:1901699) 1/438 0.18072 0.191021163 
-
2.05282397 3.398185388 PDK4 
cellular response to 
hormone stimulus 
(GO:0032870) 1/462 0.18972 0.197615928 
-
2.00324322 3.248118432 PDK4 
cation homeostasis 
(GO:0055080) 1/465 0.19084 0.197615928 
-
1.92251321 3.117220381 PDK4 
response to other 
organism (GO:0051707) 1/462 0.18972 0.197615928 
-
1.92119481 3.115082683 PLA2G2A 
nitrogen compound 
transport (GO:0071705) 1/464 0.19047 0.197615928 
-
1.89214096 3.067973915 HBB 
blood coagulation 
(GO:0007596) 1/472 0.19345 0.197615928 
-
1.88619266 3.058329153 HBB 
coagulation 
(GO:0050817) 1/472 0.19345 0.197615928 
-
1.88360204 3.054128643 HBB 
hemostasis (GO:0007599) 1/478 0.19568 0.197615928 
-
1.87614674 3.042040403 HBB 
monocarboxylic acid 
metabolic process 
(GO:0032787) 1/473 0.19382 0.197615928 -1.8611017 3.017645924 PDK4 
lipid biosynthetic process 
(GO:0008610) 1/491 0.20049 0.201474791 
-
1.88047736 3.012695878 PLA2G2A 
organic hydroxy 
compound metabolic 
process (GO:1901615) 1/476 0.19494 0.197615928 
-
1.85637011 3.009973985 PLA2G2A 
gene expression 
(GO:0010467) 1/672 0.26483 0.264834524 
-






Supplemental Table 20. Gene ontology results for “cellular component” from Ingenuity 
Pathway Analysis 
 





endocytic vesicle lumen 
(GO:0071682) 2/16 2.2E-05 0.000387551 -2.4661 19.37315594 HBB; HBA1 
hemoglobin complex 
(GO:0005833) 2/12 1.2E-05 0.000387551 -2.4402 19.16928532 HBB; HBA1 
extracellular region 





bounded vesicle lumen 
(GO:0060205) 2/76 0.0005 0.00363052 -2.137 12.00654638 HBB; HBA1 
vesicle lumen 
(GO:0031983) 2/76 0.0005 0.00363052 -2.1108 11.85949491 HBB; HBA1 
blood microparticle 
(GO:0072562) 2/161 0.00223 0.013404023 -2.522 10.87518376 HBB; HBA1 
cytosolic part 
(GO:0044445) 2/198 0.00335 0.0161741 -2.1824 9.000859897 HBB; HBA1 
extracellular vesicular 





cytoplasmic vesicle part 
(GO:0044433) 2/363 0.01087 0.034211899 -2.2201 7.493233854 HBB; HBA1 
extracellular space 
(GO:0005615) 3/1120 0.0114 0.034211899 -2.0031 6.760721979 
NPPB; NPPA; 
PLA2G2A 
mast cell granule 
(GO:0042629) 1/18 0.00807 0.029061036 -1.8919 6.694189763 NPPA 
cytosolic small ribosomal 
subunit (GO:0022627) 1/39 0.01742 0.048232212 -1.8421 5.584864766 HBA1 
dendritic spine 
(GO:0043197) 1/71 0.03151 0.061430179 -1.8738 5.227635379 MYL7 
neuron spine 
(GO:0044309) 1/74 0.03282 0.061430179 -1.8378 5.127284847 MYL7 
myosin complex 
(GO:0016459) 1/64 0.02844 0.061430179 -1.8348 5.118816301 MYL7 
small ribosomal subunit 
(GO:0015935) 1/62 0.02756 0.061430179 -1.7713 4.941658002 HBA1 
nucleosome 
(GO:0000786) 1/71 0.03151 0.061430179 -1.7524 4.888981784 HIST1H2AC 
DNA packaging complex 
(GO:0044815) 1/77 0.03413 0.061430179 -1.7301 4.826699714 HIST1H2AC 
DNA bending complex 
(GO:1990104) 1/71 0.03151 0.061430179 -1.7266 4.816889438 HIST1H2AC 
protein-DNA complex 
(GO:0032993) 1/98 0.04325 0.074149599 -1.7808 4.633022425 HIST1H2AC 




contractile fiber part 
(GO:0044449) 1/167 0.0727 0.113794974 -1.834 3.985955491 MYL7 
secretory granule 
(GO:0030141) 1/176 0.07648 0.114725126 -1.8347 3.972485589 PLA2G2A 
ribosomal subunit 
(GO:0044391) 1/135 0.05915 0.096785732 -1.6955 3.959505965 HBA1 
mitochondrial matrix 
(GO:0005759) 1/208 0.08982 0.129335749 -1.8608 3.805919731 PDK4 
mitochondrion 




(GO:0000323) 1/261 0.11152 0.138442768 -1.799 3.557232948 NPPA 
lysosome (GO:0005764) 1/261 0.11152 0.138442768 -1.7797 3.519025579 NPPA 
vacuole (GO:0005773) 1/293 0.12441 0.149286509 -1.7819 3.388910633 NPPA 




membrane (GO:0005743) 1/341 0.14342 0.166549167 -1.7749 3.181532604 PDK4 
organelle inner membrane 
(GO:0019866) 1/360 0.15084 0.169696037 -1.777 3.151907437 PDK4 
perinuclear region of 
cytoplasm (GO:0048471) 1/411 0.17049 0.185984084 -1.7534 2.949390315 NPPA 
mitochondrial membrane 
(GO:0031966) 1/457 0.18786 0.193223696 -1.7167 2.822023032 PDK4 
cytoplasmic membrane-
bounded vesicle 
(GO:0016023) 1/492 0.20086 0.200856006 -1.7176 2.757096016 PLA2G2A 
endoplasmic reticulum 






Supplemental Table 21. Gene ontology results for “molecular function” from Ingenuity 
Pathway Analysis 






activity, acting on 
peroxide as 
acceptor 














(GO:0005344) 2/14 1.6335E-05 9.801E-05 
-
2.775041681 25.6148578 HBB; HBA1 
antioxidant 
activity 







(GO:0019825) 2/37 0.000118911 0.000570771 
-
2.395657228 17.89202107 HBB; HBA1 
hormone activity 







(GO:0046906) 2/146 0.001842388 0.005527164 
-
2.271718933 11.80857763 HBB; HBA1 
heme binding 
(GO:0020037) 2/137 0.001624924 0.005527164 
-
2.266033372 11.77902362 HBB; HBA1 
iron ion binding 




(GO:0004602) 1/18 0.00807251 0.01614502 
-
2.574585679 10.62311032 GSTT1 
peptide hormone 
receptor binding 
(GO:0051428) 1/17 0.007625562 0.01614502 
-




(GO:0004364) 1/25 0.011196142 0.020669801 
-
2.511179384 9.741069625 GSTT1 
phospholipase A2 
activity 
(GO:0004623) 1/29 0.012977146 0.022246536 
-





(GO:0047498) 1/9 0.004043525 0.00970446 
-




or aryl (other than 1/54 0.024043964 0.038470342 
-















(GO:0004620) 1/90 0.039786418 0.056169061 
-
2.073175967 5.969480469 PLA2G2A 
lipase activity 
(GO:0016298) 1/105 0.046278873 0.061705164 
-
2.100801189 5.851545715 PLA2G2A 
carboxylic ester 
hydrolase activity 
(GO:0052689) 1/111 0.048864909 0.061724095 
-
2.056264556 5.726863137 PLA2G2A 
hormone receptor 
binding 
(GO:0051427) 1/160 0.069752004 0.083702404 
-
2.116892259 5.250924951 NPPA 
phospholipid 
binding 
(GO:0005543) 1/296 0.125604565 0.143548074 
-




(GO:0046982) 1/408 0.169341136 0.184735784 
-




(GO:0004674) 1/449 0.184858766 0.192896104 
-
2.252252364 3.706314502 PDK4 
ATP binding 
(GO:0005524) 1/1494 0.5028586 0.5028586 
-
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Background: We recently identified in human cardiac hypertrophy a gene expression signature 
containing nine differentially-expressed genes (DEG) that are body-mass index (BMI) and sex-
dependent. To study mechanistic roles of these genes in hypertrophy, we asked whether these 
nine genes are differentially expressed in OZR known to develop cardiac hypertrophy. 
Results: Rat LV were grouped according to sex (male, female) and obesity (obese, lean). OZR 
hypertrophy was characterized by increased left ventricular (LV) mass, LV inner diameter, inter-
ventricular septum, and LV wall thickness in a sex-specific manner. Altered electrophysiology in 
OZR was characterized by decreased resting heart rate, increased ST elevation, and suppressed 
sympathetic activity. 89 DEG were found when comparing all samples for obesity, but males 
alone had 2859 DEG and females had 826. Obese humans and rats shared 337 DEG. Five DEG 
in human LVH previously identified (Hbb, Hist1h2ac, Nppa, Nppb, Pdk4) were validated by 
qPCR and protein expression in OZR. 
Conclusions: We identified a five-gene expression signature that is shared between rat and 
human LVH in an obesity and sex-specific manner. Expression of established biomarkers 
Anp/Nppa and Bnp/Nppb were already significantly increased in hypertrophy compared to 
controls, with the absolute levels of Nppa significantly higher than Nppb. New genes (Hbb, 
Hist1h2ac, Pdk4) may provide potential new targets for early prognostic diagnosis in sex-
dependent obesity-related cardiac LVH. 
Background 
Obesity has been recognized as an independent risk for cardiovascular disease (1, 34). In 
fact, a high rate of sudden cardiac death in morbid obesity had been recognized in ancient times 




kg/m2 increase in body mass index (BMI), the HF risk is increased by 5% in men and 7% in 
women (37). In ventricular biopsy samples from obese patients, the number of adipocytes 
increases as the ejection fraction decreases (46). How these excessive adipocytes contribute to 
HF is unknown on the molecular level. 
While HF is frequently the final state of cardiovascular disease, cardiac hypertrophy is a 
major independent predictor of progressive heart disease and increased mortality (15). Cardiac 
hypertrophy is also one of the most common independent features in obesity, even in the absence 
of hypertension or diabetes mellitus (1, 3, 31, 58, 76, 79). Myocyte hypertrophy has been found 
to be the most common cause of sudden cardiac death in morbid obese patients (19). Advances 
in studies of signaling pathways in both physiological and pathological hypertrophies have led to 
a recent proposal that aims to treat cardiac hypertrophy as a new therapeutic target (10, 25). 
Development of cardiac hypertrophy in obesity, especially in a sex-dependent manner, is an 
important question with significant clinical relevance.  
 Our previous study has found left ventricular myocyte hypertrophy in OZR, a common 
animal model for studies of obesity and metabolic syndrome (45). We have recently identified a 
sex-dependent gene expression signature for obesity-related human cardiac hypertrophy (56). To 
understand the genetic mechanisms that may mediate obesity-induced changes in cardiac 
electrophysiology and hypertrophy, we set out to identify an obese animal model associated with 
cardiac hypertrophy. We also noticed that almost all the previous studies used only male OZR. In 
this study, we examined the gene expression profile of OZR relative to the lean Zucker rats 
(LZR) in both sexes. We focused on genes that exhibited similar expression patterns from human 






Lean and obese Zucker rats of both sexes (Charles River) were purchased at age of 8-10 
weeks old. Experiments were performed when rats were at 14-17 weeks old. They were given 
access to food and water ad libitum. Proposed research using animals in this work was approved 
by West Virginia University Institutional Animal Care and Use Committee. 
Euthanasia and heart collection 
Animals were maintained for up to 10 days during the experiments. After 
echocardiography recordings, surgery was performed to insert the electrical leads. Recovery 
takes at least two days to warrant full recovery before electrocardiography recordings for up to 
48 hours. Animals were sacrificed immediately following final electrocardiography data 
collection. Then, hearts were removed under deep anesthesia (3-5% isoflurane), exsanguinated in 
Tyrode’s solution, then flash-frozen and stored in liquid nitrogen until further RNA isolation and 
protein chemistry experiments. 
Echocardiography 
Echocardiography was performed using Vevo 2100 Micro-Ultrasound Imaging System 
(VisualSonics). An MS200 transducer (9-18 MHz) was used to obtain high-resolution heart 
images. Animals were anesthetized (2-3% isoflurane) for 1-2 hours. Supplemental heat and close 
monitoring of temperature, pulse, and respiration were provided during study. LVH was 
identified as significantly increased left ventricular (LV) mass (animal body sized corrected, 
M=mode) (24). Other measured ventricular parameters included left ventricular internal diameter 
(diastole) (LVID, d), inter ventricular septum (diastole) (IVS, d), and left ventricular posterior 





Surgical procedure, Post-surgical recovery 
All survival surgeries were performed accordance with the WVU IACUC policy on 
Rodent Surgery and Post-Operative Care as well as the Pain and Distress Policy.  Rats were 
weighed and anesthetized using an isoflurane (3-5%) induction chamber.  Sterile ophthalmic 
ointment was applied to the eyes of the animal to reduce corneal desiccation. Animals were 
shaved in relevant areas then transferred to the surgical area and externally heated with a 
temperature-controlled warming pad. Deep anesthesia was maintained with isoflurane.  After 
disinfecting relevant areas with Betadine and 70% isopropanol, surgery was performed.  
Animals were implanted with telemetry transmitters (Data Science Inc., St. Paul, MN) 
according to manufacturer’s specifications. Briefly, a small midline incision was made below the 
xiphoid process to expose the abdominal muscles and a small pocket was made on the animals’ 
left side, just slightly larger than the body of the transmitter. The pocket was then filled with 
sterile saline and the transmitter body inserted into the pocket.  The ECG leads were then cut to 
allow for them to be placed subcutaneously while remaining flat along the muscle wall and with 
enough length to allow for normal animal movement. The red lead was then placed at the lowest 
rib and a 4-0 suture was used to secure the lead to the abdominal wall muscle. The clear lead was 
positioned on top of the right pectoral muscle. The leads were sutured into the subcutaneous 
muscle as described above. The skin was then sutured shut after gently cleaning up any excess 
blood and applying antibiotic ointment. Carprofen (5 mg/kg subcutaneous) was administered 
parenterally to ensure pain relief without suppressing respiration. Animals were monitored for 
signs of pain twice daily post-surgery for five days and analgesics (stated above) were given 




Data acquisition and analysis were performed using the Ponemah 5.20 platform (Data 
Sciences International). A pair of lean and obese rats was studied simultaneously under identical 
conditions. Heart rate variability data analysis was performed according to procedures 
recommended directly by the manufacturer. ECG recordings of five minutes in length were 
isolated if they contained no signs of inconsistencies in the data or arrhythmias. Data were 
interpolated at 20Hz and the Hanning method was applied for windowing. Default rate frequency 
bins were used, VLF (very low frequency): 0.05-0.25, LF (low frequency): 0.25-1, HF (high 
frequency): 1-3. LF and HF data were normalized to the sum of original LF and HF data. Graphs 
were produced by inserting raw R-wave interval (R-R) data from Ponemah into Kubios HRV 
Standard v. 3.0.0 (72, 73). 
Transcriptome (RNA-Seq), bioinformatics analysis, and RT-qPCR 
Total RNA was isolated using an RNA Fibrous tissue miniprep kit (Qiagen). Quality of 
RNA was tested and passed with (1) Nanodrop for purity (OD260/OD280), (2) Agarose gel 
electrophoresis for RNA degradation and potential contamination, and (3) an Agilent 2100 
Bioanalyzer for RNA integrity. Only samples that had RNA Integrity Number (RIN)>7.0 were 
submitted for sequencing.  
After the QC procedures, mRNA was enriched using oligo (dT) beads and then 
fragmented randomly in fragmentation buffer, followed by cDNA synthesis using random 
hexamers and reverse transcriptase. After first-strand synthesis, a custom second-strand synthesis 
buffer (Illumina) was added with dNTPs, RNase H and Escherichia coli polymerase I to generate 
the second strand by nick-translation. The final cDNA library was generated after purification, 
terminal repair, A-tailing, ligation of sequencing adapters, size selection, and PCR enrichment. 




then diluted to 1 ng/µl before checking insert size on an Agilent 2100 and quantifying to greater 
accuracy by quantitative PCR (qPCR) (library activity >2 nM). 
Single-end sequencing with 20 million raw reads was performed using HiSeqTM PE150 
(Illumina). The raw data were transformed to sequenced reads by base calling and converted to 
FastQ using onboard instrument software. Reads were mapped to human reference genome 
(hg38) using TopHat2 (39). 
Differential expression analysis was performed with NOISeq (v.2.14.1) (71) using 
RStudio version 0.99.879 (65). NOISeq is a newly-developed tool for differential expression 
analysis. Compared to the commonly used DeSeq (2), NOISeq offered a set of tools for better 
quality control to avoid false positive discoveries (71). Gene annotation information was 
obtained from the Ensembl Biomart database, release 85 (80). Gene expression levels are 
indicated by FPKM (fragments Per Kilobase of transcript per Million mapped reads) (74). FPKM 
was then normalized for batch effect using the ARSyNseq module included with the NOISeq 
package. Data were analyzed using the noiseqbio method under default conditions. The CPM 
filtering method was used for differential analyses where at least one group contained five or 
fewer replicates; otherwise, the Wilcoxon test was used for filtering. 
RT-qPCR was run on either a BioRad CFX96 Real Time System or Applied Biosystems 
7500 using a Luna Universal One-Step RT-qPCR Kit (NEB E3005L) according to the 
manufacturer's instruction. Briefly, components were prepared for a 20µL reaction volume per 
well using 100-300ng template RNA and primers at 10µM concentration (primer sequences are 
listed in Supplemental Table 1). Each sample was prepared as two technical replicates, with three 
biological replicates total per group. GAPDH was used as a loading control on each plate. 




denaturation at 95oC. This was followed by 40 cycles of 95oC denaturation (10 seconds) and 
60oC extension (30 seconds). After the plate was read, melt curves were recorded using a 0.5oC 
step from 60-95oC.  
Gene expression levels were plotted in log2-fold (y-axis) from both transcriptome and 
qPCR. 
Immunoblotting 
Tissues sections were submerged in minimal lysis buffer (fresh protease and phosphatase 
inhibitors (Sigma), 20mM Tris, 150mM NaCl, 10mM EGTA and 10mM EDTA at pH 7.4) on ice 
and homogenized briefly at high speed. Samples were then centrifuged for 15 minute increments 
at 10,000 x g to pellet debris. Supernatants were placed into new tubes and protein concentration 
was recorded using Bradford’s method on an Eppendorf Biophotometer. 
 For Western blotting procedures, protein concentrations were normalized between 
samples to 10 µg and mixed with Non-Reducing Lane Marker (Thermo Scientific) with 5% b-
mercaptoethanol. After heating in a water bath to 95oC for five minutes, samples were cooled to 
4oC then loaded into a 4-12% bis-tris gel (Invitrogen). Electrophoresis was carried out at 80V for 
30 minutes then 140V for the remainder.  
 Proteins were transferred to pre-wetted nitrocelluose membranes at 30V for one hour. 
Blots were blocked with 3% BSA-V in TBS-T for one hour before primary antibody (1:1000 
dilution; Cell Signaling) was added on a shaker at 4oC overnight. Primary antibody solution was 
replaced with fresh 3% BSA-V in TBS-T containing secondary antibodies at 1:10,000 dilution 
for one hour at room temperature on a shaker. After five washes with TBS-T, blots were 
developed with a standard ECL kit (Life Technologies) on x-ray film or using a G:BOX digital 





Data are presented as mean ± SD. Student’s t test was used for statistical analysis on 
paired groups, with p<0.05 being considered as statistically significant, marked with the symbol 
*. One-way ANOVA with Tukey’s post-hoc test was used for statistical analyses on more than 
two groups. Blinding and randomization was not performed during in vivo analysis due to the 
small number of animals in the study. For gene expression, gene size adjusted p-value (FDR – 
false discovery rate) less than 0.05 was used (p_adj<0.05) to identify significant genes.  
Results 
Characterization of OZR 
Table 1 shows that in both sexes, body and heart weight in OZR are significantly 
increased compared to age-matched LZR. Echocardiogram (Echo) recordings revealed that 
although heart rate is decreased in OZR, it is statistically not significantly altered compared to 
lean controls of both sexes. On the other hand, left ventricular (LV) mass was significantly 
increased in OZR compared to LZR in both sexes: 32.7% increase in male and 59.1% increase in 
female, consistent with the enlarged heart. In comparison to LZR, the interventricular septum at 
diastole (IVS;d) was increased in OZR, but reached statistically significance only in female. Left 
ventricular internal diameter at diastole (LVID;d) was increased by 24.2% in male OZR, but the 
increase in female OZR was not statistically significant compared to LZR. Left ventricular 
posterior wall thickness at diastole (LVPW;d) thickness was increased in OZR in OZR compared 
to their lean controls. We found no changes in OZR contractility since both ejection fraction (EF) 
and fraction shortening (FS) were not statistically significant.  




To investigate potential electrical abnormalities in OZR, we performed telemetry ECG 
recordings on paired OZR and LZR. A representative set of recordings is shown in Figure 1. In 
addition to apparent slowing in heart rate, the R-wave amplitude is larger in OZR than in LZR, 
especially in male OZR compared to male LZR (1A), which is a strong indicator of LVH (12, 
17). However, averaged peaks of R-wave between obese and lean rats showed no statistical 
difference, although R-wave mean value in OZR-M is more than doubled than in LZR-M (OZR-
M: 0.862, LZR-M: 0.367, p=0.065, n=4. OZR-F: 0.761±0.416, LZR-F: 0.696±0.158, p=0.813, 
n=4) 
Table 2 summarized the most significant changes from ECG recordings. In comparison to 
age-matched male LZR controls, resting heart rate was significantly decreased, while ST 
elevation (STe) was significantly increased in male OZR. These changes were not observed in 
female OZR.  
Heart rate variability also showed sex-dependent changes. To eliminate large inter-
subject variability in the total raw heart rate variability spectral power, we used normalized 
frequency power (11). Normalized low-frequency (nLF) power (11, 21) were decreased by 67% 
in male and by 40% in female obese rats compared to LZR controls, respectively. Normalized 
high-frequency (nHF) power was increased by 110% in male and by 57% in female obese rats. 
The ratio of LF/HF was decreased by 61% in female, but insignificantly decreased by 86% in 
male obese rats (possibly due to small number of animals). 
Identification of Differentially Expressed Genes (DEG) in OZR 
When comparing obese to lean left ventricular samples, 89 DEG (75 down, 14 up) 
associated with LVH were found (Figure 2). However, when female and male samples were 




1620 up in obesity) were identified (Figure 2). There are 43 DEG that were upregulated in both 
sexes, whereas 253 DEG downregulated in both, and another 83 that were up in one sex and 
down in the other (Supplemental Table 2). 
 PCA plots to show cohesion of males and females are shown in Supplemental Figure 1. 
Detailed upregulation and downregulation of these DEG are shown in the volcano plots 
(Supplemental Figure 3) and heatmaps (Supplemental Figure 3).  
Shared Differentially Expressed Genes between rat and human obesity-related cardiac 
hypertrophy 
We have recently identified an RNA expression signature in LV for obesity-related 
human cardiac hypertrophy from 12 males and 12 females (Male BMI: 31.08±12.49 (LVH), n=6; 
25.93±6.57 (non-failure, NF, controls), n=6. Female BMI: 27.78±9.92 (LVH), n=6; 28.13±7.02 
(NF controls), n=6. Male age: 48.17±14.54 (LVH), n=6; 48.83±12.38 (NF controls), n=6. 
Female age: 43.83±11.72 (LVH), n=6; 48.00±15.91 (NF controls), n=6) (56). The expression 
signature contains nine genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, 
PDK4, PLA2G2A) with altered expression levels in a BMI- and sex-dependent manner (56). We 
compared expression profiles between rat and human heart samples and identified 337 shared 
DEG. In female hypertrophied samples (Figure 3A), 6 DEG are upregulated in both rat and 
human (lower left), 27 DEG are downregulated in both rat and human (upper right), 5 DEG are 
upregulated in rat but downregulated in human (lower right), and 55 DEG are downregulated in 
rat but upregulated in human (upper left). In male hypertrophied samples (Figure 3B), 28 DEG 
are upregulated in both rat and human (lower left), 22 DEG are downregulated in both rat and 
human (upper right), 8 DEG are upregulated in rat but downregulated in human (lower right), 




Among the nine-gene expression signature (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, 
NPPA, NPPB, PDK4, PLA2G2A) identified in obesity-related human cardiac hypertrophy (56), 
seven DEG (Nppa, Nppb, Gstt1, Hbb, Hba1, Myl7, Pdk4) are potential DEG found in OZR 
compared to LZR in a sex-dependent manner. Figure 4 compares the expression levels of seven 
DEG in rat and human LVH. NPPA and NPPB expression levels were significantly increased in 
LVH of both rat and human of either sex. However, NPPA levels are notably higher than NPPB 
in rat and human of either sex. HBB gene expression was also drastically upregulated in rat and 
human LVH, but only in female. Upregulation of PDK4 is more significant in female than in 
male in both rat and human. MYL7 was upregulated in male but downregulated in female human 
LVH. In rats, Myl7 expression levels were significantly increased in females, inconsistent with 
that in human LVH. In human, GSTT1 and HBA1 levels were very low compared the other 
DEG. 
Validation of differentially expressed genes shared in OZR and obese human 
hypertrophied heart 
We set out to validate six DEG expression using qPCR and protein expression using 
western blotting. We did not include Hba1 due to very low expression in human heart (Figure 4 
bottom) (but dramatically high expression in rat heart (Figure 4 top)) and we could not detect 
protein expression in human heart. We included Gstt1 because it has a similar low expression 
pattern in both rat and human heart. 
Figure 5A indicates a significant increase in Nppa transcript levels in OZR of both sexes 
from transcriptome experiment. Quantitative PCR experiments confirmed the statistically 
significant increase in male OZR, but not in female OZR (Figure 5B). At protein expression 




results are statistically significant (male: p=0.007, n=3; female: p=0.01, n=3) (Figure 5D), 
similar to human ANP protein expression patterns (56).  
Figure 6A shows Nppb transcriptional level from transcriptome experiment, suggesting a 
higher expression in obese than in lean rats of both sexes, which was confirmed by quantitative 
PCR (Figure 6B). However, immunoblots (Figure 6C) did not reveal statistical difference in 
protein expression levels in either sex (Figure 6D) (p>0.05, n=3). 
Figure 7 shows Gstt1 transcript levels that are not significantly altered in OZR of both 
sexes (upper panel). Quantitative PCR also revealed insignificant changes of gene expression 
levels between OZR and LZR in both sexes (lower panel). We did not perform immunoblot 
experiments due to lack of justification. 
Figure 8A shows an increase in Hbb transcriptional level only female OZR over LZR, 
which was confirmed by quantitative PCR (Figure 8B). However, immunoblots (Figure 8C) 
suggested that the protein expression levels are increased in OZR compared to LZR in both sexes 
(Figure 8D), which are statistically significant (male: p=0.007, n=3; female: p=0.0003, n=3). 
Figure 9A shows a dramatic increase in Myl7 transcript levels in OZR compared to LZR 
in both sexes. However, quantitative PCR failed to validate increased gene expression, although 
very close in female OZR (Figure 9B) (p=0.0608). Immunoblots (Figure 9C) confirmed a 
significantly increased protein expression in female OZR compared to female LZR (Figure 9D) 
(OZR-F: 1.693, LZR-F: 0.769, p<0.05, n=3). 
Figure 10A shows an increase in Pdk4 transcript levels in OZR compared to LZR in both 
sexes. Quantitative PCR validated these increases at gene expression levels (Figure 10B). 
Immunoblots (Figure 10C) confirmed an increased protein expression in female OZR, but not in 




Sex- and obesity-dependent NPPA/NPPB expression 
Figure 11A shows that NPPA gene expression levels are higher in obese female than in 
obese male rat and human with LVH. NPPB levels are higher only in obese female human 
compared to obese male human LVH; its levels are lower in obese female than in obese male rat. 
Figure 11B shows that in addition to LVH-mediated increase in expression of both NPPA and 
NPPB in human heart, obesity is associated with a significantly decreased expression of NPPB in 
both sexes, decreased expression of NPPA in male, but increased expression of NPPA in female 
human with LVH. 
Discussion 
Obesity drastically increases the risk of sudden cardiac death and HF, with severity 
varying in a sex-specific manner. Cardiac hypertrophy is an independent feature from obesity but 
is the most common cause of sudden cardiac death in morbidly obese patients. Discovery of 
cross-species DEG validates an animal model to study how individual genes may contribute to 
sex-specific obesity-related cardiac hypertrophy in vivo. Novel biomarkers of cardiac 
hypertrophy should allow early intervention to delay or even prevent sudden cardiac death and 
HF. 
In the present work, we investigated gene expression profiles of LV from OZR and LZR 
to test a hypothesis that OZR can serve as an animal model to study sex-specific obesity-related 
cardiac hypertrophy. 
Echocardiography and electrophysiological characterizations of OZR 
Enlargement of heart associated with obesity in Zucker rats can be detected at 12-weeks 
old and established in 14 weeks old of age (62). Our data on heart weight and LV mass in OZR 




cellular hypertrophy in OZR we previously reported (45). Although female hearts are smaller 
and lighter compared to males, the percent increase in LV mass is larger in female (59%) than in 
male (33%) (Table 1). The LVID is significantly increased in male OZR over LZR, but not in 
female OZR/LZR, although there is a tendency to increase. An increased IVS was found in 
female, but not in male, OZR compared to the respective LZR controls. OZR of both sexes 
showed an increased LVPW. 
 OZR has been known to have dysfunctional cardiac functions such as reduced 
contractility (81). However, we do not detect statistically significant changes in this study. 
Studies showing reduced contractility used old OZR (e.g. 20 weeks) (81), while younger OZR 
(e.g. 10-12 weeks old) do not exhibit altered contractility (40, 51). It is possible that while there 
is no significant difference in contractility between obese and lean rats at the tissue or whole-
heart level, depressed contraction at the level of myocytes has already occurred (62).  
ECG recordings showed that in comparison to LZR the resting heart rate was decreased 
in male but not in female OZR, although there is a statistically insignificant decrease in female 
OZR. ST elevation was also found to increase only in male OZR (Table 2). In OZR of both sexes 
LF (a combination of sympathetic and parasympathetic activities) was decreased, while HF 
(predominately vagal modulation) was increased, in agreement with reduced sympathetic 
baroreflex sensitivity in OZR due to leptin receptor dysfunction (14, 28, 33, 60). Increased HF 
component is more significant in male than in female OZR (Table 2). Reduced ratio of LF/HF 
further supported that the sympathetic tone in the obese heart was suppressed (21). It has been 
well established that reduced heart rate variability is a powerful independent risk factor for 




41, 42, 57), type 2 diabetes and metabolic disorders (6, 70), as well as in the general population 
(63, 75). 
Differentially expressed genes associated with sex-specific obesity-related cardiac 
hypertrophy 
It is not surprising for significantly increased Anp expression levels in both sexes of OZR 
compared to LZR, similar to what we found in obesity-related human cardiac hypertrophy (56). 
Consistent with human data, the Anp increase in LVH is significantly larger than Bnp, which has 
been clinically used as biomarker for diagnosis of HF (5, 22, 54, 61).  
ANP can directly modulate all voltage-dependent ion channels known to control heart 
rate and action potential duration (52, 59), yet, yields inconsistent results in experimental models 
and in humans. Nonetheless, ANP was found anti-arrhythmic, since a protein degradation-
resistant mutant can trigger atrial fibrillation (32). ANP can potentiate isoproterenol stimulation 
of the L-type voltage-gated calcium channel, while mutant ANP cannot (32). 
While the mechanistic roles of ANP in cardiac electrophysiology and especially on ion 
channels remain to be clarified, the roles of ANP in hypertrophy and HF has been extensively 
studied and well defined (38, 61, 69, 77). ANP is predominantly released from atria, while it was 
later found also present in the ventricle (A:V ratio 40:1) (27). The synthesis of ANP is 
dramatically increased in the ventricle in response to hypertrophy, making it one of the surrogate 
markers (other than BNP) in advanced HF patients (54, 69). It was noted that the total amount of 
ANP in the failing ventricles is about 9-fold higher than BNP (ANP: 135±31 pmol/g; BNP: 
16.9±4.2) (54). In Anp knockout mice, overload volume-induced cardiac hypertrophy was 
worsened, indicating that Anp protects the heart from hypertrophy development (53). 




have recently been found in human studies. Increased LV mass and wall thickness were found in 
patients who carried allele 664C>G in the ANP promoter, which results in lower levels of 
circulating ANP (66). On the other hand, patients with the rs5068 allele at the NPPA-NPPB 
locus, which results in higher circulating levels of ANP and BNP, had reduced LVH (36).  
Consistent with our previous findings in obese human hypertrophied hearts (56), ANP 
expression levels are significantly increased in OZR of both sexes compared to LZR. Particular, 
ANP gene expression levels are higher in female than in male LZR and OZR, respectively 
(Figure 5), also in agreement with our previous findings in obese human hypertrophied heart 
(56). Unlike human hypertrophied heart, significant increases in BNP gene expression levels 
were found only in male OZR, which failed to be validated in protein expression (Figure 6). In 
both obese rat and human hypertrophied heart of both sexes, ANP expression levels are 
significantly higher than BNP. Thus, ANP not only can be used as an early biomarker in obesity-
related cardiac hypertrophy, but also a potential target to study how ANP affects cardiac 
electrophysiology during early development of hypertrophy under obesity condition.       
Interestingly, we found several genes that were previously understudied or unknown with 
regard to their respective roles in cardiac hypertrophy and arrhythmias (Figure 4). In female (but 
not male) obese human hypertrophied heart, HBB expression was upregulated (56). In female 
OZR, Hbb gene expression was significantly upregulated compared to female LZR (Figure 8). 
Interestingly, immunoblots confirmed upregulated protein expression in both male and female 
OZR. The Hbb gene encodes b-globin, a subunit of hemoglobin. Its upregulation along with a-
globin (encoded by Hba1 gene) may help explain the increased oxygen transport to peripheral 




Myosin light chain 7 (MYL7) was identified as a DEG in female (but not male) obese 
human hypertrophied heart (56). In OZR, Myl7 gene expression was significantly increased in 
both sexes, particularly in female (64-fold). Both quantitative PCR and immunoblots validated 
its upregulated expression in female OZR, in agreement with human data. MYL7 encodes 
myosin regulatory light chain protein, atrial isoform (MLC2a) in humans. Its expression is 
restricted to atria in healthy individuals, modulating cardiac development and contractility (23). 
In hypertrophic cardiomyopathy, MYL7 expression is readily detected in the ventricle (30). Its 
gene expression levels are very low in LZR of both sexes, but dramatically increased in OZR, 
consistent with its expression pattern in obese-related human cardiac hypertrophy (56).  
We found PDK4 was significantly upregulated in male (but not female) obese human 
hypertrophied heart (56). In OZR, however, PDK4 was significantly upregulated in both male 
and male) heart (Figure 10). Its upregulation was validated by qPCR. PDK4 encodes a 
mitochondrial enzyme pyruvate dehydrogenase kinase 4. PDK4 downregulates glucose 
utilization and increases fat metabolism by decreasing glucose conversion to acetyl-CoA (43), 
resulting in a decreased production of ATP. Therefore, its upregulation may be resulted in 
increased demand for fat metabolism in obesity. 
Currently, we do not know the biological roles of upregulated expression of Hbb, Myl7, 
and Pdk4, in association of obesity-related cardiac hypertrophy. Neither do we know whether 
these DEG might be used as potential new sex-dependent biomarkers for cardiac hypertrophy in 
obesity. 
Unexpectedly, we did not detect the anticipated alterations of expression levels of genes 
that have been well documented in their contributions to development of cardiac hypertrophy 




cardiac hypertrophy induced by angiotensin II and isoproterenol and that of 30 distinct genes 
were changed during regression of hypertrophy  (26). Recently, using personalized and multi-
omics approaches in 100+ strains of genetically distance mice, 36 differentially expressed genes 
were identified (67). Microarray studies in a young hypertrophied heart rat model in the absence 
of hypertension, 65 genes altered their expression levels, and significantly more genes (390) 
changed their expression levels in the old hypertrophied heart (20). Notably, the Ras/mitogen-
activated protein kinase (MAPK) signaling pathway and the tumor necrosis factor (TNF) 
receptor-mediated activation of nuclear factor-kB (NF-kB) were found to play a crucial role in 
the development of hypertrophy (20). In human patients with cardiac hypertrophy, PCR 
screening found 35 (the article stated 36) genes were increased compared to normal human heart 
(44). 
It is imperative to point out that hypertrophy has diverse phenotypes revealed by cardiac 
magnetic resonance imaging (47-49, 68). Pathologic hypertrophy caused by genetic mutations in 
sarcomere proteins are rare, representing 0.6% of prevalence in 3,600 unrelated subjects from the 
Framingham Heart Study and Jackson Heart Study cohorts (8, 68). The majority (88.8%) of 
hypertrophic patients have benign mutations or variant of uncertain significance (8, 68). Cellular 
hypertrophy should occur earlier than changes in phenotype detected by echocardiography or 
cardiac magnetic imaging. Thus, altered gene expression patterns are important early markers 
during development of hypertrophy. 
It is interesting to notice that obesity seems to inhibit gene expression of human NPPA 
and NPPB, except that in female with LVH obesity increased gene expression of NPPA (Figure 





Genes related to cardiac arrhythmias 
Electrical disturbance can be triggered by heart remodeling such as hypertrophy. 
Alterations of gene expression levels of membrane ion transporters including ion channels, 
pumps, and exchangers cause ionic imbalance which can trigger arrhythmias. Studies from 
experimental animal models demonstrated that ion channel remodeling occurs preceding clinical 
hypertrophy phenotype is diagnosed (9), since properties of ion channels can be altered when 
myocytes are enlarged (cellular hypertrophy). 
We did not find changes in expression of genes that encode ion channels controlling the 
heart rate, such as hyperpolarization-activated, cyclic-nucleotide modulated (HCN) and voltage-
gated calcium channels (Cav1.2, Cav3.1) (64). Lack of heart rate-related ion channel gene 
expression changes supports the notion that the decreased heart rate in OZR is more likely 
caused by post-translational modulation under the hypertrophy conditions. Clinically, elevated 
ST segment is frequently associated with acute ischemic conditions such as acute coronary 
syndrome (29), however, it often occurs in healthy male individuals (78). In this study, STe was 
increased with statistical significance only in male OZR, but not in female OZR. ST elevation is 
associated with myocardial infarction (55). Recently, ST elevation is found to also occur in LVH 
(55) and in obesity (4, 18). The likely explanation for increased STe in male OZR is the LVH-
related cardiovascular dysfunction (50), female OZR may be more resistant to ischemic 
conditions at this age group (14-17 weeks).   
Limitations of the study 
The sample size is small (four animals per each group), which may have caused 
insignificant changes in expression levels for many genes related to cardiac hypertrophy and 




provided us an opportunity to focus on genes with significant alteration of expression levels. If 
confirmed in large samples of obese human cardiac hypertrophy, these genes (particularly the 
new genes) may represent novel targets for exploring early pharmacological treatment of sex-
specific cardiac hypertrophy in obesity. 
Conclusions 
 We identified five differentially expressed genes in LVH shared between OZR and 
human heart in obesity in a sex-dependent manner. ANP has the highest expression levels in 
LVH in both sexes. Future investigations of these five DEG may provide mechanistic insights in 






Figure 1: Representative ECG recordings of male (A) and female (B) Zucker rats 
 
Figure 1A: Representative ECG data from males; B: Representative ECG data from females. 





Figure 2: Sex-specific distribution of significant genes in Zucker rat LVH 
 
Figure 2. Significantly upregulated, downregulated, or not statistically significantly different 
total gene expression when comparing A) all rats; B) females only, and C) males only. The 
discrepancy in total number of genes between analyses is due to sex-specific expression: some 
genes are exclusively expressed in either males or females. If a gene had 0 expression in all 









Figure 3. A: female, B: male. Bottom-left quadrants represent genes upregulated in human and 
rat LVH; upper-right quadrants represent genes downregulated in human and rat LVH; bottom-
right quadrants represent genes upregulated in rats but downregulated in humans; top-left 





Figure 4. Comparison of seven obesity- and LVH-related differentially expressed genes 
levels between human and rat. 
 
Figure 4. Gene panel transcript levels from transcriptome dataset in rats (top) and humans 
(bottom). The original nine-gene panel from humans was reduced to seven because two of the 













C. Western blots 
 
D. Protein quantification 
 
Figure 5. A: Gene expression from transcriptome. B: Gene expression from qPCR. C: Protein 
expression. D: Protein expression quantification. Protein level was normalized to α-actin. * 













C. Western blots 
 
D. Protein quantification 
 
Figure 6. A: Gene expression from transcriptome. B: Gene expression from qPCR. C: Protein 
expression. D: Protein expression quantification. Protein level was normalized to α-actin. * 




Figure 7: Gstt1 validation 
 
 













C. Western blots 
 
D. Protein quantification 
 
Figure 8. A: Gene expression from transcriptome. B: Gene expression from qPCR. C: Protein 
expression. D: Protein expression quantification. Protein level was normalized to α-actin. * 













C. Western blots 
 
D. Protein quantification 
 
Figure 9. A: Gene expression from transcriptome. B: Gene expression from qPCR. C: Protein 
expression. D: Protein expression quantification. Protein level was normalized to α-actin. * 













C. Western blots 
 
D. Protein quantification 
 
Figure 10. A: Gene expression from transcriptome. B: Gene expression from qPCR. C: Protein 
expression. D: Protein expression quantification. Protein level was normalized to α-actin. * 




Figure 11: Roles of sex (A) and obesity (B) in NPPA and NPPB gene expression levels 
between rat and human LVH.  
 
Figure 11. Black arrow: increase in paired group comparison. Red arrow: decrease in paired 






Table 1: Characteristics of OZR and echocardiogram results 
 Male (14-17wk) (n=4)   Female (14-17wk)(n=4) 
 Lean Obese Lean Obese 
Body weight(g) 350±82 607±57* 273±15 575±24* 
Heart weight(g) 1.16±0.06 1.75±0.15* 0.85±0.07 1.55±0.06* 
HR (bpm) 417±36  371±11 384±18 374±6 
LV mass (mg)& 786±39  1043±96* 443±8 705±33* 
IVS;d (mm) 1.79±0.21 2.05±0.04 1.72±0.04 2.02±0.12* 
LVID;d (mm) 5.94±1.04 7.84±0.1* 5.38±0.13 6.95±0.15 
LVPW;d (mm)# 1.75±0.15 2.31±0.35* 1.29±0.11 1.76±0.11* 
EF (%) 83.16±7.25 80.10±12.13 89.92±6.90 86.90±12.42 
FS (%) 53.96±8.08 51.67±12.25 64.08±13.12 60.81±15.08 
*: p<0.05 compared to sex-matched lean control group 
#: n=6-8 as more than one area was measured. 






Table 2: Resting heart rate, ST elevation, and heart rate variability from ECG 
 Male Female 
 Lean Obese Lean Obese 
HR (bpm) 394±16 310±17* 228±16 198±19 
STe(mV) 0.092±0.008 0.140±0.025* 0.10±0.12 0.079±0.057 
nLF 0.621±0.169 0.205±0.082* 0.589±0.009 0.350±0.059* 
nHF 0.379±0.169 0.795±0.082* 0.414±0.009 0.650±0.059* 
LF/HF 1.951±1.062 0.267±0.129# 1.419±0.052 0.545±0.136* 
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Figure S1: Principle component analysis (PCA) in female (left) and male rats showing that 





Figure S1. PCA plots displaying clustering of individual samples. Red triangles represent LZR 





Figure S2: Differential expression profiles between obese and lean animals (volcano plots)  
 
 Figure S2. A: All samples analyzed without regard to sex. B: Obese versus lean females. C: 
Obese versus lean males. Black dots represent genes with p-value < 0.05. Red dots represent 
genes with p-value < 0.05 but less than a two-fold change in expression. Green dots represent 









Figure S3. Each column represents one animal. Transcriptome data were analyzed for differential 
expression in obese versus lean animals for A: all samples (regardless of sex), B: females only, 







Supplemental Table 1. Primers used in qPCR. 
Gene Strand Sequence 
NPPA F GCAAACATCAGATCGTGCCC 
  R GGTCTAGCAGGTTCTTGAAATCC 
NPPB F AGCTCTCAAAGGACCAAGGC 
  R CGATCCGGTCTATCTTCTGCC 
HIST1H2AC F ACACCTTACCTTTTCCACTTCC 
  R GCGTCCAGACATCGTTATGC 
GSTT1 F TCCAGATGCATACTGTGGAGC 
  R TGGCCACACTCTCACACAAGG 
PDK4 F TGGTGAAGAGCTGGTACATCC 
  R ATCCCTTGTGCCATCGTAGG 
MYL7 F CTCAATGTTCGAGCAAGCCC 
  R GACACTTACCCTCCCGAGC 
HBB F CTGGGCAGGCTGCTGG 
  R TCAGATGAGCAAAGGTGCCC 
GAPDH F CAACTCCCTCAAGATTGTCAGCAA 




















AABR06002048.1 5.474802166 0.046768716 
-
5.899857199 0.020329196 
AABR06003762.1 5.64791736 0.021892925 
-
6.049120464 0.020924976 
AABR06008694.1 6.612430939 0.029549546 
-
8.620401091 0.005975624 
AABR06009495.2 6.641521781 0.026806303 6.739967734 0.032850468 
AABR06009537.6 
-
7.593939062 0.030485885 7.054664058 0.014314151 
AABR06022532.1 5.425902591 0.04852144 
-
4.676637294 0.044207941 
AABR06024198.1 6.630507627 0.027811611 6.834896348 0.030537616 
AABR06024761.1 6.267520439 0.041113763 
-
6.497590744 0.014741877 
AABR06025560.2 4.921446692 0.03784446 
-
6.584814784 0.015513413 






AABR06027333.1 4.885063042 0.041975951 
-
7.725504514 0.018014809 
AABR06028157.1 7.606891073 0.043823061 
-
8.620401091 0.005975624 
AABR06028909.1 5.569160597 0.045447886 
-
6.724777073 0.016953624 
AABR06030345.1 4.999134344 0.044856331 -5.21384995 0.026995547 






AABR06031580.1 5.402081585 0.049376162 
-
4.845748232 0.03894374 
AABR06031627.1 5.437967602 0.048072641 
-
5.761342842 0.00989319 
AABR06042542.1 6.268881516 0.041184128 6.473725938 0.021827543 











AABR06046610.1 5.404688557 0.049289009 
-
4.905580062 0.035350768 





AABR06047625.1 6.344460351 0.044357662 
-
6.724777073 0.016953624 
AABR06050424.1 6.202888777 0.038097669 
-
8.160302291 0.012895458 
AABR06052098.1 6.123638752 0.037293865 
-
9.756404167 0.04203545 






AABR06055554.1 0.34234201 0.023637241 0.192215961 0.044637305 








7.100043994 0.043508355 6.183120784 0.028000384 








AABR06062642.1 5.598698447 0.045957994 
-
8.547480448 0.012940666 





AABR06065718.1 5.61563547 0.036360555 
-
5.040411106 0.027845096 
AABR06066181.1 0.211521378 0.033099913 0.163550338 0.042769867 
AABR06066677.1 
-
7.409937527 0.010771029 8.757888266 0.008370517 
AABR06067381.1 5.417373268 0.048832775 
-
6.466272791 0.014651542 
AABR06068951.1 6.389230195 0.044904553 
-
7.812441519 0.01483145 
AABR06072704.1 6.176198847 0.037337944 6.101534315 0.034619997 
AABR06072709.2 7.613910522 0.033687553 7.790094159 0.005310569 
AABR06074433.1 5.964886462 0.004543887 
-
7.079067219 0.021408484 
AABR06080098.1 7.548375195 0.037056911 -10.0337192 0.023031626 
AABR06081787.1 7.157602788 0.023438023 
-
8.615733531 0.006343379 
AABR06082987.1 6.071939834 0.022714779 6.210594527 0.025812336 
AABR06086439.1 6.284162273 0.041952119 
-
9.569094396 0.001149496 
AABR06086499.1 5.624067943 0.025697759 
-
6.880029517 0.016140955 










AABR06094518.1 6.257829499 0.040614306 -6.37649517 0.014842829 
AABR06095711.1 6.165015485 0.037148165 
-
8.629781936 0.005308213 
AABR06097617.1 7.54269473 0.036424528 -7.02241795 0.015220933 
AABR06098671.1 6.572853403 0.033570852 
-
7.792798317 0.013885729 
AABR06099363.1 6.257829499 0.040614306 
-
6.637953465 0.016207932 
















Acadsb 0.890668799 0.010911172 0.610398798 0.011814675 
Acot2 -0.58120987 6.99441E-15 
-
0.504184284 0.015381101 




Acss1 0.763344511 0 0.602589679 4.40688E-05 
Acy1 0.463633853 0.049980363 0.587055716 0.033199143 
Adk 0.255682302 0.029114696 0.219784555 0.04166912 
Agxt2 2.900470908 0.049948297 
-
5.904998099 0.0147047 
Ahsa1 0.317805903 0.045691948 0.367810994 0.017583951 
AI314180 0.322588664 0.045671081 0.262099643 0.041062529 
Akt2 0.364876397 0.045299693 0.33098406 0.034807733 
Aldh6a1 0.291433591 0.020504617 0.367517539 0.02018224 
Alkbh6 5.021755859 0.037088315 4.378209885 0.049806205 






Ap1s2 0.575564747 0.04320077 0.421136111 0.022738184 
Aqp1 0.84779176 9.99201E-15 0.617937721 0.007820683 
Araf 0.444347287 0.046882239 0.488105854 0.015403714 
Armc2 0.708916431 0.046359758 0.858175176 0.036384405 
Art3 0.290284023 0.022083772 1.072787005 1.52989E-13 
Asb11 0.607055833 2.7531E-08 0.629178896 0.020466789 
Asb12 0.518211405 0.025290917 0.418729307 0.022169072 
Asb15 1.084577028 0.036407893 0.683651026 0.045816184 






Atad1 0.540673758 0.010307023 0.461574235 0.022269345 
Atp1b4 
-
5.325617057 0.040634128 -3.50164309 0.045642034 
Atp2a2 0.430244727 5.44872E-05 0.578136476 0.020096166 
Atp5a1 0.192687016 0.020807169 0.281540223 0 
Atp5b 0.226766549 0.02560679 0.233284958 1.9984E-15 
Atp5c1 0.305654859 0.025697696 0.322398406 0.024072964 
Atp5g1 0.335923395 0.049960102 0.351669153 0.009577905 




















Ccdc47 0.373580226 0.025874844 0.273695476 0.038963574 
Ccni 0.196308539 0.021827199 0.161339802 0.043513846 
Cct2 0.386163662 0.000938688 0.310511156 0.02105802 
Cct7 0.357514942 0.044513607 0.234008547 0.048434217 




Cd40lg 4.844293419 0.044485478 4.446372587 0.043451139 
Cdh5 0.859440965 1.97549E-05 0.264170594 0.044545653 
Cdkn1b 0.527213781 0.019219126 0.346736296 0.047470007 
Cdrt4 6.031707691 0.014068845 
-
6.662422172 0.012687202 
Chchd3 0.375916331 0.038491516 0.485882399 0.010444244 
Cldn6 5.428940032 0.032789751 
-
7.080481776 0.004976843 
Cmbl 0.293924191 0.025443429 0.478210835 0.032304264 






Cog6 1.010510381 0.049082095 0.95711025 0.028081709 
Coq10a 0.700806087 0.039580092 0.6523307 0.000652482 
Corin 0.636234278 0.020801064 0.648546707 0.021778514 
Cox7c 0.531007141 0.022827842 0.397048926 0.034978937 
Cox8b 0.646584078 0.044211433 0.49960678 0.033445553 
Cpe 0.199099236 0.021580116 0.431308743 0.006734814 
Crip3 4.501527016 0.046122986 -6.27141985 0.014287448 
Ctnnal1 0.537455804 0.023560928 0.543498667 0.036115532 
Ctsc 0.287475747 0.03884358 0.554831424 0.002319039 
Cxcr7 0.499272399 0.016356332 0.429882573 0.045035387 




Dazap2 0.154060009 0.022751422 0.186642237 0.038636295 
Dbt 0.575277014 0.028058767 0.561446863 1.39888E-14 
Dcaf11 0.275451382 0.048440423 0.307994112 8.57317E-08 
Ddx17 0.501210902 0.043938017 0.323964102 0.036532778 
Ddx5 0.268576837 0.04375523 0.249992452 0.02984819 
Decr1 
-
0.652163543 0.027509875 -0.5187071 0.014851021 
Defb19 6.703738406 0.001312885 6.747663372 0.008733623 
Dhrs7c 0.515875476 0.048739116 0.587829231 0.031375558 
Dmrtc1c1 5.388778039 0.020900257 
-
6.242374048 0.016689447 
Dnajb9 0.635788109 0.015122747 0.571528072 0.005376241 
Dnajc21 0.327115997 0.049947392 0.339162937 0.043396026 
Eef2 0.18197047 0.044097174 0.195351092 0.002458975 
Eif2s3y 0.258550834 0.025319813 0.152370094 0.048715015 
Eif4a2 0.280357602 5.13946E-05 0.228207161 0.026698777 
Eif4g2 0.357566676 0.028476509 0.167969528 0.048776968 
Errfi1 1.047374125 0.048916665 1.501277055 0.009129899 
Esd 0.34672104 0.024354071 0.444086828 0.009875889 
Etfa 0.088128009 0.04994981 0.093316917 0.009267487 
Etfdh 0.179875567 0.014792225 0.169547658 0.021716521 











Fndc5 0.687941377 0.003705992 0.561655702 0.022023328 












Ghitm 0.418202297 0 0.312865784 0.006634025 
Ghr 0.500716695 0.020634013 0.371526065 0.035498162 
Gja1 0.734775814 0 0.63683554 1.9984E-15 
Glud1 0.237804532 0.022793058 0.170494083 0.044330289 
Gmps 0.373609811 0.023583596 0.328009742 0.002981603 
Gnb3 0.631796953 0.031813391 0.535669487 0.017021638 
Gnpat 0.405501911 0.048741215 0.408989621 0.022544858 
Got1 0.193117007 0.046556087 0.213334232 0.021815551 
Gpd1 
-
0.693296476 0.045779873 -0.60646849 0.018061497 
Gramd3 0.386905724 0.015547556 0.528983479 0.009995589 
Gstz1 0.904332157 0.031692461 0.973211633 0.012731107 
H1f0 0.363319967 0.045481856 0.243498786 0.044077889 










Helt 5.36513805 0.020991311 
-
7.449490192 0.017796224 
Hibadh 0.159283107 0.01226501 0.221075202 0.002311097 
Higd1a 0.624835392 0.02141784 0.487003321 0.031342491 
Hist1h2an 5.864474687 0.025573167 7.209439129 0.022926782 
Hk2 1.33009822 0.023686687 0.92024078 0.00988869 
Hnrnpa2b1 0.202225554 2.7491E-05 0.169472424 0.031424014 
Hnrnph1 0.231889251 0.048935285 0.204406336 0.04417692 
Hnrnpu 0.197748288 0.021401164 0.229043924 0.045871693 
Hsp90ab1 0.256396299 0.043298454 0.409652815 0.036188435 
Hsp90b1 0.403250982 4.996E-14 0.646557788 0.008653939 
Hspa5 0.575206625 0 0.672649519 3.9968E-15 
Hspa9 0.383406673 0.022723811 0.405433998 0.012355414 
Hspd1 0.296398909 0.02366013 0.319764537 0.002528457 
Hsph1 0.667322164 0.011084534 0.458800505 0.041292638 
Hyou1 0.43884038 0.042917088 0.578139493 0.020104822 
Ift81 0.496921735 0.046693081 0.611991751 0.021793987 
Igfbp1 4.876591993 0.022645134 3.435201662 0.043325498 
Igfbp3 0.488950937 0.02475388 1.221064305 0.007897261 




Jam2 0.519705325 0.024190673 0.330714399 0.048432169 
Klhl13 0.876381078 0.022533084 0.737878985 0.04048652 
Klhl23 0.653898816 0.021900883 0.560113954 0.044188559 
Kpna2 0.302032745 5.02835E-06 0.496528075 0.012669943 
Lamp2 0.370940598 0.028197874 0.321798796 0.02183601 
Lbh 0.448217973 0.031293342 0.357983796 0.036397665 












LOC100361144 0.446578986 0.035059134 0.251863873 0.043349505 
LOC100909678 4.285349624 0.045514903 
-
4.719098969 0.043554887 
LOC100909892 0.343172566 0.037213383 0.263903409 0.040023567 
LOC100910554 
-
6.487970228 0.02155601 5.999675928 0.03604115 












LOC680913 5.139484174 0.033896942 -6.20223866 0.017623722 
LOC686066 7.922826547 4.84603E-05 
-
3.232189001 0.044311173 
LOC688924 5.508452434 0.021488548 
-
6.247875493 0.021049443 
LOC690096 6.671551504 0.023709355 
-
8.929140371 0.005623601 
Lpl 0.621404397 0.012641857 0.449218712 0 
Lppr4 4.840325657 1.12681E-05 4.559431485 0.040330654 
Lrrc2 0.421303682 0.006401647 0.306901233 0.04404651 
Lsamp 0.93932807 1.10439E-07 0.395534115 0.044526818 
Lsm14a 0.278617135 0.022688379 0.188545533 0.048017797 
Man1c1 0.58497033 0.037109006 0.769959253 0.020621537 
Manf 0.508168431 0.022870533 0.543207913 0.026367214 
Mccc1 0.489089221 0.029125498 0.458541728 0.01263405 
Mdh1 0.260865848 0.048808294 0.27247243 0 
Mipep 0.43569083 0.045441366 0.351585974 0.049402502 
Mir106b 6.464125953 0.04273539 6.669207761 0.030672039 
Mir146b 6.375938015 0.044875145 -8.42814873 0.021840097 
Mir185 6.60527377 0.030260155 7.501240133 0.026355749 
Mir208b 1.733044849 0.023087588 2.77161138 0.005244696 
Mir215 8.261364471 0.010788094 6.17403579 0.028786807 





Mir291a 6.476929064 0.041980394 6.668336976 0.030633138 
Mir34b 6.442459895 0.043778416 
-
9.493619944 0.000152867 
Mir3558 5.993562764 0.045828521 6.19714448 0.026840829 
Mir3565 5.993562764 0.045828521 6.001284771 0.036077594 
Mir3574 6.002450732 0.045012008 6.147908798 0.031084988 
Mir6329 7.321269164 0.022741912 
-
6.801412021 0.016781534 
Mirlet7c-1 7.11402254 0.026788678 
-
6.556130256 0.015181646 
Mlf1 0.442539355 0.020875663 0.746257924 0.006799298 
MORF4L1 0.269771631 0.001026021 0.360598336 0.021356446 
Morf4l2 0.298507711 0.015985569 0.23363319 0.047139379 




































Mylk3 0.364253423 0.040744886 0.61881681 0.013239686 
Myoz2 0.477453054 0.032560618 0.389574779 0.00606133 
Naa20 0.353671584 0.048926165 0.316937715 0.044198825 






Nde1 0.761744761 3.48818E-05 0.529236216 0.021653924 
Ndufa5 0.358119294 0.037786127 0.361412897 0.014493893 
Ndufs2 0.320122194 0.036685242 0.158936416 6.10063E-07 
Nhp2l1 0.418574103 0.025257259 0.265651562 0.043265386 






Nqo2 0.421595158 0.007587719 0.323755669 0.007605026 
Nrd1 0.286643287 0.022615264 0.238406886 0.044404817 
Nudt4 0.444316208 5.4956E-14 0.514099741 0.0068294 





ORF1 6.947558389 0.023160009 
-
7.066652498 0.014681191 
Oxct1 0.859356796 0 0.522432963 0 
Oxr1 0.338849137 0.037049793 0.343603787 0.020950045 
Oxt 4.781612056 0.037103387 
-
7.765527447 0.003316296 
P4hb 0.353801096 7.99805E-07 0.435828318 0.018487266 
Pabpc4 0.184400659 0.023130308 0.309675586 0.011851011 
Paip2 0.147105462 0.046469447 0.279511843 0.031960318 
Pcbp2 0.409162586 0.03835754 0.232195112 0.032978935 
Pcca 0.438856185 0.004480733 0.305408389 0.021879486 
Pcmt1 0.320113105 0.042688464 0.222062654 0.021684379 
Pcmtd1 0.651640312 0.038305947 0.430851599 0.034487043 
Pcnp 0.311853604 0.042918382 0.250522661 0.032984969 
Pdia3 0.270490103 0.001245801 0.382375449 0.010957247 
Pdia6 0.306357319 0.047800947 0.42094529 0.021742818 
Pdk1 0.401996033 0.033524546 0.300200469 0.007800279 
Pdp2 0.795951197 0.040646033 0.760647675 0.046460252 
Perm1 0.433966853 0.023660323 0.563449527 0.012307557 
Pfkfb2 1.343677476 0.025134986 1.051009502 0.028162362 
Pfkm 0.374332624 5.16527E-08 0.311904931 0.010215595 





Pink1 0.303467083 1.9984E-15 0.353786174 0 
Pla2g12a 0.429167334 0.046783241 0.497362911 0.019218194 
Pla2g1b 5.394230948 0.049637094 
-
6.033111504 0.021139342 
Pla2g5 0.531964139 0.012158376 0.418484755 0.00302196 
Pln 0.611885545 0 0.487171083 0 
Ppap2b 0.369534507 0.02452327 0.212369891 0.045522686 
Ppm1k 1.04256048 0.024098594 0.800913001 0.021906365 
Prdx3 0.172331767 0.024719934 0.216779735 0.021343972 






Prkar1a 0.354324266 0.047191068 0.364608273 0.031162539 
Prodh 0.670490676 0.040112361 1.047710129 7.99361E-15 
Pygm 0.177098891 0.04679001 0.307668088 0.027693398 
Rab1 0.311944494 0.04335158 0.175881975 0.043402545 
Rab1b 0.267434992 0.042236772 0.274824774 0.025815033 
Rab2a 0.193801686 0.020703123 0.296478933 0.012287851 
Rabggtb 0.374152168 0.024417697 0.301979266 0.047154418 
Rangrf 0.442322126 0.037094256 0.510070576 0.032934084 






Rcan2 0.166987093 0.039926419 0.344161112 0.006382592 
Reep5 0.363332992 0.023827933 0.319514914 0.020343535 
RGD1311933 8.360321364 0 7.683618454 1.39888E-14 
RGD1359290 6.280055689 0.036709687 -6.54281647 0.010808496 
RGD1562055 5.388757506 0.021510049 
-
7.161374236 0.012051296 
RGD1562977 6.39601092 0.04487618 
-
8.990813971 0.002255316 
RGD1564827 -2.29110917 0.018501671 -3.70354597 0.008954433 
Rgs5 0.815605773 1.61128E-07 
-
0.262803809 0.041313901 
Rhox4g 4.768200089 0.024449831 
-
6.784021813 0.016881253 
Rilpl1 0.293857942 0.023018377 0.607469596 2.9976E-15 
Rn50_1_1348.1 5.913640424 0.022710316 
-
5.542297373 0.01615152 
Rn50_13_0855.2 5.476329943 0.046717937 
-
8.751788286 0.004494618 
Rn50_X_0554.2 7.028341431 0.011078713 -7.02241795 0.015220933 
Rn50_X_0648.2 5.573718404 0.045486901 
-
6.623984792 0.016026185 






Rn50_X_0749.4 3.791794496 0.049947288 -5.70081855 0.01923353 
Rn5s 6.002450732 0.045012008 
-
7.190719821 0.007305141 
Rpn1 0.34064496 0.023902986 0.354985577 0.031364484 
Rps25-ps2 7.418557907 0.010404298 
-
7.235210277 0.0085834 
Rragd 0.579680961 0.025698149 0.395609451 0.048330715 
RT1-O1 4.825195624 0.03770872 
-
4.264155894 0.048020153 
Sat2 0.77246277 0.025685517 0.742306141 0.018788701 
Sctr 2.956339816 0.010797109 3.376015416 0.009691025 
Sdha 0.35019745 0.039134469 0.304294586 0.013006413 
Sdhd 0.221620844 0.040137032 0.230100248 0 
Sdr39u1 0.421524854 0.045464425 0.467998642 0.034635779 
Serinc1 0.27693989 0.026747424 0.244276175 0.007837025 
Set 0.353025993 0.043537938 0.254170122 0.049427633 
Sh3bp5 0.497247391 0.032909297 0.39812856 0.00753254 
Sh3glb1 0.206964735 0.033614384 0.347115403 0.005565973 






Slc2a4 0.654282011 0.000134543 0.726193595 0.005782333 




Slc4a1ap 0.519567558 0.041338813 0.483934951 0.049798653 
Slc4a3 0.33876168 0.048698851 0.548709379 0.014402994 






Spink8 0.386421654 0.025694247 0.265747102 0.043299275 
Spop 0.402770866 6.72427E-08 0.238048871 0.034654498 
Spp2 4.671133308 0.025519088 
-
5.862048085 0.019812403 
Spryd7 0.184628386 0.029054706 0.594132823 0.016066519 
Srsf5 0.267118927 0.048027235 0.3463088 0.024224051 
Sspn 0.439932453 0.045421261 0.42167133 0.043764684 
Stip1 0.506683269 0.028194993 0.39469689 0.009583563 
Stx4 0.439790665 0.028729016 0.422336005 0.013082737 
Suclg2 0.255190729 0.023472475 0.272232127 0.021658218 
Sypl1 0.442189035 0.025134988 0.355162059 0.031693223 
Tasp1 0.606585577 0.044612875 0.473013139 0.034715117 
Tcp1 0.29262856 0.016166257 0.33729851 0.02972758 
Tcp11l2 0.63296282 4.29345E-05 0.554766865 1.29896E-14 











Tex37 4.20211932 0.048465795 
-
5.955943617 0.021165841 
Tfpi 0.57414975 0.024658757 0.595962395 0.006691825 
Tmed10 0.193621479 0.044902391 0.22526948 0.040122885 
Tmed2 0.367457129 0 0.384159887 0.018175829 
Tmem182 0.269216724 0.044261483 0.194705949 0.046737539 
Tmem261 0.439418432 0.048301147 0.396610755 0.043369518 
Tmem262 4.897158934 0.041542947 4.857810664 0.049180656 
Tmem38a 0.404869712 0.029018463 0.429458054 0.008415459 
Tmem59 0.257934708 0.03835183 0.253998399 0.0437482 
Tmod4 1.416557914 0.005591951 1.047646179 0.011330011 
Tnni3k 0.30914724 0.04115943 0.415083184 0.00253396 
Tpp1 0.375004846 0.049396333 0.415871286 0.038192909 
Trav7d-5 5.454847753 0.047454887 5.449836507 0.04968536 
Trim35 0.322030152 0.048002951 0.339185352 0.049867665 
Trim54 
-
0.585604296 0.047417392 0.346719167 0.045384247 
Trim63 0.414119694 0.044891724 0.460606744 0.01331858 
Trim72 0.218160248 0.045660042 0.292551644 0.03189256 
Tspan3 0.279582296 0.029474992 0.215675049 0.032321022 
Ttc7b 0.399996563 0.046013492 0.303823738 0.047123805 
Tuba8 0.651823455 8.23755E-06 0.526405928 0.011618731 




Txn2 0.788925347 1.51281E-06 0.936578764 1.4988E-14 
Ube2b 0.235490055 0.012824273 0.241000663 0.021381362 
Ucp2 0.559836801 0.023534574 
-
0.622780018 0.010528044 
Ugp2 0.229337073 0.01056207 0.586374642 0 
Uqcrc2 0.301896919 3.99812E-06 0.256027418 0.007314627 
Uqcrfs1 0.205493555 0.041204366 0.119762276 0.044525471 
Vdac2 0.180692074 0.023427809 0.294830726 2.9976E-15 
Vdac3 0.180565705 0.044786409 0.288191871 5.9952E-15 
Vegfa 0.571307806 0.004749552 0.403157109 0.027571594 
Vopp1 0.399416721 0.014177199 0.366496352 0.03517043 
Wfdc1 0.604375385 0.001768803 0.788228807 5.9952E-15 
Ywhae 0.105603012 0.047735897 0.151129557 0.022615446 
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Nppa is a gene that encodes for Anp, a hormone that causes diuresis and decreased blood 
volume. Despite the known beneficial roles in LVH and HF in reducing blood pressure and 
cardiac fibrosis, elevated levels of circulating Anp, have been shown to modulate electrical 
properties in cardiac tissue and cell preparations in many species, including dogs, rabbits, 
rodents, and humans, which may contribute to later development of arrhythmias and HF. 
Previous research has shown that complete knockout of Nppa or its primary receptor is 
embryonic lethal in rodents, but reducing the expression of the gene postnatally has not been 
explored. This study aims to validate whether rat Nppa can be knocked down using targeted 
siRNA duplexes in a rat cardiomyocyte cell line as a proof-of-concept for further application. 
The efficacy of three siRNA sequences targeted at Nppa were evaluated for their efficacy at 
reducing Anp secreted into cell culture media. All three Nppa siRNA significantly decreased 
Anp levels for three days post-treatment. siRNA sequence 1 decreased Anp levels to the greatest 
extent when comparing all three targeted siRNA, while siRNA 2 and 3 were not statistically 
different over multiple days. Day 2 Nppa levels were confirmed to be decreased in the siRNA-
treated groups and positive control group via RT-qPCR. These results show that rat Nppa can be 
targeted using any of the three siRNA duplex sequences detailed herein. This study provides a 
tool for specific targeting of expression of this gene that can be used in further studies to 






Previously, Nppa gene expression has been demonstrated to be increased in both male 
and female OZR and obese humans. Its peptide product, Anp, followed the same pattern when 
analyzed via Western blot. Nppa is a gene expressed exclusively within cardiac tissue (15), thus 
the sole origin of Anp in circulation is the heart. As Nppa is part of the calcineurin-NFAT 
genetic program that is active primarily during fetal development with expression reduced over 
time (9, 16). In pathological LVH, this genetic program becomes re-activated and Nppa levels 
rise in order to compensate for cardiac overload by decreasing blood volume by action at the 
kidney and therefore reducing blood pressure. Anp is secreted from cardiomyocytes in response 
to cardiac damage as a means of controlling fluid volume: it primarily acts to induce sodium 
secretion in the kidney. It is considered to be a physiological antagonist to the action of 
angiotensin (3, 4, 6, 7, 12). 
Despite the beneficial effects of Anp in many cardiovascular diseases, research has 
shown that exposure of cardiac tissues and cells to high concentrations of Anp can alter heart rate 
(HR), effective refractory period (ERP), and action potential duration (APD) from mice, rats, 
dogs, rabbits, guinea pigs, and humans (1, 2, 8, 10, 14). Humans possessing a frameshift 
mutation that causes Anp to have an extended C-terminus and increased persistence in the blood 
exhibited atrial fibrillation, as well as mice with the gene knocked-in (5). Thus, the potential for 
elevated Anp to have a detrimental effect in situations of LVH cannot be ruled out.  Deletion of 
Nppa or its cognate receptor gene, NPR1, has been shown to be cardiac-lethal in animal models 
(5, 11). To circumvent this issue, in this study, I sought to reduce, but not totally ablate, Nppa 





Materials and Methods 
Cell culture and siRNA transfection 
H9c2 cells, an immortalized rat cardiomyocyte cell line, were purchased from ATCC and 
routinely cultured in standard high glucose DMEM supplemented with 1X 
penicillin/streptomycin and 10% fetal bovine serum. After cells reached 70-80% confluence in 
six-well plates, they were treated with 75 pmol siRNA for 1, 2, or 3 days. Control cells at day 0 
were not treated with siRNA. Transfection was carried out using 7.5 µL Lipofectamine 3000. Rat 
Nppa siRNA duplexes were purchased from ABM (product i564970) and are listed in Table 1. 
Day 0 samples were taken from media that was already in the wells. Following this, all media 
was replaced and siRNA/Lipofectamine was added. Day 0 wells were used for day 1 samples. 
All wells were exposed to siRNA at the same time but no individual well was re-used beyond 
day 0, e.g. samples for day 1 were not re-sampled for days 2 or 3. Anti-Gapdh siRNA in 
Lipofectamine (positive control, known for effectively knocking down a known gene but not 
sharing sequence homology with Nppa), a scrambled siRNA (also referred to as “Negative 
Control siRNA”) construct, and Lipofectamine without siRNA were used as controls. Cell 
culture supernatant or cell pellets in RNALater were immediately frozen at -80 °C for further 
use. 
ELISA 
ANP Competitive ELISA Kits (Thermo Fisher #EIAANP) were used for all ELISA 
experiments following the manufacturer's instructions. Briefly, wells in pre-coated 96-well plates 
were incubated with standards or samples. Next, assay buffer, Anp conjugate, and Anp antibody 
were added sequentially (Anp antibody was not added to non-specific binding wells). Plates were 




washes with wash buffer, TMB substrate was added to the wells and incubated for 30 minutes at 
room temperature. Stop solution was then added and readings were taken immediately at 450 nm 
on a plate reader. Data were fit to a four parameter logistic curve (by the manufacturer's 
suggestion) using Softmax Pro software. All ELISA samples consisted of three technical 
replicates and three biological replicates. Information about intra- and interassay coefficients of 
variation, detection limit, and cross-reactivity are available via the product manual. 
RT-qPCR 
RNA was extracted from cell pellets using an RNA Fibrous Tissue Miniprep Kit 
(Qiagen) according to the manufacturer's instructions and as previously described (13). RT-
qPCR for Nppa was only performed on Day 2 samples. 
Statistics 
 ELISA data were analyzed using 1-way ANOVA with Tukey’s test for multiple 
comparisons. RT-qPCR data were analyzed using the ddCt method.  
Results 
In order to address whether expression of Nppa could be knocked down using siRNA, 
three different siRNA duplexes were designed against rat Nppa (Table 1). These sequences were 
run through the Thermo Fisher BLOCK-iT platform and verified via NIH blastn to be suitable 
for testing due to low homology with other known rat gene sequences. Using lipofectamine, a 
standard transfection vehicle, each sequence was tested in H9c2 (rat immortalized cardiomyocyte 
cells) in comparison with a Gapdh siRNA (a positive control with known anti-proliferative 
effects on cells), scrambled Nppa siRNA (negative control), and vehicle with no siRNA. Media 




media from wells might have an effect on cell proliferation, each well was only sampled at one 
time point. For each individual treatment, three wells were sampled in triplicate. 
Figure 1 displays the time-course trend for all of the data. Overall, levels of Anp in 
culture media decreased in the three siRNA-treated groups compared to all of the controls. The 
positive control Gapdh siRNA resulted in reduced levels of Anp compared to the two negative 
control groups, but this reduction was not to the same degree as the targeted siRNA. Figure 2 
shows baseline data (i.e. no siRNA treatment). There was a statistically significant different 
between the "no treatment" and "Nppa siRNA 3" groups, but this may have been due to outliers. 
No other comparisons were significant. Figure 3 shows day one exposure data. All group 
comparisons resulted in significance (p < 0.05) with the exception of the siRNA 2 versus siRNA 
3. For days two and three (Figures 4 and 5), the same trends resulted: all comparisons were 
statistically significant (p < 0.05) except for scrambled siRNA versus lipofectamine only (no 
treatment), siRNA 1 versus siRNA 2, and siRNA 2 versus siRNA 3.  
Figure 6 shows quantification of RT-qPCR for Nppa and Gapdh (normalized to β-actin) 
in cells from day 2 in order to verify the effect of these siRNA on transcript expression instead of 
Anp peptide production from ELISA. These data show that the anti-Nppa siRNA and Gapdh 
siRNA reduced Nppa transcript levels compared to controls (A, top panel) but only Gapdh 
siRNA reduced Gapdh transcript levels (A, bottom panel). Figure 6B confirms singular end 
products from RT-qPCR. Overall, these results show that the Nppa siRNA are effective at 
reducing Anp compared to the controls, but Nppa siRNA 1 has a slightly greater effect. 
Discussion 
In this study, the potential to reduce Anp secretion was investigated using siRNA 




the risk of these constructs producing side effects due to off-target binding in other tissues is 
minimal. Despite the potential for siRNA constructs to have off-target effects, none of them 
showed significant homology to other mRNA via BLAST (siRNA 1 and 2 had 66% homology to 
the next non-Nppa gene and siRNA 3 had 71%). All three sequences did reduce Anp levels in 
culture media, but siRNA 1 appeared to have a slightly greater effect overall. Reducing 
circulating Anp levels via siRNA knockdown may have effects in other tissues in an animal 
model, primarily in the kidney, by increasing volume retention and decreasing diuresis, but this 
depends on the degree to which Anp is knocked down: if Anp receptors are super-saturated, 
reducing the amount of circulating hormone may not have a measurable effect. 
As the ELISA assay only looks at secreted Anp and does not include intracellular stores, I 
attempted several western blots to verify a reduction in cellular Anp levels. Unfortunately, given 
the weak signal produced, these all required too much contrast adjustment above the background 
threshold to be usable for any kind of analysis. The weakness in signal is may be due to low 
concentrations of Anp in cells and is compounded by the lower sensitivity of Western blots 
compared to ELISA.  In retrospect, the cells that I used for Western blots would have been much 
better used for RT-qPCR. In future studies, it might be advisable to perform and repeat more RT-
qPCR. 
siRNA-based therapeutics are a newer technology with currently only limited use in 
approved pharmaceuticals. For laboratory research, their major use is for targeting individual 
genes without the need to modify the endogenous genome. Chemical modifications, such as 
replacing the phosphate backbone with thiophosphate or cholesterylation increase half-life and 




siRNA 1 sequence into a modified siRNA construct and test it in OZR during the course of LVH 
development in order to gauge whether elevated Anp is necessary, beneficial, or detrimental. 
In addition to using siRNAs, there are many other methods one could use to reduce the 
effect of circulating Anp. Small molecular agonists and antagonists of the Anp receptor, NPRA, 
have been researched in the past. However, due to the high homology between Anp and BNP, 
these drugs typically have affinities for both NPRA and NPRB, the cognate receptor for BNP. 
Another potential route to reduce the effect of Anp is direct administration of antibodies, but 
these have not been explored in obesity-related LVH models. An alternative way to modulate 
Nppa expression is through altering transcription of the gene Nppa antisense-1 (Nppa-AS1), an 
alternatively-spliced gene that runs concurrently with and beyond the length of Nppa. Its product 
is a long non-coding RNA whose role in disease is not understood. Induction of this gene, 
perhaps through siRNA or microRNA stabilization, is another avenue worth investigating. 
Overall, the preliminary studies here show that knock-down of rat Nppa is achievable 
using the siRNA sequences presented. Future studies in whole animals are necessary to validate 
the safety and toxicity of reducing, while not completely ablating, Anp levels using the siRNA 
approach.  Despite Anp being an important adaptive hormone against hypertrophic development, 
understanding the point in the development of LVH that circulating Anp levels are putting the 
individual at a higher risk of HF is critical. Application of the approach presented here in OZR 
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Figure 1: Time-course data from Anp ELISA from days 0 through 4. 
 
Figure 1. Time-course data from Anp ELISA from days 0 through 4. Data points on each day are 
discrete (i.e. media was not sampled from the same wells on multiple days), but data points are 
connected in this plot to delineate the groups. Data are displayed as means +/- standard deviation 




Figure 2: Day 0 quantification of Anp via ELISA 
  
Figure 2. Day 0 quantification of Anp via ELISA. All pairwise comparisons were not statistically 
significant (p < 0.05) except for siRNA 2 versus siRNA 3. Bars represent mean +/- standard 
deviation for three separate wells, each with three technical replicates. Each symbol represents a 




Figure 3: Day 1 quantification of Anp via ELISA 
  
Figure 3. Day 1 quantification of Anp via ELISA. All pairwise comparisons were statistically 
significant (p < 0.05) except for siRNA 2 versus siRNA 3. Bars represent mean +/- standard 
deviation for three separate wells, each with three technical replicates. Each symbol represents a 




Figure 4: Day 2 quantification of Anp via ELISA 
 
Figure 4. Day 2 quantification of Anp via ELISA. All pairwise comparisons were statistically 
significant (p < 0.05) except for scrambled siRNA versus lipofectamine only (no treatment), 
siRNA 1 versus siRNA 2, and siRNA 2 versus siRNA 3. Bars represent mean +/- standard 
deviation for three separate wells, each with three technical replicates. Each symbol represents a 




Figure 5: Day 3 quantification of Anp via ELISA 
  
Figure 5. Day 3 quantification of Anp via ELISA. All pairwise comparisons were statistically 
significant (p < 0.05) except for scrambled siRNA versus lipofectamine only (no treatment), 
siRNA 1 versus siRNA 2, and siRNA 2 versus siRNA 3. Bars represent mean +/- standard 
deviation for three separate wells, each with three technical replicates. Each symbol represents a 













Figure 6. A: RT-qPCR quantification of Day 2 Nppa and Gapdh levels, normalized to β-actin 






Table 1. Nppa siRNA Duplex Sequences 
  Sequence 
siRNA 1 GGAGAAGAUGCCGGUAGAATT 
  UUCUACCCGCAUCUUCUCCTT 
siRNA 2 CCGAUAGAUCUGCCCUCUUTT 
  AAGAGGGCAGAUCUAUCGGTT 
siRNA 3 GACUAGGCUGCAACAGCUUTT 









In Chapters 1 and 2, I aimed to describe the effects of sex and obesity on the 
transcriptome of LVH in both humans and Zucker rats in order to investigate the use of Zucker 
rats as translational model. Given the difficulty of studying LVH in humans due to the scarcity of 
live tissue, particularly from healthy controls, there is a major need for research models of LVH. 
LVH is considered to be irreversible, but once it has progressed into HF, quality of life is 
significantly decreased and risk of death is majorly increased. Obesity is one of the most 
common comorbidities of both LVH and HF. Given these facts, early detection of LVH is 
pivotal in preventing the transition to HF. The results of these studies reveal a litany of potential 
gene targets that may serve as biomarkers or pharmaceutical targets for the detection or 
treatment, respectively, of LVH. 
When comparing the overall transcriptomes of our human and rat samples, I identified a 
set of 45 genes that were differentially expressed during LVH in both species and in the same 
direction (i.e. upregulated in male or female humans and rats or downregulated in male or female 
humans and rats) and other genes with sex- or species-specific expression (Chapter 3, 
Supplemental Table 2). Because these genes are differentially expressed in a consistent direction 
for one or both sexes, they warrant examination into their potential roles in LVH. Data from my 
human studies provided a “gene signature” of nine genes, validated at both the RNA 
transcriptome and protein level, which may indicate the presence of LVH. Using that same 
signature as a starting point for my rat studies, I was able to validate five of those genes as 







Summary of Validated Genes 
 
This model summarizes the main pathways that cause the development of LVH (and 
finally HF) as a result of obesity. Obesity, an increase in body mass, brings heightened demand 
for oxygen and nutrients to new tissue. Proteins such as HBB, an oxygen carrier, may play a role 
here. Obesity also means greater bioavailability of fat, therefore, a protein such as PDK4 may 
play a role in helping to utilize this energy source. A larger body mass means a larger blood 
volume is necessary. This is facilitated by a number of factors: 1, obesity directly causes 
increases in aldosterone which causes fluid retention; 2, obesity causes increases in circulating 
angiotensin II to increase, which causes further increases in aldosterone levels. The resultant 
elevation in blood volume raises right atrial pressure, which is reflected as a larger preload in the 
heart. Under normal conditions, under the Frank-Starling mechanism, this would cause increased 
cardiac output. Another branch of this mechanism is the rise in angiotensin II and 
catecholamines from obesity. This causes hypertension and therefore increased afterload, 

























These factors all contribute to increased cardiac work. Chronically, these factors cause the 
Frank-Starling mechanism to fail and cardiac output decreases despite right atrial pressure. 
Circulating angiotensin II and catecholamines also contribute directly to cellular hypertrophy and 
fibrosis, which together lead to electrical remodeling of the ventricle and independently to 
promote LVH. Hormones like ANP and BNP are released from the heart as “rescue” signals, to 
antagonize hypertension and reduce blood volume, but in the end, all of these compensatory 
mechanisms ultimately cause reductions in cardiac output that cannot be sustained, thus resulting 
in HF. 
NPPA and NPPB 
I found NPPA to be the gene with the largest fold increase during LVH and obesity in 
both humans and OZR, with NPPB as the second-highest. Activity of NPPA in the ventricles is 
high during fetal development but later subsides under normal physiological conditions, while 
NPPB follows a similar trajectory but does not decrease to as large of an extent postnatally. 
ANP, the final peptide product encoded by NPPA, and BNP, the final peptide product encoded 
by NPPB, are circulating hormones that are primarily produced and secreted by the atria in 
adults, but are also produced and secreted from the ventricles in LVH (24, 38). My findings are, 
thus, consistent with previous findings. 
My research revealed several fold changes in NPPA and ANP expression to super-
physiological levels in both sexes with the presence of obesity. As discussed in the introduction, 
elevated ANP has been shown to decrease heart rate in rats and dogs but increase it in humans 
(1, 2, 26), increase the effective refractive period in dogs but decrease it in humans (26), and 
decrease action potential duration in human, dog, rabbit, and guinea pig cardiac preparations 




terminal, degradation-resistant ANP, all mutation carriers had atrial fibrillation (9). Although 
deletion of NPPA or its cognate receptor in mice produces early cardiac hypertrophy and 
ultimately death via HF (28, 32), elevated ANP may be a contributing factor in LVH as a 
precursor to HF. 
In order to study the role of ANP further, a conditional knock-down, or an siRNA-
mediated knock-down of NPPA/ANP during the progression of LVH would be worth 
investigating. There is currently no research into the balance between NPR1 and NPR2 receptor 
saturation by ANP and activity of the clearance receptor NPR3; it is unknown whether ANP 
clearance is increased via NPR3 upon NPR1 and NPR2 saturation or if translation of the 
signaling receptors is upregulated instead. In a model such as OZR, where LVH presents before 
hypertension (unlike other transgenic obese rodent models), the role of supra-physiological ANP 
activity, specifically in cardiac disturbances, may be better elucidated. 
HBB 
HBB is a gene that encodes for the protein precursor of hemoglobin subunit beta (HBB). 
It functions in coordination with hemoglobin subunit alpha, HBA1, to form an active 
hemoglobin complex (9). In my human studies, we found significant increases in HBA1 and 
HBB in both males and females via transcriptome analysis, but protein levels for each were 
increased only in females (30). In our rat studies, HBB was significantly increased in females 
only in transcriptome analysis, but both obese males and females showed increased protein 
levels. Measurable HBA1 protein levels were difficult to detect via Western blot but were not 
significantly different when quantified; this is likely due to fatty contamination of samples. HBB 
has not been previously implicated directly in population-wide hypertrophic conditions. 




sickle cell disease (16) and beta-thalassemia (3), but these diseases are associated with patient-
specific gene polymorphisms and mutations (3, 16). One study of post-mortem hearts described 
increased levels of HBA1 and HBB mRNA associated with sudden cardiac death, but no direct 
mechanism was suggested (41). Increases in levels of HBA1 and HBB may occur in response to 
reactive oxygen species (19), which are elevated in the development of LVH and HF (37). The 
mechanism underlying HBB upregulation is not currently understood, though it may serve as an 
oxygen reserve or buffer to protect against hypoxic insult, and as a site to sequester reactive 
oxygen species. Unfortunately, HBB may not be a useful circulating biomarker as it is also 
always present in circulating erythrocytes, and elevated urinary poryphyrins (such as heme, 
produced by the breakdown of HBB) are common markers of liver dysfunction; however, LVH 
has been found in 12-30% of patients with cirrhosis (7, 31). Ventricular HBB levels may be 
indicative of underlying LVH, but the risk of cardiac biopsy may outweigh its ultimate 
prognostic outcome compared to established biomarkers like pro-NT BNP. 
PDK4 
PDK4 is a gene that encodes for the protein precursor of pyruvate dehydrogenase kinase-
4 (PDK4). This mitochondrial enzyme is expressed in low-to-moderate amounts in many tissues, 
but cardiac and skeletal muscles have the greatest enrichment (45). Our studies found PDK4 to 
be significantly upregulated in LVH-presenting males and females via transcriptome analysis, 
but the protein was significantly increased only in males (30). In rats, expression was increased 
in both sexes in transcriptome analysis, but increases in protein were only significant in males. 
Despite these conflicting protein expression results, PDK4 has previously been positively 
associated with cardiac hypertrophy and HF (12, 27, 47), though some studies show a negative 




fat catabolism. PDK4 inhibits pyruvate dehydrogenase complexes, which are responsible for 
converting pyruvate (derived from glucose metabolism) to acetate (as acetyl-CoA) and carbon 
dioxide. Acetyl-CoA from this process is normally then used as a substrate for cellular 
respiration. Increased PDK4 activity decreases acetyl-CoA production from glucose which is 
counterbalanced by increases in fat metabolism to produce acetyl-CoA. Elevated concentrations 
of PDK4 in obesity may be simply due to the increased bioavailability of fats. Insulin 
insensitivity, a common comorbidity with obesity, has been linked to overexpression of PDK4 
(44); this is likely due to decreased activation of PI3K, leading to reduced inhibition of the PDK4 
promoter (18). PDK4 inhibitors have been explored with regard to treatment of cancers, diabetes, 
and acute cardiac ischemia (34), but have not been used to treat cardiac hypertrophy. Given the 
crucial role of PDK4 in regulating energy metabolism and the metabolic disturbances that are 
associated with obesity, and the widespread presence of PDK4 in skeletal muscle, inhibition of 
PDK4 may not be a suitable treatment for hypertrophy. PDK4 mRNA and protein enrichment in 
the heart may make it a useful local biomarker. Circulating PDK4 mRNA and protein levels have 
not been reported in the literature.  
MYL7 
MYL7 is a gene that encodes for the protein precursor of myosin light chain-7 (MYL7). 
Like NPPA, it is involved in cardiac development, but its expression is restricted to the atria in 
healthy adults (8, 40). Nonetheless, the presence of MYL7 in the ventricles has been reported in 
cardiac hypertrophy previously, but was not examined with regard to sex or obesity prior to my 
study (17, 21, 30). The main function of MYL7 is to facilitate contractility; its upregulation in 
hypertrophy is attributed to the increased force demand from heart muscle (8). The functional 




hypertrophy due to being uniquely expressed within cardiac tissue, but whether it can be detected 
in blood is unknown. Due to its critical role in muscle contraction and sequence homology (36) 
with other, more ubiquitous myosin light chains (including MYL2, MYL5, MYL10, and 
MYL12), direct, specific targeting to increase the activity MYL7 by pharmaceutical intervention 
may be difficult. However, inhibition of myosin light chain kinase, which directly modulates the 
activity of MYL7 via reduced phosphorylation, has been explored as a treatment for 
cardiovascular conditions such as atherosclerosis (4) and heart ischemia/reperfusion injury (22) 
in rabbits and mice, respectively. These treatments have not been tested in humans. 
Remainder of the Transcriptome 
 My studies uncovered a variety of ventricular genes that are shared in LVH by obese 
humans and Zucker rats. We validated a select group of them in humans and then examined 
these in our rat model. Not surprisingly, there are additional putative gene candidates within the 
dataset that may also be translationally relevant, but they are not within the scope of the present 
research. Both my human and rat data sets are limited by small sample size and age variability 
between samples. Beyond this, the human heart samples lacked full disclosure of pathology data, 
therefore we are not aware of any comorbidities or medications the patients were taking. Future 
studies would ideally rectify these issues (age-paired samples, number of samples, underlying 
conditions) and include functional human cardiac data for cross-comparison with the Zucker rat 
model. Given that LVH develops slowly over time, more research is warranted into 
transcriptomic and proteomic changes during the course of development, particularly with regard 
to specific isoforms of proteins that vary between atrial and ventricular expression. Our current 
transcriptome dataset does not differentiate between alternatively-spliced forms of genes. 




function (42). Other future studies might include identification of various species of RNA, such 
as long non-coding RNA (20) and microRNAs (6, 13, 25, 35, 46), whose roles in the 
development of LVH are poorly understood. HF is not necessarily a death sentence but 
identifying and understanding what leads to it will save millions of lives in the future by 
allowing timely treatment. 
Future Directions 
Ideally, in order to continue to validate OZR as a model of human LVH, I would add 
more groups of animals: 1) LZR fed ad libitum, 2) OZR fed ad libitum, 3) LZR on a restricted 
diet, 4) OZR fed a restricted diet. Grouping the animals like this would allow for the results to be 
parsed better for the effect of obesity on LVH development. The LZR fed ad libitum and LZR 
fed a calorie-restricted diet should not show many transcriptomic changes and would serve as 
controls. The OZR with calorie restrictions will provide the most significant data in terms of 
overall LV expression: OZR with a restricted diet neither develop obesity nor LVH. Comparing 
these rats’ transcriptomes to lean rats will reveal what genes are differentially-expressed as a 
product of deficient Ob-Rb signaling in the obese animals. Comparing the calorie-restricted 
obese animals to the ones fed ad libitum will reveal which genes are differentially-expressed as a 
function of obesity. Leptin has effects on heart rate and parameters such as contractility but its 
direct role in LVH is poorly understood (10, 23). Adipose tissue, which directly secretes leptin, 
is known to be directly adjacent to cardiac tissue in obesity, therefore local levels of leptin are 
elevated above circulating concentrations. Comparing the calorie-restricted obese animals to the 
ones fed ad libitum will also help differentiate the effects of local leptin in the absence of Ob-Rb 
on the cardiac transcriptome in obesity-related LVH. If there are no differences between the 




of the OZR mutation does genomically and proteomically would be massive. However, the 
likelihood of there being zero differences between the two populations is minimal, as leptin 
signaling affects myriad second messenger and transcriptional pathways that have differential 
effects on the final proteome. 
Similarly, with these groups, I would like to isolate LV RNA at different time points over 
the course of typical LVH development in the untreated obese group with free food access—i.e., 
before (e.g. week 8-10), during (e.g. week 11-14), and after pronounced LVH presentation (e.g. 
week 17-19). Genes and proteins involved in the development of LVH may not be present in the 
final presentation of LVH, and these may serve as useful mechanistic or stage-specific markers 
of LVH, whether for drug targeting or diagnosis. Adding groups such as Zucker diabetic fatty 
rats, a strain of OZR that develops diabetes, to these experiments would also allow for the effects 
of diabetes to be distinguished from obesity alone. 
I would propose that the same experiments performed in Zucker rats herein should be 
performed in ob/ob and db/db mice. As discussed previously, these mice are similar to OZR with 
regard to dysfunctional leptin signaling at the level of the receptor (db/db) and leptin itself 
(ob/ob). These species develop many common pathological conditions to OZR despite not 
sharing the exact genetic mutation, but not all are the same or to the same degree, such as 
diabetes and hypertension. Moving into mice and comparing transcriptomic profiles would 
reveal differentially expressed genes that are shared between humans, rats, and mice, therefore 
further validating the translatability of the gene in the model and reducing the risk that a gene has 
different roles between species, e.g. a gene that is upregulated in mice but downregulated in 




Another potential avenue for continuing this research would be to induce the mutation 
found in OZR Ob-Rb protein, Gln269Pro, in another common rat strain, such as Wister-Kyoto 
rats. This would serve as a secondary confirmation for the role of the functional leptin receptor, 
Ob-Rb, as a contributor to obesity-related LVH. The same groups in the previous paragraph 
would be useful, again, to look at the developmental profile of LVH with or without obesity. The 
same mutation could be introduced to a common mouse strain, as well, such as BALB/c. Unlike 
ob/ob and db/db mice, having the exact mutation would allow for stricter control in cross-species 
analysis for the role of LepR in the development of LVH and obesity. Whereas OZR, ob/ob 
mice, and db/db mice, all are considered to have monogenically-derived obesity, Wister-Kyoto 
rats and TALLYHO mice have a polygenic background that better represents genetic variability 
like the general human population. 
In order to further confirm the role of the leptin receptor in the development of LVH, 
complete or partial ablation of the gene LepR within specific tissues or cell types might be 
considered. Numerous cell type-specific knockouts have been made, such as in endothelial cells 
(14), hepatocytes (15), neurons (5), astrocytes (29), and cardiomyocytes (11). Notably, the 
cardiomyocyte LepR knockout mice, which had a tamoxifen-inducible deletion, suffered from 
cardiac enlargement and eventual HF within ten days of induction (11). This evidence alone 
implies that LepR is critical in early development of cardiac tissue. Given that only one of the six 
LepR isoforms is considered dysfunctional in OZR (Ob-Rb) and they do not die of HF at such a 
young age, then the other isoforms might be playing a critical role in development. As discussed 
in Chapter 1, many leptin receptor isoforms have leptin binding capacity and therefore may serve 
to buffer circulating leptin levels or import leptin into cells, for example. The contributions of 




roles have not been completely elucidated. Further mutating LepR to render the other isoforms 
inactive may be a useful way to look at their role in the development of LVH and ultimately HF.  
Summary 
In the studies presented here, I sought to validate novel biomarkers of LVH in humans as 
they pertained to HF and then define a model to further explore these genes and proteins. My 
human studies resulted in the generation of thousands of transcriptomic changes that have not 
been previously identified, particularly with respect to sex and obesity status. The genes and 
proteins that I validated for humans serve as a template signature that can be verified clinically, 
and the process described in those studies serves as a rapid pipeline to qualify genes for further 
investigation in humans. The goal of my rat studies was to show that there were genes and 
proteins shared across species in an obesity- and sex-specific manner. Genes that are 
differentially expressed in each species are viable tools for research into the mechanistic 
underpinnings of LVH. The role of sex, in particular, has not been explored frequently with 
regard to LVH, especially in model systems. It is well-known that estrogen has cardioprotective 
effects, and differentiating how LVH develops between males and females is critical in the 
development of appropriate biomarkers and suitable pharmaceutical interventions. Overall, there 
are myriad more directions that this research could be taken, but most importantly, the outcomes 
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